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Abstract
Within the herpes simplex type-1 (HSV-1) capsid the heterotrimeric protein complex, the 
triplex, plays an essential structural role in both the capsid assembly pathway and 
subsequent conformational changes involved in the maturation of the procapsid into the 
WT polyhedral T=16 icosahedral capsid. Cryo-EM has shown that the HSV-1 capsid 
contains 6 different types of triplexes (Ta-Tf) which contribute to a single asymmetric unit 
and occupy the local and, with respect to triplex ‘Tf, global 3-fold rotational axes. These 
triplexes in themselves represent unique asymmetrical structures within the HSV-1 capsid 
that violate the rules of quasi-equivalence. The triplexes have been shown not only to be 
involved in the interconnection of hexon and penton capsomers but also to interact with, 
and probably influence the development of, the capsid floor. This thesis analyses the 
structural relationship between the single copy of VP 19c and the two copies of VP23 
which make up the triplex and the means by which these unique asymmetric structures 
form their unusual interactions within the HSV-1 capsid.
The interactions between the triplex proteins were analysed by using a genetic approach 
based on the yeast two-hybrid system, termed the reverse yeast two- hybrid system 
(described in section 3.1). Using this system, VP23 and VP 19c were shown to interact 
within yeast.
Since little is known about the structure of the individual HSV-1 capsid proteins, it was 
decided to analyse their biophysical properties through the use of size exclusion 
chromatography, near and far-UV circular dichroism (CD), differential scanning 
calorimetry (DSC), fluorescence spectroscopy, and 8-anilino-l-naphthalene sulfonate 
(ANS) binding studies. In order to carry out these experiments both bacterial and 
baculovirus recombinant expression systems were employed to express the individual 
triplex proteins VP23 and VP 19c, as well as, co-expressing these proteins to form triplexes 
in vivo. Proteins were engineered to contain a 6xHis epitope tag at their N-termini. Using 
this tag, purification strategies were developed to maximise the recovery and solubility of 
the recombinantly expressed proteins. Monoclonal antibodies raised against these proteins 
were used in their characterisation.
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VP23 was shown to exist either as a monomer or a dimer, depending on the purification 
buffer used during the analysis, and both were shown to be functionally active in capsid 
assembly. Dimers were shown not to be linked by inter-molecular disulphide bonds. 
Conserved cysteine residues within VP23 were also shown not to be essential for either 
triplex formation or capsid assembly.
Biophysical experiments were performed on both triplexes and triplex proteins purified to 
homogeneity through the use of Ni-NTA agarose affinity chromatography and shown to be 
functionally active via in vitro capsid assembly experiments. Fluorescence and far-UV CD 
analysis demonstrated that these purified proteins and complexes were folded and 
contained high levels of secondary structure. DSC and near-UV CD analysis demonstrated 
that VP23, either as a monomer or dimer, contained little or no stable tertiary structure. 
This was also demonstrated for purified VP 19c. ANS binding studies demonstrated that 
these proteins were able to bind ANS and that the organic moiety could become 
fluorescent following excitation. This indicates that ANS had access to the hydrophobic 
core of these proteins suggesting that they were able to undergo further conformational 
rearrangements. Triplexes, in comparison, were shown to contain well-defined tertiary 
structure while still retaining the ability to bind ANS that could become fluorescent 
following excitation.
Taken together, the results show that the individual triplex proteins exist in a "molten 
globule" like intermediate state of folding. Molten globule-like proteins typically 
demonstrate a compact state with a high degree of secondary structure but with little or no 
rigid tertiary structure. Triplexes were shown to contain well-defined tertiary structure 
but still retained some of the characteristics of a molten globule. These results suggest that 
partial folding of the triplex proteins plays an important role in the formation of the triplex 
and its extensive interactions with other capsid proteins required for procapsid assembly 
and subsequent maturation. These results are discussed in relation to the known functions 
of the triplex and their overall importance to capsid structure.
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1.0 Introduction
1.1 Classification of the Herpesviruses
Herpesviruses belong to the family of Herpesviridae, a large family of viruses containing
over 112 known species that infect a wide variety of warm and cold blooded animals
(reviewed by Roizman and Sears, 1996). The virions of all species that belong to the
Herpesviridae consist of 4 morphological compartments:
I. The nucleic acid - a linear double stranded (ds) DNA molecule, typically 120- 
250kb in length, with variable G+C content (31-75%).
II. The capsid - an icosahedral protein shell which surrounds the nucleic acid.
III. The tegument - an amphorous protein shell that surrounds the capsid.
IV. The envelope - the outermost layer of the virion composed of a lipid bilayer 
containing glycoprotein spikes protruding from its surface.
The architecture of a typical HSV-1 virion is shown in fig: 1.1.
All members of the Herpesviridae also share 4 common biological properties (reviewed by
Roizman, 1992):
I. Their respective nucleic acid encodes all the enzymes and co-factors that are 
required for nucleic acid synthesis and metabolism.
II. The synthesis of viral DNA, capsid assembly, and packaging of viral DNA occurs 
within the nucleus. Envelopment of the capsid occurs by the budding of the capsid 
through the inner nuclear envelope. Viral membrane proteins within the envelope 
may become modified upon transit through the Golgi apparatus.
III. Production of infectious progeny virus invariably leads to the destruction of the 
infected cell.
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Fig. 1.1: Electron micrograph o f a frozen hydrated HSV-1 virion.
The major structural features o f the virion, including envelope, tegument, 
capsid, and DNA core are indicate by the appropriate arrows. The diameter 
o f capsid and the approximate diameter o f the virion are also indicated.
This figure was reproduced with permission from W. Chiu, Baylor College of 
Medicine, USA.
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IV. All herpesviruses examined to date are capable of establishing and maintaining a 
latent state of infection within their natural hosts where genome expression is 
restricted to a small subset of viral genes.
1.1.1 Subfamily classification o f herpesviruses
Herpesviruses are widely distributed throughout nature with most vertebrate animals so far 
examined being a natural reservoir to at least one herpesvirus. Historically herpesviruses 
have been classified into three subfamilies based upon their biological properties. The 
three subfamilies are the Alpha-, Beta-, and Gamma-herpesvirinae. The basis for such 
subfamily classification has historically included such characteristics as host range, 
duration of reproductive cycle, cytopathology, and characteristics of latent infection. 
However, more recently genome sequencing has provided a more detailed understanding 
of the evolutionary relatedness of herpesviruses within the Herpesviridae (Roizman, 1992; 
McGeoch et al., 1995). The three distinct subfamilies of herpesviruses are briefly 
summarised below:
• Alphaherpesvirinae
Herpesviruses within this subfamily demonstrate a variable host range in vitro, relative 
short reproductive cycle (<24 hours), rapid spread within tissue culture that results in the 
efficient destruction of infected cells, and a capacity to establish a latent state of infection 
predominantly within the sensory ganglia. The subfamily of Alphaherpesvirinae has been 
further divided into two genera; Simplexviruses, which include herpes simplex virus type-1 
and type-2 (HSV-1 and HSV-2), and Varicelloviruses, which includes varicella-zoster 
virus (VZV).
• Betaherpesvirinae
Herpesviruses within this subfamily demonstrate a restricted host range in vitro, a long 
reproductive cycle, and slow spread in tissue culture. Infected cells commonly 
demonstrate an enlarged appearance (cytomegalia). Viruses within this family 
predominantly maintain a latent state of infection within lymphoreticular cells. The
2
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subfamily of betaherpesvirinae has been further divided into three genera; 
Cytomegalovirus, which includes the human cytomegalovirus (HCMV-1),
Muromegalovirus, which includes murine cytomegalovirus, and Roseolovirus, which 
includes the human herpes virus type-6 and type-7 (HHV-6 and HHV-7).
• Gammaherpesvirinae
Herpesviruses within this subfamily typically demonstrate an in vitro host range restricted 
to the family or order to which the natural host belongs. In vitro all members of this 
subfamily replicate in lymphoblastoid cells and some also cause lytic infection within 
epitheliod and fibroblastic cells. Within the natural host, viruses tend to be specific for 
either T or B-lymphocytes. Viruses within this subfamily frequently maintain a latent state 
of infection within lymphoid tissue. The subfamily of Gammaherpesvirinae has been 
further divided into two genera; Lymphocryptovirus, which includes the Epstein-Barr virus 
(EBV), and Rhadinovirus, which includes human herpes virus type-8 (HHV-8).
1.1.2 Classification o f herpesviruses based upon sequence analysis
Mirroring the remarkable developments in DNA sequencing and sequence analysis over 
the past two decades the classification of herpesviruses within the three subfamilies has 
been reanalysed based upon DNA sequence homology and genome organisation. Factors 
taken into consideration include the arrangement of terminal sequences required for DNA 
packaging, conservation and positioning of genes and gene clusters, and the presence of 
nucleotides subject to methylation (reviewed by Roizman, 1992; McGeoch et al, 1995). 
Fortunately the historical classification based upon the biological properties of the viruses 
has proved remarkably accurate. However, there are a few notable exceptions. The most 
prominent is that of gallid herpesvirus type-1 (GHV-1, also known as Marek’s disease 
virus) which was originally classified as a member of the Gammaherpesvirinae. The 
assignment of GHV-1 to the Gammaherpesvirinae subfamily was based upon the virus’s 
ability to cause tumour like growths within lymphoid tissue of chickens. However, 
sequence analysis demonstrated that the GHV-1 genome arrangement resembled that of 
Alphaherpesvirinae rather then Gammaherpesvirinae and it was subsequently reassigned 
(Buckmaster et al., 1988). Similarly, both HHV-6 and HHV-7 were originally classified
3
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Fig. 1.2: This figure is reproduced from McGeoch et al., (1995) and 
illustrates the divergence over time for some of the herpesviruses 
within the herpesviridae family from a common ancestor. Horizontal 
lines of branches are proportional to their respective time of 
divergence. Subfamily groups are indicated by the presence of their 
appropriate Greek letter. The oldest parts of the tree are indicated by 
broken lines to represent the low confidence in the exact time scale of 
divergence.
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as Gammaherpesvirinae as they exhibited lymphotropism, but were subsequently 
reassigned to the Betaherpesvirinae following sequence analysis.
1.1.3 Divergence o f the Herpesviridae family
Detailed sequence examination and phylogenetic analysis of those herpesviruses that have 
been sequenced has clearly demonstrated a common ancestry among the Alpha-, Beta-, and 
Gamma-herpesvirinae (McGeoch et al, 1995). It has been estimated that the divergence of 
the three subfamilies arose approximately 180-200 million years ago with divergence 
within individual subfamilies occurring approximately 80 million years ago. Fig: 1.2 
schematically illustrates the sequence relatedness between some of the herpesviruses 
within the three subfamilies and demonstrates their evolutionary divergence over time.
1.2 Herpesviruses which infect humans
There are currently eight herpesviruses that have been isolated from humans (summarised 
in table 1.1). Most of these viruses are widespread and are distributed both in the 
developed and underdeveloped world. As with all herpesviruses, infection can result in the 
establishment of a latent infection. The viral DNA remains associated with the host for its 
entire life as a circular episome within the nuclei of cells. Sporadic reactivation from 
latency into a full lytic infection is poorly understood but usually requires external or 
internal stimulus. Such stimuli include; mental and physical stress, hormonal changes, 
immunocompromisation, and exposure to UV radiation (reviewed by Roizman and Sears, 
1996). HSV-1 latency is discussed in further detail within section 1.6.
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Introduction
1.3 Virion architecture
The architecture of the virion is conserved throughout the herpesviridae and comprises 
four distinct components; DNA core, nucleocapsid, tegument, and envelope (fig. 1.1) 
(Wildy et al., 1960). Attention will be paid to the architecture of the HSV-1 virion, 
especially the structure and composition of the capsid, as this forms the basis to the work 
presented within this thesis.
1.3.1 The HSV-1 genome
The entire genome of HSV-1 (strain 17) has been sequenced and consists of 152,260bp of 
dsDNA encoding a minimum of 73 open reading frames (ORFs) with an overall G+C 
content of 68.3% (McGeoch et al., 1988). The genome of HSV-1 consists of two regions, 
unique long (UL) and unique short (US). Genes within these unique sequences are prefixed 
with either UL or US and are numbered according to their relative position within the 
genome. These sequences are flanked by internal and terminal repeat sequences 
designated TRl/IRl and IRs/TRs (fig. 1.3, panel A). A sequence of variable length, termed 
the "a ” sequence, is present as a direct repeat at each terminus of the DNA molecule and 
as an inverted repeat at the L-S junction. During infection the UL and US sequences can 
invert relative to each other with progeny viral DNA typically being present in equimolar 
amounts of the four isomers. These isomers are termed; P (prototype), IL (inversion of L), 
IS (inversion of S), and ISL (inversion of both S and L) (summarised in fig. 1.3, panel B).
1.3.2 The “a” sequence.
The “a ” sequence mediates a number of important functions during the life cycle of 
herpesviruses and is composed of a number of repeat elements (reviewed in Roizman and 
Sears, 1996). It is directly involved in the inversion of L and S segments, the 
circularisation of DNA following infection, site specific recombination, and plays an 
integral role in the cleavage of replicated DNA during packaging. The HSV-1 “a ” 
sequence can be divided into both unique (U) and directly repeated (DR) elements. The 
structure of the “a ” sequence in HSV-1 (strain F) is represented as:
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DR1 -Ub-DR2n-DR4m-Uc-DRl
Where Ub and Uc consist of unique sequences of 65 and 68bp in length and DR1, DR2, and 
DR4 are direct repeats containing 20, 12, and 37bp respectively. DR2 is present in 19 to 
23 copies, and DR4 is present in 2 to 3 copies per “a ” sequence. The size of the “a ” 
sequence varies depending on the strain and generally reflects the number of repeats of 
DR2 and DR4. Linear virion DNA contains asymmetric ends with the terminal “a ” 
sequences of the L component ending in 18bp of DR1 and that of the S component ending 
in lbp of DR1. A single 3’ residue overhang occurs at both termini and allows the linear 
DNA molecule to circularise. The number of “a ” sequences at the L-S junction and at the 
L terminus can vary, although only a single “a ” sequence is present at the S terminus. The 
relevance of the “a ” sequence is discussed further in section 1.5.5.
1.3.3 DNA structure within the nucleocapsid
The DNA within the nucleocapsid of HSV-1 virions was originally proposed to exist as a 
toroid by Furlong et al., (1972). Analysis of thin sections of HSV-1 virions and gradient 
purified capsids by EM showed that the DNA within the nucleocapsids of these samples 
appeared as an electron-opaque toroid partially surrounding a less dense cylindrical mass. 
This lead the authors to speculate that the DNA was wound around a central protein plug. 
The plug was proposed to be composed of VP21 by Gibson and Roizman (1972). 
However, Puvion-Dutilleul et al., (1987) argued that the toroid structure of DNA observed 
within the core was a direct result of dehydrating agents used in the specimen preparation. 
Cryo-EM and computer reconstruction analysis of HSV-1 capsids has not provided any 
supporting evidence for a toroid arrangement of viral DNA coiled around a central protein 
plug. Booy et al., (1991) proposed that the DNA within the nucleocapsid was packaged in 
a liquid crystalline state, similar to that observed for bacteriophage X and T4, where the 
DNA is packaged in parallel bundles. The packaging of DNA in this manner into the core 
of icosahedral capsids circumvents the requirement for a central protein plug to wind the 
DNA around (Lepault et al., 1987). Recent cryo-EM analysis upon purified HSV-1 virions 
has provided additional support for the packaging of viral DNA into HSV-1 capsids in the 
absence of a central protein plug. Zhou et al., (1999) showed the DNA within HSV-1
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Fig. 1.4: Cross-section through a cryo-EM reconstruction o f  the HSV-1 
virion
resolved to 20A.
The cross-section is viewed along a 2-fold axis and illustrates the 
concentric layers o f DNA packaged within the capsid (coloured in 
brown). The spacing between the concentric layers o f DNA is 
approximately 26A. The capsid is radially coloured from light 
(yellow/interior) to dark (purple/exterior). Inner and outer capsid shells 
are coloured yellow and green respectively. The icosahedrally ordered 
tegument is coloured blue and purple.
This figure was reproduced with permission from W. Chiu, Baylor 
College o f Medicine, USA.
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virions was packaged as regularly spaced concentric layers approximately 26A apart. Up 
to 10 concentric layers of DNA could be successfully resolved at the resolution of analysis 
with the DNA occupying 90% of the total internal volume of the capsid. The structure of 
the DNA within the HSV-1 capsid is consistent with a spooling model of DNA packaging, 
as seen within the T7 bacteriophage (Harrison, 1983; Cerritelli et al., 1997). However, 
unlike that of T7 bacteriophage, no central protein plug was observed around which the 
genome could be spooled. Instead, Zhou et al., (1999) speculated that the linear DNA 
molecule wrapped itself around the inner surface of the capsid shell accumulating one 
layer at a time with the DNA becoming less densely packaged further away from the inner 
surface of the capsid (fig. 1.4). Although the DNA is closely associated with the inner 
surface of the capsid shell no icosahedral symmetry could be detected and therefore it 
seems unlikely that the viral DNA makes any specific DNA/protein interactions (Zhou et 
al., 1999).
1.4 Virion morphology
The HSV-1 genome encodes over 73 major ORFs of which approximately 40 are reported 
to encode proteins that can be found within the mature virion. Therefore, over 50% of the 
HSV-1 genome encodes proteins that are utilised in the production of infectious progeny 
virions. However, it should be noted that not all of the proteins found within mature virion 
are required for infectivity. Indeed, transfection of naked HSV-1 DNA into cells is 
sufficient for initiating infection. The majority of the virion proteins are responsible for 
effectively delivering the viral DNA into the cell nucleus and directing the process of 
infection (Rixon, 1993).
1.4.1 The tegument
The tegument is an amorphous protein layer situated between the capsid and the envelope 
(see fig. 1.1) (Wildy et al., 1960). In comparison to the rest of the virion, little is known 
about the structural organisation of the tegument (reviewed by Rixon, 1993). However, 
the tegument accounts for approximately 50% of the total volume of the virion and 
consists of at least 18 viral proteins (Haarr and Skulstad, 1994). Although some of these 
proteins have yet to be assigned functional roles, proteins within the tegument are
7
Fig. 1.5: Visualisation o f the icosahedrally ordered tegument proteins.
The tegument proteins are coloured from light (green/low) to dark 
(purple/high) representing their radial distance from the center o f the 
capsid. Protein densities attributed to the B-capsid are coloured in gray. 
Structural components which make up one asymmetric unit, 1 penton 
(5), hexons (P, E, and C), and triplexes (Ta-Tf) are labeled in blue.
This figure was reproduced with permission from W. Chiu, Baylor 
College o f Medicine, USA.
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generally considered to be involved in virion morphogenesis, uncoating, and regulation of 
gene expression. The functions of the known tegument proteins are summarised in table 
1.2 .
1.4.1.1 Tegument assembly
Although little is known about tegument assembly and virion tegument acquisition it 
should be noted that the tegument does contain a degree of structural organisation. Szilagi 
and Cunningham (1991) demonstrated that tegument proteins could assemble into stable 
particles (L-particles) that sediment more slowly than normal HSV-1 virions during 
gradient purification. These particles were shown to consist solely of tegument and 
envelope proteins (Rixon et al., 1992). L-particles are unable to initiate infection, due to 
the lack of a viral genome, but are capable of penetrating cells and increasing the 
efficiency of HSV-1 lytic replication (McLauchlan et al., 1992; Dargan and Subak-Sharpe,
1997). The tegument proteins found within L-particles also appeared similar to those 
proteins found within mature virions indicating that the capsid is not required for tegument 
formation (McLauchlan and Rixon, 1992).
1.4.1.2 Tegument structure
Recent cryo-EM analysis performed by Zhou et al., (1999) upon gradient purified virions 
demonstrated that some of the tegument proteins associated with the capsid are 
icosahedrally ordered (see fig. 1.5). Although these proteins have yet to be identified their 
extensive interactions around the penton lead the authors to speculate that they may be 
involved in the regulation of DNA transport through the penton channel.
It is of interest to note that similar cryo-EM analysis performed upon purified HCMV 
virions reveals significant differences in the structural organisation of the icosahedrally 
ordered tegument proteins surrounding the capsid (Chen et al., 1999). The principle 
difference in HCMV can be seen in the extensive association of tegument protein 
complexes with both pentons and hexons. The tegument densities surrounding the HCMV 
capsid also appear conformationally distinct from those surrounding the penton in the 
HSV-1 virion. As with HSV-1 these icosahedrally ordered tegument proteins have yet to
Gene Protein Approx. 
Mr (kDa)
Properties Reference(s)
UL11 -  17-22 Myristylated, role in envelopment 
and virion transport
MacLean et al., (1989) 
Baines and Roizman,(1992)
UL13 VP18.5 57 Protein kinase, phosphorylates VP22 
(UL49)
Prod'hon et al., (1996)
UL21 * - Function unknown, dispensable in 
tissue culture
Baines et al., (1994)
UL25 - 63 Required for packaging but not 
cleavage of replicated viral DNA
McNabet al., (1998)
UL36 VP 1/2 270 Possible DNA binding protein McNabb and Courtney, (1992)
UL37 - 121 Phosphoprotein, function unknown Schmitz et al., (1995)
UL41 vhs 55 Virion host shut (vhs) off protein Everly and Read, (1999)
UL46 VP11/12 79 Modulates Vmw65 (a TIF/VP16) 
and TK transactivation
Zhang et al., (1991) 
Zhang and McKnight, (1993)
UL47 VP13/14 74 Modulates Vmw65 (a TIF/VP16) 
and TK transactivation
Zhang et al., (1991) 
Zhang and McKnight, (1993)
UL48 Vmw65 
(VP 16)
55 Transactivates IE genes Berket al., (1998)
UL49 VP22 32 Stabilises microtubule assembly Elliott and O'Hare, (1998)
UL54 Vmw63 55 IE2 transcription/post-transcriptional 
regulator
Sinclair et al., (1994)
UL56 _ _ Function unknown, Kehm et al., (1998)
RL2 Vmwl 10 
(ICPO)
110 IE1 transcriptional activator, blocks 
mitosis, disrupts ND10 domains
Lomonte and Everett, (1999) 
Muller and Dejean, (1999)
RSI Vmwl75
(ICP4)
133 Transcription activator Allen and Everett, (1997)
US3 " 53 Protein kinase, partial inhibitor of 
apoptosis
Jerome et al., (1999)
US9 “ 10 Ubiquitinated phosphoprotein, 
function unknown
Brandimarti and Roizman, (1997)
US10 - 34 Phosphoprotein, function unknown Yamada et al., (1997)
US11 " 18 RNA binding regulatory protein 
associated with 60S ribosome
Roller et al., (1996)
Table 1.2: Summary of the HSV-1 tegument proteins and their known properties.
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be identified. However, the substantial differences in their structural organisation are 
probably indicative of their divergent roles during infection.
1.4.2 The envelope
The outer layer of the HSV-1 virion is composed of a trilaminar envelope that contains a 
large number of prominent protein spikes protruding from its surface (fig. 1.1) (Wildy et 
al., 1960). Utilising immuno-gold labelling Stannard et al., (1987) demonstrated that these 
protruding spikes corresponded to HSV-1 glycoproteins which varied in length (80-240A) 
and shape. There are currently 11 glycoproteins which have been identified. Although no 
glycoprotein has been shown to be essential for virion assembly, four glycoproteins are 
necessary for infectivity (reviewed by Spears, 1993; Haarr and Skulstad, 1994). The 
properties of the 11 glycoproteins are summarised in table 1.3. The nomenclature of 
glycoproteins is alphabetical, with the prefix “g” denoting the protein as being fully 
processed. Originally the list contained glycoprotein A (gA). However, this glycoprotein 
was later shown to be indistinguishable from glycoprotein B (gB) (Eberle and Courtney, 
1980). Similarly, Glycoprotein F (gF) originally discovered in HSV-2 was subsequently 
shown to be the homologue of glycoprotein C (gC) in HSV-1 (Zezulak and Spear, 1984). 
Consequently both gA and gF are absent from the summary table.
1.4.3 The capsid
The HSV-1 capsid is an icosahedral protein shell (~125nm in diameter, see fig. 1.13) that 
directly surrounds the viral DNA (Wildy et al., 1960). Gibson and Roizman (1972) 
originally demonstrated that three distinct types of capsid could be isolated from HSV-1 
infected Hep-2 cells. Three types of capsids could be observed by EM within the nuclei of 
infected cells which appeared uniform in size and conformation. Two types of capsid 
could be separated based upon differences in their respective mass by gradient 
sedimentation. The upper band was termed A-capsids and the lower band B-capsids. 
Characterisation of the proteins found within these capsids lead Gibson and Roizman 
(1972) to propose that A-capsids, which lacked VP22a and VP21, differed from B-capsids 
in their internal core protein composition. B-capsids also appeared to contain 
approximately lOx more DNA than A-capsids. The third type of capsid, termed the C-
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Protein Gene Approx. 
Mr (kDa)
Properties
gB UL27 120 Forms homooligomers, required for viral 
penetration and cell fusion
gc UL44 120 Mediates cell attachment, may be required for 
entry on some polarised cell types
gD US6 60 Required for viral penetration and cell fusion
gE US8 80 Forms oligomers with gl, involved in cell-to- 
cell spread
gG US4 60 Non-essential for viral replication in cultured 
cells
gH UL22 115 Forms heterooligomers with gL, required for 
viral penetration and cell fusion
gl US7 70 Forms oligomers with gE, involved in cell-to- 
cell spread
gJ US5 10 Non-essential for viral replication in cultured 
cells
gK UL53 40 Involved in cell fusion
gL UL1 40 Forms heterooligomers with gH, required for 
viral penetration and cell fusion
gM UL10 60 Phosphorylated by US3 protein kinase, non- 
essentail for viral replication in cultured cells
Table 1.3: Summary of HSV-1 glycoproteins and their known properties. 
Those genes underlined are essential for viral infectivity.
(Subak-Sharpe and Dargan, 1998; Steven and Spear, 1997; Haarr and Skulstad, 1994).
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capsid, was isolated from infectious virions present within the cytoplasm of infected cells. 
Treatment of virions with the non-ionic detergent NP-40 and urea removed the 
surrounding envelope and tegument layers. C-capsids, as with B-capsids, were found to 
contained DNA and lack the internal protein VP22a. When C-capsids were sedimented on 
sucrose gradients in conjunction with A and B capsids they appeared as a faint band 
beneath B-capsids. Subsequent to this work, all three types of capsid have been purified 
from the nuclei of infected cells (reviewed by Rixon, 1993).
The three types of capsid are now defined as:
I. A capsids - empty capsids with no internal structure.
II. B capsids - intermediate capsids that lack viral DNA but contain a core in the form 
of a proteinaceous layer.
III. C capsids - capsids that contain the viral DNA and lack the internal proteinaceous 
core.
A fourth type of capsid, termed the procapsid, has recently been identified from in vitro 
capsid assembly experiments (Newcomb et al., 1996; Trus et al., 1996). This type of 
capsid was proposed to be a precursor to mature capsids. Procapsids have subsequently 
been characterised in and isolated from HSV-1 infected cells and therefore represent a true 
assembly intermediate during virion assembly (Rixon and McNab, 1999; Newcomb et al., 
2000). The procapsid is discussed in further detail within section 1.9.
1.4.3.1 Structural composition o f the capsid
Gibson and Roizman (1972 and 1974) originally characterised the protein composition of 
B capsids and identified six virion proteins (VP); VP5, VP 19, VP21, VP22a, VP23, and 
VP24. Heilman et al., (1979) and Cohen et al., (1980) further identified the presence of a 
small (12kDa) capsid protein which they termed pl2 and NC-7 respectively. Newcomb 
and Brown (1991) standardised the nomenclature of the capsid proteins and renamed the 
pl2/NC-7 capsid protein as VP26. The virion protein VP 19 was also renamed to VP 19c in 
order to differentiate it from a glycosylated virion protein that co-migrated during SDS-
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Gene Protein Mr (Da) Location 
in capsid
No. of copies 
per capsid
Presence in A-, B-, 
and C-capsids
UL18 VP23 34,268 Triplexes 640 A, B, C
UL19 VP5 149,075 Hexons & 
Pentons
960 A, B, C
UL26-N VP24 26,618 Internal
scaffold
~ 147 A, B, C
UL26-C VP21 39,875 Internal
scaffold
~ 87 B
UL26.5 VP22a 33,765 Internal
scaffold
~ 1153 B
UL35 VP26 12,095 Tips of 
Hexons
900 A, B, C
UL38 VP19c 50,260 Triplexes 320 A, B, C
Table 1.4: Summary of the major capsid proteins within HSV-1 A-, B-, and C-capsids 
(table modified from Homa and Brown, 1997).
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PAGE analysis (Heine et al., 1974; Newcomb and Brown, 1991). The individual capsid 
proteins are discussed in detail below and summarised in table 1.4.
1.4.3.2 Protein composition o f  the HSV-1 capsid
• VP5 (UL19)
The 155kDa capsid protein VP5 was first shown to be a constituent of the virion by Spear 
and Roizman (1972) and subsequently identified as a component of the capsid by Gibson 
and Roizman (1972).
VP5 is encoded by the UL19 ORF, initiating at 40528 and terminating at 36406, see fig.
1.3 (Costa et al., 1984; McGeoch et al., 1988). The UL19 ORF encodes a protein with a 
predict MW of approximately 150kDa which corresponds well to the observed MWs of 
150-155kDa indicating that the protein does not undergo any significant post-translational 
modification (Gibson and Roizman, 1972; Cohen et al., 1980; Rixon et al., 1990). VP5 has 
been shown to make up 60-70% of the protein mass of HSV capsids and commonly is 
referred to as the major capsid protein (MCP). Indeed, VP5 has been shown to make up 
the entire mass of the pentons and the majority of the mass of hexons (Gibson and 
Roizman 1972; Newcomb et al., 1993; Zhou et al., 1994).
As VP5 is the MCP it is not surprising therefore that it is essential for capsid formation. 
Weller et al., (1987) demonstrated that ts mutations within the UL19 ORF were sufficient 
to prevent the formation of capsids at non-permissive temperatures. Similarly, 
experiments performed by Desai et al., (1993) demonstrated that insertion of the lacZ gene 
into the beginning of the UL19 ORF to generate a VP5 null mutant virus (K5AZ) abolished 
the formation of capsid particles in non-permissive Vero cells. Furthermore, infection of 
non-permissive cells with the K5AZ mutant produced similar levels of concatameric viral 
DNA as was seen within permissive cells. However, mutant viruses were defective in the 
processing of concatameric DNA into genome length molecules suggesting that capsid 
formation is a prerequisite for DNA cleavage to occur. HSV-1 capsid assembly analysis 
utilising the baculovirus expression system has also demonstrated that VP5 is essential for 
the formation of capsids both in vivo and in vitro (Newcomb et al., 1994; Tatman et al.,
11
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1994; Thomsen et al., 1994; Newcomb et a l, 1999). The fact the VP5 is essential for 
capsid formation is consistent with the observation that VP5 is the MCP and present within 
all capsid types. The structural organisation of VP5 within the capsid is discussed in 
further detail within section 1.8. It is interesting to note that VP5 has been shown by non­
reducing SDS-PAGE to be covalently linked to VP 19c within purified HSV-2 capsids 
(Zweig et al., 1979). The high degree of conservation between HSV-1 and HSV-2 would 
suggest that such an interaction should also exist in HSV-1 although attempts to identify it 
within HSV-1 capsids have failed so far (personal communication; Rixon, 1996).
VP5 has been directly implicated in binding to the C-terminal 25 amino acid of the internal 
scaffold proteins encoded by UL26 and UL26.5 (Thomsen et al., 1994; Kennard et al., 
1995; Desai and Person, 1996; Hong et al., 1996). The residues within VP5 that 
participate in this interaction have yet to be identified, although recent experiments 
utilising second site mutations within VP5 to rescue scaffold protein mutants that are 
unable to undergo maturational cleavage, have indicated that residues within the N- 
terminus of VP5 may be involved (Desai and Person, 1999).
• VP 19c (UL38)
The 53kDa capsid protein VP 19c was first shown to be a constituent of the virion by Spear 
and Roizman (1972) and subsequently identified as a component of the capsid by Gibson 
and Roizman (1972).
VP19c is encoded by the UL38 ORF, initiating at 84531 and terminating at 85926, see fig.
1.3 (McGeoch et al., 1988; Rixon et al., 1990). The UL38 ORF encodes a protein with a 
predicted MW of approximately 50kDa which corresponds well to the observed MWs of 
50-54kDa indicating that the protein does not undergo any significant post-translational 
modifications (Gibson and Roizman, 1972; Cohen et al., 1980; McGeoch et al., 1988; 
Rixon et al., 1990).
VP 19c forms part of the heterotrimeric complex termed the triplex, discussed in further 
detail within section 1.8.2 (Newcomb et al., 1993). The VP 19c homologue within HSV-2
12
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capsids has been reported to be covalently linked to VP5, although this has yet to be 
identified with HSV-1 capsids (Zweig et a l, 1979).
VP 19c has been shown to be essential for capsid formation and is present within A, B, and 
C-capsids. Pertuiset et al., (1989) demonstrated that a ts mutant (A44to2) that located to 
the UL38 ORF could not form capsids at the non-permissive temperature. Like the VP5 
mutants described above, A44ts2 mutant virus, although not defective in DNA replication, 
was defective in the processing of concatameric DNA into genome length molecules. 
Similarly, a VP 19c null mutant virus was shown to be inhibited in the formation of virions 
on non-permissive cells (Person and Desai, 1998). Furthermore, capsid assembly analysis 
utilising the baculovirus expression system has also demonstrated that VP 19c is essential 
for the formation of capsids both in vivo and in vitro (Newcomb et al., 1994; Tatman et al., 
1994; Thomsen et al., 1994; Newcomb et al., 1999).
• VP23 (UL18)
The 33kDa capsid protein VP23 was first shown to be a constituent of the virion by Spear 
and Roizman (1972) and subsequently identified as a component of the capsid by Gibson 
and Roizman (1972).
VP23 is encoded by the UL18 ORF (Rixon et al., 1990), initiating at 36051 and 
terminating at 35097, see fig. 1.3 (McGeoch et al., 1988). The UL18 ORF encodes a 
protein with a predicted MW of approximately 34kDa which corresponds well to the 
observed MWs of 30-34kDa indicating that the protein does not undergo any significant 
post-translational modifications (Gibson and Roizman, 1972; Cohen et al., 1980; McGeoch 
et al., 1988; Rixon et al., 1990).
Two copies of VP23 interact with a single copy of VP 19c to form a heterotrimeric 
complex termed the triplex, discussed in further detail within section 1.8.2 (Newcomb et 
al., 1993).
VP23 has also been shown to be essential for the formation of WT polyhedral capsids in 
the baculovirus expression system (Newcomb et al., 1994; Tatman et al., 1994; Thomsen et
13
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al., 1994; Newcomb et a l, 1999). A null mutant virus (K23Z) generated by the insertion 
of the lacZ gene into coding region of VP23 failed to produce capsids on non-permissive 
cells (Desai et al., 1993). K23Z mutant virus synthesised WT levels of DNA but was 
defective in the processing of concatameric DNA into genome length molecules. 
Furthermore, baculovirus analysis has shown that in the absence of VP23 VP5/VP19c 
particles form that are smaller and more densely stained than WT capsids (Tatman et al., 
1994; Thomsen et al., 1994; Rixon et al., 1996; Saad et al., 1999).
• VP2 6 (UL35)
VP26 is the smallest structural protein associated with the capsid and was originally 
identified by Heilman et al., (1979).
VP26 is encoded by the UL35 ORF, initiating at 70566 and terminating at 70902, see fig.
1.3 (McGeoch et al., 1988; Davison et al., 1992). The UL35 ORF encodes a protein of a 
predicted MW of approximately 12kDa which corresponds exactly to the observed MW of 
12kDa indicating that the protein does not undergo any post-translational modifications 
(Heilman et al., 1979; Cohen et al., 1980; McGeoch et al., 1988; Rixon et al., 1990).
VP26 is located on the tips of the hexons and is present within A, B, and C-capsids, 
discussed in further detail within section 1.8.2 (Trus et al., 1992; Booy et al., 1994; Zhou et 
al., 1994; Zhou et al., 1995; Wingfield et al., 1997; Desai and Person, 1998).
Capsid assembly analysis utilising the baculovirus expression system has shown VP26 to 
be non-essential for the formation of capsids both in vivo and in vitro (Tatman et al., 1994; 
Thomsen et al., 1994). VP26 has also been shown to be absent from purified HSV-1 
procapsids (Newcomb et al., 2000). The function of VP26 therefore remains ambiguous. 
However, Desai et al., (1998) demonstrated that a VP26 null mutant virus (KA26Z), which 
replicated at WT levels in tissue culture, had a 30- to 100-fold decrease in virus yield from 
the trigeminal ganglia compared to that of WT virus. Furthermore, latent KA26Z genomes 
also had a reduced ability in reactivate from latency compared to latent WT virus. VP26 
therefore appears to be important for infectious virus production within neuronal cells.
14
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• VP21, VP24, and VP22a (UL26/UL26.5)
VP21, VP24, and VP22a are the three major capsid scaffold proteins and are encoded by 
overlapping in-frame genes UL26 (VP21 and VP24) and UL26.5 (VP22a) (illustrated 
schematically in fig. 1.6; Liu and Roizman, 1991a and 1991b; reviewed by Rixon, 1993 
and Steven and Spear, 1997). Both genes are essential for the efficient maturation of 
capsids that are capable of packaging viral DNA (Gao et al., 1994; Sheaffer et al., 2000).
UL26 encodes an N-terminal protease (VP24) and a C-terminal oligomerisation and VP5 
binding protein domain (VP21) (Preston et al., 1992; Pelletier et al., 1997). The UL26 
ORF initiates at 50809 and terminates at 52714, see fig. 1.3 (Davison et al., 1992; 
McGeoch et al., 1988). Following translation the proteolytic activity of the N-terminal 
VP24 domain results in self-cleavage between alanine 247 and serine 248 to generate two 
cleavage products, namely VP24 and preVP21 (Dilanni et al., 1993; Weinheimer et al., 
1993). Further proteolytic cleavage of preVP21 by VP24 between alanine 610 and serine 
611 results in the removal of the C-terminal 25 amino acids and the production of mature 
VP21. VP24 and VP21 have observed MWs of 24-26kDa and 40-44kDa respectively 
(Gibson and Roizman, 1972, Cohen et al., 1980, and Rixon et al., 1990).
VP22a is encoded by the UL26.5 gene (Liu and Roizman (1991b); Davison et al., 1992). 
The UL26.5 ORF initiates at 51727 (within the UL26 ORF) and terminates at 52714 
(McGeoch et al., 1988). The full-length UL26.5 gene product is termed preVP22a and can 
be proteolytically processed by VP24 between alanine 610 and serine 611 resulting in the 
cleavage of the C-terminal 25 amino acids to produce mature VP22a, see fig. 1.6.
Differential regulation of the UL26 and UL26.5 promoters results in the increased 
expression of VP22a over that of VP21 and VP24. As a consequence VP22a is present in 
much higher quantities within B-capsids, approximately 1000-1500 copies per capsid, than 
either VP24 or VP21, approximately 100 copies per capsid (Liu and Roizman, 1991a, and 
1991b; Newcomb et al., 1993).
Mature forms of VP22a and VP21 are expelled from the capsid upon packaging of viral 
DNA (Gibson and Roizman, 1974; Addison et al., 1990). Consequently, VP21 and VP22a
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Fig. 1.6: Schematic illustration o f the structural organisation o f the HSV-1 
genes UL26 and UL26.5. The two 3’ co-terminal mRNAs are represent by 
the arrows and their respective ORFs by the yellow boxes. The vertical 
lines indicate sites o f proteolytic cleavage between Alanine (Ala) and Serine 
(Ser) residues. Cleavage at site (a) results in the release o f capsid proteins 
VP21 and VP24. Cleavage at site (b) results in the removal o f the C- 
terminal 25 amino acids from either preVP21 or preVP22a.
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can only be detected within B-capsids. The relevance of the C-terminal 25 amino acids of 
preVP21 and preVP22a for HSV-1 capsid assembly is discussed in further detail within 
section 1.8.3. VP24 can be detected within all three types of capsids as well as within 
mature HSV-1 virions (Gibson and Roizman 1974, Sheaffer et al., 2000).
1.4.3.3 Minor capsid proteins
Six proteins encoded by UL6, UL12.5, UL15, UL17, UL25, and UL28 have recently been 
identified as minor constituent proteins of the capsid. However, both in vivo and in vitro 
capsid assembly analysis has shown that these proteins are not required for efficient capsid 
assembly to occur (Tatman et al., 1994; Thomsen et al., 1994; Newcomb et al., 1996; 
Newcomb et al., 1999). Although these proteins may not be required for the assembly of 
capsids they have a strong association with the capsid. For example, gene products of the 
UL6, UL12.5, and UL15 have been shown to be resistant to extraction from capsids treated 
with 2M GdnHCl (Patel and MacLean, 1995; Bronstein et al., 1997; Salmon and Baines, 
1998). Similar treatment of purified B-capsids capsids by Newcomb et al., (1993) 
demonstrated that 2M GdnHCl could induce the disassociation of VP26 from the tips of 
the hexons, pentons from the 5-fold vertices and strip triplexes Ta and Tc. These minor 
capsid proteins are associated with the cleavage and packaging of viral DNA into the 
capsid (discussed in further detail in section 1.5.5 and summarised in table 1.5). Therefore, 
although these proteins are not required for the assembly of viral capsids their strong 
association to the capsid highlights the direct correlation between capsid assembly and the 
efficient cleavage and packaging of viral DNA.
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1.5 The HSV-1 lytic life cycle
The processes involved in the lytic reproduction of HSV-1, from initial infection through 
to the release of progeny virions resulting in cell death, are briefly discussed below and 
summarised schematically in fig. 1.7.
1.5.1 Attachment and entry o f HSV-1 into the cell
Attachment of HSV-1 virions to the cell surface and subsequent fusion requires a chain of 
events involving several of the 11 glycoproteins within the envelope of the HSV-1 virion 
(reviewed by Spear, 1993; Steven and Spear, 1997). Initial attachment of the virion to the 
cell is thought to involve the glycoproteins gC and/or gB binding to cell surface 
glycosaminoglycans (GAGS), preferentially heparan sulfate (Shieh and Spear, 1994). 
However, the initial attachment to GAGS is not sufficient for virus penetration (Lee and 
Fuller, 1993). Recently a group of receptors termed the herpesvirus entry mediators 
(HveA-D) have been implicated in the entry of herpesviruses into a number of cell types. 
However, the specificity of these receptors varies and they can be cell specific. For 
example, HveA is a member of the tumour necrosis factor receptor family and has been 
shown to be the principle receptor for HSV-1 within human lymphoid cells but will not 
support the entry of other a-herpesviruses such as PRV (Montgomery et al., 1996). HveB- 
D are related to the poliovirus receptor proteins which belong to the immunoglobulin 
superfamily. Both HveB and HveD have been shown to be specific entry mediators for a 
number of a-herpesvirus but do not support the entry of various strains of WT HSV-1. 
Conversely, HveC has been shown to be an entry mediator of HSV-1 and binds strongly to 
gD. It has also been shown to be an active entry mediator for a number of other a- 
herpesviruses, including HSV-2, PRV and BHV-1 (Geraghty et al., 1998; Krummenacher 
et al., 1998).
Following attachment fusion of the viral envelope with the host cell membrane occurs in a 
pH-independent manner and requires the presence of number of glycoproteins including 
gD, gB, and the gH-gL complex (Wittels and Spear, 1991; Spear, 1993).
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Fig. 1.7: Schematic overview of the lytic reproductive cycle ofHSV-1
(1-3) Virions bind to the cell surface, initially through cell surface glycosaminoglycans, and Hve 
receptor-mediated fusion occurs (discussed in section 1.5.1). (4) Following internalisation, tegument 
proteins are released into the cytoplasm (discussed in section 1.5.3) and the capsid is transported along 
microtubules to the nucleus (discussed in section 1.5.2). (5a-5c) Tegument proteins become localised, 
either to the nucleus where they stimulate viral transcription or remain within the cytoplasm where they 
restrict host protein synthesis (discussed in section 1.5.3 and 1.5.4). (6+7) Transported capsids dock at 
the nuclear pore where the viral DNA is released into the nucleus and circularises to form an episome. 
(8+9) The gene cascade begins with immediate early (IE) transcription. Transcripts move into the 
cytoplasm and become translated. IE gene products are transported into the nucleus where they activate 
early gene transcription and regulate IE gene transcription. (10-12b) Early gene transcription results in 
the production of proteins primarily involved in viral DNA replication (gene expression cascade is 
discussed in section 1.5.4). (13) DNA replication results in the production of long concatamers
(discussed in section 1.5.5). (14+15) Late gene expression predominantly results in the production of 
structural proteins (late gene expression discussed in section 1.5.4). (16a-16d) Membrane associated 
structural proteins, predominantly glycoproteins, become incorporated into the rough endoplasmic 
reticulum. Membrane proteins may then become modified by glycosylation and localise to both inner 
and outer nuclear membranes and the endoplasmic reticulum. Further modification occurs within the 
Golgi apparatus. Mature glycoproteins become transported to the plasma membrane. (17) Some late 
proteins, including capsid proteins, are transported to the nucleus. (18) Capsid assembly initiates 
(discussed in section 1.9 and 4.0) and DNA packaging occurs (discussed in section and 1.4.3.3 and 
1.5.6). (19) DNA containing capsids, in association with tegument proteins, acquire an envelope by 
budding through the inner nuclear membrane and pass into the lumen of the endoplasmic reticulum. The 
exact processes concerning virion egress remain unresolved and much debated. However, two popular 
theories exist regarding virion transport to the cell surface. Both the de-envelopment and luminal 
pathways are discussed in further detail in section 1.5.7. (19a-19c) Depicts the de-envelopment pathway. 
The enveloped virus fuses to the endoplasmic reticulum membrane and naked capsids and associated 
tegument proteins become released into the cytoplasm. Further accumulation of tegument proteins 
occurs within the cytoplasm before fusing with late Golgi compartments containing mature viral 
membrane associated proteins. (20a-20e) Depicts the luminal pathway. Enveloped virus is engulfed by 
a transport vesicle and delivered to the Golgi compartments. The precursor viral envelope proteins are 
processed in situ as part of the virion. In both cases the mature virion is then transported to the plasma 
membrane and released via exocytosis. (23) Progeny virions in the extracellular space can infect 
surrounding epithelial cells or neuronal cells where they may become transported to the sensory ganglia 
and establish a latent state of infection (discussed in section 1.6). Diagram reproduced from Flint et al.,
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1.5.2 Nucleocapsid transport.
The events following fusion of the viral envelope with the cell membrane are not 
particularly well defined but must involve the release of the nucleocapsid from the 
envelope and subsequent release of tegument proteins into the cytoplasm of the host cell. 
Once inside the cell the capsid is rapidly transported to the vicinity of the nucleus. Due to 
the high viscosity and the presence of steric obstacles within the cytoplasm, capsids cannot 
diffuse efficiently to the nucleus from the cell membrane. Within neurones transport 
occurs by retrograde transport along the axon from the presynaptic membrane to the 
nucleus (Lycke et al., 1988; Penfold et al., 1994). However, the transport mechanism 
within other cell types, particularly epithelial cells, is less well understood. Cytoskeletal 
assisted transport has recently been implicated in the transport of capsids from the 
periphery of cells to the nucleus (Sodeik et al., 1997). Capsids are thought to bind to 
cytoplasmic dynein, a microtubule-dependent motor protein. This binding is thought in 
part to be mediated by a virion protein encoded by UL34 (Ye et al., 2000). Capsids are 
then propelled along microtubules towards the nucleus by an unknown mechanism and in 
an ATP dependent manner. Once at the nucleus the capsid attaches to the nuclear pore 
and the DNA is released into the nucleus where it circularises into an episome (Tognon et 
al., 1981; Batterson et al., 1983; Ojala et al., 2000).
1.5.3 Disruption o f host cell protein synthesis
Uncoating of the virion following fusion of the viral envelope with the cell membrane 
results in the release of the tegument proteins into the cytoplasm of the host cell. Some of 
these proteins serve to stall host protein synthesis and accelerate the activation of viral 
gene transcription (reviewed by Roizman and Sears, 1996). The primary mechanism that 
initiates the shut-off of host protein synthesis during the initial stages of infection is 
regulated by the virion associated host shut-off (VHS) protein. The 53kDa VHS protein, 
encoded by the UL41 ORF, has been shown to degrade both cellular and viral mRNAs in a 
non-specific manner. Although viral mRNA is also degraded, its rate of synthesis is 
greater than that of VHS-induced degradation (Schek and Bachenheimer, 1985; Kwong 
and Frenkel, 1987; Kwong et al., 1988; Elgadi et al., 1999). However, it should be noted 
that VHS is not solely responsible for regulating host protein synthesis. The IE protein
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ICP27 and the UL13 protein kinase have also been shown to play roles in the regulation of 
host cell protein synthesis (Overton et al., 1994; Sandri-Goldin, 1998; Laurent et a l, 
1998).
1.5.4 HSV-1 gene expression
Transcription of the viral DNA within the nucleus of host cells is carried out by DNA 
dependent RNA polymerase II and occurs in a regulated cascade (reviewed by Roizman 
and Sears, 1996). There are three main groups of genes that have been classified according 
to their time of expression during the viral replication cycle. These are: immediate early 
(IE or a), early (E or p), and late (L or y) genes (Honess and Roizman, 1974).
Following initial infection, the tegument protein VP 16 (aTIF) together with the cellular 
transcription factor oct-1 (octamer DNA-binding protein) induce the expression of IE (a) 
proteins by binding to the upstream consensus a-promoter element ‘TATGARAT’. There 
are five gene products that are expressed within the IE cascade: ICPO (VmwllO), ICP4 
(Vmwl75), ICP22 (Vmw68), ICP27 (Vmw63), and ICP47 (Vmwl2). IE protein 
expression serves to transactivate early (P) gene expression, with IE protein synthesis 
peaking at 2-4 hours post-infection. The early genes primarily encode proteins that are 
generally required for DNA replication such as: DNA polymerase, single stranded DNA- 
binding protein (SSB or ICP8), DNA helicase-primase, and the origin binding protein. 
Early genes also include enzymes that are required for nucleotide metabolism and DNA 
repair. The synthesis of early genes can be detected as early as 3 hours post-infection and 
reaches a peak at 5-7 hours post-infection. Viral DNA synthesis commences shortly after 
the onset of early gene expression and continues up to 15 hours post-infection, with a peak 
between 7-10 hours post-infection. The regulated cascade of gene expression ends with 
the expression of late genes that generally encode structural proteins of the virion, such as 
the capsid proteins. Late genes can be subdivided into leaky late, such as VP5 encoded by 
UL19, and true late, such as VP 19c encoded by UL38. Leaky late genes are expressed in 
the absence of DNA although their expression is enhanced during DNA replication 
whereas true late genes are only expressed after the onset of DNA replication. Late gene 
expression peaks at 8-10 hours post-infection and persists for the remainder of the lytic 
cycle (Harris-Hamilton and Bachenheimer, 1985).
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1.5.5 DNA replication
As early as 30 minutes post-infection the input viral DNA reaches the nucleus where it 
forms a circular episome. Following early gene expression the replication of the viral 
DNA occurs at specific sites within the nucleus (Quinlan et al., 1984; de Bruyn Kops and 
Knipe, 1994; de Bruyn Kops et al., 1998). DNA replication is thought to be initiated by a 
theta mode of replication. However, at some point, by an unknown mechanism, theta 
replication switches to the rolling circle mode of DNA replication (reviewed by Lehman 
and Boehmer, 1999; Boehmer and Lehman, 1997). Seven HSV-1 genes are required for 
ori (origin of replication) dependent DNA replication. These genes are UL5, UL8, UL9, 
UL29, UL30, UL42, and UL52. Their properties are summarised in table 1.5.
Initiation of replication occurs at one of the three cis-acting elements within the HSV-1 
genome that function as origins of replication (ori). The origin binding protein (UL9) 
forms a homodimer and binds to specific sequences within the ori in association with the 
single stranded DNA binding protein ICP8 (UL29). Helicase activity associated with UL9, 
stimulated by the presence of ICP8, separates the two DNA strands permitting entry of the 
DNA polymerase complex (a heterodimer of UL30/UL40). DNA replication commences 
by a Theta mode of replication before switching to a rolling circle mode of replication and 
the addition of the DNA helicase-primase (primosome) complex comprising of a 1:1:1 
ratio of UL5/UL8/UL52 gene products respectively. DNA synthesis is continuous along 
one strand and discontinuous along the other strand. The progeny viral DNA accumulates 
as large concatemeric molecules at specific sites within the nucleus (de Bruyn Kops et al.,
1998). Other HSV-1 viral proteins important in DNA replication include those involved in 
nucleic acid metabolism, such as thymidine kinase (UL23), ribonucleotide reductase 
(UL39 and UL40) and dUTPase (UL50), and proteins which have been implicated in DNA 
repair, such as uracil DNA glcosylase (UL2) and alkaline exonuclease (UL12).
1.5.6 Packaging o f  progeny DNA
Cleavage and packaging of DNA into capsids are tightly linked processes and require 6 
essential gene products (UL6, UL15, UL25, UL28, UL32, and UL33). Although the exact 
role of these individual gene products has yet to be identified, their correlation to DNA
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Gene Approx. 
Mr (kDa)
Properties
UL5 98 Subunit of the primosome holoenzyme 
required for DNA helicase-primase activity
UL8 79 Stimulates primer synthesis. Subunit of the primosome 
holoenzyme required for DNA helicase-primase activity. 
Required for optimal DNA-helicase and DNA-dependent 
ATPase activity
UL9 94 Homodimeric origin binding protein, complexes with
UL29
UL29 128 Commonly refered to as ICP8. Binds single stranded 
DNA, increases helicase and DNA-dependent ATPase 
activity of UL9
UL30 136 DNA polymerase with exonuclease (3’—>5’) and RNaseH 
activity, forms a heterodimer with UL42
UL42 51 phosphoprotein with dsDNA binding activity, forms a 
heterodimer with UL30; increases processivity of UL30
UL52 114 Subunit of the primosome holoenzyme required for DNA 
helicase-primase activity, proposed divalent metal 
binding motif
Table 1.5: Summary of the essential HSV-1 DNA replication proteins. 
(Boehmer and Lehman, 1997; Lehman and Boehmer, 1999).
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cleavage and/or packaging has typically been characterised through the use of ts mutants 
(the properties of these gene products are summarised in table 1.6 and reviewed by Homa 
and Brown, 1997).
DNA replication results in the production of large, branched, head-to-tail concatamers of 
viral DNA (Zhang et al., 1994). The UL12 and UL12.5 genes encode alkaline nucleases, 
which although not essential for cleavage or packaging of viral DNA, aid the processing of 
branched DNA molecules prior to cleavage. Mutants that fail to produce an alkaline 
nuclease have been shown to reduce viral yield by 100- to 1000-fold (Martinez et al., 
1996; Bronstein et al., 1997).
Replicated DNA is packaged into the capsid and cleaved into unit length monomers at the 
novel a-a junction. This results in a single copy of the genome being packaged per 
capsids, with an “a ” sequence being present at each terminus of the DNA molecule 
(Mocarski and Roizman, 1982). The “a ” sequence therefore appears to act as a marker in 
order to determine when a full genome length has been package and should be cleaved. 
The cleavage of DNA is also dependent upon capsid formation as mutants that fail to 
express either the UL19 (VP5) or UL18 (VP23) capsid proteins appear to be unable to 
cleave concatemeric DNA (Desai et al., 1993). Indeed, several of the DNA packaging 
proteins have been shown to be strongly associated to capsids (summarised in table 1.6). 
The exact mechanism by which DNA enters the capsid has yet to be identified. However, 
the structure of the DNA within virions (discussed in section 1.3.3) would suggest that the 
DNA is packaged by a spooling mechanism forming coiled layers (Zhou et al., 1999). 
During infection the DNA is thought to be released from the capsid in a reverse process, 
whereby the DNA uncoils from the centre outwards (Zhou et al., 1999).
1.5.7 Tegument acquisition and virion egress
Following DNA packaging the capsid leaves the nucleus and acquires tegument and 
envelope layers before mature virions leave the cell via the exocytic pathway (reviewed by 
Rixon, 1993 and Steven and Spear, 1996). Although the exact mode of tegument and 
envelope acquisition is not known there are currently two popular models to describe this 
stage in the HSV-1 lytic reproductive cycle (schematically illustrated in fig. 1.6). One
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Gene Approx 
Mr (kDa)
Capsid
association
Function Reference(s)
UL6 74 YES Associated with DNA cleavage and 
packaging
Patel et al., (1996)
UL12 67.5 NO Alkaline nuclease thought to be 
involved in DNA processing prior to 
encapsidation
Shao et al., (1993); 
Goldstein and Weller (1998)
UL12.5 67.5 YES Capsid associated alkaline nuclease 
thought to be involved in DNA 
processing during packaging
Bronstein et al., (1997)
UL15 81 YES Associated with DNA cleavage and 
packaging. Homologous to 
bacteriophage T4 terminase. Transports 
UL28 to the nucleus
Yu and Weller (1998); 
Koslowski et al., (1999)
UL17 77 YES Associated with DNA cleavage and 
packaging
Goshima et al., (2000); 
Salmon et al., (1998)
UL25 62.5 YES Associated with DNA packaging McNab et al.,(1998)
UL28 85.5 YES Associated with DNA cleavage and 
packaging
Cavalcoli et al., (1993)
UL32 64 Unknown Associated with DNA cleavage and 
packaging
Lamberti and Weller (1998)
UL33 19 NO Associated with DNA cleavage and 
packaging
Reynolds et al., (2000); 
Patel et al., (1996)
Table 1.6: Summary of the HSV-1 DNA packaging proteins. Genes that are 
underlined are essential for DNA cleavage and/or DNA packaging
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model, the luminal pathway, proposes that the capsids acquire an envelope at the inner 
nuclear membrane, with subsequent modifications to the tegument and envelope 
glycoproteins proteins occurring as the virion exits the cell through the Golgi apparatus by 
the exocytic pathway (schematically illustrated in fig. 1.6, 20a-20e). The second model, 
the envelopment, deenvelpoment, and reenvelopment (EDR) pathway, proposes that 
capsids exiting the nucleus acquire an envelope by budding through the inner nuclear 
membrane into the perinuclear space. These membrane bound capsids are then 
deenveloped at the outer nuclear membrane and naked capsids are released into the 
cytoplasm. Capsids acquire a tegument on route to the Golgi apparatus where they are 
reenveloped and acquire membrane-associated proteins before exiting the cell via an 
exocytic pathway (schematically illustrated in fig. 1.6, 19a-19c). EM analysis of infected 
cells supports both models with enveloped capsids within cytoplasmic vesicles and naked 
capsids having been observed (Campadelli-Fiume et al., 1991; Steven and Spear, 1997).
However, recently there is a growing body of data to support the EDR pathway of virion 
egress. Van Genderen et al., (1994) demonstrated that the phospholipid composition of 
extracellular virions resembles that of membranes derived from the Golgi apparatus and 
plasma membranes as opposed to that of membranes derived from the nuclei of infected 
cells. However, the authors could not rule out that the lipids present within extracellular 
virions were not typical of those associated with the inner nuclear membrane, nor could 
they rule out that the phospholipid composition was modified during virion egress.
The most conclusive evidence for the EDR pathway comes from the use of recombinant 
HSV-1 viruses. HSV-1 mutants expressing modified forms of the glycoproteins gD and 
gH that carry an ER retention signal to localise these proteins to the inner nuclear 
membrane have been shown to produce non-infectious progeny virions. This therefore 
supports the theory of deenvelopment at the outer nuclear membrane, with the loss of 
glycoproteins gD and gH, and the reenvelopment at the Golgi apparatus. The envelopment 
of virus particles in the absence of gD and gH therefore results in the production of non- 
infectious progeny virions (Browne et al., 1996; Whiteley et al., 1999). Furthermore, it has 
been recently shown through time lapse confocal microscopy that the tegument protein 
VP22 does not enter the nucleus of cells during the course of HSV-1 lytic infection (Elliot 
and O’Hare, 1999). This led the authors to conclude that at least some of the tegument
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proteins are acquired within the cytoplasm during egress and providing further evidence to 
substantiate the EDR pathway.
1.6 Overview of HSV-1 latency
One of the unusual characteristics of all herpesviruses is their ability to establish a life­
long dormant or latent state of infection within the natural host. Sporadic reactivation of 
latent viral genomes can lead to recurrent lesions at the initial site of peripheral infection. 
The viral mechanisms involved in establishing and maintaining a latent state of infection 
have been, and still are, extensively studied and as such a detailed account is outside the 
remit of this general introduction into the HSV-1 life cycle. However, as latency is such 
an integral part of the viral life cycle a brief summary is given below (for detailed reviews 
see Preston, 2000; Wagner and Bloom, 1997; Steiner and Kennedy, 1995).
1.6.1 Definition o f latency
HSV-1 latency can be defined as the maintenance of viral genomes within the nuclei of 
infected cells without the production of virus particles. The genome is genetically 
equivalent to that present within the mature virus particle but the highly regulated cascade 
of gene expression (described above) does not occur. However, the virus genome retains 
the ability to reactivate and resume replication that can lead to the recurrence of disease.
1.6.2 Establishment o f latency
Following lytic replication at the site of peripheral infection HSV-1 enters the nerve 
termini and becomes transported intra-axonally to the sensory ganglia, frequently the 
trigeminal ganglia, by retrograde transport. Infected neurones can support viral 
replication. However, in most instances latency is soon established and the viral genome 
becomes sequestered in its non-replicative state within the nuclei of infected cells as a non­
integrated circular episome. There are estimated to be 10-100 copies of the viral genome 
per latently infected neurone. Although the exact mode in which viral genomes become 
suppressed is not known, the lack of certain viral factors, such as Vmw65 (ICP27), and the
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presence of cellular regulatory factors, such as the transcription factor Oct-2, have been 
implicated in the down regulation of viral gene expression (Lillycrop et al., 1993; Steiner 
and Kennedy, 1995).
1.6.3 Maintenance o f latency
During latent infection no viral gene expression associated with the lytic replication cycle 
can be detected. The only detectable gene expression is that of a major class of transcripts 
termed the latency associated transcripts (LATs), the major accumulative products of 
which are 2.0 and 1.5-1.4kb RNAs that are transcribed anti-sense to, and partially 
overlapping the coding sequences of VmwllO (ICPO). These are thought to represent 
stable non-polyadenylated introns cleaved from a longer 8.3kb precursor RNA which is in 
part complementary to the entire coding sequence of Vmwl 10 (Wagner and Bloom, 1997). 
The number of LATs varies, ranging between 40,000-100,000 copies per neurone, and 
their stability is thought to be attributed to their non-linear structure making them resistant 
to degradation (Rodahl and Haarr, 1997). The exact biological role of LATs remains 
unclear and much debated, as they appear to have a minimal effect upon the establishment 
and reactivation of viral genomes. However, a number of popular theories exist. For
example, Pemg et al., (2000) recently demonstrated through the use of a LAT mutant
HSV-1 virus (dLAT2903), that infected neurones were more susceptible to apoptosis than 
neurones infected with LAT+ HSV-1. Thus, Pemg and co-workers postulated that LATs 
promote neuronal survival following HSV-1 infection. LATs contain a number of ORFs 
suggesting that they could possible encode an as yet, unidentified viral protein. Thomas et 
al., (1999) demonstrated that the deregulated expression of the 2 kb LAT, both in neuronal 
and non-neuronal cells, promoted the growth of HSV-1 in a protein rather then an RNA 
specific manner. Therefore, the LAT may encode a tightly regulated viral protein, the 
expression of which although non-essential, could enhance the reactivation of latent HS V- 
1 genomes. Alternatively, as LATs are partially complementary to the Vmwl 10 ORF they 
may act as antisense inhibitors repressing genome expression and therefore maintaining 
latency, as VmwllO has been shown to specifically enhance IE gene expression and 
consequently viral replication (reviewed by Preston, 2000; Everett, 2000).
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1.6.4 Reactivation from latency
HSV-1 reactivation, as with other elements of HSV-1 latency, is not fully understood. 
Reactivation of latent HSV-1 genomes within humans can be induced by local stimuli, for 
example tissue damage to surrounding neurones harbouring latent genomes, and by 
systemic conditions, such as UV radiation, stress, and immunosuppression. With such a 
wide variety of stimuli inducing reactivation it appears likely that both viral and cellular 
factors are involved in triggering the onset of reactivation. Reactivation results in the 
production of infectious progeny virions without significant destruction of the host 
neurones (Gominak et al., 1990). Furthermore, repeated recurrences of reactivation of 
HSV-1 appear to have no deleterious effects upon the function or physiology of the 
trigeminal ganglia (Wagner and Bloom, 1997).
1.7 Capsid Structure
Capsid assembly plays an essential role in the life cycle of most viruses characterised to 
date. Successful formation of the capsid is fundamental in order to provide a robust 
structure that can enclose and thus protect the viral nucleic acid. Therefore, viruses have 
evolved specific assembly pathways to produce regular macromolecular structures that are 
capable of packaging their viral genomes. Furthermore, these intricate and comparatively 
large structures are produced in the context of a limited coding capacity. For example, 
herpesvirus capsids are composed of approximately 4000 proteins that become associated 
to form a structure of -1250A in diameter. The construction of this complex piece of 
protein architecture only requires the expression of 7 virally encoded genes (Tatman et al., 
1994; Thomsen et al., 19994; Steven and Spear, 1997). As the processes involved in the 
assembly of viral capsids become better understood, principally through developments in 
image processing and a better understanding of protein folding pathways, the analysis of 
capsid assembly is beginning to provide general insights into the assembly of large cellular 
macromolecular multiprotein complexes.
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1.7.1 Capsid architecture and the requirement for redundancy
Crick and Watson (1956) realised that small viruses lacked sufficient coding capacity 
within their nucleic acid genomes to encode a single asymmetric coat protein molecule 
large enough to surround and protect the viral genome. From this observation they 
deduced that virus capsids, both helical and icosahedral, were comprised of one or a small 
number of protein molecules organised in symmetrical arrays where an individual subunit 
would have specific bonding properties that were repeated exactly throughout the particle. 
The repetition of a single subunit within a capsid structure was termed redundancy. Their 
hypothesis holds true for helical viruses such as tobacco mosaic virus (TMV). The inter­
subunit connections within this capsid are essentially identical within the mature virion, 
with the exception of those subunits at the ends of the helical array which have unsatisfied 
bonding capacities. (Namba et al., 1989; Casjens, 1997). In relation to icosahedral 
viruses, Crick and Watson (1956) specifically proposed that these particles were composed 
of 60 subunits, where each subunit was identically bound to its neighbouring subunit. 
Although this theory holds true for small icosahedral capsids, such as satellite tobacco 
necrosis virus (STNV) which is composed of a single repeated polypeptide subunit, their 
theory could not account for icosahedral viruses which were observed to contain 
considerably more than 60 identical subunits.
1.7.2 Quasi-equivalence
Caspar and Klug (1962) subsequently suggested a hypothesis that circumvented this 
paradox. They postulated that if inter-subunit bonds could be “deformed” this would allow 
certain multiples of 60 subunits, termed the triangulation (T) number, to be incorporated 
into an icosahedral protein shell. T represents the total number of bonding differences a 
protein subunit would encounter within a single icosahedral face. The simplest 
icosahedron would therefore be created from 60 subunits (T=l) with 12 vertices, 20 
triangular facets, and 30 edges (see fig. 1.8). Caspar and Klug (1962) envisaged that 
within an icosahedral capsid where more than 60 identical subunits were used, subunits 
would be symmetrically inserted between the rings of five subunits (pentamers) at the 12 
vertices, as rings of six subunits (hexamers). Incorporation of pentamers at the 12- 
icosahedral vertices would therefore provide the curvature required, within a hexamer
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Fig. 1.8: Schematic diagram depicting triangulation symmetry
Following the theory of quasi-equivalence (Caspar and Klug, 1962) 
icosahedral capsids could be composed from multiples of 60 subunits 
by the insertion of hexons (represented by the red dots in b and c) 
between the pentons located at the 5-fold vertices. Where T would 
represent the total number of bonding differences a protein subunit 
would have to encounter within a icosahedral face. The simplest 
icosahedron (T=l) is composed of 60 subunits (a). (b) T=4
icosahedron would contain 240 (4x60) subunits via the insertion of 3 
hexons per icosahedral face, (c) T=16 icosahedron would contain 
960 subunits via the insertion of 12 hexons per icosahedral face. The 
global 5-, 3-, and 2-fold icosahedral axis of symmetry are 
highlighted in (c) by green circles.
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lattice, in order to form a closed spherical particle (see fig. 1.10, panel B). Thus, a T=4 
capsid would be composed of 240 (4x60) subunits where each subunit would have to take 
on 4 slightly different conformations within an icosahedral face. If the subunits assembled 
totally from hexamers then the surface lattice formed would be a flat sheet and would be 
unable to form a closed particle which could encapsidate nucleic acid. Caspar and Klug 
(1962) postulated that the individual protein molecules within a given subunit structure 
would have to display subtle differences in their bonding relationships, in order to form 
both hexons and pentons. The subtle non-equivalence in bonding capacity between 
individual protein molecules was subsequently labelled “quasi-equivalent” and defined as 
‘any small non-random variation in regular bonding pattern that leads to a more stable 
structure than does strictly equivalent bonding’ (Caspar and Klug, 1962; Johnson, 1996; 
Casjens, 1997; Johnson and Speir, 1997).
The general principles of quasi-equivalence have been applied to a number of virus 
structures that display icosahedral symmetry. A good example of quasi-equivalence is the 
core particle of blue tongue virus (BTV). The icosahedral BTV contains two layers, an 
outer layer, which is primarily involved in cell attachment and penetration, and a core layer 
that contains the segmented dsRNA genome (Mertens, et al., 1987). The 700A diameter 
core of BTV has recently been resolved to 3.5A by X-ray crystallography and has been 
shown to be segregated into a further two layers (Grimes et al., 1998). The outer core 
layer is composed of 780 copies of a single polypeptide (VP7) arranged in a lattice of 260 
essentially identical trimers. A single asymmetric unit comprises 13 VP7 molecules (T=13 
icosahedral symmetry) arranged into 5 quasi-equivalent trimers (P, Q, R, S, and T). The 
bonding interactions between these trimers follows the quasi-equivalent hypothesis put 
forward by Caspar and Klug (1962) and allows the outer core layer to form a robust 
structure. The size of the outer core layer is determined by the inner core (discussed below 
in section 1.7.1.5).
1.7.3 Departure from quasi-equivalence
The principle of quasi-equivalence put forward by Caspar and Klug (1962) showing how 
icosahedral viruses could be composed of more than 60 identical subunits, provides a 
convenient means by which capsid architecture can be described. However, increased
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structural data accumulated through X-ray crystallography and high-resolution electron 
microscopy analysis has challenged the universality of quasi-equivalence (Rossmann, 
1984; Casjens, 1997). Indeed, many capsid proteins demonstrate a remarkable ability to 
break the rules of geometrical symmetry, such that chemically identical subunits that 
occupy distinct lattice sites have significantly different conformational structures and 
bonding relationships.
1.7.4 Flexibility o f proteins within capsid structures
The breakdown in the principles of quasi-equivalence is dramatically highlighted within 
the icosahedral structure of polyoma virus. Low resolution X-ray crystallography of the 
polyoma virus capsid to 22.5k revealed that all the hexon positions were occupied by 
pentons thereby contradicting the rules of quasi-equivalence (Rayment et al, 1982). High- 
resolution structures of SV40 to 3.8A demonstrated that these pentamers, composed of 5 
copies of VP1, were inter-linked by their a-helical C-terminal arms which inserted into 
their adjacent pentamer subunits. The flexibility of these a-helical arms ensured the 
correct specificity of interaction with adjacent pentamers without requiring rigid capsomer 
geometry and strong symmetry restrictions (Liddington et al., 1991; Steven et al., 1997). 
The structure of papillomavirus, another member of the genus papovaviruses, has recently 
been solved to 9A and also demonstrates similar pentamer lattice arrangements and inter- 
pentameric connections (Trus et al., 1997). Although pentamers occupy both pentamer 
and hexamer positions within the icosahedral lattice, there are distinct conformational 
differences between the capsomers. In the centre of the hexavalent capsomers there is a 
25A hole that is occluded in the pentavalent capsomers. Both pentavalent and hexavalent 
capsomers are predominantly composed of LI protein but the occlusion of the hole in the 
pentavalent capsomers may be attributed to an additional protein mass from the minor 
capsid protein L2 (Trus et al., 1997). This would therefore suggest the LI protein exhibits 
conformational flexibility in order to accommodate the incorporation of the L2 protein into 
the pentavalent capsomer.
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1.7.5 Flexibility o f proteins within quasi-equivalent capsid structures
Even in those virus structures that display quasi-equivalence, flexibility between protein 
structures plays an essential role in virion assembly. This is particularly highlighted by the 
inner sub-core of BTV and the interactions it forms with the outer core. As previously 
discussed, the outer core of BTV forms a strictly quasi-equivalent T=13 icosahedral lattice 
(section 1.7.1.2). However, the inner core of BTV has been shown by X-ray 
crystallography to form a T=2 lattice (Grimes et al., 1998). This triangulation number 
should not occur under the rules of quasi-equivalence. However, the BTV inner subcore 
circumvents the rules of quasi-equivalence by forming a flexible, triangular shaped, 
elongated dimer, composed of two molecules of the same protein, designated VP3A and 
VP3B. Five of these dimers are arranged around the 5-fold rotational axis which bind 
together through different protein interfaces to form an intermediate decamer, with a total 
of 12 decamers forming the inner subcore. The conformational flexibility required for this 
arrangement is centred on an a-helix within the VP3 dimerisation domain. The modest 
pivoting provided by the a-helix and conformational differences within the loop regions of 
VP3A and VP3B allow the subunits to form close fitting interlocking decamers while still 
retaining a local two-fold symmetry axis (Grimes et al., 1998). Flexibility within the BTV 
virion is further highlighted by the interactions between the outer core composed of VP7 
trimers, and inner VP3 subcore. Due to the symmetry mismatch there are 13 different sets 
of contacts between the outer (T=13) and inner (T=2) cores. The polymerisation of trimers 
around the inner core is predominantly achieved through subtle alterations in the 
hydrophobic interactions between inner and outer cores. The flexibility in this protein- 
protein interface provides the outer core with a scaffold for assembly of the strict quasi­
equivalent T= 13 shell.
1.7.6 Symmetry mismatches in caps ids.
Although such large deviations from quasi-equivalence have only been highlighted 
comparatively recently due to the advances in high-resolution imaging. Breakdowns in 
symmetry and consequent divergences from quasi-equivalence have been observed for 
some time. The basic capsid shell often requires the addition of specific proteins to the 
outer capsid layer, which contribute important functional attributes that are essential in the
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production of infectious virions. However, addition of further structural proteins into the 
geometrical capsid lattice can introduce symmetry mismatch at the point of introduction, 
commonly the 5-fold symmetry axis, and therefore requires capsomer flexibility in order to 
be accommodated (Steven et al., 1997). Viruses that have been well documented to have 
such symmetry mismatches include bacteriophages, such as P22, A,, and T4, and 
adenovirus (Valpuesta, 1994; Hendrix, 1978; Steven et al., 1997). Bacteriophages have a 
tail spike that protrudes from one of the 12 pentonal vertices and is responsible for the 
attachment to and delivery of the viral nucleic acid into the new bacterial host. The 
adenovirus capsid has 12 fibres, approximately 120 to 330A in length, that project out 
from the 12 pentons at each 5-fold axis. These are responsible for receptor binding and 
internalisation within the host cell (Philipson et al., 1968). Both adenovirus and 
bacteriophage capsids have been shown to assemble in the absence of their fibres and tail 
spikes respectively. Although virion infectivity in both cases is greatly impaired the 
attachment of these structural proteins is non-essential for the assembly of their respective 
capsid structures (Falgout and Ketner, 1988; Bazinet and King, 1988). Since they are not 
themselves pentamers, incorporation of fibres and tail spikes into their capsid structures 
must cause alterations in the symmetry of the bonding relationships between their 
surrounding capsomers. Tail and fibre attachment must therefore require capsomer 
flexibility at the site of attachment for efficient incorporation without subsequent 
disruption of the surrounding capsomer bonding interfaces. Indeed, this has been 
demonstrated to occur within the penton base and fibre attachment of adenovirus capsids. 
Recombinant expression within the baculovirus system of the penton base from adenovirus 
type 3 (Ad3) in the absence of other capsid proteins leads to the production of 
dodecahedral particles. Cryo-EM and computer reconstruction analysis of these particles 
in the presence and absence of fibres demonstrates a remarkable difference in the 
conformation of the penton base structure in the presence of the fibre (Schoehn et al., 
1996). The conformational rearrangements observed are thought to be due to the 
movement of densities attributed to flexible loops within the penton base. The degree of 
individual capsomer flexibility involved in these examples, far exceeds the limited 
deformable interactions implied by the theory of quasi-equivalence.
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1.8 HSV-1 capsid structure
The HSV-1 capsid is one of the largest and most complex of virus icosahedral particles and 
as such there has been considerable interest in analysing its three dimensional structure. 
Through the use of EM the HSV-1 capsid has long been known to consist of 150 hexons 
and 12 pentons, arranged in T=16 icosahedral symmetry (Wildy et al., 1960; Furlong et al., 
1978). The overall structure of the HSV-1 capsid appears to be well conserved throughout 
the herpesvirus family. Similar structures have been identified from a wide variety of 
herpesviruses whose natural hosts span those from mammals, such as HSV-1 (Schrag et 
al., 1989), SCMV (Trus et al., 1999), and HCMV (Butcher et al., 1998), to fish, such as the 
channel catfish virus (Booy et al., 1996), and invertebrates, such as oyster herpes virus 
(personal communication, Andrew Davison 2000). Cryo-EM analysis in conjunction with 
three-dimensional computer image processing has provided the clearest detail of the native 
structure of the HSV-1 capsid (to date) to a resolution of 8.5A, see fig. 1.9 (Zhou et al., 
2000). The capsid shell, comprising outer, middle, and inner (or floor) areas, is 125nm in 
diameter and approximately 15nm thick. The outer shell is composed of protruding 
capsomers, 150 hexons and 12 pentons, that are interconnected in the middle area by 320 
triplexes. These capsomeric subunits associate to form a densely packed network, which 
makes up the 4nm thick inner or capsid floor area (Wildy et al., 1960; Schrag et al., 1989; 
Booy et al., 1991; Zhou et al., 1994; Zhou et al., 1998).
1.8.1 Asymmetric unit
The asymmetric unit is a single building block that contains all the structural information 
required to build a capsid. With respect to the HSV-1 capsid, each of the 20 icosahedral 
faces is composed of three asymmetric subunits consisting of one fifth of a penton, one P- 
hexon, one C-hexon, one-half of an E-hexon, one of each of the five triplexes Ta-Te 
triplexes, and one third of the triplex Tf (Zhou et al., 1994; Zhou et al., 1998). A single 
asymmetric unit is illustrated schematically in relation to a single icosahedral face in fig. 
1.10 (panel B).
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Fig. 1.9: 3D Surface reconstruction o f the HSV-1 B-capsid at 8.5A, 
generated by cryo-EM and image processing.
The outer shell o f the HSV-1 capsid consists o f 162 capsomers 
arranged around T=16 icosahedral symmetry. Out o f  the 162 
capsomers; 150 are hexons (coloured blue) and 12 are pentons 
(coloured red). The capsomers are interconnected by 320 triplexes 
(coloured green).
This figure was reproduced with permission from W. Chiu, Baylor 
College o f Medicine, USA.

Fig. 1.10: Asymmetric unit of the HSV-1 capsid
3D reconstruction to 13A resolution of the contiguous morphological 
components making up a single asymmetric unit from the HSV-1 B- 
capsid. Shown in (A) are one penton (coloured in yellow), one P- 
hexon (coloured in blue), one C-hexon (coloured in green), one E- 
hexon (coloured in pink), and the six different types of triplexes (Ta, 
Tb, Tc, Td, Te, and Tf (highlighted in various colours). The arrows 
indicate the positions of external attachment above the capsid floor 
between triplexes and their adjacent hexons and/or penton. (B) 
Schematic diagram of one triangular face of the HSV-1 capsid 
illustrating the interactions between the VP5 subunits from the penton 
and hexons (1-16) with their respective triplexes Ta-Tf. Subunits 
comprising a single asymmetric unit are highlighted in the same 
colours as for (A). The four types of interaction between the triplex 
and VP5 are represent by the thickness of line; strong triplex head 
connection (thick solid line), weak triplex head connection (thick 
dashed line), triplex tail connection (thin solid line), and triplex arm 
connection (thin dashed line).
This figure was reproduced with permission from W. Chiu, Baylor 
College of Medicine, USA.
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1.8.2 Protein composition o f  the capsomers
Although the icosahedral structure of the HSV-1 capsid has been established for some time 
(Wildy et al., 1960; Schrag et ah, 1989) the protein composition of capsomers has only 
been resolved comparatively recently. Two approaches, namely antibody labelling (Trus 
et ah, 1992) and systematic depletion of structural components from purified capsids 
(Newcomb and Brown, 1989; Newcomb and Brown, 1991; Newcomb et ah, 1993) have 
been employed. Newcomb and Brown (1989) originally demonstrated through the use 
argon (Ar+) etching that VP5, VP 19c, and VP23 were more readily disassociate from the 
capsid than VP21, VP24, and VP22a when purified B-capsids were exposed to low doses 
of ion plasma. From this they concluded that VP5, VP 19c, and VP23 were present on the 
outer surface of the capsid whereas VP21, VP24, and VP22a were more likely to be 
internal components of the capsid as they required longer periods of exposure to become 
disassociated. Similar depletion analysis utilising denaturants, such as urea and GdnHCl, 
in conjunction with cryo-EM and SDS-PAGE analysis have determined which proteins 
make up the various structures.
1.8.2.1 Pentons and hexons are composed o f  VP5
Trus et ah, (1992) demonstrated through cryo-EM analysis of immune precipitated capsids, 
utilising monoclonal antibodies against VP5, that both the pentons and hexons within the 
HSV-1 capsid were composed of VP5. The fact that the pentons as well as the hexons 
were composed of VP5 was consistent with the observation that VP5 was the MCP 
(Gibson and Roizman, 1972). Newcomb and Brown (1991) went on to demonstrate that 
the pentons could be disassociated when purified capsids were treated with 2M GdnHCl. 
Subsequent SDS-PAGE analysis confirmed the findings of Trus et ah, (1992) that indeed 
the pentons were composed of VP5. Quantitative analysis of showed that pentons were 
composed of five copies of VP5 (Newcomb et ah, 1993). However, high-resolution cryo- 
EM analysis has provided the best insight into the structural arrangement of VP5 within 
capsomers. Each penton can be readily observed to be composed of five copies of VP5 
that form a cylindrical tower 145A in diameter and 140A in height. A channel runs 
through the centre of the penton tower with a diameter of 50A. Each VP5 subunit within 
the penton is well separated from its neighbouring subunits (Zhou et ah, 1994; Zhou et ah,
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1998). In comparison, each hexon is composed of six copies of VP5 that are not as well 
separated as those within the penton. The incorporation of an additional VP5 subunit into 
the hexon also highlights the conformationally flexible nature of VP5 (discussed in further 
detail within section 1.8.4 and 4.0). The quasi-equivalent P (peripentonal), E (edge) and C 
(central) hexons, are similar but not identical in their overall conformation, reflecting their 
slightly different quasi-equivalent environments within the icosahedral face. Each hexon 
is cylindrical in shape with a diameter of 170A and a height of 140A. Located on top of 
each hexon is a horn shape density attributed VP26 (Trus et al., 1995, Zhou et al., 1995). 
The hexons, as with the pentons, have a channel running throughout their centre. 
However, unlike the channel within the penton, the hexon channel is constricted by a 
bundle of short a-helices (Zhou et al., 1994; Zhou et al., 2000; personal communication 
Frazer Rixon 2000). As VP5 is the MCP and contributes the entire mass of pentons and 
the majority of the mass of hexons it is not surprising that VP5 also comprises the majority 
of the mass within the capsid floor area. Here it is thought that the termini of the VP5 
molecules from individual capsomers form an intricate network of connections (Baker et 
al., 1990; Zhou et al., 2000).
1.8.2.2 Triplexes are heterotrimers o f VP 19c and VP23
Early negative stain EM analysis of capsids originally identified triplexes, initial termed 
fibrils, as a component of the capsid lattice, interconnecting adjacent capsomers (Vernon et 
al., 1974). Mirroring the early developments in cryo-EM analysis, low-resolution images 
of the capsid identified the triplexes as Y-shaped masses located at the 3-fold axes of 
symmetry interconnecting adjacent capsomers (Schrag et al., 1989; Baker et al., 1990; 
Booy et al., 1991). However, it has only been comparatively recently that the composition 
and the structural nature of the triplex has been identified. Newcomb et al., (1993) 
demonstrated that 2M GdnHCl treatment of purified capsids could disassociate triplexes 
surrounding the penton, namely triplexes Ta and Tc. Quantitative analysis of the proteins 
associated with the removal of these triplexes suggested that the triplexes were probably a 
heterotrimer comprising of one copy of VP 19c and two copies of VP23. Furthermore, 
high-resolution cryo-EM analysis of the capsid has subsequently demonstrated that most of 
the triplexes are asymmetrical, and not Y-shaped (Zhou et al., 1994; Zhou et al., 1998). 
There are a total of six different types of triplex (termed Ta-Tf) that contribute to a single
33
Triplex head
Triplex tail
(A)
.
—  —
)d
—  Triplex head
Triplex tail 
Triplex leg
Capsid floor
(B)
Fig. 1.11: 3D reconstruction of the HSV-1 triplex to 13 A.
Aerial view of an averaged triplex connecting two out of three 
surrounding hexons (A). Side view of a triplex connecting to 
an adjacent capsomer through protein densities in the head 
domain of the triplex attributed to VP 19c (B). Triplex leg and 
tail domains anchor the triplex to the capsid floor. Both (A) 
and (B) are coloured from light (yellow/high) to dark (red/low) 
representing their radial distance from the center of the capsid..
This figure was reproduced with permission from W. Chiu, 
Baylor College of Medicine, USA.
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asymmetric unit with a total of 16 triplexes within a single icosahedral face (see fig. 1.10). 
The extent of interaction between the triplexes and their surrounding capsomers varies and 
depends upon their position within the icosahedral lattice. For example, the head 
connection made by triplex Ta to the penton is significantly different to that of the head 
connections made by triplexes Tb-Te to their respective hexon capsomers (personal 
communication, Zhou, 1999). The exact nature of the interactions between triplex Tf and 
its surrounding hexons remains unresolved. Triplex Tf is located at the global 3-fold axis 
of symmetry (see fig. 1.10, panel B) and as a consequence image processing in conjunction 
with computer reconstructions makes it appear symmetrical. However, from triplexes Ta- 
Te four types of exterior triplex connections to surrounding VP5 capsomers have been 
shown to occur. These consist of strong and weak head connections, and tail and arm 
connections (Saad et al., 1999; Zhou et al., 1994; Zhou et al., 1998). The triplex is 
discussed in further detail within section 1.8.5 and section 4.0 in association with the 
findings presented within this thesis and other current published data.
1.8.2.3 VP2 6 is located on the tips o f the hexons
The location of VP26 within the capsid was initially suggested by comparison of penton 
and hexon subunits and through depletion analysis of purified capsids, in conjunction with 
cryo-EM (Zhou et al., 1994). Newcomb and Brown (1991) demonstrated that VP26 could 
be readily detached from purified capsids treated with either urea or GdnHCl. 
Subsequently, Booy et al., (1994) demonstrated by cryo-EM analysis of VP26 depleted and 
VP26 re-associated capsids that VP26 was specifically located to the tips of the hexons. 
Six copies of VP26 are thought to bind to each hexon and form a star-shaped ring at each 
hexon tip (Zhou et al., 1995; Wingfield, 1997).
1.8.3 Internal scaffold composition
Although the external characteristics of the HSV-1 capsid have been known for some time 
the internal core composition has only comparatively recently been resolved. As 
previously stated, Newcomb and Brown (1989) originally demonstrated through Ar+ 
etching of purified B-capsids that VP22a, VP21 and VP24 were relatively well protected 
from erosion by low intensity plasma. This led the authors to conclude that these proteins
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formed internal components of the capsid. Subsequent to this, cryo-EM comparison of A-, 
and B-capsids highlighted additional protein masses within the interior of B-capsids that 
correlated to the presence of internal core proteins (Baker et al., 1990). It is now known 
that the major internal scaffold component of B-capsids is VP22a, with over 1000 copies 
per capsid compared to VP21 and VP24, which are present in approximately 100 copies 
per capsid (Newcomb et al., 1993). The scaffold has been shown to exist in two forms 
within the interior of capsids. Large cored capsids, where the C-terminal 25 amino acids 
of either preVP22a and/or preVP21 have not been cleaved by the VP24 protease, or small 
cored capsids, where the C-terminal cleavage has taken place. Large cored capsids can be 
made using the baculovirus system by omitting the UL26 gene, encoding VP21 and the 
scaffold protease VP24 (Tatman et al., 1994; Thomsen et al., 1994). Temperature sensitive 
(to) mutants within the UL26 gene, such as til 201, that are defective in the processing of 
the UL26 into VP21 and VP24 at the non-permissive temperature also produce large cored 
capsids. Downshifting to 1201 infected cells to their permissive temperature results in the 
correct processing of UL26, and the production of small cored capsids (Preston et al., 
1983).
The interaction between preVP22a and VP5 has specifically been shown to occur through 
the C-terminal 25 amino acids and as such these residues are essential for capsid formation 
(Kennard et al., 1995; Matusick-Kumar et al., 1995; Hong et al., 1996). Cryo-EM has 
recently shown that the majority of the scaffold mass, either within large or small cored 
capsids, exhibits no icosahedral symmetry. However, some localised regions of the 
scaffold do appear to be icosahedrally arranged and form rod-like densities, approximately 
40A in length, protruding into the interior of the capsid. These densities appear to be 
located beneath the triplexes Tb, Tc, Td and Te and are thought to represent the positions at 
which the C-terminus of the scaffold interacts with capsid shell (Zhou et al., 1998).
Through baculovirus studies, the minor constituent scaffold protein, preVP21, has been 
shown to be able to substitute for preVP22a in the formation of capsids. However, the 
efficiency with which capsids were assembled was greatly impaired. Furthermore, larger 
numbers of aberrant shells were formed when compared to UL26.5 mediated assembly 
(Newcomb et al., 1993; Thomsen et al., 1994; Tatman et al., 1994). Sheaffer et al., (2000) 
went on to demonstrate that UL26 mediated capsid assembly, in the absence of UL26.5
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expression occurred without the increased incorporation of VP21 and VP24 into the 
capsid. This lead the authors to conclude that although preVP21 to preVP22a shared C- 
terminal sequence identity, capsid assembly could occur, although substantially less 
efficiently, on a minimal scaffold composed of VP21.
1.8.4 Quasi-equivalence within the HSV-1 capsid
As previously stated, VP5 comprises the entire mass of pentons (5 copies of VP5) and the 
majority of the mass of hexons (6 copies of VP5). Computational separation of VP5 
molecules from pentons and hexons demonstrates that the individual VP5 molecules have 
similar conformational arrangements that display overlapping mass densities (Zhou et al., 
1994). Although the exact bonding relationship between VP5 molecules within individual 
hexon and penton subunits remains unresolved at the current resolution, VP5 molecules 
clearly display similar interactions and therefore fit the criteria required by the theory of 
quasi-equivalence (Zhou et al., 1994; Zhou et al., 1998; Zhou et al., 2000; personal 
communication; Jing He, 2000; personal communication, Frazer Rixon). However, it 
should be noted that three distinct conformational differences have been identified between 
individual VP5 molecules from pentons and hexons. The most obvious is the presence of 
an additional horn shape density at the distal tip of VP5 from hexons attributed to VP26 
(Zhou et al., 1995). Hexons also contain an extra mass density in the middle domain of 
VP5, attributed to a bundle of seven short a-helices, which constricts the hexon channel 
(Zhou et al., 2000). Further differences in mass density can also be seen within the lower 
domains of VP5 molecules, in particular the predicted long N-terminal a-helix. 
Differences in the angle of this a-helix can be seen not only between VP5 molecules from 
pentons and hexons but also between VP5 molecules from the P, E and C hexons. Indeed, 
these quasi-equivalent hexons appear skewed in relation to each other, reflecting their 
slightly different locations within the icosahedral lattice (Zhou et al., 1994; Zhou et al., 
2000). Although subtle differences in the density masses do exist between the various 
quasi-equivalent hexons they typically display good 6-fold local symmetry throughout 
their structures, particularly in the tower regions which are highly conserved (personal 
communication, Jing He, 2000).
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1.8.5 The non-equivalence o f  triplexes
Triplexes occupy positions of local, and with respect to the triplex Tf> global, 3-fold 
symmetry. However, due to the apparent asymmetry of the triplex molecule, as 
determined by cryo-EM and computer reconstruction, and the heterotrimeric arrangement 
of this complex (2 copies of VP23:1 copy of VP 19c) it has been difficult to elucidate how 
this complex occupies a 3-fold symmetrical positions since rotation of a triplex around its 
axis would not result in equivalent interactions (Zhou et al., 1994; Zhou et al., 1998; Zhou 
et al., 2000). Furthermore, cryo-EM and computer reconstruction analysis of the HSV-1 
capsid has long since demonstrated that the triplexes Ta-Tf have slightly different degrees 
of interaction with their adjacent capsomers. The most significant different is that of 
triplex Ta compared to that of triplexes Tb-Te, (Zhou et al., 1994; Zhou et al., 1998). The 
variation in the degree of association between triplexes with pentons and hexons can also 
be detected biochemically possibly reflecting differences in their respective bonding 
interfaces. Newcomb et al., (1993) demonstrated that the peripentonal triplexes (Ta and 
Tc) were more readily disassociated from capsids treated with 2M GdnHCl than those 
triplexes surrounding adjacent hexons. Conway et al., (1993) demonstrated similar 
findings between perihexonal and peripentonal triplexes when capsids were treated with 
high doses of radiation.
Although the differences in bonding between triplexes with their surrounding capsomers, 
and their clear asymmetry, violate the rules of quasi-equivalence, analysis of the triplex 
connections to the capsid floor at 8.5A resolution has recently revealed how triplexes 
occupy a 3-fold rotational axis (Zhou et al., 2000). This is discussed in detail in section 
4.0 in relation to the results presented within this thesis.
1.8.6 Quasi-equivalence within the procapsids
During the assembly of HSV-1 capsids the initial assembly product is a transient 
intermediate termed the procapsid (discussed within section 1.9.3 and 1.9.4; Newcomb et 
al., 1996; Rixon and McNab, 1999; Newcomb et al., 1999; Newcomb et al., 2000). The 
procapsid is markedly rounder then the mature capsid and lacks the flat facets, angular 
edges, and vertices associated with the mature icosahedron (see fig. 1.13; Newcomb et al.,
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1996). The pentons and hexons within the procapsid are less compact than those of the 
mature capsid with individual VP5 subunits making little connection to each other or 
adjacent capsomers (Trus et al., 1996). Thus, although the capsomers are arranged on a 
T=16 icosahedral lattice, the general spherical and porous nature of the procapsid, in 
conjunction with the loose packing of individual capsomers, reflects a high degree of non­
equivalence within the procapsid. The non-equivalent nature of VP5 subunits within 
hexon capsomers of the procapsid, opposed to that of mature capsid, also makes procapsid 
hexons unable to bind VP26 (Newcomb et al., 1999). Thus, the high degree of non­
equivalence within the procapsid prevents the procapsid from fitting the criteria required 
by the theory of quasi-equivalence proposed by Caspar and Klug (1962).
1.9 Capsid assembly
Although the structure of the HSV-1 capsid has been extensively studied over a number of 
decades the mechanisms involved in the actual assembly of the capsid have only 
comparatively recently been examined. Developments in recombinant protein expression 
techniques, such as the baculovirus expression system, have provided a means by which 
the mechanisms involved in HSV-1 capsid assembly can be investigated. Utilising this 
approach the minimal protein components required for the assembly of HSV-1 capsids 
have been identified (discussed in section 1.9.2) and their structural locations within the 
capsid have been revealed (Tatman et al., 1994; Thomsen et al., 1994; Zhou et al., 1995). 
Furthermore, the assembly of HSV-1 capsids has been reconstituted in vitro using infected 
cell extracts and more recently from individual purified capsid protein components 
(Newcomb et al., 1994; Newcomb et al., 1996; Newcomb et al., 1999). Such recent 
developments have led to a better understanding of the protein-protein interactions 
associated with HSV-1 capsid assembly and of the protein folding pathways that are 
required to form such a large and architecturally complex structure.
1.9.1 Nuclear assembly o f  HSV-1 capsids
One of the defining characteristics of all herpesviruses is that DNA replication, capsid 
assembly and subsequent DNA packaging occur within the nucleus. This therefore,
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necessitates that HSV-1 capsid proteins translated within the cytoplasm must be 
transported to the nucleus. Immuofluorescent analysis performed by Nicholson et al, 
(1994) and Rixon et al., (1996) demonstrated how the major structural components of the 
capsid were localised to the nucleus. VP 19c and preVP22a were shown to be capable of 
localising to the nucleus independently, whereas VP5, VP23, and VP26 were unable to 
localise selectively to the nucleus. PreVP22a was shown to associate with VP5, whereas 
VP 19c could associate with either VP5 or VP23, and in turn localise these proteins to the 
nucleus. However, it was observed that VP26 did not localise to the nucleus when 
expressed with either preVP22a or VP19c. Co-expression of VP26 with VP5, and either 
VP 19c or preVP22a, did result in the nuclear localisation of VP26. This led the authors to 
conclude that VP26 binds directly to VP5 and subsequent interactions between VP5 and 
either VP 19c and/or preVP22a resulted in the efficient nuclear localisation of VP26. 
Furthermore, detailed analysis of capsid protein nuclear localisation utilising confocal 
microscopy has demonstrated that capsid assembly occurs at defined foci within the 
nucleus. This has led to suggestion that capsid assembly occurs at specific sites within the 
nucleus in close proximity to DNA replication compartments (Ward et al., 1996; de Bruyn 
Kops et al., 1998). The capsid protein interactions identified through their nuclear 
localisation capability are summarised in fig. 1.12.
1.9.2 HSV-1 capsid assembly analysis within insect cells
Comparatively recent advances in recombinant expression techniques have allowed the 
study of HSV-1 capsid protein interactions to be accomplished in greater detail than by 
electrophoretic and electron microscopy analysis alone. One approach that has been 
integral in the study of HSV-1 capsid assembly is that of the baculovirus expression 
system. Baculoviruses naturally infect arthropods and can be recombinantly manipulated 
to express single or multiple genes of interest within cultured insect cells. One of the most 
commonly utilised insect cell lines is that of Spodoptera frugiperda (SF). Infection of 
these cells with recombinant baculoviruses expressing gene(s) of interest under the strong 
late polyhedrin promoter results in high levels of protein expression. Tatman et al., (1994) 
and Thomsen et al., (1994) utilised the baculovirus expression system to analyse the 
requirement for HSV-1 gene products in the assembly of HSV-1 capsids. Capsid 
particles, resembling those of WT B-capsids, of normal composition and structure were
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Cytoplasm
N ucleus
preVP22a
Fig. 1.12: Diagram schematically illustrating the protein-protein
interactions within the HSV-1 capsid determined through the re­
localisation of HSV-1 capsid proteins from the cytoplasm to the 
nucleus (Nicholson et al., 1994; Rixon et al., 1996).
Introduction
produced by infecting insect cells with a panel of baculoviruses (designated Ac) expressing 
six capsid protein genes: AcUL19 (VP5), AcUL18 (VP23), AcUL38 (VP 19c), AcUL35 
(VP26), AcUL26 (VP21/VP24), and AcUL26.5 (preVP22a). Omission of AcUL35 
(VP26) had little effect on the production of capsids indicating that it is not required for the 
efficient formation of capsids. However, omission of either AcUL19 (VP5), AcUL18 
(VP23), or AcUL38 (VP 19c) prevented the formation of capsids.
These studies also demonstrated that capsid assembly was not prevented by the omission 
of either one of the scaffold protein genes, AcUL26 (VP21/VP24) or AcUL26.5 
(preVP22a). Therefore, the expression of preVP21 or preVP22a was sufficient to serve as 
a scaffold for the formation of capsids. However, omission of both scaffold protein genes 
prevented the formation of capsids leading instead to the formation of aberrant particles 
and curved capsid shells. Although co-infection with AcUL26 could support the assembly 
of capsids, in the absence UL26.5, the number of capsid produced was significantly lower 
than that of AcUL26.5 mediated assembly. This could possibly reflect the higher copy 
number incorporation of preVP22a, over 1000 copies per B-capsid, compared to that of 
preVP21, approximately 100 copies per B-capsid (Newcomb et al., 1993). Indeed, 
subsequent analysis into the specific incorporation of preVP21 into capsids during 
assembly was shown to be lower than that of preVP22a even in the presence of excess 
preVP21 protein. Thus, capsid formation can occur on a minimal scaffold but at reduced 
efficiency (Sheaffer et al., 2000). Expression of AcUL26.5 alone results in the production 
of large numbers of core-like structures indicating that preVP22a can self assemble in the 
absence of other capsid proteins (Newcomb and Brown, 1991; Preston et al., 1994). 
Gradient purified scaffold particles have been shown to be sufficient to act as scaffold 
material for the formation of capsid particles in vitro (personal communication, 
McClelland, 1999; Newcomb et al., 1999).
1.9.3 In vitro HSV-1 capsid assembly and procapsid formation
Recombinant expression of capsid proteins utilising the baculovirus system has led to the 
development of an in vitro based capsid assembly model. Newcomb et al., (1994) 
originally demonstrated through the mixing of lysed SF cell extracts, which had been 
individually infected with baculoviruses expressing VP5, VP 19c, VP23, and preVP22a,
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(A)
(B )  lOOnm
Fig. 1.13: EM analysis of negative stained in vitro formed procapsids 
and mature B-capsids
Purified capsid proteins VP5, triplexes (VP19cHis + VP23), and 
preVP22a were mixed and incubated at 28°C for either 1 hour (B) or o/n 
(A) before being immunoprecipitated with a VP5 monoclonal antibody 
(DM165). Pelleted capsids and related structures were subsequently 
analysed under negative staining by EM. Panel (A) demonstrates a 
typical field of view of in vitro assembled mature B-capsids. Capsomers 
can be readily identified in their icosahedral lattices. Panel (B) 
demonstrates a typical field of view of in vitro assembled procapsids. 
Capsids appear more spherical in nature with individual capsomers 
appearing less defined. Scale bar represents lOOnm.
This fig. was reproduced with permission from F. Rixon, MRC Virology 
Unit, Institute of Virology, Glasgow.
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that capsid formation could occur in vitro. EM analysis of extracts incubated o/n at 28°C 
demonstrated the presence of capsids that resembled WT capsids in their size, morphology 
(T=16), and presentation of specific surface epitopes to monoclonal antibodies. The in 
vitro formation of capsids was also shown to be cold sensitive with particle formation 
being inhibited when extracts were incubated at 4°C. Subsequently, Newcomb et al., 
(1996) went on to identify a series of intermediate capsid structures by immune 
precipitation of complexes from in vitro assembly-competent reaction mixtures in 
conjunction with EM analysis. Partial capsids, closed spherical particles (procapsids), and 
mature polyhedral capsids could be identified 1 min, 90 min, and 8 hours respectively after 
combined extract incubation. EM analysis revealed partial capsids as arc-shaped wedges 
with angles ranging from 30° to greater than 270°. These partial capsids were suggested to 
be precursors to procapsids as they were rarely identified in reactions incubated over 90 
min. Partial capsids consisted of an outer shell, composed of VP5, VP 19c, and VP23, 
surrounding a region of scaffold. Procapsids were the predominant assembly product 
following 90 minutes of incubation. EM analysis of procapsids revealed that they were 
highly uniform in morphology consisting of a round closed outer shell with identifiable 
capsomer protrusions (composed of VP5, VP 19c and VP23) surrounding a scaffold core 
(see fig. 1.13, panel B). Continued incubation of purified procapsids resulted in the 
production of mature, angularised, icosahedral particles (see fig. 1.13, panel A). This lead 
the authors to conclude that procapsids were indeed a true HSV-1 capsid assembly 
intermediate which does not require the association of further viral proteins to induce 
capsid maturation. Intriguingly, both partial capsids and procapsids disintegrated upon 
incubation at 2°C, whereas angularised particles resembling those of mature B-capsids 
appeared stable at 2°C. The cold sensitivity of these particles was consistent with other 
well documented dsDNA viruses which assembled through procapsid intermediates, such 
as T4 phage, and with earlier in vitro cell-free capsid assembly data (Steven et al., 1976; 
Newcomb et al., 1994). Newcomb and co-workers went on to propose a model for the 
assembly of HSV-1 capsids based upon their in vitro observations. Capsid assembly 
begins with the nuclear localisation of capsid proteins and the initial formation of partial 
arc-shaped capsids. These arcs grow in size by the addition of further capsomer subunits 
and triplexes until they form a closed spherical particle (procapsid). The procapsid then 
undergoes maturation to form a mature angularised polyhedral capsid. The stages in 
capsid assembly and morphogenesis are schematically depicted in fig. 1.14.
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Introduction
1.9.4 The structure o f  the procapsid
Cryo-EM analysis of procapsids to 27A performed by Trus et al., (1996) revealed that 
procapsids were indeed spherical, and not polyhedral as with mature HSV-1 capsids, 
consisting of 162 capsomers lying on a T=16 icosahedral lattice. A large number of 
differences could be visualised between procapsids and mature polyhedral capsids. The 
most evident is that procapsid were more open and porous than mature capsids, with 
relatively little contact between the VP5 subunits within either the pentons or hexons 
except at their bases. The axial channels are fully open in both pentons and hexons with 
individual capsomers having no direct contact with surrounding capsomers. The 
capsomers are held together principally through the triplexes located at the local 3-fold 
axis of symmetry which appear more trimeric than the triplexes within mature polyhedral 
capsids. Large gaps are also evident within the procapsid floor which are absent from 
mature polyhedral capsids, indicating that capsid floor development occurs during capsid 
maturation and not initial assembly (see fig. 1.15). The hexons varied slightly in size 
within the procapsid and were not 6-fold symmetrical, but formed distorted oval (E-, and 
P-hexons) and triangular shaped (C-hexons) capsomers. The structure of the procapsid 
and procapsid maturation is discussed further in section 4.0.
1.9.5 Identification o f  procapsids during HSV-1 infection
Initial in vitro observations that HSV-1 capsids assembled through a procapsid 
intermediate stage prompted analysis of HSV-1 infected cells to identify such an 
intermediate during the lytic reproductive cycle. Rixon and McNab (1999) demonstrated 
through the use of the HSV-1 ts mutant (tel201) that capsids at the non-permissive 
temperature were cold sensitive and disassembled upon incubation at 0°C in the same 
manner as in vitro formed procapsids (Newcomb et al., 1996). 7H201 contains a ts lesion 
within the UL26 protease responsible for maturational cleavage of scaffold proteins 
(Addison et al., 1984). Infection of cells with tel201 at the non-permissive temperature 
results in the production of large cored B-capsids (Bjx-capsids) containing uncleaved 
scaffold core. Downshifting tel201 Bu:-capsids to their permissive temperature results in 
the reactivation of the protease and subsequent cleavage of the scaffolding proteins. These 
particles can then go on to mature into A-, B-, and C-capsids, and finally mature virions if
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Fig. 1.15: Structural changes that accompany HSV-1 procapsid maturation
Cryo-EM reconstruction to 18 A of procapsids before (panels A and C) and 
after (panels B and D) maturation. Procapsids were isolated from m l00 
infected cells (see section 1.9.5 for details). The outer shell surface is 
shown in each instance. Panels A and B represent protein masses surround 
the E-hexon. Panels C and D represent protein masses surrounding the 
penton. In the left hand side of panels A and C the less ordered density 
represents the protein mass associated with the monoclonal antibody 
utilised in procapsid precipitation (computationally removed in the right 
hand side of panels A and C). Procapsids demonstrate a more open and 
porous nature compared to that of the mature capsid with little 
intercapsomer connections other then through the triplexes located at the 3- 
fold axis of symmetry. The floor of the capsid remains undefined within 
the procapsid compared to that of the mature capsid. Triplexes also appear 
more Y-shaped than in the mature capsid where they form their unique 
asymmetric connections between their respective hexon and penton 
capsomers (picture modified from Newcomb et al., 2000).
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the infection is left to proceed (Preston et a l, 1983; Addison et al., 1990). Downshifting 
BLc-capsids to their permissive temperature resulted in the loss of their cold sensitive 
phenotype in the same manner as those in vitro purified procapsids that were allowed to 
angularise. Through the use of HSV-1 tel 201 mutant Rixon and McNab (1999) concluded 
that the procapsid had a biologically relevant role within the virus life cycle. They also 
speculated that the cleavage of the scaffold may be directly responsible for procapsid 
maturation and that, as BLc-capsids capsids can mature into DNA containing C-capsids, 
DNA packaging may occur during the procapsid state. Newcomb et al., (1999) went on to 
isolate procapids from cells infected with a HSV-1 mutant wlOO, which was deficient in 
the protease, and a second HSV-1 mutant teProt.A, which (as with te l201) contained a 
reversible temperature sensitive lesion within the protease. Isolated procapsids were 
shown by cryo-EM to be indistinguishable from those procapsids assembled in vitro. 
Furthermore, isolated procapsids from teProt.A infected cells that were down shifted to 
their permissive temperature matured into polyhedral capsids identical to those isolated 
from WT HSV-1 infected cells.
1.9.6 Other capsid assembly models
Although the general principles in HSV-1 capsid assembly are now becoming better 
understood, the precise mechanisms involved in the folding of proteins during the 
assembly of HSV-1 capsids remains largely unknown. As the HSV-1 capsid structure is 
determined to higher resolutions the greater the number of discrepancies away from the 
predicted quasi-equivalence structure become identified. Indeed, if individual protein 
subunits within capsomers can interact with their neighbouring subunits in a number of 
different bonding configurations, as depicted by quasi-equivalence or non-equivalent 
bonding, then in principle a myriad of “incorrect” capsid related structures as well as the 
“correct” capsid structure should be formed. However, capsid assembly appears to be 
universally economical in the production of effective structures that can package viral 
nucleic acid during the course of a normal infection. It is becoming increasingly evident 
that capsid subunits undergo a series of folding transitions as they assemble and 
polymerise into their respective native structures. Indeed, procapsid formation in some 
instances represents a late stage along the capsid protein folding-assembly pathway. For 
example, during P22 procapsid maturation little change in the secondary structure of
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individual capsid protein subunits occurs but extensive changes in the packing of their 
respective side chains takes place upon maturation (Prevelige et al., 1993a; Tuma et al., 
1998). Therefore, individual protein subunits of P22 represent partially folded proteins 
that only achieve their “true” native conformation within the mature capsid particle. Some 
of the principles involved in protein folding are discussed below in relation to P22 capsid 
assembly, one of the most comprehensively studied dsDNA viruses, in order to introduce 
terminology discussed elsewhere within this thesis and to provide a more general 
understanding of other capsid assembly pathways.
1.9.7 P22 capsid assembly
The bacteriophage P22 is a dsDNA virus of Salmonella typhimurium (reviewed by 
Hendrix and Garcea, 1994; King and Chiu, 1997). The capsid assembly pathway of P22 
has been extensively studied and is generally regarded as the prototype for capsid 
assembly in dsDNA bacteriophages (summarised schematically in fig. 1.16). Furthermore, 
the mechanisms involved in the protein folding pathways of individual capsid proteins 
have also been extensively studied.
The mature capsid of P22 is composed of 60 hexamers and 12 pentamers and conforms to 
T=7 icosahedral symmetry. The capsomers are linked by connecting arms which form 7 
distinct intercapsomeric connections reflecting each of the T=7 quasi-equivalent 
environments (Prasad et al., 1993). The capsid has been shown to pass through a 
procapsid intermediate stage during which the scaffold core is removed and the viral 
dsDNA becomes packaged (Prevelige and King, 1993). The P22 procapsid is composed of 
420 47kDa coat protein subunits (gp5) surrounding a scaffold core of 300 34kDa subunits 
(gp8). Assembly initiates around the portal complex, composed of 12 copies of the 90kDa 
portal protein (gpl), located on an eventual 5-fold axis of symmetry. Following procapsid 
assembly additional minor capsid proteins attach to the capsid, including gp l6, gp20, and 
gp7, which are required for the injection of the viral DNA into the new host following 
attachment. However, these proteins, and the portal complex, are dispensable for capsid 
assembly in vitro (Fuller and King, 1982; Prevelige et al., 1988; Prevelige et al., 1993a). 
The P22 procapsid, like the HSV-1 procapsid (described above), is spherical and contains 
holes at the 6-fold axes that are absent within the mature P22 capsid (Prasad et al., 1993;
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M a t u r e  Tail  At t achment  
P h a g e
Fig. 1.16: Schematic illustration of the capsid assembly pathway o f  
the bacteriophage P22
Assembly initiates by multiple copies of the coat protein (gp5) and 
scaffold protein (gp8) locating around the portal complex (composed 
o f  12 copies o f  gpl). Further polymerisation o f  the capsid shell 
continues by subsequent addition of coat proteins surrounding a 
scaffold core until a closed spherical particle, the procapsid, is formed 
with T=7 icosahedral symmetry. Addition pilot proteins (g p l6, gp20, 
and gp7) are subsequently added and the scaffold protein is released 
through holes in the procapsid structure. Scaffold proteins can be 
utilised for future rounds of assembly. The dsDNA is packaged into 
the procapsid and the portal closed by the addition of  gp4, gp 10, and 
gp26. The procapsid subsequently undergoes maturation and 
expansion increasing in diameter by -10%  and becoming more 
polyhedral. Tail attachment represents the final stage in assembly. 
Diagram reproduced from Zhang et al., (2000).
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Zhang et al., 2000). The capsomers appear skewed in comparison to their larger and more 
regular mature form. The holes are thought to be the sites at which the internal scaffold 
protein exits the procapsid prior to or during maturation (Greene and King, 1994). 
Maturation is thought to be initiated by the packaging of the DNA genome through the 
portal complex and results in a 10% expansion in the total volume of the capsid in an ATP 
dependent manner (Eamshaw and Casjens, 1980; Galisteo and King, 1993). However, 
scaffold release can be triggered in vitro by treating procapsids with low concentrations of 
denaturants or by mild heating (Fuller and King, 1981; Prevelige et al., 1988; Galisteo and 
King, 1993). During maturation the most extensive conformational transformations to 
occur are around the trimer clusters, termed the trimer tips, located at the strict 3-fold axes 
on the procapsid inner surface. The trimer tips have been shown to be the positions at 
which the scaffold binds on the inner surface of the procapsid. As a consequence this 
implicates the scaffold protein not only in the assembly of the P22 capsids but also directly 
in the maturation of the capsid during DNA packaging (Zhang et al., 2000).
Interestingly, unlike HSV-1, the scaffold of P22 does not undergo any proteolytic cleavage 
and can therefore go on to aid the assembly of other P22 procapsids following its release 
(King and Casjens, 1974). The efficient release of scaffold proteins from the interior of the 
procapsid is thought to be due to its flexible nature (Tuma and Thomas, 1997).
1.9.8 The molten globule-like characteristics o f the P22 scaffold protein (gp8)
Recent characterisation of gp8 by Tuma and Thomas (1997) demonstrated that the scaffold 
protein contains a high degree of a-helical secondary structure but contains little 
measurable tertiary structure. Such characteristics are indicative of molten globule 
proteins, proteins that are in a intermediate stage of protein folding. The concept of molten 
globular proteins was originally introduced to describe equilibrium intermediates in protein 
folding pathways (reviewed by Ptitsyn, 1995a; Privalov, 1996). Molten globular proteins 
usually have a relatively compact and near native conformation, with much of their 
secondary structural features, in particular a-helices, having been formed. However, 
molten globules typically contain little defined tertiary structure due to an absence in the 
packing of amino acid side chains and terminal loops. Such folding characteristics give
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Native state Molten-globule state
Fig. 1.17: Diagrammatic representation o f  a molten-globule state.
The molten globule contains the overall structural features of its 
native state, in particular secondary structural elements such as a -  
helices (represented by shaded cylinders), but lacks tertiary 
structural features through the looser packing of amino acid side 
chains (represented by shaded blocks) and greater mobility of 
loops and ends of protein chains (represented by shaded lines). 
Diagram reproduced from Ptitsyn (1995).
Introduction
these proteins a large amount of domain flexibility (the molten globule-like state is 
schematically illustrated in fig. 1.17).
The native molten globule-like character of gp8 is likely therefore to play a fundamental 
role in the scaffold exit from procapsids, since an elongated and flexible gp8 molecule 
could exit through the 25A holes present at the 6-fold axes of symmetry. The lack of a 
rigid tertiary core would therefore make exiting these holes relatively easy. The 
interaction between the highly a-helical structure of gp8 is thought to be stabilised by the 
highly (3-stranded nature of the gp5 coat protein. Their interaction stabilises the a-helical 
nature of gp8, and provides sufficient structure to form the procapsid shell (Tuma and 
Thomas, 1997). The onset of DNA packaging is thought to disrupt this balance causing 
the scaffold protein to exit the procapsid shell resulting in the initiation of maturation.
The molten globule-like nature of other proteins are discussed in relation to the findings 
within this thesis in sections 3.0 and 4.0.
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Chapter 2 
Materials & Methods
Materials: 2.1
2.1 Materials
2.1.1 Chemicals
Chemicals and reagents used for EM analysis were purchased from either Agar Aids or 
TAAB laboratories. All other chemicals and reagents were purchased from either Sigma 
Chemical Company or BDH chemicals UK unless otherwise stated below or in subsequent 
sections:
Chemical 
Acetic acid
Ammonium hydroxide 
Ampacillin
APS (ammonium persulphate)
Butanol
Chloroform
Citifluor
Complete Protease Inhibitors 
Coomassie Brilliant Blue 
DMSO (dimethyl sulphoxide) 
dNTPs 
ECL
Ethanol (ultra pure)
Formaldehyde and formamide 
Glacial acetic acid 
Gluteraldehyde 
Glycerol
Hydrochloric acid 
IPTG
Isopropanol
Methanol
Nitro-cellulose membrane 
Octyl-P-glucoside 
Rainbow Markers™
S.O.C.
TEMED (N,N,N ’ ,N ’ -tetramethylethylene)
Supplier 
Rhone-poulenc Ltd 
Fisons
Beecham Research Laboratories Ltd
Aldrich
Prolabo
May and Baker Ltd 
Citifluor Ltd 
Boehringer Mannheim 
Aldrich
Koch-Light Laboratories Ltd 
Pharmacia
Amersham Pharmacia Biotech UK Ltd
Joseph Mills Ltd
Fluka
Prolabo
Agar Scientific Ltd 
Prolabo
Rhone-poulenc Ltd
Gibco-BRL
Prolabo
Joseph Mills Ltd
Hybond
Pierce
Amersham Pharmacia Biotech UK Ltd
Gibco-BRL
Aldrich
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• Radiochemicals
Chemical Supplier
[35S]-L-methionine (lOpCi/pl) Amersham
2.1.2 Enzymes
All enzymes and their appropriate buffers were purchased either from Boehringer
Mannheim, Gibco-BRL, or New England Biolabs (NEB).
2.1.3 Oligonucleotides
All oligonucleotides were synthesised in house (MRC Institute of Virology, Glasgow) by
D. McNab or A. Orr on a Biosearch 8600 DNA synthesiser.
2.1.4 Tissue culture
• Spodoptera frugiperda 21 (SF21) insect cells were derived from Ovarian tissue 
(Vaughn et al., 1977). SF21 cells were cultured in TCI00/5 medium which consists of 
TCI00 medium (Gibco/BRL) supplemented with 5% foetal calf serum (FCS) 
(Gibco/BRL) and 1% P/S (1000 units/ml penicillin, lOmg/ml streptomycin) 
(Gibco/BRL).
• Baby hamster kidney-21 C13 (BHK-21 C l3) fibroblast cells were derived from baby 
hamster’s kidney (MacPherson and Stoker, 1962). BHK-21 C13 cells were cultured in 
ETC/10 medium which consists of Glasgow-modified Eagles medium (GMEM) 
(Gibco-BRL) supplemented with 10% (v/v) tryptose phosphate broth, 10% newborn 
calf serum (NCS) (Gibco-BRL) and 1% P/S.
Variation: EMC/10 -  Eagles medium containing 1% carboxymethyl cellulose 
and 10%NCS
• Vero cells were derived from African green monkey’s kidney. Vero cells were grown 
in MEM/10 medium which consists of Dulbecco’s modified Eagle’s medium (DMEM)
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(Gibco-BRL) supplemented with 10% FCS and 1% P/S. G5-11 cells (UL18 
complementing Vero cell line) was a kind gift from P. Desai (Desai et al., 1993). G5- 
11 cells were grown in MEM/10.
2.1.5 Viruses
• Baculoviruses: Autographica californica nuclear polyhedrosis virus (AcNPV) and a 
polyhedrin negative derivative which has a lacL gene under the control of the 
polyhedrin promoter (AcPAK6) were both gifts to the MRC Institute of Virology 
(Glasgow) from R. Possee.
• HSV-1 UL18 null mutant virus (K23Z) was a kind gift from P. Desai (Desai et al, 
1993).
2.1.6 Bacterial culture medium
All bacteria were cultured using Lauria-Bertani medium (LB) described below: 
Medium Composition
L-Broth (pH7.5): 10g/l NaCl, 10g/l bactopeptone, 5g/l yeast extract
L-Broth agar L-Broth + 1.5% agar
Supplemented antibiotics: Ampicillin (50pg/ml), Kanamycin (25pg/ml)
2.1.7 Bacteria
• E.coli BL21 (DE3) pLysS: Commercially available bacterial cells (Promega) used for 
protein expression vectors under the control of the T7 promoter, for example pET28a.
• E.coli DH5a: Used for the maintenance and propagation of plasmid DNA.
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• E.coli CJ236 duf ung: Commercially available bacteria (New England Biolabs) used 
in site directed mutagenesis to produce uracil enriched ssDNA plasmid DNA (Kunkel 
et al., 1985).
• E.coli GM48 dam' dcm'\ Commercially available bacterial cells (New England 
Biolabs) used in the preparation of unmethylated DNA.
2.1.8 Yeast culture medium
Yeast were cultured using either YPD medium or synthetic dropout (SD) medium 
(Clontech) supplemented with the appropriate 10X dropout (DO) amino acid powder mix 
(Clontech) described below:
Medium Composition
YPD (pH5.8) 20g/L Bacto peptone (Difco) + lOg/L Yeast extract (Difco),
2.1.9 Yeast
• MaV103: Yeast strain used in all experiments, characterised in section 3.1. Gift from
M. Vidal (Vidal et al., 1996a).
• MaV103pPc97UL38: MaV103 cells transformed and propagated with the pPc97 GAL4 
DB fusion vector containing UL38. Used in the selection of FOA resistant colonies.
YPD agar 
SD
SD agar
1 OX DO supplement:
20g/L Dextrose 
YPD + 20g/L agar
26.7 g/L Minimal SD base + DO (Clontech)
46.7g/L Minimal SD agar base + DO (Clontech) 
-Leu (0.69g/L), -Trp (0.74g/L), -Leul-Trp (0.64g/L), 
-Leu/-Trp/-Ura (0.62g/L) (Clontech)
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2.1.10 Plasmids
• pAcAB3: Commercially available (Pharmingen) baculovirus transfer vector
• pCMVio: Transient expression plasmid containing the immediate early promoter of 
HCMV and the RNA processing signals of SV40 (Stow et al., 1993).
• pET28a(+): Commercially available expression plasmid (Novagen) containing T7 
RNA polymerase promoter.
• pPc86: Yeast expression plasmid containing a GAL4 activation domain (AD) 
downstream of the multicloning site. Gift from M. Vidal (Chevray and Nathans, 
1992).
• pPc97: Yeast expression vector containing a GAL4 DNA binding (DB) domain 
downstream of the multicloning site. Gift from M. Vidal (Vidal et al., 1996a).
2.1.11 Antibodies
• Penta His antibody: Commercially available (Qiagen) mouse monoclonal antibody 
used against 6xHis epitope tagged proteins.
• 187: Rabbit polyclonal antibody used against VP23 protein in HSV-1, gene product of 
UL18. Gift from David McClelland.
• TrpE/VP19c: Rabbit polyclonal antibody used against VP 19c protein in HSV-1, gene 
product of UL38. Antibody produced against TrpE- VP 19c fusion peptides. Gift from 
W. Wold (Yei et al., 1990).
• GAM-HRP: Commercially available (Sigma) goat anti-mouse conjugated to horse 
radish peroxidase used in Western blots.
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• FITC-GAM: Commercially available (Sigma) goat anti-mouse antibody conjugated to 
fluoroscein isothiocyanite used in immunofluorescence studies.
• Cy3-GAR: Commercially available (Amersham Pharmacia Biotech) goat anti-rabbit 
antibody conjugated to Cy3 used in immunofluorescence studies.
2.1.11 Buffer and solutions
Some of the commonly used buffers and solutions are detailed below:
• Commonly used buffers:
Buffer/Solution Composition
PBSa/T
PBSa/TN
PBScomplete
PBSa 170mM NaCl, 3.4mM KC1, 10mM Na2H P04, 
1.8mM KH2P 04 (pH7.2)
PBSa + 6.8 mM CaCl2, 4.9mM MgCl2 
PBSa, 0.05% Tween-20 
PBSa/T, 5% NCS (Gibco-BRL)
• DNA manipulation: 
Buffer/Solution 
Phenol/chloroform (1:1)
Composition
Mixed phenol/chloroform (1:1) saturated with 
lOmM Tris (pH8.0)
25mM Tris (pH8.0), lOmM EDTA, 50mM glucose 
0.2M NaOH, 1% SDS
150mM NaCl, 15mM trisodium citrate (pH7.5), 
40% sucrose, 0.25% bromophenol blue,
0.25% xylene cyanol
89mM Tris (pH8.0), 89mM boric acid, 2mM EDTA 
20mM Tris (pH7.5), 0.5M NaCl, ImM EDTA 
200mM Tris (pH8.0), 50mM MgCl2
Solution 1
Solution 2 
Solution 3 
Loading buffer
TBE
TAE
TM buffer
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• Yeast solutions: 
Buffer/Solution 
10X TE
10X Li Ac 
50% PEG 4000 
IX TE/LiAc 
PEG/LiAc/TE solution 
Z-buffer
X-gal (20mg/ml) stock 
Z buffer/X-gal Solution
Yeast plasmid lysis solution
TCA buffer
• Tissue culture: 
Buffer/Solution 
TBS
Trypsin
Versene
• SDS-PAGE: 
Buffer/Solution 
BM
RGB
SGB
Tank buffer
Coomassie Brilliant Blue 
Destain
Composition
lOOmM Tris-HCl, lOmM EDTA (pH7.5)
1M lithium acetate
50g PEG 4000 per 100ml of dH20
1:10 dilution of 1 OX TE + 1 OX LiAc
8:1:1 mix of 50% PEG 4000:1 OX LiAc: 1 OX TE
8.52g/L Na2HP04, 5.5g/L NaH2P 0 4, 0.75g/l KC1,
0.246g/L MgS04 (pH7.0).
lOOmg of X-gal made up in 5ml DMSO
100ml Z-buffer, 0.27% P-mercaptoethanol,
1.67ml X-gal stock solution
2% Triton X-100, 1% SDS, lOOmM NaCl,
lOmM Tris-HCl (pH8.0), ImM EDTA
20mM Tris-HCl (pH8.0), 50mM Ammonium acetate,
2mM EDTA
Composition
20mM Tris-HCl (pH7.5), 500mM NaCl 
TBS, 0.25% (w/v) trypsin, 0.0002% phenol red 
PBSa, 600mM EDTA, 0.0002% phenol red
Composition
40% SGB, 10% glycerol, 4.75% p-marcaptoethanol, 
2% SDS, 0.01% bromophenol blue 
0.74M Tris-HCl (pH8.0), 1% SDS 
0.122M Tris-HCl (pH6.7), 0.1% SDS 
52mM Tris, 53mM glycine, 0.1% SDS 
Methanol:H20:acetic acid (50:880:70),
0.2% Coomassie Brilliant Blue R250 
Methanol:H20:acetic acid (50:880:70)
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• Western blotting: 
Buffer/Solution 
Transfer buffer 
Stripping buffer
PBS/T
Blocking buffer
Composition
40mM Tris, 48mM glycine, 20% methanol, 0.4% SDS 
lOOmM P-mercaptoethanol, 2% SDS,
62.5 mM Tris pH6.7 
PBSa, 0.05% Tween-20 
PBS/T, 5% Marvel milk powder
• Common purification buffers: 
Buffer/Solution Composition
Sonication buffer 
G-150 buffer 
Buffer O
Buffer OL 
Buffer OG 
Buffer P
20mM Tris, 10% glycerol, 0.1% NP40
20mM Tris (pH8.0), 150mM NaCl, 0.1% Tween-20
150mM Na2HP04 (pH7.5), 0.1% glycerol,
0.1% Octyl-13-glucoside
Buffer O, 0.1% NP40, 150mM NaCl
Buffer O, 5% glycerol
20mM Na2HP04 (pH7.5), 0.004% NP40
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2.2 Methods
2.2.1 Recombinant DNA manipulation
2.2.1.1 Preparation o f  electrocompetent bacteria
50ml of pre-warmed L-broth was inoculated with approximately lOpil of a glycerol stock 
of DH5a or BL21 DE3 bacteria and incubated o/n in an orbital shaker at 37°C. This 50ml 
starter culture was used to inoculate 1 litre of pre-warmed L-broth media in a 2 litre flask 
and incubated at 37°C in an orbital shaker until the OD630nm reached 0.5-0.6. The culture 
was transferred to the appropriate number of pre-chilled 250ml Falcon tubes and allowed 
to chill on ice for 5 minutes. Bacteria were pelleted by centrifugation at 3500 r.p.m. for 15 
minutes at 4°C in a Sorvall RT7 centrifuge. The supernatant was removed and the 
individual bacterial pellets were resuspended in ice-cold dFLO to a final volume of 160ml 
before being pelleted by centrifugation (as described above). The supernatant was 
removed and the individual bacterial pellets were combined by progressive resuspension in 
ice-cold dE^O to a final volume of 500ml. Bacteria were pelleted (as described above), the 
supernatant removed, and the pellet resuspended in 40ml of ice-cold dFLO containing 10% 
sterile glycerol. The culture was transferred to a pre-chilled 50ml (SS-34) tube and the 
bacteria pelleted at 6,000 r.p.m. for 15 minutes at 4°C in a Sorvall SS-34 rotor. The 
supernatant was removed and the pellet resuspended in 2ml of ice-cold dFLO containing 
10% sterile glycerol, aliquoted (80pl) into pre-chilled 1.5ml reaction vials and frozen on 
dry ice before being stored at -70°C.
2.2.1.2 Transformation o f  electrocompetent bacteria
Typically 1-3 pi of DNA was mixed with approximately 80pl of electrocompetent bacteria 
and electroporated using a Hybond cell shock electroporator (following the manufacturers 
guidelines) in a 0.1cm gene pulser® cuvette (Bio-Rad). Following electroporation the 
bacteria were resuspended in 1ml of ultrapure S.O.C. medium (Gibco-BRL), and incubated 
a 37°C for 45 minutes in an orbital shaker. 50-200pl of this culture was plated out onto an
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L-Broth agar plate containing the appropriate antibiotic and incubated o/n at 37°C. Single 
colonies were used to generate starter cultures.
2.2.1.3 Glycerol stock preparation
For long term storage of bacteria containing recombinant plasmids, 1.5ml of a bacterial 
starter culture was centrifuged at 6,500 r.p.m. for 1 min at RT in a microfuge. The culture 
supernatant was removed and the cell pellet was resuspended in 1ml of a sterile mixture 
consisting of 80% glycerol and 20% bactopeptone. Glycerol stock cultures were 
subsequently frozen on dry ice and stored at -70°C.
2.2.1.4 Small scale plasmid DNA isolation
Small scale DNA preparations were performed using the alkaline lysis method (described 
by Maniatis et al., 1982). Briefly, 1.5ml of bacterial starter culture, grown from a single 
bacterial colony, was centrifuged at 6,500 r.p.m. for 1 minute at RT in a microfuge. The 
culture supernatant was removed and the cell pellet was resuspended in lOOpl of ice-cold 
solution 1 (see Materials for solution details) and incubated for 5 minutes at RT. 200pl of 
freshly prepared solution 2 was added to the mixture and briefly vortexed before 150pl of 
ice-cold solution 3 was added. The mixture was briefly vortexed and incubated on ice for 
5 minutes. The resulting white precipitate, consisting of cell debris, was pelleted by 
centrifugation at 14,000 r.p.m. for 5 minutes at RT in a microfuge. The supernatant was 
removed and the DNA recovered by phenol/chloroform extraction and ethanol 
precipitation (described below). DNA pellets were typically resuspended in 30pl of dt^O 
containing lOpg/ml ofRNaseA.
2.2.1.5 Phenol/chloroform extraction and ethanol precipitation o f  DNA
If the volume of the original DNA solution was <200pl then the volume was brought up to 
200pl by the addition of dt^O. An equal volume of phenol/chloroform (1:1) was added to 
the DNA solution and briefly vortexed before being centrifuged at 13,000 r.p.m. for 5 
minutes at RT in a microfuge and the upper aqueous phase removed. If the aqueous phase 
appeared cloudy then the phenol/chloroform extraction was repeated until the aqueous
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phase appeared clear. The DNA was precipitate by the addition of a 1/10th volume of 3M 
sodium acetate and 2 volumes of 100% ethanol. The mixture was vortexed and incubated 
for 20 minutes on dry ice. Precipitated DNA was pelleted by centrifugation at 13,000 
r.p.m. for 5 minutes at RT in a microfuge. DNA pellets were washed in approximately 
200-500pl of 70% ethanol to remove excess salts and the DNA pelleted by centrifugation 
at 13,000 r.p.m. for 5 minutes at RT DNA pellets were allowed to air dry before being 
resuspended in the appropriate volume of dELO containing lOpg/ml RNaseA and stored at 
-20°C until required.
2.2.1.6 Large scale plasmid DNA isolation
Either a single colony from an L-broth agar plate or approximately lOpl of glycerol stock 
was used to inoculate 10ml of pre-warmed L-broth containing the appropriate antibiotic. 
This was incubated for 4-8 hours in an orbital shaker at 37°C and used to inoculate 100ml 
of pre-warmed L-broth (containing the appropriate antibiotic) in a 500ml flask. This 
bacterial culture was incubated o/n in an orbital shaker at 37°C. Cultures were transferred 
to 50ml (SS-34) tubes and the bacteria pelleted by centrifugation at 6,000 r.p.m. for 10 
minutes at 4°C in a Sorvall SS-34 rotor. The supernatant was discarded and the DNA was 
extracted using a Qiagen midi prep kit following the manufacturer’s guidelines (Qiagen).
2.2.1.7 Restriction endonuclease digestion o f DNA
Restriction digests were carried out in the buffer and at the temperature specified by the 
manufacturer. The number of units of enzyme used was dependent upon the concentration 
of DNA, typically 10 units/1 pg of DNA. If the DNA was to be dephosphorylated then 1 
unit of calf intestinal phosphatase (CIP) was added to the reaction mixture following 
digestion and incubated for an additional hour at 37°C. In situations where double 
restriction digestions were required and the buffer specifications were incompatible, the 
DNA was phenol/chloroform extracted and ethanol precipitated (as described in section 
2.2.1.5) following the first digestion and resuspended in dELO before the second digestion 
was carried out in the appropriate buffer.
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2.2.1.8 Analytical DNA agarose gel electrophoresis
DNA that was to be analysed was mixed with a 1/5* volume of loading buffer and loaded 
onto a horizontal (10cm by 11cm) 1% agarose gel made in lx TBE containing EtBr (0.5 
pg/ml). lkb or lOObp size markers (Gibco-BRL) of known concentrations were run 
alongside the sample DNA in order to estimate fragment sizes. Electrophoresis was 
carried out with the gel submerged in lx TBE at 75V for approximately 30-45 minutes. 
DNA was visualised using a short wave UV transilluminator and photographed using a 
digital camera.
2.2.1.9 Purification o f  DNA from agarose
DNA fragments that were required for cloning procedures were purified from 1% agarose 
gels made in lx  TAE containing EtBr (0.5pg/ml). Electrophoresis was carried out (as 
described in section 2.2.1.8) with the gel submerged under lx TAE buffer. The DNA was 
visualised using a long wave UV transilluminator in order to prevent UV nicking. The 
appropriate DNA band(s) was excised from the gel using a sterile disposable scalpel and 
placed into the appropriate number of 1.5ml reaction vials. DNA was extracted from the 
agarose by a Qiaquick gel extraction kit (Qiagen) following the manufacturer’s guidelines. 
Extracted DNA was checked for its integrity by analysing it on a 1% agarose gel run in lx 
TBE buffer (as described in section 2.2.1.8).
2.2.1.10 DNA ligation
Vector and insert were digested with the relevant restriction endonucleases and purified. 
To prevent the vector from self-annealing it was typically treated with 1 unit of CIP per pg 
of DNA following the endonuclease digestion. DNA fragments were mixed at a vector to 
insert ration of 1:3 in the presence of lx ligation buffer (Gibco-BRL) and 1 unit of T4 
DNA ligase (Gibco-BRL) in a total volume of 20pl. The ligation mixture was incubated 
either at RT for 5 hours or o/n at 15°C. The DNA was subsequently electroporated into the 
appropriate electrocompetent bacteria or frozen at -20°C until required.
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2.2.1.11 Linker ligation
If the cloning strategy required the addition of non-phosphorylated oligonucleotide linkers 
to a blunt ended recombinant DNA molecule then essentially the same procedure was 
carried out as described in section 2.2.1.10. Oligonucleotide linkers were used in a 50-fold 
molar excess over that of the blunt ended recombinant DNA molecule. DNA were blunt 
ended by the addition of dNTPs (50pM/dNTP) and 2 units of DNA polymerase I Klenow 
to digestion mixtures and incubated for an additional 20-30 minutes at 37°C.
2.2.1.12 Oligonucleotide purification
Synthetic oligonucleotides were prepared using a Biosearch 8600 DNA synthesiser 
courtesy of D. McNab and A. Orr.
The oligonucleotides were eluted from the preparation column over a period of 
approximately 60 minutes in 1.5ml of concentrated ammonium solution (Fisons). The 
ammonia/oligonucleotide solution was then transferred to a 1.5ml screw cap reaction vial 
and incubated for 5 hours at 55°C before being placed on ice for approximately 2 minutes. 
The solution was then aliquoted into 4 equal volumes in 1.5ml reaction vials and the 
ammonia solution removed by o/n evaporation in a rotary evaporator. The dried
oligonucleotides were stored at -20°C until required.
2.2.1.13 PAGE o f synthetic oligonucleotides.
Oligonucleotide pellets were resuspended in lOOpl of a 1:1 mix of dH20/formamide. 
Typically 25pl of the resuspended pellet was loaded on to a 10% Sequagel (National 
diagnostics) in 0.5% TBE. lOpl of loading dye (containing 0.5% (x/v) xylene cyanol and 
0.5% (w/v) Bromophenol blue) was loaded into a neighbouring well to act as migration 
markers. The gel was electrophoresed in 0.5x TBE buffer at 50mA until the Bromophenol 
dye front had migrated to the bottom of the gel.
Following electrophoresis the gel was transferred on to cling film and the DNA visualised 
by short wave UV radiation. The oligonucleotides would appear as a dark band against an
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imager enhancer screen. The area of which was marked in the gel using a sterile scalpel. 
The band was excised from the acrylamide gel in the absence of UV radiation and 
transferred to a universal bottle containing 3ml of dLLO. The oligonucleotides were 
allowed to diffuse from the gel slice by incubating the gel in the dELO o/n at 37°C in an 
orbital shaker. The oligonucleotide solution was transferred to a 10ml snap cap tube and 
the DNA recovered by phenol/chloroform extraction and ethanol precipitation. 
Oligonucleotide pellets were typically resuspended in lOOpl of dELO and stored at -20°C 
until required. The concentration of the oligonucleotide was measured by absorbance at 
OD260 (1 OD260 unit = 20pg of ssDNA).
2.2.2 M13 phage site directed mutagenesis of UL18.
A modified version of the Kunkel method (Kunkel et al., 1985) was used to generate a 
panel of cysteine UL18 mutants. The specific oligonucleotides used during the 
mutagenesis are described in section 3.3. The stages involved in the mutagenesis are 
described below.
2.2.2.1 Preparation o f  uracil enriched pETUL18 ssDNA
Electrocompetent CJ236 duf ung bacteria (NEB) were electroporated in the presence of 
lpg of pETUL18 vector DNA and plated out on L-broth agar plates containing kanamycin 
(50pg/ml), as described in section 2.2.1.2. A single recombinant colony was used to 
inoculate 10ml of pre-warmed L-broth (containing 50pg/ml of kanamycin and lOOpg/ml 
of uridine) and incubated o/n at 37°C in an orbital shaker. This starter culture was used to 
inoculate 200ml of pre-warmed L-broth (containing 50pg/ml of kanamycin and 100pg/ml 
of uridine) in a 2 litre flask and incubated at 37°C for an additional 30 minutes in an orbital 
shaker. This culture was infected with 1011 p.f.u./flask of M13 R408 bacteriophage 
(Promega) which was incubate for a further 9 hours at 37°C. The bacteria were pelleted by 
centrifugation at 9,000 r.p.m. for 10 minutes at 4°C in a SS-34 rotor. The supernatant was 
transferred to a sterile 500ml GSA bottle and 0.25 volumes of a mixture containing 20% 
PEG 6000 in 2.5M NaCl was added, mixed by inversion, and incubated on ice for 30 
minutes. The bacteriophage were pelleted by centrifugation at 12,000 r.p.m. for 15
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minutes at 4°C in a SLA-3000 rotor. The supernatant was carefully removed and the 
phage pellet resuspended in 5 ml of the supernatant media. The resuspended phage were 
transferred to a 50 ml (SS-34) tube and pelleted by centrifugation at 7,000 r.p.m. for 15 
minutes at 4°C in a SS-34 rotor. The supernatant was removed and the pellet resuspended 
in 2ml of lx TE. This mixture was then transferred to a 10ml snap cap tube and an equal 
volume of phenol/chloroform was added and mixed for 1 hour on an end over end mixer 
with intermittent periods of vigorous vortexing. The mixture was then centrifuged at 4°C 
for 5 minutes at 3,000 rpm in a Sorvall RT7 centrifuge. The aqueous phase was removed 
to a fresh tube. The phenol/chloroform was re-extracted using 1ml of lx TE. The aqueous 
phases were pooled and re-extracted with phenol/chloroform until the aqueous phase 
appeared clear. The DNA was precipitated by adding 80pl/ml of 4M NaCl, 50mM EDTA, 
and 2.5 volumes of 100% ethanol and incubating at -20°C for a minimum of 2 hours. The 
precipitated DNA was pelleted by centrifugation at 7,000 r.p.m. for 20 minutes at 4°C in a 
SM-24 rotor. The supernatant was removed and the phage DNA resuspended in lOOpl of 
dELO and stored at-20°C until required.
2.2.2.2 Oligonucleotide mutagenesis
A series of oligonucleotides (sequences detailed in section 3.3) were phosphorylated in lx 
kinase buffer (Gibco-BRL) containing 20mM ATP + 2 units T4 kinase (Gibco-BRL) and 
were incubated for 40 minutes at 37°C. The reaction mixture was heat inactivated at 70°C 
for 10 minutes and stored at -20°C until required.
Approximately l.Opg of phosphorylated oligonucleotides were annealed separately to 
0.5pg of the uracil enriched ssDNA by heating the mixture in a hot block to 70°C and 
allowing the block to cool naturally to RT. 30pl of a solution containing lx ligation buffer 
(Gibco-BRL), 0.5 units of T4 ligase (Gibco-BRL), and 0.5 units of T7 polymerase (Gibco- 
BRL), was added to the annealed DNA. Samples were incubated for 1 hour at RT 
followed by an additional 1 hour at 37°C. The DNA was then phenol/chloroform extracted 
and ethanol precipitated (as described in section 2.2.1.5), resuspended in 20pl of dELO and 
stored at -20°C until required.
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The DNA was electroporated into electrocompetent DH5a bacteria (as described in section 
2.2.1.2) and individual colonies analysed for oligonucleotide incorporation by restriction 
mapping (as described in section 3.3). Those colonies that tested positive were 
subsequently sequenced in house on an ABI PRISM™ 377 DNA sequencer. 200ng of 
recombinant DNA was used per sequence analysis using commercially available T7 
primers (Novagen). Correctly mutated plasmids were subsequently electroporated into 
electrocompetent BL21 DE3 bacteria and analysed for recombinant protein expression (as 
described in section 3.3).
2.2.3 Generation of monoclonal antibodies
The production of monoclonal antibodies against the triplex proteins VP 19c and VP23 was 
carried out in house by Susan Graham. BALB/c mice were immunised with recombinantly 
expressed and Ni-NTA agarose purified triplex proteins (described in section 3.2) 
following the protocol outline in table 2.2.1. Test bleeds were performed and analysed for 
the presence of anti-sera against the triplex proteins by quantitative ELISA analysis. Mice 
that had positive anti-sera against the triplex proteins were subsequently used in the 
production of hybridoma cell lines. Quantitative ELISA analysis and the production of 
hybridoma cell lines were carried out by Susan Graham. The supernatants from these cell 
lines were tested for their specific reactivity towards VP 19c and VP23 by Western blot and 
immunofluorescence analysis (discussed in section 3.2).
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Days post- Immunisation/analysis details
immunisation
1 Primary immunisation in FCA (20pg/triplex) SC
29 Boost in FIA (20pg/triplex) SC
43 Boost in FIA (20pg/triplex) SC
57 Boost in FIA (20pg/triplex) SC
64 Test bleed animals #1-4 -  low ELISA titre (<1:50)
71 Boost in FIA (20pg/triplex) SC
86 Boost in FIA (20pg/triplex) SC
102 Final Boost in PBSa (200pg/triplex) IP
120 Test bleed animals #1-4. Fusion with spleen cells from animal #4
184 Boost in FIA (20pg/VP19cHis) SC
197 Boost in FIA (20pg/VP19cHis) SC
204 Test bleed animals #1-3
220 Final Boost in PBSa (200pg/VP19cHis) IP for animals #1 and #3
225 Fusion with spleen cells from animals #1 and #3
241 Final Boost in PBSa (200pg/VP19cHis) IP for animal #2
246 Fusion with spleen cells from animal #2
Table 2.2.1: Summary of the immunisation regime of BALB/c mice for the production of 
VP 19c and VP23 monoclonal antibodies. Mice were initially immunised with purified 
triplexes (Acl8638) in FCA (Freund’s complete adjuvant) and boosted in FIA (Freund’s 
incomplete adjuvant). Following poor test bleed analysis by ELISA for VP 19c, mice #1, 
#2, and #3 were subsequently immunised and boosted 184 days post-immunisation with 
VP 19c denatured in urea (described in section 3.2.1). SC and IP denote subcutaneous and 
intraperitonial injections respectively.
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2.2.4 Immunofluorescence analysis
2.2.4.1 Transfection o f  plasmid DNA
13mm sterile coverslips were placed into limbro wells, seeded with BHK-21 C13 cells in 
ETC 10 medium at lx l0 4 cells/well and left to grow o/n at 37°C. In separate 15ml Falcon 
tubes, 1 jag of plasmid DNA and 15pl of liposomes (Gibco-BRL) was mixed with 500pl of 
OPTIMEM (Gibco-BRL) and allowed to incubate for 15 minute at RT. The diluted 
liposomes were added to the DNA/OPTIMEM mixture, gently mixed by agitation, and 
allowed to incubate for a further 10 minutes at RT. Growth media was removed from the 
BHK-21 C13 cells and the cell monolayer (approximately 50% confluent) was washed in 
lml of serum-free OPTIMEM and drained thoroughly. 500pl of the liposome/DNA mix 
was added to each coverslip and incubated for 4 hours at 37°C before 500pl of ETC 10 
medium containing 10% FCS was added to each well and incubated for a further 16-24 
hours at 37°C. The transfection mixture was then removed and the coverslips washed in 
PBSa before being fixed in pre-chilled methanol (-20°C). Coverslips were stored at -20°C 
in methanol until they were required for analysis.
2.2.4.2 Immuno staining and microscopy analysis
All incubations were carried out in a humidified chamber and all dilutions were made in 
PBSa/TN (PBSa, 0.05% Tween-20, 5% NCS (Gibco-BRL)). Using microscope forceps, 
coverslips were removed from the methanol and rehydrated in PBSa/TN for 10 minutes at 
RT. The coverslips were blotted dry and 50pl of the appropriately diluted primary 
antibody (see table 2.2.1) was added to each coverslip and incubated for 45 minutes at RT. 
Coverslips were then washed 3x by immersion in a beaker containing PBSa/TN and 
blotted dry between each wash. After the final wash the coverslips were blotted dry and 
50pl of appropriately diluted secondary antibody was added and incubated for 45 minutes 
at RT. The coverslips were washed (as above) with a further 2 washes in dH20. The 
coverslips were blotted dry and mounted cell side down onto a glass slide in Citifluor 
(approximately lOpl) and stored a 4°C in the dark until required. For long-term storage 
clear nail varnish was applied to the outer edge of the coverslip. Immunofluorescence
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analysis was carried out on a Zeiss Axioplan fluorescence microscope. Photographs were 
taken using a mounted digital camera and edited using PhotoShop 3.1 software.
Antibody Dilution
CB040 (MAb. VP23) Neat
CB2017 (MAb. VP 19c) Neat
CB2032 (MAb. VP 19c) Neat
CB2034 (MAb. VP 19c) Neat
CB2040 (MAb. VP19c) Neat
CB2064 (MAb. VP 19c) Neat
CB2068 (MAb. VP 19c) Neat
CB2184 (MAb. VP 19c) Neat
CB2231 (MAb. VP 19c) Neat
187 (PolyAb. VP23) 1:200
FITC 1:100
Cy3 1:100
Table 2.2.2: Summary of antibody dilutions used in immunofluorescence analysis.
2.2.5 Yeast manipulation
2.2.5.1 Glycerol stock preparation
In order to preserve the viability of yeast containing plasmid DNA constructs and for long 
term storage of yeast strains and isolates, 1.5ml of an o/n culture grown in the appropriate 
drop out medium (Clontech) was centrifuged at 6,500 r.p.m. for 1 minute at 4°C in a 
microfuge. The culture supernatant was removed and the cell pellet was gently
resuspended in 1ml of 100% sterile glycerol, frozen on dry ice and stored at -70°C until 
required.
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2.2.5.2 Transformation o f plasmid DNA into yeast
Yeast transformation was carried out following the method described in Clontech 
Matchmaker™ Two-Hybrid System product protocol manual which is briefly described 
below.
2.2.5.2.1 Preparation o f yeast cells
A single colony, approximately 2-3mm in diameter, was used to inoculate 20ml of pre- 
warmed YPD medium and incubated o/n at 30°C in an orbital shaker. This starter culture 
was used to inoculate 300ml of pre-warmed YPD medium in a 1 litre flask to an OD600 of 
0.2. This culture was then incubated at 30°C in an orbital shaker for a further 3 hours 
before the yeast cells were transferred to a 250ml Falcon tube. The yeast cells were 
sedimented by centrifugation at 2,200 r.p.m. for 5 minutes at RT in a Sorvall RT7 
centrifuge. The supernatant was removed and the cell pellet resuspended in 50ml of dH20. 
The yeast cells were then pelleted (as described above), the supernatant removed, and the 
cell pellet resuspended in 1.5 ml of lx TE/LiAc buffer (see Materials).
2.2.5.2.2 Transformation o f  competent yeast cells
0.1 pg of the appropriate plasmid DNA and lOOpg of salmon sperm carrier DNA (Sigma) 
were mixed in a 1.5ml sterile reaction vial. lOOpl of competent yeast cells were added to 
each reaction vial, mixed thoroughly by pipetting, and 0.6ml of PEG/LiAc buffer (see 
Materials) was added. The reaction vials were placed into a 50ml Falcon tube and 
incubated for 30 minutes at 30°C in an orbital shaker. Following the incubation, 70pl of 
sterile DMSO was added to each reaction vial and gently mixed. The yeast cells were then 
heat shocked at 42°C for 15 minutes in a dry block before being transferred onto ice for 1 
minute. The yeast cells were pelleted by centrifugation at 14,000 r.p.m. for 5 seconds at 
RT in a microfuge. The supernatant was removed and the cell pellets resuspended in 0.5 
ml of lx TE buffer.
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2.2.5.2.3 Yeast colony selection
Yeast cells containing the appropriate plasmid construct(s) could be selected by their 
growth on the appropriate SD agar medium. For a 90mm Petri dish, lOOpl of transformed 
yeast cells were plated out onto the appropriate synthetic selection medium and spread 
evenly across the surface using a flamed glass rod. The plates were then inverted and 
transferred to a 30°C incubator. Incubation times for single colony development varied 
depending on the stringency of selection. For selection of leu or trp plasmids, colonies 
could typically be observed after 2-3 days. Selection of colonies containing plasmids 
expressing hybrid proteins which have interacting Gal4 domains to induce uracil 
biosynthesis typically required 6-10 days incubation.
2.2.5.3 Replica plating and picking o f yeast colonies
Replica plating was carried out using 220 x 220mm pieces of 100% cotton velvet. The 
velvets were placed over a 85mm wooden replica-plating block (made in house) and fixed 
into position using a metal ring. Master plates were inverted and gently lowered on to the 
velvet with even pressure to ensure a good lift of all yeast colonies across the entire plate. 
The master plate was then gently lifted off the velvet and a new selective plate containing 
the appropriate synthetic medium was lowered onto the velvet with even pressure. This 
plate was then replica cleaned to dilute the number of yeast cells on the plate by repeating 
the process with a sterile velvet. Replica plates were incubated at 30°C and colony 
formation would typically occur within 2-3 days. The velvets were cleaned by soaking 
them o/n in 1% Virkon, and washing thoroughly in warm water before being dried o/n at 
37°C. Sets of 10 velvets were then wrapped in tin foil and sterilised by autoclaving.
In some instances, a minimal number of yeast cells were transferred from a single yeast 
colony using sterile cocktail sticks. These cells were then transferred directly either to a 
new selection plate, nitro-cellulose filter, or the appropriate liquid culture medium, before 
being incubated at 30°C.
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2.2.5.4 fi-galactosidase filter assay
Colonies that were to be analysed for the presence of p-galactosidase were transferred by 
picking (as described above) onto their appropriate SD selective agar plate. These colonies 
were then incubated for 2 days at 30°C. A reinforced nitro-cellulose filter (Hybond) was 
cut to the appropriate size and pre-soaked in Z buffer/X-gal solution (see Materials). The 
filter was then transferred to the selective plate containing the transformed colonies and 
orientated to the plate by puncturing 3 holes at asymmetric points. The filter was gently 
lifted from the plate and submerged colony side up into a liquid nitrogen bath for 10 
seconds then allowed to thaw at RT (approximately 10 seconds). The filter was then 
placed in the lid of a Petri dish onto 2 pieces of Whatman filter paper (Whatman #541) pre­
soaked in Z buffer/X-gal solution. The Petri dish was then covered and incubated o/n at 
37°C.
2.2.5.5 Isolation o f plasmid DNA from yeast
Plasmid isolation was carried out following the method described in Clontech 
Matchmaker™ Two-Hybrid System product protocol manual. Briefly, a single 
transformed yeast colony grown on the appropriate SD agar selection media was used to 
inoculate 2ml of YPD liquid medium and incubated o/n in an orbital shaker at 30°C. 1.5ml 
of this yeast suspension was transferred to a 1.5ml reaction vial and the yeast cells pelleted 
at 6,000 r.p.m. for 5 seconds at RT in a microfuge. The media was removed and the yeast 
cells resuspended in 200pl of yeast lysis solution (see Materials). To this mixture, 200pl 
of Phenol/Chloroform and 0.3g of acid washed glass beads (Sigma) were added. The 
mixture was vortexed continuously for a minimum of 2 minutes. The cellular debris was 
pelleted at 14,000 r.p.m. for 5 minutes at RT in a microfuge. The supernatant was 
transferred to a clean 1.5ml reaction vial and the DNA recovered by phenol/chloroform 
extraction and ethanol precipitation. The DNA pellets were typically resuspended in 20pl 
of dH20 and stored at -20°C.
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2.2.5.6 TCA extraction o f  proteins from yeast cells
Yeast cells were prepared and proteins extracted using the TCA protein extraction protocol 
described in Clontech Laboratories Inc. yeast protocols handbook and is briefly described 
below.
2.2.5.6.1 Yeast cell culture and preparation for protein extraction
A single colony was used to inoculate 5ml of the appropriate SD media and incubated o/n 
at 30°C in an orbital shaker. This starter culture was vortexed to break up any cell clumps 
and used to inoculate 50ml of pre-warmed YPD medium in a 500ml conical flask. This 
yeast culture was incubated for a further 4-8 hours until the OD600 reached 0.4-0.6. For 
each culture the total number of OD600 units was calculated using the equation below:
OD600 (lml sample) x Total volume of culture = Total OD600 units
The yeast culture was transferred to a pre-chilled 250ml Falcon tube containing 100ml of 
ice and the yeast cells were pelleted by centrifugation at 1000 r.p.m. for 5 minutes at 4°C 
in a Sorvall RT7 centrifuge. The supernatant and any unmelted ice was poured off and the 
yeast cell pellet resuspended in 50ml of ice-cold dFLO. The yeast cells were pelleted (as 
described above) and the supernatant removed before the cell pellet was frozen on dry ice 
and stored at -70°C until required.
2.2.5.6.2 TCA protein extraction
Unless otherwise stated all sample preparations were kept on ice. Frozen yeast cell pellets 
were thawed on ice and resuspended in 100pl/7.5 OD600 units of ice cold TCA buffer. The 
mixture was transferred to a 1.5ml reaction vial containing lOOpl of acid washed glass 
beads (Sigma) and lOOpl of ice cold 20% (w/v) TCA per 7.5 OD600 units. If the volume 
was greater than 1.5ml the sample was split between two 1.5ml reaction vials. The tubes 
were vortexed for 4x 1 minute intervals and were placed on ice between each period of 
vortexing for a minimum of 30 seconds. The glass beads were allowed to settle before the 
supernatant was transferred to a fresh pre-chilled 1.5ml reaction vial. 500pl of a 1:1 mix
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of 20% TCA and TCA buffer was added to the glass beads and vortexed for a further 2x 1 
minute intervals (as described above). The glass beads were allowed to settle and the 
supernatant was pooled with the first extract. The combined cell extracts were incubated 
on ice for an additional 1 minute to allow any glass beads carried over to settle. This 
supernatant was transferred to a fresh pre-chilled 1.5ml reaction vial and the proteins 
pelleted by centrifugation at 14,000 r.p.m. for 10 minutes at 4°C in a microfuge. The 
supernatant was removed and the pellet resuspended in 10pl/OD6oo unit of BM. The 
sample was heated in a dry block for 10 minutes at 100°C and stored at -70°C prior to 
SDS-PAGE analysis.
2.2.5.7 Random PCR mutagenesis
Random PCR mutagenesis was carried out using universal primers that encoded sequences 
flanking the multicloning site of pPc86 plasmid (primers detailed in section 3.1). The 5’ 
primer corresponds to sequences located within the activation domain (AD), approximately 
lOObp upstream of the multicloning site of pPc86. The 3’ primer corresponds to sequences 
located within the yeast transcriptional terminator (Term) approximately lOObp 
downstream of the multicloning site. Thus, a DNA fragment amplified using these two 
primers can be re-incorporated back into a linearised (Kpnl digested and CIP treated) 
pPC86 vector via gap repair by transforming yeast cells with the appropriate linearised 
vector and PCR products.
Random PCR mutagenesis was carried out using; lOOng of linear pPc86UL18 DNA (as a 
DNA template), lpM  of each of the AD and Term primers, 50pm of each dNTP, 50mM 
KC1, lOmM Tris (pH 9.0), 1.5mM MgCl2, and 5 units of Taq DNA polymerase. The PCR 
reaction was carried out in a final volume of 50pl initially for 10 elongation cycles 
(described below) before MnCh was added to a final concentration of IOOjjM. The 
reaction was continued for a further 30 cycles (1 min at 94°C, 1 min at 45°C, 2 min at 
72°C). Each PCR reaction was analysed by electrophoresis on a 1% agarose TBE gel.
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2.2.6 Tissue culture and virus manipulation
2.2.6.1 Baculovirus manipulation
2.2.6.1.1 SF cell culture
SF21 cells were passage every 3-4 days in large (600ml) tissue culture flasks containing 
50-75ml of TC100/5 medium. The cells were removed from the base of the flask by the 
addition of 10ml of TCI00/5 medium and gentle tapping of the flask against the hand. 
Cell clumps were broken up by pipetting the medium up and down. Confluent flasks were 
typically passaged using a 1:4 split. Where appropriate cell densities were calculated using 
a Nebauer counting chamber. Cells were counted using a inverted light microscope 
(Olympus).
2.2.6.1.2 Freezing and storage o f SF cells
SF21 cells were grown in large flasks (600ml) at 28°C until confluent. They were then 
harvested in 10ml of TCI00/5 medium and the cell suspension transferred to a 15ml 
Falcon tube. Cells were pelleted by centrifugation at 1,500 r.p.m. for 5 minutes in a 
Sorvall RT7 centrifuge. The supernatant was removed and the cells resuspended in 2ml 
TCI00/10 and a equal volume of ice cold freezing mix (80% (v/v) TCI00/10, 20% (v/v) 
DMSO). The cell suspension was aliquoted into cryogenic vials (1 ml/vial) before being
frozen o/n at -70°C. Frozen cells were then transferred to liquid nitrogen for long term 
storage.
2.2.6.1.3 Recovery ofSF21 cells
Aliquots of SF21 cells removed from liquid nitrogen were thawed quickly in a water bath 
at 37°C before being resuspended in a small volume of TCI 00/5 (approximately 5ml). The 
cell suspension was then transferred to a 15ml Falcon tube, and cells pelleted by 
centrifugation at 1,000 r.p.m. for 5 minutes in a Sorvall RT7 centrifuge. The supernatant 
was discarded and the cell pellet resuspended in 5ml of TCI00/5, which was used to seed
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to a medium flask (200ml). The flask was incubated at 28°C until the cells had firmly 
attached to the solid substrate before the medium was replaced with fresh TCI00/5. Once 
the monolayer had reached confluency the cells were passaged into a large (600ml) flask 
and cultured as normal.
2.2.6.1.4 Construction o f recombinant baculoviruses
Transfection of DNA into SF21 cells followed the method described by Rose et al (1991) 
utilising a synthetic lipid reagent. Transfections were performed in 35mm dishes at a cell 
density of 60-70%. 0.5pg of AcPAK6 DNA, which had been digested with Bsu361 and 
subsequently phosphatased using CIP, was mixed in a 15ml Falcon tube with 5pg of 
transfer vector DNA in 500pl of TC100 medium. To this mixture 15pl of liposomes was 
added, gently vortexed, and incubated at RT for 15 minutes. The medium from the SF21 
cell monolayer was removed and the cells were washed with 2ml of TCI00 medium 
containing no foetal calf serum. The wash medium was removed and the transfection 
mixture added to the cell monolayer with an additional 500pl of TCI 00 medium. The cells 
were incubated at 28°C for 4 hours before an additional 1ml of TCI00/10 media was 
added. The cells were then incubated for a further 65 hours at 28°C when the supernatant 
was removed and transferred to a sterile 1.5ml reaction vial. Any cells that were carried 
over were pelleted by centrifugation at 14,000 r.p.m. for 2 minutes in a microfuge. The 
supernatant was transferred to a fresh 1.5ml screw cap reaction vial, frozen on dry ice and 
stored at -70°C until required.
2.2.6.1.5 Isolation o f recombinant viruses
Recombinant viruses were selected on their /acZ-minus phenotype. 100pl of the harvested 
transfection supernatant was assayed for plaque formation and lacZ phenotype at dilutions 
from neat to 10' (described in section 2.2.6.1.8). Plaques that did not stain blue were 
picked under a plate microscope (WILD M7A, Heerbrugg) using a sterile Pasteur pipette 
and transferred to 1ml of TCI00/5 medium in a sterile 1.5ml screw cap tube. Virus was 
released from the agar by freeze/thawing the samples on dry ice 3x before being stored at -  
70°C. Baculoviruses were subsequently grown by infecting 50% confluent monolayers of 
SF21 cells (lxlO6 cells/plate) in 35mm dishes. The media was removed from the cells and
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500j l x 1 of released virus suspension was added and allowed to absorb for 1 hour at 28°C 
before an additional 1ml of TCI 00/5 media was added. After a further 4-5 day incubation 
the supernatant, termed plate harvest one (PHI), was harvested (as described above) and 
used for a second round of plaque purification. PH2 was used for a final round of plaque 
purification and the PH3 virus supernatant was subsequently used for generating low titre 
virus stocks. Cells from each round of plate harvests were analysed by SDS-PAGE and 
stained with Coomassie Brilliant Blue to assay for the continued expression of the 
recombinant protein of interest.
2.2.6.1.6 Production o f low titre baculovirus stocks.
Small tissue culture flasks (200ml) were seeded with SF21 cells in TCI00/5 media and 
allowed to grow at 28°C until the monolayer reached a confluency of 50%. The media was 
removed and 500pl of PH3 supernatant was inoculated onto the cells and allowed to 
absorb for 1 hour at 28°C. Following the incubation, 10ml of fresh TCI00/5 media was 
added to the cells and incubated for a further 4-5 days at 28°C. The media was transferred 
into a 15ml Falcon tube and the cells pelleted by centrifugation at 2,000 r.p.m. for 5 
minutes in a Sorvall RT7 centrifuge. The supernatant was transferred to a fresh 15ml 
Falcon tube and stored a -70°C until required. 5ml of this supernatant was used to infect a 
50% confluent monolayer of SF21 cells in a large (600ml) flasks (as described above). 
After absorption, 50ml of TCI 00/5 media was added to the cells, which were subsequently 
incubated for 4-5 days at 28°C, after which the supernatant was harvested (flask harvest, 
FH), as described above, and stored at -70°C. The FH was subsequently titered as 
described in section 2.2.6.1.8.
2.2.6.1.7 Production o f high titre baculovirus stocks
High titre stocks of parental (AcPAK6) and recombinant baculoviruses were routinely 
grown in roller bottles containing SF21 cells at a cell density of 5xl05 cells/ml (typically 
300ml/bottle). Cells were infected at a m.o.i. of 0.1 p.f.u./ml and cultured for 5 days at 
28°C. Cultures were transferred to 250ml Falcon tubes and the cells pelleted by 
centrifugation at 3,000 r.p.m. for 5 minutes in a Sorvall RT7 centrifuge. The supernatant 
was removed and baculovirus pelleted by centrifugation at 12,000 r.p.m. for 5 hours at 4°C
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in a Sorvall SLA-3000 rotor. Virus pellets were resuspended in TCI00/5 media (typically 
4ml/300ml supernatant), transferred to sterile 1.5ml screw cap tubes and stored at 4°C until 
required.
2.2.6.1.8 Baculovirus titration
Stocks of baculovirus were titrated by the method first described by Brown and Faulkner 
(1977). 35mm dishes were seeded with lxlO6 SF21 cells in 1.5ml of TC100/5 medium 
and allowed to grow o/n at 28°C to generate a 70-80% confluent monolayer. Serial 10 
fold dilutions of the virus were performed in TCI00/5 medium from neat to 10'6 for low 
titre stocks and from 10'5 to 10'10 for high titre stocks. The medium was removed from the 
cells and 100pl of the diluted virus was added to each 35mm dish and allowed to absorb 
for 1 hour at 28°C with occasional rocking to prevent the cell monolayer from drying out. 
Following absorption, 1ml of overlay medium was added (50% TCI00/5 and 50% 3% 
LTG agarose (SeaPlaque)), which had been previously melted and incubated at 45°C to 
prevent the agar from setting. Once the overlay medium had set (approximately 10 
minutes), 1.5ml of TCI 00/5 was added and the plates were incubated for a further 4-5 days 
at 28°C. The medium was removed and 1.5ml of neutral red stain (0.4% neutral chloride 
mixed 1:50 with TCI00/5) was added on top of the agar and the plates incubated for a 
further 5 hours at 28°C. The stain was removed and the plates inverted onto tissue paper 
and allowed to air dry o/n at RT. Plaques were counted and the titre calculated as 
p.f.u./ml. If the titration was required to identify recombinant viruses then 250pg of X- 
gal/ml (made up as a 3mg/ml stock solution in DMSO) was added to the initial stain. 
Recombinant virus plaques (clear plaques) were selected for their absence of (3- 
galactosidase activity due to the disruption of the lacZ gene within the parental baculovirus 
(AcPAK6).
2.2.6.2 BHK-21 C l3 cell culture.
BHK cells were typically passaged every 3-4 days in 850cm2 roller bottles. The cell 
monolayer was washed with 40ml of versene and the cells removed from the substrate by 
trypsinisation, 2x washes of a 20ml trypsin/versene (1:4) solution. The cells were left until 
the monolayer dispersed before 10ml of ETC/10 was added. A confluent monolayer
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typically yielded approximately lxlO8 cells. Sterile roller bottles were seeded with 2xl07 
cells in 100ml of ETC/10, gassed with 5% CO2 and incubated at 37°C with gentle rotation.
2.2.6.3 Vero cell culture.
Vero cells were typically passaged every 3-4 days in large (600ml) tissue culture flasks 
containing 50-75ml of MEM/10. The monolayer was washed in 20ml of versene and the 
cells removed from the substrate by trypsinisation, 2x washes of a 20ml trypsin/versene 
(1:4) solution. The cells were left until the monolayer dispersed before 10ml of MEM/10 
medium was added. Cell clumps were dispersed by pipetting the medium up and down. 
Confluent flasks were typically passaged 1:4. into sterile flasks containing fresh medium 
and gassed with5% CO2. Flasks were incubated at 37°C.
2.2.6.4 Complementation ofUL18 null mutant virus (K23Z)
35mm dishes were seeded with 4xl05 BHK-21 C13 cells in ETC 10 medium and allowed to 
grow o/n at 37°C in 5% CO2. 1 pig of the appropriate plasmid DNA was transfected into 
cells using the transfection procedure described in section 2.2.4.1. 18-24 hours post
transfection the medium was removed and the cell monolayer infected with the UL18 null 
mutant virus (K23Z) at a m.o.i. of 3 p.f.u./cell in lOOpl of ETC 10 medium. The 
construction of K23Z is described in Desai et al., (1993). The cells were incubated for 1 
hour at 37°C in 5% CO2 with occasional rocking to prevent the cell monolayer from drying 
out. Following the incubation the virus innoculum was removed and the cells washed with 
lml of sterile PBScomplete. Unpenetrated virus particles were removed from the surface 
of cells by acid washing in 500pl of pH3 buffer (see Materials) for 1 minute at RT. The 
cell monolayer was then washed in lml of ETC 10 medium before lml of ETC 10 medium 
was added to the cells and incubated for 24 hours at 37°C in 5% CO2. Following the 
incubation, the cells were removed from the plate by scraping into the culture medium, 
using a sterile lml syringe plunger. The medium was then transferred to a Bijoux bottle 
and briefly bath sonicated in a soni-bath (Kerry) to release virus particles.
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2.2.6.5 Titration o f  complemented HSV-1 UL18 null mutant virus (K23Z)
HSV-1 UL18 null mutant virus progeny (generated as described in section 2.2.6.4) were 
titred on 80% confluent monolayers of Vero cells or G5-11 Vero cells (a UL18 
complementing cell line, described in Desai et al., 1993) in 35mm dishes. The virus was 
diluted through 10-fold serial dilutions, the medium removed, and the cells inoculated with 
lOOpl of serial 10-fold dilutions from neat to 10'4 in MEM/10 medium. The plates were 
incubated at 37°C for 1 hour with occasional rocking to prevent the cell monolayer from 
drying out. Following the incubation 2ml of EMC/10 (see Materials) was gently added to 
each plate and they were incubated for a further 3-4 days at 37°C. To visualise plaques, 
the cells were fixed in 2ml of Giemsa stain for 4 hours at RT. Excess stain was removed 
by gentle washing in cold water before the plates were inverted and allow to air dry o/n on 
tissue paper. The plaques were then counted using a plate microscope (WILD M7A, 
Heerbrugg).
2.2.7 Expression of recombinant proteins
2.2.7.1 Protein expression in BL21 DE3 bacteria
A single colony or approximately lOpl of a glycerol stock was used to seed 5ml of pre­
warmed L-Broth (containing the appropriate antibiotic) and incubated in an orbital shaker 
for 4-5 hours at 37°C. This starter culture was then used to inoculate 100ml of pre-warmed 
L-Broth (containing the appropriate antibiotic) in a 500ml flask and allowed to grow o/n at 
37°C in an orbital shaker. 50ml of the o/n culture was transferred to a 2 litre flask 
containing 1 litre of pre-warmed L-Broth (containing the appropriate antibiotic) and 
cultured until the OD630nm reached 0.5-0.6. Expression of the gene(s) of interest was 
induced by adding 0.1 mM IPTG and incubating for a further 16 hours at 18°C (unless 
otherwise stated). 600ml of the induced bacterial suspension was then transferred to a GS3 
centrifuge bottle and the bacteria pelleted by centrifugation at 6,000 r.p.m. for 15 minutes 
at 4°C in a Sorvall SLA-3000 rotor. The culture supernatant was removed and the 
bacterial pellets were frozen at -20°C until required.
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2.2.7.2 Protein expression using the baculovirus expression system
Recombinant protein expression was carried out using 35mm or 60mm dishes that were 
seeded with lxlO6 or 4xl06 SF21 cells respectively, or roller bottles containing 300ml of 
SF21 cells at a cell density of lx l0 6 cells/ml. In all instances, SF21 cells were infected 
with recombinant baculoviruses expressing the gene(s) of interest at 5 p.f.u./cell and 
incubated at 28°C for 48 hours. SF21 cells cultured on plates were allowed to reach a 
confluency of 80% (typically o/n post-seeding), after which the growth medium was 
removed. lOOpl (for a 35mm dish) or 200pl (for a 60mm dish), of the appropriately 
diluted baculovirus in TCI00/5, was added to the cell monolayer and incubated for 1 hour 
at 28°C with occasional rocking. Following absorption, 1.5ml (for a 35mm dish) or 3ml 
(for a 60mm dish) of TCI00/5 was added to the cell monolayer and incubated for 48 hours 
at 28°C. The plates were harvested in 1 ml of PBSa by gentle pipetting before being 
transferred to a 1.5ml reaction vial, and pelleted by centrifugation at 6,500 r.p.m. for 1 
minute at RT in a microfuge. The supernatant was removed and the cell pellet was frozen 
on dry ice and stored at -20°C until required. For SF21 cells cultured in roller bottles, 
baculovirus was added directly to the ell suspension. 48 hours post infection the cell 
suspension was transferred to a 250ml Falcon tube and the cells pelleted by centrifugation 
at 3,000 r.p.m. for 5 minutes at RT in a Sorvall RT7 centrifuge. The supernatant was 
removed and the cell pellets frozen on dry ice and store at -20°C until required.
2.2.8 Purification of 6xHis epitope tagged proteins
2.2.8.1 Ni-NTA agarose column chromatography
The majority of protein purification’s shown in this thesis utilised the expression of 
recombinant proteins that had a 6xHis amino acid tag located at their N-termini. This 
allowed the purification of both bacterial and baculovirus expressed proteins through the 
use of Ni-NTA affinity chromatography. The principles of which are discussed in detail in 
section 3.3. The protocols outlined below describe the general methods involved in 
extracting and purifying recombinantly expressed proteins from bacteria and SF21 cell
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extracts. The specific composition of buffers used in individual cases are detailed within 
the appropriate text sections and figure legend texts.
2.2.8.2 Preparation o f bacterial extracts for Ni-NTA purification
Frozen 600ml bacterial pellets (grown and induced as described in section 2.2.7.1) were 
typically resuspended in 20ml of the appropriate purification buffer (see fig. legends for 
details) and lysed using a Branson sonifier 450 soni-probe over approximately 5x 20 
second bursts set at the 50% duty cycle and an output of 5. The lysed bacterial suspension 
was then transferred to the appropriate number of 1.5ml reaction vials and clarified at
14,000 r.p.m. for 5 min at RT in a microfuge. The supernatant fraction was transferred to a 
15ml falcon tube for Ni-NTA agarose purification (described in section 2.2.8.4).
2.2.8.3 Preparation ofSF21 cell extracts for Ni-NTA purification
Frozen SF21 cell pellets from 300ml cultures (cultured and infected as described in section 
2.2.7.2) were typically resuspended in 5ml of the appropriate purification buffer (see fig. 
legends for details) containing Complete™ (EDTA-free) protease inhibitors (Boehringer
Mannheim) prepared following the manufacturer’s instructions. The cell suspension was
lysed by sonication in a soni-bath (Kerry) for approximately 5 minutes at RT. The cell 
suspension was then transferred to the appropriate number of 1.5ml reaction vials and 
clarified at 14,000 r.p.m. for 5 minutes at RT in a microfuge (unless otherwise stated). The 
supernatant fraction was then transferred to a 15ml Falcon tube for Ni-NTA agarose 
purification (described in section 2.2.8.4).
2.2.8.4 Ni-NTA agarose purification
350-700pl of Ni-NTA coupled to Sepharose® CL-6B (Qiagen), was typically equilibrated 
in a 1.5ml reaction vial over 4x 1.5ml washes in the appropriate purification buffer. After 
each wash stage the agarose was pelleted by centrifugation at 14,000 r.p.m. for 5 seconds 
at RT in a microfuge, the buffer phase removed, and the agarose gently resuspended in 
1.5ml of fresh purification buffer. Following the final wash stage the agarose was 
resuspended in 1.5ml of the appropriate purification buffer and added to the soluble protein
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fraction. The 6xHIS epitoped tagged recombinant proteins were allowed to bind by 
mixing end over end for 1 hour at RT (unless otherwise stated). The agarose and bound 
protein complexes were then pelleted by centrifugation at the appropriate temperature at
1,000 r.p.m. for 5 minutes in a Sorvall RT7 centrifuge. The supernatant was removed and 
the agarose gently resuspended in 10ml of the purification buffer. The agarose was 
pelleted and washed a further 2x (as described above) before being transfer to a disposable 
column (BIO-Rad) in 5ml of the appropriate buffer. The agarose was washed with a 
further 5ml of the appropriate purification buffer. When required the Ni-NTA agarose was 
washed with 10 ml of purification buffer containing low concentrations imidazole 
(typically <25mM) to remove cellular proteins that had non-specifically bound to the 
agarose. The 6xHIS epitoped tagged recombinant proteins were eluted from the Ni-NTA 
agarose using a suitable concentration of imidazole (typically between 100-250mM) in the 
desired volume of purification buffer and collected in 1.5ml reaction vials. Specific details 
for each protein purified using Ni-NTA agarose are described in their respective results 
sections.
2.2.8.5 Ni-NTA agarose pull downs
Frozen 35mm or 60mm plate harvests of SF21 cells infected with recombinant 
baculoviruses (as described in section 2.2.7.2) were resuspended in 150pl of the 
appropriate purification buffer (see fig. legends for details). The cell extracts were allowed 
to lyse on ice for 15 minutes with intermittent vortexing before being clarified by 
ultracentrifugation at 30,000 r.p.m. for 5 minutes at 4°C in a Beckman TLA 100.2 rotor. 
The supernatant was transferred to a fresh 1.5ml reaction vial and mixed with a second 
lysed and clarified extract or with 200pl of buffer. The extracts were incubated for 1 hour 
at an appropriate temperature before being mixed with 20pl of equilibrated Ni-NTA 
agarose (Qiagen). The extracts were incubated for a further 15 minutes with intermittent 
vortexing. The Ni-NTA agarose was pelleted at 14,000 r.p.m. for 5 seconds in a 
microfuge and washed in 3x lml and 2x 200pl of the appropriate buffer + 500mM NaCl. 
If the experiment was carried out at 4°C then all buffers were pre-chilled on ice before use. 
Following the final wash, the Ni-NTA agarose was resuspended in 30pl of BM + 250mM 
imidazole and heated in a dry block for 5 minutes at 100°C. The extracts were stored at -  
20°C until required.
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2.2.8.6 Quantification o f  protein concentration
Purified protein concentrations were calculated by measuring the OD280 and calculating the 
amount of protein in mg/ml using the following equation:
Extinction Co-efficient = OD280
MW X (mg/ml)
2.2.9 Analysis of purified proteins
2.2.9.1 SDS-polyacrylamide gel electrophoresis (SDS-PAGE)
Protein samples in all cases were resolved using a 10% polyacrylamide gel (37.5:1 
acrylamide:bisacrylamide, Bio-Rad) prepared in lx resolving gel buffer (see materials) 
within a vertical mini gel plate system (Bio-Rad), on top of which a 5% polyacrylamide 
stacking gel prepared in lx stacking gel buffer (see Materials) was poured. Both resolving 
and stacking gels were polymerised by adding 200pl of 10% ammonium persulphate and 
1 O jj.1 of TEMED. Unless otherwise stated, protein samples were prepared in boiling mix 
(BM) buffer (see Materials) and heated at 100°C for 2 minutes prior to loading. Gels were 
typically electrophoresed at 150-200 volts until the dye front had reached the bottom of the 
resolving gel. If protein standards were required then 3 pi of Rainbow™ markers 
(Amersham Pharmacia Ltd) or 3 pi of purified capsids (prepared in house by J. Mitchell) 
were analysed next to the protein samples for comparison. Gels that were not going to be 
used for Western blotting were fixed and stained using Coomassie Brilliant Blue stain (see 
Materials) solution for 10-20 minutes before being transferred into a destain solution to 
remove excess back ground staining. Gels were photographed using a digital camera and 
images processed using PhotoShop 3.1 software (Adobe).
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2.2.9.2 Semi-dry Western blot analysis
2.2.9.2.1 Protein transfer
The transfer of proteins to a nitro-cellulose membrane was carried out by semi-dry 
transfer. SDS-PAGE was carried out (as described in section 2.2.9.1) and the stacking gel 
was separated from the resolving gel. 6 pieces of 3mm Whatman paper and the nitro­
cellulose membrane (Hybond) were cut to the appropriate size and pre-soaked for 5-10 
minutes in transfer buffer. The nitro-cellulose membrane was placed on to a stack of 3 
pieces of 3mm Whatman paper and the resolving gel was placed on to the nitro-cellulose 
before an additional stack of 3 pieces of 3mm Whatman paper were placed on top of the 
resolving gel. The transfer of proteins on to the nitro-cellulose membrane was carried out 
using a 2117 Multiphor II Electrophoresis Unit (Pharmacia) typically at 40mA for 3-4 
hours.
2.2.9.2.2 Detection o f  proteins
When the transfer was complete, non-specific binding sites on the nitro-cellulose 
membrane were blocked by immersing the membrane in 100ml of 3% Marvel milk powder 
made up in PBSa/T and incubating at RT on a orbital shaker for a minimum of 1 hour. The 
blocked membrane was then washed 3x 15 minutes in approximately 50ml of PBSa/T. 
The membrane was subsequently probed at RT in approximately 10ml of PBSa/T, 
containing the appropriately diluted primary antibody, for a minimum of 1 hour on an 
orbital shaker. The membrane was then washed (as described above) before the addition 
of a secondary antibody, typically GAM-HRP or Protein A peroxidase (both used at 
1:1000 dilution), which was incubated for a minimum of 1 hour at RT on an orbital shaker. 
The membrane was then thoroughly washed, 3x 15 minutes and 4x 5 minutes in 
approximately 50ml of PBSa/T. Immuno-detection was carried out using ECL (Amersham 
Pharmacia Ltd) following the manufacturers instructions. Kodak XS-1 film was used for 
visualisation of immuno-complexes and was exposed for variable amounts of time.
81
Methods: 2.2
2.2.9.4 Stripping and re-probing nitro-cellulose membranes
Nitro-cellulose membranes were stripped by incubating the blot in 50ml of stripping buffer 
(see Materials) for 30-40 minutes at 55°C. Plots were then washed a minimum of 3x in 
30ml of PBSa/T before being blocked and re-probed (as described above).
2.2.9.3 TCA precipitation
50% (w/v) TCA was added to the protein solution in a 1.5ml reaction vial to give a final 
concentration of 5%. The mixture was incubated on ice for 10 minutes and the 
precipitated proteins were pelleted by centrifugation at 14,000 r.p.m. for 5 minutes at RT 
in a microfuge. The pellet was washed in 100% ethanol and pelleted (as above) and 
resuspended in the appropriate volume of BM buffer. Samples were either analysed 
directly by SDS-PAGE or frozen at -20°C until required.
2.2.9.4 Sucrose gradient sedimentation
5-20% sucrose gradients in buffer O were prepared in 13x51mm Ultra Clear tubes 
(Beckman) using a BIOCOMP gradient maker (Gradient Master# 106), following the 
manufacturers guidelines. The gradients were allowed to cool at 4°C for a minimum of 5 
hours before application of sample and ultracentrifugation. Typically 300pl of sample was 
mixed with 50pl of BSA (5mg/ml) and gently layered onto the top of the gradient. The 
gradient was then centrifuged at 40,000 r.p.m. for 16 hours at 4°C in a AH650 rotor. 
Following ultracentrifugation, the gradients were carefully removed from the rotor and 
placed into a clamp. A 1.5mm gauge needle (Microlance3) was used to pierce the 
centrifuge tube approximately 5mm from the base and successive 150pl fractions were 
collected into 1.5ml reaction vials (typically 35 fractions/gradient). Gradient protein 
profiles were analysed by SDS-PAGE, in conjunction with Coomassie Brilliant Blue 
staining or Western blot analysis, of every third fraction. Once the relative fractions 
containing the appropriate protein samples were identified, further SDS-PAGE analysis 
was carried out in conjunction with Coomassie Brilliant Blue staining or Western blot 
analysis. The relative intensity profile for each sample across the gradient was calculated 
by taking a digital picture of the appropriate SDS-PAGE gel or autoradiograph. This
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profile was analysed using Quantity ONE software (BIO-Rad, following the manufactures 
guidelines) to provide an intensity profile of the protein samples across the gradient. 
These profiles were then plotted as a percentage change in relative intensity for each 
sample against their appropriate fraction number using Origin 3.1 software.
2.2.9.5 Capsid assembly analysis
2.2.9.5.1 In vitro capsid assembly
To test the functionality of purified proteins, in vitro capsid assembly was carried out as 
described by Newcomb et al (1994). Briefly, frozen cell pellets (typical 30ml) of SF21 
cells infected singly at 5 p.f.u./cell with recombinant baculoviruses expressing one of the 
four essential capsid proteins; AcUL19 (VP5), AcUL26.5 (preVP22a), AcUL38 (VP19c), 
AcUL18 (VP23), were resuspended in 50pl of the appropriate buffer and freeze/thawed a 
minimum of 4x on dry ice. The lysates were clarified at 14,000 r.p.m. for 5 minutes at RT 
in a microfuge. The appropriate soluble lysate fractions were then mixed, typically lOpl 
of each clarified extract, and incubated o/n at 28°C to allow capsid formation to take place. 
Capsids were sedimented at 30,000 r.p.m. for 45 minutes at 4°C in a Beckman TLS-55 
rotor. Following sedimentation the supernatant was removed and the pellet resuspended in 
10-20pl of PBSa. Typically 5.0pl of the resuspended pellet was transferred to a parlodion 
coated copper grid and allowed to absorb for 2-3 minutes. Grids were then stained with 
1% phosphotungstic acid, analysed for the presence of capsids using a JEOL 100S electron 
microscope and photographed using Kodak 4489 film.
2.2.9.5.2 In vivo capsid assembly
35mm dishes of SF21 cells at 80% confluency were infected at 5 p.f.u./cell each with a 
panel of recombinant baculoviruses expressing individually one of the four essential capsid 
proteins; AcUL19 (VP5), AcUL26.5 (preVP22a), AcUL38 (VP 19c), AcUL18 (VP23). Or 
in the case of the dual expression baculoviruses Ac 1863 8 and 18386 which co-express 
VP19c/VP23His or VP19cHis/VP23 respectively, baculoviruses expressing AcUL18 
(VP23) and AcUL38 (VP 19c) were omitted. Infected cells were harvested at 48 hours 
post-infection in lml of PBScomplete and transferred to a BEEM capsule (TAAB
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Laboratories). The cells were pelleted by centrifugation at 1,000 r.p.m. for 5 minutes at 
RT in a vertical centrifuge (Beckman microfuge-12). The supernatant was carefully 
removed and the cell pellets fixed o/n at 4°C in 500pl of 2.5% glutaraldehyde (1:10 
dilution of 25% glutaraldehyde in PBScomplete). The pellets were subsequently washed 
3x in PBS complete before being overlayed for 1 hour at RT with lOOpl of osmium 
tetroxide. The fixed pellets were then wash 2x in PBScomplete before being dehydrated in 
consecutive 500pl washes of 30%, 50%, 70%, 90%, and 2x 100% ethanol. Each 
dehydration step was carried out for a minimum of 2 hours and care was taken not to 
dislodge the fixed cell pellet. After the final dehydration step the ethanol was removed and 
the fixed pellets were infiltrated with EponlOO resin and left o/n at RT. The resin was then 
removed by inverting the tube on to tissue paper and leaving it to drain for 30-60 minutes 
at RT. Fresh resin was overlayed and incubated o/n at RT and subsequently baked at 60°C 
for 2 days. The resin blocks were then cut into thin sections using a diamond knife on a 
ultra-microtome (Ultracut-E, Reichart-Jung) before being mounted on parlodion coated 
copper grids and stained for 1 hour with saturated uranyl acetate in 50% (v/v) ethanol. The 
grids were washed in dFLO and counter-stained with lead citrate for 1 minute before being 
gently rinsed in dFLO to remove excess stain. The sections were examined using a JEOL 
100S electron microscope and photographed on Kodak 4489 film.
2.2.10 Biophysical characterisation techniques
2.2.10.1 Fluorescence and ANS binding.
Proteins analysed by fluorescence were purified to homogeneity using Ni-NTA affinity 
chromatography (as described in section 2.2.8.4). Protein fluorescence was monitored at 
RT using a Perkin-Elmer LS-50B spectrofluorimeter in a lml semimicrocuvette with a 
path length of 1 cm. The excitation wavelength was 295nm and the emission spectra were 
recorded between 310-380nm. For ANS binding experiments, ANS was added to the 
protein samples to a final concentration of 20pM. The samples were then excited at 
370nm and the emission spectra were recorded between 440-540nm (unless otherwise 
stated). For both fluorescence and ANS spectra the appropriate buffer profiles were 
subtracted from the recorded emission spectra.
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2.2.10.2 Circular-dichroism (CD)
CD spectra were obtained on a Jasco-600 spectropolarimeter (Japan Spectroscopic Co., 
Tokyo, Japan). Near-UV CD spectra (320-260nm) were recorded using a cylindrical 
quartz cell with a path length of 0.5 cm. Far-UV CD spectra (260-190nm) were recorded 
using a cylindrical quartz cell with a path length of 0.5 cm. The content of secondary 
structure was estimated by using the CONTES! procedure. All experiments were carried 
out at 25°C with appropriate buffer only control spectra being subtracted from the recorded 
emission spectra.
2.2.10.3 Digital scanning calorimetry (DSC).
Calorimetric measurements were carried out using a MC-2 precision differential scanning 
micro-calorimeter (Microcalc). The rate of heating was l°C/min, and the excess pressure 
was kept at 8x106 Pa. Protein was analysed at a concentration of 0.5mg/ml in the 
appropriate buffer. The molar heat capacity of the protein was calculated by comparison 
with duplicate samples containing the identical buffer from which the protein had been 
omitted.
2.2.10.4 Size exclusion chromatography.
Chromatography was carried out using a 25ml (1 by 30 cm) superose-12 gel filtration 
column (Pharmacia) in the appropriate buffer that had been filter through a 0.2pm filter. 
All protein samples were clarified before analysis, either by filtration through a 0.2pm 
filter or by ultracentrifugation at 35,000 r.p.m. for 10 minutes at RT in a Beckman TLA
100.2 rotor. In all experiments the column was run at 0.5 ml/min. Protein size standards 
used to generate a standard curve were; p-amylase (MW, 200,000), alcohol dehydrogenase 
(MW, 150,000), bovine serum albumin (MW, 66,000), ovalbumin (MW, 45,000), and 
carbonic anhydrase (MW, 29,000) (SIGMA). Protein standards were analysed in the same 
buffer at the same concentration as the protein sample for comparative analysis. Standard 
curves were generated by plotting peak elution volumes against their given Logio MW 
(Sigma) using Origin 3.1 software. Linear regression analysis was performed upon the
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data utilising the spreadsheet software to generate a best-fit line, from which the native 
MW of purified sample proteins could be calculated.
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Results
Results: 3.1
3.1 Reverse Yeast Two Hybrid System
Due to time constraints during my PhD the experimental work within this section was 
unable to be finished and is currently ongoing within the laboratory. However, as a record 
of work undertaken during the course of my PhD and for future reference the preliminary 
results are presented below and discussed in relation to published experimental findings.
3.1.1 Yeast two hybrid system
Fields and Song (1989) were the first group to describe the use of the yeast two hybrid 
system to analyse protein-protein interactions within yeast Saccharomyces cerevisiae. 
They took advantage of the yeast transcriptional activator GAL4 that is required for the 
efficient expression of enzymes involved in the galactose utilisation pathway (Johnston et 
al., 1987). The GAL4 activator can be separated into two functional domains: an N- 
terminal DNA binding (DB) domain, which specifically binds to UASg sequences; and a 
C-terminal activator domain (AD) containing acidic residues, which is required for 
efficient transcriptional activation (Ma and Ptashne, 1987). If these domains are expressed 
separately the activation domain cannot localise efficiently to the chromosome and activate 
gene expression. Fields and Song (1989) went onto describe the construction of plasmids 
expressing SNF1, a serine threonine protein kinase, fused to the DB domain of GAL4 and 
SNF4, a protein physically associated with SNF1, fused to the AD of GAL4. The 
interaction of these two proteins when expressed in Saccharomyces cerevisiae was 
sufficient to bring the AD and DB domains into close enough proximity to reconstitute 
GAL4 activity and induce the efficient expression of a lacZ reporter gene that was fused 
down stream of GALl. Fig. 3.1.1 summarises the theory of the yeast two hybrid system 
described by Field and Song (1989).
3.1.1.1 Yeast two hybrid analysis o f HSV-1 capsid protein interactions
Desai and Person (1996) utilised the yeast two-hybrid system in conjunction with deletion 
mutagenesis to investigate the protein-protein interactions amongst the HSV-1 capsid
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Fig. 3.1.1: Schematic representation of the yeast two hybrid system. 
X and Y represent recombinant proteins under analysis. 
(Modified from Fields & Song 1989)
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proteins. Interestingly, the experiments by Desai and Person did not detect all the HSV-1 
capsid protein interactions, specifically the interaction between VP 19c and VP5. The 
inability to detect such an interaction could be explained in a number of ways. It is now 
becoming clear that virus capsid assembly is a dynamic process involving a number of 
folding stages (Trus et al., 1996; Newcomb et al., 1996; Johnson, 1996). Therefore, in 
order to detect certain protein-protein interactions utilising the yeast two hybrid system 
there may be a requirement for additional capsid proteins, over that of the two 
recombinantly expressed hybrid capsid proteins. In other words, the ability to present 
specific residues required for a detectable interaction may require the presence of a third 
partner in order to ensure the correct conformation required for further protein interactions 
to develop. However, in this specific instance, the interaction between VP5/VP19c, the 
requirement for a third capsid protein partner would seem unlikely. Immunofluorescence 
experiments performed by Rixon et al., (1996) demonstrated that VP 19c can localise VP5 
in the nucleus of transfected cells. This would imply therefore that these two proteins 
alone can form a stable protein-protein interaction in the absence of other capsid proteins. 
The lack of a detectable interaction between VP5/VP19c may be a direct result of the 
fusion of AD and DB domains to the termini of these proteins. The fusion of such domains 
may interfere with their folding or prevent specific amino acids or epitopes from being 
presented in the correct conformational arrangement required for a detectable protein- 
protein interaction.
3.1.1.2 Deletion mapping o f protein-protein interactions within the yeast two hybrid 
system
i  It is worth noting that deletion mutagenesis, which is often applied in mapping protein-
i
! protein interactions, may affect protein stability. The deletion of an N- or C-terminal
|l domain for example may present hydrophobic residues to the solute which would
otherwise be buried within the interior of the protein or disrupt the protein backbone 
sufficiently to generate a mis-folded protein. Moreover, the sites of protein-protein 
interaction under analysis may be in broad non-overlapping domains and not condensed 
into a single specific domain. This would therefore not be detected using deletion 
mutagenesis and could lead to ambiguous and/or misleading results regarding sites of 
possible protein-protein interaction (Vidal and Legrain 1999; Desai and Person, 1996).
88
Results: 3.1
3.1.2 Reverse yeast two hybrid system
Vidal et al., (1996a and 1996b) were the first group to describe a reverse genetic selection, 
yeast two-hybrid system, termed the reverse yeast two-hybrid system. This yeast two- 
hybrid system could select, through the use of a counter-selectable marker, discrete single 
amino acid mutations that disrupted a defined protein-protein interaction. Vidal et al., 
(1996b) analysed the interaction between the transcription factor E2F1 and its partner DPI. 
They utilised random PCR mutagenesis to generate libraries of mutant E2F1 alleles and 
reverse genetic selection within yeast cells to identify those alleles with mutated amino 
acids, which abolished the interaction between E2F1 and DPI. Using this system they 
could identify, not only site specific mutations which affected the interaction but also 
second site compensatory mutations within DPI which could restore the interaction. This 
ability to genetically select and map single mutations and compensatory mutations 
circumvented the typical problems associated with the yeast two hybrid system. For this 
reason, the reverse two-hybrid system was chosen to analyse the interaction between 
VP 19c and VP23 and is summarised schematically in fig. 3.1.2 and discussed below.
3.1.3 Reverse yeast two hybrid analysis of VP19c and VP23
3.1.3.1 Generation o f  mutant alleles
Libraries of mutant UL18 alleles were made by random PCR mutagenesis (as described in 
Methods) using generic forward and reverse primers (shown in fig. 3.1.10, panel B) 
located within the GAL4 AD and T Ad c i  (see fig. 3.1.3) sequences respectively (described 
by Vidal et al., 1996b). MaV103 cells that had already been transformed with pPc97UL38 
(MaV103pPc97UL38) were subsequently transformed with the mutant UL18 alleles and a 
linearised EcoRI/Notl digested and CIP treated pPc86 backbone vector. Due to the 
overlapping AD and T a d c i  sequences within the UL18 PCR products and the vector, 
recombination and gap repair can occur within yeast cells to regenerate a functional 
pPc86UL18Mut. plasmid. UL18 alleles that produced a mutated VP23AD fusion protein 
that abolished the interaction with VP19cDB were then selected for their resistance to the 
counter selectable marker.
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Fig. 3.1.2: Schematic representation of the reverse yeast two hybrid system
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3.1.3.2 Negative selection o f mutant alleles
The reporter gene URA3 can act as both a negative and positive growth selection marker 
on medium containing 5-fluoroorotic acid (FOA) or on medium lacking uracil 
respectively. URA3 encodes orotidine-5’-phosphate decarboxylase, an enzyme required 
for the biosynthesis of uracil. Orotidine-5’-phosphate decarboxylase can also convert the 
non-toxic FOA into a toxic uridine analogue 5-fluorouracil. Therefore, any transcriptional 
activation of URA3 due to the interaction of hybrid AD and DB fusion proteins will result 
in the cell developing a FOA sensitive (FOA ) phenotype which will prevent growth.
r  n
Thus, a large population of FOA cells containing a few FOA resistant (FOA ) cells can be 
screened and those that are FOAR selected for further analysis.
3.1.3.3 Regulation ofURA3 and lacZ reporter genes within MaV103 cells
Basal levels of most GAL4 inducible promoters in S. cerevisiae are high enough to confer
o
an FOA phenotype. To counter this in MaV103 cells a URA3 reporter gene promoter was 
manufactured to contain a strong cis-acting upstream repression sequence (URS). The 
URS containing element within the URA3 reporter gene promoter is the yeast sporulation 
gene, SP013, promoter. SP013 is tightly repressed within yeast cells during mitotic 
growth and only activated under sporulation conditions. Therefore the fusion of the 
SP013 promoter to the wild type URA3 ORF confers a very tight Ura-, FOAR phenotype 
under normal growth conditions. To allow induction by GAL4 the SP013 promoter was 
modified to contain 10 GAL4-DNA binding sites (SPAL10::£/&43) to allow efficient 
GAL4 dependent activation. To ensure stability and reproducibility of results within 
MaV103 cells the SPAL10::(/&43 promoter construct was integrated into the yeast 
genome replacing the endogenous, disrupted Ty element at the ura3-52 locus on 
chromosome IV.
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3.1.3.4 Other reporter genes within MaV103 cells
The lacZ reported gene is fused to the full length GAL1 promoter to generate GALl::lacZ 
at an unknown locus within the yeast chromosome. MaV103 cells also contain an 
integrated single copy of the His3 reporter gene linked to its own promoter containing an 
integrated 125bp G A L u a s  sequence to generate GAL1::HIS3. HIS3 encodes imidazole 
glycerol phosphate dehydratase, an enzyme required in histidine biosynthesis. This 
enzyme can be inhibited in a dose dependent manner by 3-aminotriazole (3-AT). 
Therefore, the strength of GAL4 transcriptional activation can be titrated in a dose 
dependent manner by 3-AT, using the induction of transcriptional activation of 
GAL1::HIS3 as a positive selection for interacting fusion proteins. Reporter gene 
construction and regulation is discussed in detail in Vidal et al., (1996a); Kishore and Shah 
(1988); Fields and Song (1989); Durfee et al. (1993).
3.1.3.5 GAL4 fusion vectors used in the reverse yeast two hybrid system
pPc86 and pPc97 expression vectors were obtained from Marc Vidal and are illustrated 
schematically in fig. 3.1.3 (panels A and B respectively). pPc86 encodes the GAL4(AD) 
sequence and pPc97 encodes the GAL4(DB) sequence, which are expressed from the yeast 
constitutive promoter P a d c i -  The polylinker region is flanked by a terminator ( T a d c i )  
sequence from the yeast ADC1 gene. The pPc86 plasmid carries a Trpl selection marker 
and has a NLS sequence fused to the GAL4(AD) codons for efficient translocation of AD 
hybrid proteins to the nucleus. The pPc97 plasmid carries a Leu2 selection marker. Both 
pPc86 and pPc97 encode a bacterial origin of replication (ColEl ori), a yeast centromere 
(CEN6), a yeast origin of replication (ARSH4) and an ampicillin resistance gene {Amp). 
Unique restriction sites are marked in red. The construction of pPc86 and pPc97 is 
described in Chevray and Nathans (1992), and Vidal et al (1996b).
3.1.3.6 Cloning ofUL18 into pPc86
The UL18 ORF was subcloned from pETUL18 (described in section 3.3) as a EcoRI/Notl 
fragment. This removed the ATG start codon and the 6xHis tag from the ORF. The pPc86 
vector was digested with EcoRI/Notl and the overhanging ends dephosphorylated using
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CIP (as described in Methods). The UL18 fragment was ligated into the linear vector and 
electroporated into DH5a bacteria. Recombinant colonies were isolated and plasmid DNA 
obtained. Plasmids were analysed for the presence of the UL18 ORF by EcoRI/Notl 
digestion. The UL18 ORF cloning strategy is schematically represented in fig. 3.1.4.
3.1.3.7 Cloning o f VP 19c into pPc97
The UL38 ORF was sub cloned from pETUL38 as an EcoRI/Notl fragment, this removed 
the ATG and 6xHis tag from the ORF. This fragment was subcloned into the pPc86 vector 
to generate pPc86UL38 (as described above for the UL18 ORF cloning strategy). The 
UL38 ORF was then sub cloned out of pPc86UL38 as a Sall/Notl fragment and cloned in 
to Sall/Notl digested and CIP treated pPc97 vector. Recombinant plasmids were analysed 
for the presence of the UL38 ORF by a Sall/Notl digest. The UL38 ORF cloning strategy 
is schematically represented in fig. 3.1.5.
3.1.3.8 Fusion protein C-terminal truncations
One of the possible outcomes of random PCR mutagenesis is the generation of transcripts 
that encode a premature stop codon within the ORF and thus generate a truncated fusion 
protein. In order to screen out these truncated fusion proteins, and due to the lack of 
monoclonal antibodies against VP 19c, it was decided to clone a small epitope tag onto the 
C-terminus of VP 19c that could be screened for by Western blotting. The epitope chosen 
was pp65 from HCMV.
3.1.3.9 Cloning strategy for UL38 pp65 epitope tagged into pPc97
The UL38 ORF was sub cloned from the pETUL38 vector as a EcoRI/SphI fragment, 
removing the ATG and the 6xHis tag from the ORF. The SphI digest also removed the 
stop codon and the last 4bp of the UL38 ORF. The C-terminus was reconstructed by the 
ligation of an oligonucleotide (fig. 3.1.6, panel B) that encoded the pp65 epitope tag and 
contains an engineered Notl site down stream from the stop codon. The sense and anti­
sense oligonucleotides were purified as described in Methods and heated in a dry block at 
100°C for 2 minutes in the presence of lx ligation buffer (Gibco-BRL). The
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oligonucleotides were annealed by allowing the dry block to cool naturally to RT. The 
EcoRI/Sphl UL38 ORF was ligated into EcoRI/Notl digested and CIP treated pPc86 vector 
in the presence of the annealed oligonucleotides. The ligation mix was electroporated into 
DH5a bacteria and single recombinant colonies were grown. The plasmid DNA was 
screened for the presence of the reconstituted UL38 ORF by EcoRI/Notl digestion. 
Plasmids containing the correct insert (pPc86UL38Epi) released a DNA fragment of 
~1500bp. The tagged UL38 ORF was sub cloned from pPc86UL38Epi as a Sall/Notl 
digest and ligated into Sall/Notl digested and CIP treated pPc97 vector. Recombinant 
plasmids were isolated and analysed for the presence of the UL38 ORF by a Sall/Notl 
digest. The cloning strategy is schematically represented in fig. 3.1.6, panel A.
3.1.6 Conclusions
3.1.6.1 Yeast two hybrid analysis
MaV103 cells were unable to grow on synthetic agar medium lacking either Leu or Trp 
(fig. 3.1.7). Growth of colonies was dependent on the successful transformation of either 
pPc86 or pPc97 yeast hybrid vectors when plated out on to synthetic medium lacking Trp 
or Leu respectively. Colony development of MaV103 cells only proceeded on synthetic 
agar medium lacking Leu/Trp/Ura when the MaV103 cells were co-transformed with 
plasmids expressing both the GAL4 AD and DB domains fused to VP23 and VP 19c 
respectively (figs. 3.1.8, panel A). MaV103 cells expressing plasmids encoding only 
VP 19c or VP23 but co-transformed with the appropriate complementing empty GAL4 
fusion plasmid did not induce the transcriptional activation of URA3 or p-galactosidase. 
This requirement for both capsid fusion proteins to be expressed indicates that the protein- 
protein interaction between VP 19c and VP23 within yeast cells is sufficient to co-localise 
AD and DB domains and restore GAL4 transcriptional activity. This result also 
demonstrates that the fusion of the AD and DB domains on to VP23 and VP 19c 
respectively does not appear to disrupt their interaction.
The interaction between VP 19c and VP23 was further validated colourmetrically by the p- 
galactosidase filter assay (fig. 3.1.8, panel B). Only those cells co-transformed with
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Fig. 3.1.7: Phenotypic characterisation of the MaV103 yeast cells
Single MaV103 colonies were isolated from a master YPD-agar plate 
and resuspended in 200pl of sterile dH20. A flamed loop was used to 
streak the individual resuspended colonies onto YPD agar or onto 
synthetic agar medium lacking Trp or Leu  (as indicated). Plates were 
incubated for 2 days at 30°C before being photographed.
?
(A)
(B)
Fig. 3.1.8: Yeast two hybrid analysis and P-galactosidase filter 
assay.
MaV103 cells were co-transformed with the appropriate plasmids 
and plated out onto SD-agar plates deficient in Leu/Trp/Ura. Yeast 
colonies were allowed to grow for 10 days at 30°C before being 
photographed. MaV103 cells co-transformed with; (A) Panel 1: 
pPc86 and pPc97. Panel 2: pPc86 and pPc97UL38 (VP19cDB). 
Panel 3: pPc86UL18 (VP23AD) and pPC97. Panel 4: MaV103 
pPc86UL18 (VP23AD) and pPc97UL38 (VP19cDB). (B) p- 
galactosidase filter assay. Colonies containing the appropriate 
plasmids (2-3 days old) were transferred to a reinforced nitro­
cellulose membrane and cultured as described in Methods. The 
cells were permeabilised in liquid nitrogen and assayed for the 
presence of p-galactosidase as described in Methods. MaV103 
cells were co-transformed with; Lane 1: pPc86 and pPc97. Lane 2: 
pPc86 and pPc97UL38 (VP19cDB). Lane 3: pPc86UL18 
(VP23AD) and pPC97. Lane 4: pPc86UL18 (VP23AD) and 
pPc97UL38 (VP19cDB).
Results: 3.1
plasmids expressing both VP23AD (pPc86UL18) and VP19cDB (pPc97UL38) were able 
to induce the transcriptional activation of P-galactosidase. As with URA3, the 
transcriptional activation of p-galactosidase requires the GAL4 AD and DB domains to be 
fused to VP23 and VP 19c respectively. Cells expressing plasmids where one of the hybrid 
fusion proteins was absent were unable to reconstitute GAL4 binding and consequently 
failed to induce the transcriptional activation of lacZ. These results confirm the published 
findings of Desai and Person (1996) and demonstrate that VP23 and VP 19c capsid proteins 
interact efficiently within yeast cells. The N-terminal GAL4 fusion domains do not appear 
to affect the ability of VP23 and VP 19c to interact and bring the GAL4 domains together 
to reconstitute GAL4 transcriptional activity.
3.1.6.2 Expression ofUL38 and UL38Epi in the yeast two hybrid system
It is interesting to note that the UL38 ORF cloned from the bacterial plasmid pETUL38 
was able to restore GAL4 activity (fig. 3.1.9, panel 4), since pETUL38 expression of 
VP 19c within bacteria is very poor and only detectable by Western blot analysis. The fact 
that the UL38 ORF restored GAL4 activity within yeast cells with the appropriate hybrid 
partner suggests that the poor production of VP 19c in bacteria is not due to mutations 
within the UL38 ORF. However, the construction of a VP19cDB hybrid fusion protein 
containing a C-terminal pp65 epitope tag abolished the ability of VP 19c to interact with 
VP23AD. This is shown by the inability of MaV103 cells expressing pPc86UL18 and 
pPc97UL38Epi to grow on synthetic agar medium lacking LeulTrplUra (fig. 3.1.9), in 
contrast to the positive, pPc86UL18/pPc97UL38 control. This suggests that the C- 
terminal domain of VP 19c is essential for the interaction with VP23 and that the insertion 
of the pp65 epitope tag blocked or changed the conformational arrangement of the C- 
terminal residues required for the interaction. Indeed, there is some evidence for this from 
the literature. Desai and Person (1996) could not detect any interaction between VP 19c 
and VP23 utilising the yeast two-hybrid system when the C-terminal third of either protein 
was deleted. Spencer et al., (1998) also demonstrated by immune precipitation that 
deletion of just 15 amino acids from the C-terminus of VP 19c could abolish the interaction 
with VP23. The C-terminal deletion mutant of VP 19c was also unable to support in vitro 
capsid assembly from infected cell lysates demonstrating the essential requirement for 
these residues.
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Fig. 3.1.9: Analysis of  pPc97UL38Epi (VP19cDB.Epi).
MaV103 cells were co-transformed with the appropriate plasmids and 
plated out onto SD-agar plates deficient in Leu/Trp/U ra. Yeast colonies 
were allowed to grow for 10 days at 30°C before being photographed. 
MaV103 cells co-transformed with; Panel 1: pPc86 and pPc97. Panel 2: 
pPc86 and pPc97UL38 (VP19cDB). Panel 3: pPc86UL18 (VP23DB) and 
pPc97UL38Epi (VP19cDB.Epi). Panel 4: pPc86UL18 (VP23AD) and 
pPc97UL38 (VP19cDB).
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3.1.6.3 Reverse yeast two hybrid analysis
Co-transformation of the UL18 PCR products into MaV103 cells together with linear 
pPc86 vector DNA allowed homologous recombination and gap repair that regenerated 
replicating vectors that conferred a positive Trp selection phenotype (fig. 3.1.10, panel A). 
However, the only requirement for growth in this experiment is the regeneration of a 
replicating pPc86 plasmid with or without an insert. If the linearised vector was not 
dephosphorylated using CIP then the number of false positives increased (data not shown). 
Gap repair of linearised pPc86 was only detected when co-transformed with a UL18 PCR 
product (fig. 3.1.10, panel A). No gap repair was detected between the linearised pPc86 
plasmid and endogenous pPc97UL38 within the MaV103pPc97UL38 cells (MaV103 cells 
transformed with pPc97UL38), fig. 3.1.11 (panel 1). This is important since pPc86 and 
pPc97 are closely related plasmids with much sequence homology.
3.1.6.4 FOA selection
As previously described in section 3.1.3.2, FOA can act as counter selectable marker for 
transcriptional activation of URA3. To illustrate this fig. 3.1.11 shows the growth 
phenotypes on medium lacking Leu & Trp and containing 0.2% FOA of MaV103 cells 
transformed with appropriate plasmids. In the presence of FOA the growth of MaV103 
cells is dependent upon the disruption of the interaction between the GAL4 fusion proteins. 
This FOAr was demonstrated when the growth of MaV103pPc97UL38 cells transformed 
with pPc86 vector (fig. 3.1.11, panel 2) was compared to that of MaV103pPc97UL38 cells 
transformed with pPc86UL18 (fig. 3.1.11, panel 3). These experimental controls 
demonstrate that 0.2% FOA in the selection medium is sufficient to prevent the growth of
o
colonies displaying an FOA phenotype.
FOAr  colonies could be selected when mutated UL18 alleles produced by random PCR 
mutagenesis were co-transformed together with linearised pPc86 into MaV103pPc97UL38 
cells. MaV103 cells require both GAL4 hybrid vectors to be present in a circularised form 
in order to confer growth on media lacking Leu and Trp (fig. 3.1.11, panel 1 and 2). If one 
of the GAL4 hybrid vectors is present in a linear form then the cells cannot sustain growth 
due to the inability of the linear plasmid to replicate and confer selective growth (fig.
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Fig. 3.1.10: Recombination and gap repair of mutant UL18 PCR 
alleles into linearised pPc86 vector
MaV103 cells were co-transformed with the appropriate plasmids 
and PCR products and plated out onto SD-agar deficient in Trp. 
Yeast colonies were allowed to grow for 2 days at 30°C before 
being photographed (A). MaV103 cells transformed with; Panel 1: 
pPc86. Panel 2: pPc86UL18 (VP23AD). Panel 3: linear 
(EcoRI/Notl digested/CIP treated) pPc86. Panel 4: linear 
(EcoRI/Notl digested/CIP treated) pPc86 and Mut.UL18PCR 
product. (B) Generic forward (AD) and reverse (Term) PCR 
primers used in the generation of mutant UL18 alleles by random 
PCR mutagenesis (as described in Methods).
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3.1.11, panel 1). Colony growth is therefore dependent on the reconstitution of circular 
GAL4 hybrid vectors by homologous recombination and gap repair. FOA selection 
ensures that only those colonies with a reconstituted pPc86 vector expressing a VP23AD 
fusion protein that cannot interact with VP19cDB, display a FOAR phenotype. This non­
interaction has a selective advantage on synthetic media containing FOA due to the lack of 
transcriptional activation of URA3 which prevents the formation of the toxic metabolite of 
FOA, 5-fluorouracil. The presence of uracil in the selective medium, ensures that colonies 
which contain the non-interacting proteins that confer the FOAR phenotype, are able to 
grow and form colonies. These colonies can subsequently be picked for further analysis.
It is worth noting that the number of colonies varied on plates where the pPc86 vector has 
been rescued by gap repair with different pools of mutated UL18 alleles (figs. 3.1.11, 
panels 4 and 5). This is unlikely to be due to variation in the final DNA concentration 
since the PCR reactions were analysed by agarose gel electrophoresis (data not shown) and 
the concentrations adjusted to keep an approximately uniform concentration of UL18 
alleles. The variation in the number of colonies observed is likely to reflect the frequency 
of reading errors induced by MnC^ during PCR mutagenesis. Similarly, more then one 
Taq MnCb induced error per UL18 ORF would also result in the amplification of multi­
mutant alleles that had a greater chance of affecting protein-protein interactions between 
hybrid domain partners.
3.1.6.5 Analysis o f negatively selected mutant alleles.
To ensure that colony development was due to non-interacting GAL4 fusion hybrid 
proteins and not due to a failure in FOA to select FOAR colonies. Colonies were replica 
picked with the appropriate controls onto fresh synthetic agar medium lacking Leu!Trp and 
containing 0.2% FOA (fig. 3.1.12). The positive control for FOAR, MaV103 cells 
containing pPc86 + pPc97UL38 (fig.3.1.12, panel 3) grew successfully in these conditions. 
Conversely, the negative controls for FOAR, MaV103 cells containing 
pPc86UL 18+pPc97UL3 8 (fig. 3.1.12, panel 2) did not display any growth. It is clear from 
fig. 3.1.12 (panel 1) that most of the colonies containing putative mutant UL18 alleles had 
retained their FOAR phenotype in the second round of selection. 4 colonies that readily 
grew on the second round selection plate were chosen randomly and analysed further. The
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Fig. 3.1.11: FOA negatives selection of mutants UL18 alleles
MaV103pPc97UL38 cells were transformed with the appropriate 
plasmids and mutated UL18 PCR alleles (as describe in Methods) and 
plated out onto SD-agar medium lacking Leu/Trp  containing 0.2% 
FOA. Yeast colonies were allowed to grow for 4 days at 30°C before 
being photographed. MaV103pPc97UL38 cells were transformed with; 
Panel 1: linear (EcoRI/Notl digested/CIP treated) pPc86. Panel 2: 
pPc86. Panel 3: pPc86UL18 (VP23AD). Panel 4: linear pPc86 and 
mutated UL18 alleles (PCR1). Panel 5: linear pPc86 and mutated UL18 
alleles (PCR2).
(2) * * * u a  1J (3 )
Fig. 3.1.12: Second round FOA selection o f  mutant U L 18 alleles.
A mixture o f  colonies from the first round of  negative selection 
were replica picked (as described in methods) with the appropriate 
controls onto a fresh SD-agar plate lacking Leu/Trp  containing 
0.2% FOA. Plates were incubated for 2 days at 30°C before 
being photographed. (1) Second round negative selection of 
picked colonies. (2) Negative control for non-interaction. Two 
individual replica picked colonies of MaV103pPc97UL38 cells 
transformed with pPc86UL18. (3) Positive control for non­
interaction. Two individual replica picked colonies of 
MaV103pPc97UL38 cells transformed with pPc86.
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possible outcomes of random PCR mutagenesis upon UL18 alleles and the resulting FOA 
phenotypes are summarised schematically in fig. 3.1.2. The three types of mutant allele 
that could be generated are: (I) Alleles that are mutated in regions that do not affect 
protein conformation or affect the sites of interaction with VP 19c. These alleles will 
exhibit the same FOA phenotype as the WT fusion protein and will not grow in the 
presence of FOA. (II) Alleles which contain mutations that generate stop codons within 
the ORF, leading to the production of truncated fusion proteins. If the truncation is severe 
enough to disrupt the interaction, these mutations will prevent GAL4 transcriptional 
activation of URA3 and therefore confer a FOAR phenotype. (Ill) Alleles that have random 
mis-sense mutations within the ORF and generate full length proteins that cannot interact 
with their hybrid fusion partner. The disruption of interaction could be due, either to direct 
effects on specific sites involved in protein-protein interaction or to mutations elsewhere in 
the protein altering its conformation and disrupting the sites required for interaction. 
These mutations, like those generated in (II), would prevent GAL4 transcriptional 
activation of URA3 and therefore colonies containing such alleles would have a FOAR 
phenotype and consequently grow in the presence of FOA.
In order to characterise which type of mutation (II or III) was responsible for the FOAR 
phenotype of the selected colonies, it was decided to screen for any truncated mutant 
proteins by Western blotting, probing the nitro-cellulose membrane with a monoclonal 
antibody that specifically recognised VP23. Protein cell extracts were generated from 
cultures grown form a single colony arising from the second round of FOA selection. 
Extracts were then analysed by SDS-PAGE and Western blotting. Repeated attempts were 
made to generate good yeast cell extracts using a variety of methods; these included Y- 
PER (Pierce) extraction buffer, urea/SDS extraction and TCA protein extraction protocols. 
The most successful of which was the TCA protein extraction method (described in 
Methods). The typical recovery of proteins extracted from yeast cells is shown Fig. 3.1.13 
(panel A). The poor recovery of proteins from yeast cells is probably due to the thickness 
of the yeast cell wall and the inefficient cell lysis due to milling with acid washed glass 
beads. Repeated attempts were made to identify the VP23AD fusion protein by Western 
blotting, all of which failed (fig. 3.1.13, panel B). Therefore, in order to determine 
whether or not gap repair had worked plasmid DNA was purified from yeast cultures 
grown from single colonies derived from the second round FOA selection and digested
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Fig. 3.1.13: SDS-PAGE and Western blot analysis of yeast cell
protein extracts.
Proteins were extracted from yeast cells expressing the appropriate 
plasmids using the TCA extraction protocol as described in Methods. 
(A) 20pl of the appropriate extract and 3 pi of Rainbow markers (lane 
1) were analysed by SDS-PAGE and stained with Coomassie Brilliant 
Blue. MaV103pPc97UL38 cells transformed with; Lane 2: pPc86. 
Lane 3: pPc86UL18. Lane 4: A01 FOA resistant colony. Lane 5: A02 
FOA resistant colony. Lane 6: A03 FOA resistant colony. Lane 7: 
A04 FOA resistant colony. (B) 20pl of the appropriate extract and 
3 pi of B capsids (lane 1) were analysed by SDS-PAGE and 
transferred to a nitro-cellulose membrane as described in Methods. 
The nitro-cellulose membrane was probed with a monoclonal 
antibody (CB003), which specifically recognises VP23. Lane 2: 
MaV103 pPc86UL18 cell extract. Lane 3: MaV103 cell extract.
U L18 
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Fig. 3.1.14: 1% TBE gel o f  plasmid DNA purified from yeast.
Single yeast colonies from the second round of FOA selection were 
used to seed 5ml of YPD medium and cultured o/n at 30°C in an orbital 
shaker. Plasmid DNA was isolated from each culture, as described in 
Methods and analysed for the presence o f  a -1000 bp UL18 fragment 
by an EcoRI/Notl restriction digest. 5pl o f  each analytical digest was 
electrophoresed on a 1% agarose gel in lxTBE. Lane 1: EcoRI/Notl 
digested pPc86UL18 stock DNA. Lane 2: 1 kb X BstEII marker. 
Lanes 3-6: EcoRI/Notl digested plasmid DNA from A01 - A04 FOA 
resistant colonies respectively.
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with EcoRI/Notl to release the UL18 ORF from the pPc86 expression vector. The results 
of this digest are shown in fig. 3.1.14. A control digestion was set up (fig. 3.1.14, lane 1) 
using plasmid stock DNA of pPc86UL18 to identify the appropriate UL18 ORF DNA 
fragment (indicated by an arrow in fig. 3.1.14). 3 out of the 4 FOA resistant colonies gave 
DNA fragments of the appropriate size, approximately lkb in length (A 1-3 FOAR 
colonies). This indicates that the gap repair and homologous recombination into the linear 
pPc86 vector was successful and that the FOA resistance was probably due to the VP23AD 
hybrid fusion protein containing mutation(s) which prevented interaction with VP19cDB. 
Unfortunately due to time constraints at the end of my PhD experiments to identify 
possible mutants could not be performed.
3.1.6.6 Future work
Due to the difficulty in obtaining good protein extracts from yeast cells, and due to the 
relative low level of expression of the VP23AD fusion protein, the characterisation of 
possible mutants for truncations and/or mis-sense mutations could not be carried out 
directly on yeast extracts. Other methods for generating yeast cell protein extracts could 
be tested in order to characterise possible VP23AD mutants by Western blotting. For 
example, enzymatic digestion of the yeast cell walls utilising lyticase. An alternative route 
of analysis would be to subclone possible mutant UL18 ORFs back into the bacterial 
expression vector pET28MOD. Plasmid DNA isolated from yeast cells could be analysed 
for the presence of the UL18 ORF by Southern blot analysis. This would provide direct 
evidence to establish the success of gap repair within yeast cells and provide a further 
means of testing FOAR colonies for the incorporation of UL18 alleles before subcloning.
Following cloning into pET28MOD, the mutated UL18 inserts could be analysed for 
expression of full length VP23, either by Western blotting, or by direct visualisation of the 
protein by SDS-PAGE and Coomassie Brilliant Blue staining. Any mutant UL18 alleles 
identified, which were shown to produce full length VP23 AD, would need to be reanalysed 
for their ability to disrupt the VP19cDB interaction by re-introducing the isolated plasmid 
DNA back into the reverse yeast two hybrid system. The degree of disruption between the 
interacting hybrid partners could then be quantified using a P-galactosidase liquid culture 
assay and comparing the level of p-galactosidase activity to that of the WT hybrid
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VP23DB and VP19cAD level. Mutants that demonstrate a significant decrease in the 
levels of p-galactosidase transcriptional activation could then be sequenced in order to 
identify the specific amino acid residues that are mutated. This assay could have been 
used on those colonies selected in the second round of FOA negative selection had time 
permitted. Mutations identified within the UL18 ORF that disrupt the interaction between 
VP23 and VP 19c should be characterised further, either in vivo or in vitro, where the 
capsid proteins are expressed without the GAL4 AD and DB fusion domains, for example 
in in vitro capsid assembly experiments. Such experiments would demonstrate whether or 
not those mutations detected within the reverse two hybrid system directly affect protein- 
protein interactions between VP 19c and VP23 or whether they their effects are specific to 
the reverse two hybrid system and abolish GAL4 transcriptional activation by some other 
mechanism.
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3.2 Characterisation of monoclonal antibodies
One of the consistent problems throughout the course of my PhD was the lack of 
monoclonal antibodies that could be used to detect the triplex proteins VP 19c and VP23. 
Although the majority of analyses performed upon these proteins involved the recombinant 
expression of proteins with N-terminal 6x His epitope tags, to which monoclonal 
antibodies are commercially available (Qiagen), in some cases, such as 
immunofluorescence, antibodies that could detect untagged proteins were required.
Following the successful purification of 6xHis tagged triplexes in buffer O (see section
3.5.4 for details) from Ac 18638 infected SF cells, it was decided to generate a panel of 
monoclonal antibodies that could specifically recognise amino acid sequences within VP23 
and/or VP 19c.
3.2.1 Immunisation protocol
All immunisation, test bleeds, and fusion procedures were carried out by Susan Graham. 
BALB/c mice were immunised following the protocol described in Methods (section 2.2.3) 
and summarised in table 2.2.1. Immunisation was initially carried out using purified 
triplexes from Ac 18638 (VP23His/VP19c) infected SF cells (following the purification 
strategy described in section 3.5.4). However, following poor detection of anti VP 19c 
activity in test bleeds, it was decided to boost the remaining BALB/c mice with purified 
VP19cHis. Due to the difficulty associated at the time with purifying recombinantly 
expressed VP19cHis from SF cells infected with Ac381 (discussed in section 3.4.3), it was 
decided to purify VP19cHis by denaturing purified triplexes from Ac 183 86 
(VP19cHis/VP23) infected SF cells. As the N-terminal 6xHis epitope tag was located on 
VP 19c the majority of the VP23 was removed by denaturation in 3M urea. The urea was 
removed by washing the Ni-NTA agarose in buffer O. The bound protein, predominantly
<2 i
denatured VP19cHis, was eluted from the agarose by stripping the Ni from the NTA 
agarose resin in EDTA (see section 3.4.2 and fig. 3.4.3 for further details). The mice were 
boosted with denatured VP19cHis until test bleeds showed positive detection of VP19cHis
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(approximately 60 days post VP19cHis immunisation) as determined by quantitative 
ELSIA analysis. Spleen cells from selected mice were used to generate hybridoma cell 
lines and the supernatant medium from each cell line was tested for the presence of 
antibodies against VP 19c and VP23.
3.2.2 Antibody screening by Western blot analysis
3.2.2.1 Monoclonal antibodies generatedfrom BALB/c mouse #4.
Supernatants harvested from hybridoma cell lines generated from spleen cells of a BALB/c 
mouse (#4), immunised with purified triplexes only, were tested by Western blotting (as 
described in Methods) for the presence of monoclonal antibodies which recognised 
purified triplex proteins. Table 3.2.1 summarises the information generated from testing 
supernatants from 27 hybridoma cell lines. None of these supernatants gave a strong 
signal against VP 19c, which confirms the findings of ELISA analysis showing poor anti­
sera response against VP 19c. 14 supernatants gave a strong signal against VP23His and 
these were tested by Western blotting against purified B-capsids in order to determine 
whether their specificity was directed towards the 6xHis epitope tag located on the N- 
terminus of VP23His. Fig. 3.2.1 (panel A) shows the results of the Western blot analysis 
against purified B-capsids. 7 out of the 12 supernatants tested gave a strong signal, 4 gave 
a good or detectable signal, and 1 (#CB092) failed to detect VP23 suggesting that it might 
be directed towards the N-terminal 6xHis epitope tag of VP23His. None of the antibodies 
tested against purified B-capsids recognised VP19c. Fig. 3.2.1 (panel B) shows the 
immunofluorescence analysis using CB040 to detect the cellular distribution of VP23His 
in BHK-21 C13 cells transfected with pE18H (a pCMVio based plasmid expressing 
VP23His, see section 3.3.9 for further details). In those cells expressing pE18H, VP23His 
could readily be detected throughout the cell as previously described by Nicholson et al., 
1994 and Rixon et al., 1996.
MAb. Western blot (18638) Western blot (B-capsids) IF
VP23 VP19c VP23 VP19c
CB003 +++ - ++ - n/t
CB023 +++ - ++ - n/t
CB040 +++ + +++ - +++
CB050 +++ - +++ - n/t
CB054 +++ + +++ - n/t
CB076 + - n/t n/t n/t
CB078 - - n/t n/t n/t
CB084 - - n/t n/t n/t
CB092 +++ - - - n/t
CB093 - - n/t n/t n/t
CB095 - - n/t n/t n/t
CB122 + - n/t n/t n/t
CB128 +++ - +++ - n/t
CB136 - - n/t n/t n/t
CB144 + - n/t n/t n/t
CB180 +++ - ++ - n/t
CB186 ++ - + - n/t
CB187 - - n/t n/t n/t
CB188 + - n/t n/t n/t
CB197 - - n/t n/t n/t
CB208 +++ - +H—h - n/t
CB211 +++ - +++ - n/t
CB293 +++ - +++ - n/t
CB318 - - n/t n/t n/t
CB341 +++ - n/t n/t n/t
CB351 +++ + n/t n/t n/t
CB495 + + n/t n/t n/t
Table 3.2.1: Summary of the monoclonal antibodies generated from 
BALB/c mouse #4 (120 days post-immunisation). The antibodies were 
rated for strength of signal by Western blotting against purified triplexes 
from SF cells infected with Ac 18638 (VP23His/VP19c) or purified B- 
capsids, and by immunofluorescence against cells transfected with pE18H 
(IF, as described in fig. 3.2.1); +++ (very good), ++ (good), + (weak), - 
(not detectable), and n/t (not tested).
VP23
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Fig. 3.2.1: Characterisation of monoclonal antibodies produced
from BALB/c mouse #4
Western blot analysis was performed (as described in Methods) 
against purified B-capsids. Following protein transfer and 
membrane blocking, the nitro-cellulose membrane was cut into 
strips using a sterile scalpel. The strips were individually 
probed with hybridoma cell supernatants in order to test for the 
presence of monoclonal antibodies that specifically recognised 
VP23 (A). The arrow indicates the predicted position of VP23 
as judged from transferred Rainbow markers. (B) BHK-21 C13 
cells were transfected with pE18H (VP23His), as described in 
Methods. The cellular distribution of VP23His was analysed by 
immunofluorescence using the hybridoma cell supernatant 
CB040 and a secondary goat anti-mouse IgG antibody 
conjugated to FITC (Sigma).
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3.2.2.2 Monoclonal antibodies generatedfrom BALB/c mice #1-3
Supernatants harvested from hybridoma cell lines generated from spleen cells of the 
remaining three BALB/c mice (#1-3), boosted with denatured VP19cHis (designated by 
CB2), were analysed by Western blotting (as described in Methods). Fig. 3.2.2 (panel A) 
shows Western blot analysis of hybridoma supernatants tested for the presence of 
monoclonal antibodies that recognised purified VP19cHis from Ac381 infected SF cells. 6 
out of the 8 supernatants tested gave a strong signal and 2 (#CB2034 and #CB2184) failed 
to detect the presence of purified VP19cHis. In order to determine whether or not their 
antibody specificity was directed towards the 6xHis epitope tag located on the N-terminus 
of VP19cHis, immunofluorescence was performed on BHK-21 C13 cells transfected with 
pE38 (a pCMVio based plasmid expressing VP 19c, see section 3.3.9 for further details). 
Fig. 3.2.2 (panel B) shows the cellular distribution of VP19c as detected by CB2017, 
CB2032, CB2040, CB2068, and CB2231, compared to that of a control medium (sterile 
hybridoma growth medium) and CB2184 (negative controls). In those cells expressing 
pE38, VP 19c gave a characteristic nuclear staining pattern as previously described by 
Nicholson et al., 1994 and Rixon et al., 1996, which could readily be detected within the 
nucleus using CB2017, CB2032, CB2040, CB2068, and CB2231. Control media failed to 
detect the presence of VP 19c in pE38 transfected cells. As VP 19c does not contain a His 
tag this suggests that these antibodies specifically recognise epitopes within VP 19c and are 
not directed towards the N-terminal 6xHis tag of VP19cHis which was used during the 
immunisation process. CB2184, which failed to detect VP19cHis in Western blot analysis, 
gave an unusual staining pattern in BHK cells, demonstrating a predominantly 
cytoplasmic, rather than the typical nuclear, fluorescence. These results taken together 
would suggest that CB2184 has no specific activity towards VP 19c. The characteristics of 
the monoclonal antibodies generated from BALB/c mice #1-3 are summarised in table 
3.2.2.
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Fig. 3.2.2: Characterisation of monoclonal antibodies produced
from BALB/c mice #1-3
Western blot analysis was performed (as described in Methods) 
against VP19cHis purified from SF cells infected with Ac381 (as 
described in section 3.4.3). Following protein transfer and 
membrane blocking, the nitro-cellulose membrane was cut into 
strips using a sterile scalpel. The strips were individually probed 
with Hybridoma cell supernatants in order to test for the presence 
of monoclonal antibodies that specifically recognised VP19His 
(A). Control media (sterile hybridoma growth medium) and a 
commercially available monoclonal 6xHis antibody (Qiagen) 
were also analysed for comparative purposes. The arrow 
indicates the position of VP19cHis as detected by the 6xHis 
monoclonal antibody. (B) BHK-21 C l3 cells were transfected 
with pE38 (VP 19c), as described in Methods. The cellular 
distribution of VP 19c was analysed by immunofluorescence 
using the hybridoma cell supernatants of CB2017, CB2032, 
CB2040, CB2068, and CB2231 and a secondary goat anti-mouse 
IgG antibody conjugated to FITC (Sigma). Control media and 
the hybridoma cell supernatant of CB184 were used as negative 
controls. CB2064 hybridoma cell line was not established prior 
to IF analysis and therefore remains untested.
MAb. Western blot 
(381)
IF (pE38)
CB2017 +++ +++
CB2032 +++ +++
CB2034 - n/t
CB2040 +++ +++
CB2064 +++ n/t
CB2068 +++ +++
CB2184 - -
CB2231 +++ +++
Table 3.2.2: Summary of the monoclonal antibodies 
generated from BALB/c mice #l-#3 (225 days post­
immunisation) and mouse #2 (246 days post­
immunisation). The antibodies were rated for their 
respective strengths of signal by Western blotting and 
immunofluorescence; +++ (very good), ++ (good), + 
(weak), - (not detectable), and n/t (not tested).
Results: 3.2
3.2.3 Conclusions and future work
Following the solubilisation of triplex proteins a number of monoclonal antibodies were 
raised which specifically recognised amino acid sequence epitopes within either VP 19c or 
VP23. Some of these antibodies have been used in further immunofluorescence analyses 
described within this thesis (sections 3.3.9 and 3.3.10). However, all the characterisation 
analyses described above and elsewhere in this thesis were performed using neat 
hybridoma supernatants. Work is currently on going within our laboratory to concentrate 
and purify these antibodies from large-scale cultures of their hybridoma cell lines through 
the use of affinity chromatography. Once purified these antibodies could be used to further 
characterise the interactions between VP23 and VP 19c. This could be accomplished by 
antibody blocking studies, for example either using Ni-NTA agarose pull down analysis 
(described in section 3.4.4) or through ELISA blocking studies, and epitope mapping those 
antibodies which specifically prevent triplex formation.
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Results: 3.3
3.3 Characterisation of the triplex protein VP23
3.3.1 Construction and expression of pETUL18
3.3.1.1 Cloning o f the UL18 ORF into pET28MOD
The cloning of the UL18 ORF into a modified version of the bacterial expression vector 
pET28a (Novagen Ltd.) was carried out by David McNab and is described in Kirktadze et 
al. (1998). The cloning of the UL18 ORF into pET28MOD fuses 6 histidines (6x His) and 
a thrombin cleavage site onto the 5' end of the UL18 ORF (the pET28MOD expression 
vector is schematically illustrated in fig. 3.3.1). The T7 promoter controls gene regulation 
of the UL18 ORF. Expression of the pETUL18 vector within bacteria therefore results in 
the production of VP23 with an N-terminal 6xHis epitope tag (VP23His). The pETUL18 
expression vector is schematically illustrated in fig. 3.3.2.
3.3.1.2 Bacterial expression ofVP23His in BL21 DE3 cells.
BL21 DE3 bacteria were electroporated in the presence of approximately lpg of pETUL18 
or pET28MOD vector DNA and kanamycin resistant colonies were isolated. Single 
recombinant colonies were grown and induced (as described in Methods) and analysed for 
the expression of VP23His by SDS-PAGE analysis and Western blotting. Fig. 3.3.3 (panel
A) shows the presence of a novel band in the induced pETUL18 sample when compared to 
that of the pET28MOD expression vector control. This novel band migrates with a 
slightly higher MW than that of VP23 from purified B-capsids, reflecting the additional 
amino acid sequences located at its N-terminus of VP23. This band was confirmed to be 
VP23 by Western blot analysis using the polyclonal VP23 antibody 187 (fig. 3.3.3, panel
B).
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Fig. 3.3.1: Construction of the pET28MOD expression vector.
An oligonucleotide (A) was inserted into the Ndel and EcoRI sites of the 
bacterial expression vector pET28a (Novagen Ltd.) to generate 
pET28MOD. The insertion of this oligonucleotide resulted in the 
destruction of the existing EcoRI site and the incorporation of novel 
EcoRI and Spel restriction sites (highlighted in red). (B) Schematic 
representation of the bacterial expression vector pET28MOD showing the 
6xHis epitope tag, thrombin cleavage site, and some of the unique 
restriction sites.
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Fig. 3.3.3: SDS-PAGE and Western blot analysis of VP23His expression 
in BL21 DE3 bacteria.
(A) BL21 DE3 bacterial cultures containing either pET28MOD vector 
(lane 3) or pETULl8 (lane 2) were grown and induced (as described in 
Methods). 1.5 ml of each culture was centrifuged at 14,000 r.p.m. for 30 
seconds. The supernatant was removed and the bacterial pellet was 
resuspended in 200pl of BM and heated for 2 minutes at 100°C in a dry 
block. 15pl of each sample was analysed by SDS-PAGE and stained with 
Coomassie Brilliant Blue. Purified B-capsids were run for comparison 
(lane 1). Arrows indicate the relative positions of the capsid proteins as 
determined by the B-capsid profile. * indicates the induced bacterial 
expression of VP23His. (B) Western blot analysis was performed on 
extracts from BL21 DE3 bacteria containing pETULl8 (lane 1), 
pET28MOD (lane 2), or on B-capsids (lane 3). The nitro-cellulose 
membrane was probed with a 1:1000 dilution of a polyclonal VP23 
antibody (187). The arrow indicates the position of VP23.
Results: 3.3
3.3.2 Purification of VP23His
3.3.2.1 Nickle-nitrilotriacetic acid (Ni-NTA) agarose affinity chromatography.
NTA is a tetradentate metal chelating adsorbent and occupies four out of the six ligand
2"hbinding sites in a co-ordinated sphere around the Ni ion, see fig 3.3.4 (panel A). This
2+
leaves two free Ni sites to interact with the histidine residues from the 6x His epitope tag 
located on the terminus of a recombinantly expressed protein molecule (fig. 3.3.4, panel
B). The Ni-NTA is coupled to Sepharose® CL-6B, which confers a high binding capacity 
with low non-specific binding and allows easy manipulation and purification of 
recombinantly expressed 6xHis tagged proteins by affinity chromatography. Ni-NTA 
agarose used in the purification of recombinantly expressed triplexes and triplex proteins 
was purchased from Qiagen.
3.3.2.2 Ni-NTA agarose purification ofVP23His
VP23His was readily purified using Ni-NTA agarose affinity chromatography from large- 
scale cultures of induced pETULl8 transformed BL21 DE3 bacteria (as described in 
Methods and fig. 3.3.5 legend). Fig. 3.3.5 shows a typical SDS-PAGE profile of purified 
VP23His. A single prominent band of approximately 34kDa was detected by Coomassie 
Brilliant Blue staining. The protein concentration for purified VP23His was typically in 
the range of 1.5-3.0 mg/ml for elution fractions 1 and 2 (as determined by OD28o)- Two 
other proteins were also purified (fig. 3.3.5, lane 2). A 70kDa protein, which was 
subsequently shown to be dimeric VP23His, and a 29kDa protein that was shown to be a 
breakdown/truncated VP23His product (discussed in section 3.3.3.2 and figs. 3.3.9). The 
MW of 34kDa for VP23His, as determined by SDS-PAGE analysis and comparison to 
Rainbow markers was in good agreement with the MW of 34268Da predict from the amino 
acid sequence (McGeoch et al., 1988).
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Fig. 3.3.4: Schematic representation of Ni-NTA (A) and Ni-NTA 
binding to two His residues from the 6xHis epitope tag (B).
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Fig. 3.3.5: SDS-PAGE analysis o f  Ni-NTA agarose purified
VP23His in sonication buffer.
VP23His was purified using 700pl o f  Ni-NTA agarose 
equilibrated in sonication buffer (as described in Methods). Post­
binding the Ni-NTA agarose was washed in 10ml o f  20mM 
imidazole in sonication buffer to remove proteins that had non- 
specifically bound to the Ni-NTA agarose. VP23His was eluted 
from the agarose in 5x 1ml fractions of 250mM imidazole in 
sonication buffer (lanes 2-6 respectively). 20pl of each fraction 
and Rainbow markers (lane 1) were then analysed by SDS-PAGE 
and stained with Coomassie Brilliant Blue. The position of 
VP23His is indicated by an arrow.
Results: 3.3
3.3.3 Size exclusion chromatography and sucrose gradient sedimentation
3.3.3.1 Size exclusion chromatography o f purified VP23His in G-150 buffer
GdnHCl stripping of purified B-capsids in conjunction with quantitative SDS-PAGE 
analysis (performed by Newcomb et al., 1993) demonstrated that two copies of VP23 were 
present within each triplex. In order to determine the oligomeric status of VP23His, size 
exclusion chromatography was performed utilising a 25ml (1 by 30 cm) Superose 12 gel 
filtration column (Pharmacia). This column could resolve proteins from 20-200kDa in 
size. Preliminary attempts to size VP23His in sonication buffer failed due to column 
pressure limits exceeding those recommended by the column manufacturer (>3.0 Mpa). 
The high pressure within the column was due to the buffer, as the column pressure also 
exceeded 3.0MPa during column buffer calibration. The severe increase in column 
pressure may be attributable to micelle formation between the NP-40 detergent and the 
glycerol components of the buffer. Filtration of buffers and protein samples through a 
0.2pM filter is standard procedure for column chromatography analysis (as described in 
Methods). However, filtration of sonication buffer did not prevent the column pressure 
from exceeding 3.0MPa.
As a consequence of this, VP23His was subsequently purified from bacteria using G-150 
buffer (described in Materials) which lacks NP-40. Fig. 3.3.6 (panel B, lanes 2-4) shows 
the elution profile of VP23His purified in G-150 buffer. The Ni-NTA agarose elution 
profile was the same as that for VP23His purified in sonication buffer (fig. 3.3.4) with a 
prominent band observed at approximately 34kDa. 1ml of purified VP23His from fraction 
1 (at a concentration of 0.5mg/ml) was analysed by size exclusion chromatography (fig. 
3.3.6, Panel A). A single prominent peak was detected which eluted from the column at 
14.03ml. 1.5ml fractions were collected from the column and the corresponding peak
fraction was analysed by SDS-PAGE and shown to contain VP23His (fig. 3.3.6, panel B, 
lane 6). In order to determine an accurate native MW for VP23His, commercially 
available protein standards were purchased from Sigma and analysed under the same 
conditions. Fig. 3.3.7 (panel A) shows a compilation trace of the chromatography profiles 
of the protein standards analysed on the Superose 12 gel filtration column. The
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Fig. 3.3.6: Size exclusion chromatography and SDS-PAGE analysis of Ni- 
NTA agarose purified VP23His in G150 buffer.
VP23His was purified in G150 buffer (as described in Methods and in fig.
3.3.5). VP23His was eluted from the Ni-NTA agarose in 3x 1ml of G-150 
buffer containing 250mM EDTA. Elution fraction 1 (0.5mg/ml) was 
analysed on a 25ml (1 by 30 cm) Superose 12 gel filtration column 
(Pharmacia) using a 1 ml injection superloop (as described in Methods) and 
1.5ml fractions were collected. (A) Size exclusion chromatography profile for 
VP23His purified and analysed in G150 buffer + 250mM EDTA. (B) 20pl of 
purified VP23His from Ni-NTA agarose elution fractions 1-3 (lanes 2-4 
respectively) and 20pl of the size exclusion chromatography peak fraction 
(lane 6) were analysed against Rainbow markers (lane 1) and purified B 
capsids (lane 5) by SDS-PAGE and stained with Coomassie Brilliant Blue.
Results: 3.3
information collected from the elution profile plots and the MW of each protein standard is 
summarised fig. 3.3.7 (panel B). These data were used to generate a standard curve using 
Origin 3.5 software, plotting Logio MW against the elution volume for each protein 
standard. A best fit line was generated using linear regression analysis within the Origin
3.5 software package (fig. 3.3.7, panel C). Using the best fit line an accurate Logio MW 
reading from the VP23His elution volume was recorded and the native MW calculated to 
be 36kDa.
The native MW of 36kDa for VP23His purified in G-150 buffer is in good agreement with 
the MW predicted from the amino acid sequence and suggests that purified VP23His exists 
as a monomer. Hydrodynamic studies performed by Marina Kirkitadze (described in 
Kirkitadze et al. 1998) on purified VP23His obtained from our laboratory demonstrated 
that its oligomeric status was dependent on protein concentration. Sedimentation analysis 
revealed that it was predominantly monomeric at concentrations of up to 0.8 mg/ml. This, 
therefore, supports the size exclusion chromatography data for VP23His analysed at a 
concentration of 0.5 mg/ml. However, at higher concentrations (1 mg/ml) VP23His formed 
dimers with a MW of 70kDa, while at concentrations above 1.0 mg/ml it formed oligomers 
with a MWs of over lOOkDa. As the purified VP23His used in these experiments was 
diluted from a concentrated stock, the oligomeric status of VP23His was thought to be 
reversible (Kirkitadze et al., 1998).
In order to detect such increases in the oligomeric status of VP23His, purified VP23His 
was analysed at different protein concentrations using size exclusion chromatography. 
Fig. 3.3.8 shows a compilation plot of VP23His size exclusion chromatography profiles of 
VP23His analysed at 0.25, 0.5, and 1.5 mg/ml in G-150 buffer. From these profiles no 
observable shift in the peak elution volume could be detected for the three concentrations 
tested. This would suggest that VP23His exists as a monomer under the buffer conditions 
used in the analysis.
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Fig. 3.3.7: Size exclusion chromatography of protein standards and generation 
of a standard curve.
Size exclusion chromatography was carried out on commercially available 
protein standards (Sigma); (3-amylase (200,000 Da), alcohol dehydrogenase 
(150,000 Da), bovine serum albumin (66,000 Da), ovalbumin (45,000 Da), and 
catabolic anhydrase (29,000 Da). 0.5 mg of each protein standard was 
resuspended in 1ml of G150 buffer + 250mM EDTA and analysed individually 
on a 25 ml (1 by 30 cm) Superose 12 gel filtration column (Pharmacia) using a 
1 ml injection superloop (as described in Methods). (A) Compilation plot of the 
size exclusion chromatography profiles of the 5 protein standards described 
above. (B) Summary table of size exclusion data obtained from the protein 
standards. (C) Standard curve generated from the peak elution volumes for size 
standards with an overlay of the VP23His elution profile plot. The native MW 
(36,000 Da) for purified VP23His was calculated using linear regression 
analysis software within the Origin 3.5 software package.
Results: 3.3
3.3.3.2 VP23His purification and characterisation in buffer O
Solubilisation of recombinantly expressed triplexes (described in section 3.5) required 
them to be purified in a phosphate buffer, buffer O (described in Materials). It was 
consequently decided to re-examine VP23His in buffer O to allow legitimate biophysical 
comparison.
Fig. 3.3.9 (panel A) shows the Ni-NTA agarose purification profile of VP23His in buffer 
O. The same elution pattern was observed as that of VP23His in sonication buffer (fig.
3.3.5) and G-150 buffer (fig. 3.3.6, panel B). Western blot analysis demonstrated that both 
the 70 and 29kDa bands contained VP23 sequences (fig. 3.3.9, panel B) and were assumed 
to represent SDS resistant dimers and truncated or proteolytically cleaved versions of 
VP23His respectively.
In order to determine the oligomeric status of VP23His purified in buffer O, size exclusion 
chromatography analysis was repeated. Fig. 3.3.10 (panel A) shows the peak elution 
volume for VP23His and the standard curve generated from protein standards analysed in 
buffer O. VP23His was detected as a single prominent peak with a native MW of 
approximately 63kDa. This peak was confirmed to be VP23His by SDS-PAGE analysis 
(fig. 3.3.10, panel B). The detection of a single dimeric peak corresponding to VP23His at 
a concentration of 0.5 mg/ml implies that the reversibility in oligomeric status detected by 
hydrodynamic studies may have been a buffer related effect. Numerous size exclusion 
chromatography runs were performed on purified VP23His in buffer O and in all cases a 
single peak corresponding to dimeric VP23His was detected.
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Fig. 3.3.9: SDS-PAGE and Western blot analysis of Ni-NTA 
agarose purified VP23His in buffer O.
VP23His was purified in buffer O (150mM Na2HP04 (pH7.5), 0.1% 
octyl-p-glucoside, 0.1% glycerol) as described in Methods and fig. 
3.3.5. VP23His was eluted from the Ni-NTA agarose in 5x 1ml 
fractions of 250mM imidazole in buffer O. 20pl of VP23His 
elution fractions 1 and 2 (lanes 2 and 3) were analysed by SDS- 
PAGE against Rainbow markers (lane 1) and stained with 
Coomassie Brilliant Blue (A). (B) Western blot analysis of purified 
VP23His in buffer O (lane 2) and purified B-capsids (lane 1). The 
nitro-cellulose membrane was probed with a 1:1000 dilution of a 
polyclonal VP23 antibody (187). Monomeric and dimeric VP23His 
are indicated by the appropriate arrows.
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Fig. 3.3.10: Size exclusion chromatography and SDS-PAGE analysis of 
Ni-NTA agarose purified VP23His in buffer O.
VP23His was purified in buffer O (as described in Methods and fig. 3.3.5). 
Purified VP23His (0.5mg/ml) was analysed on a 25ml (1 by 30 cm) 
Superose 12 gel filtration column (Pharmacia) using a 1ml injection 
superloop (as described in Methods) and 1.5ml fractions were collected. 
(A) Size exclusion chromatography elution volume profile for VP23His 
purified and analysed in buffer O. A Standard curve was generated (as 
described in fig. 3.3.7). All protein standards were resuspended and 
analysed in buffer O at a concentration of 0.5 mg/ml. The native MW for 
VP23His purified in buffer O (63 kDa) was calculated using linear 
regression analysis software within the Origin 3.5 software package. (B) 
20pl of purified VP23His prior to analysis (lane 1) and 20pl of the size 
exclusion chromatography peak fraction (lane 3) was analysed by SDS- 
PAGE against purified B-capsids (lane 2) and stained with Coomassie 
Brilliant Blue.
Results: 3.3
3.3.5 Sucrose gradient sedimentation analysis of purified VP23His in 
buffer O.
To confirm the dimeric status of VP23His purified in buffer O, it was co-sedimented with 
the protein standard BSA (66kDa) through a 5ml 5-25% sucrose gradient in buffer O.
Approximately 35x 150pl fractions were collected (as described in Methods) and every 
third fraction was analysis by SDS-PAGE in order to identify where VP23His localised 
within the gradient (data not shown).. VP23His could be detected over a number of 150pl 
fractions as determined by Coomassie Brilliant Blue staining. Fig. 3.3.10 (panel A) shows 
the SDS-PAGE analysis of fractions 17 to 26. The relative intensities were calculated for 
each fraction, for both VP23His and BSA, and plotted as a percentage (%) change in 
volume intensity against their appropriate fraction number (fig. 3.3.11, panel B). The 
VP23His peak intensity sediments to the same position on the gradient as that of the 
internal 66kDa BSA protein standard (indicated by a arrow in fig. 3.3.11, panel B). The 
sedimentation analysis data clearly indicates that purified VP23His in buffer O can form 
stable dimers and therefore supports the observations made by size exclusion 
chromatography that purified VP23His exists as a stable dimer in buffer O.
The ability to purify VP23His on Ni-NTA agarose implies that the N-terminal 6x His tag 
on VP23 must be exposed to the solvent and not buried within the interior of the VP23 
protein. The fact that VP23His exists as a purifiable dimer in buffer O would also imply 
that at least one of the N-termini is not directly involved in the dimerisation of VP23. 
While the work described in this thesis was in progress, Spencer et al. (1998) published 
that VP23 expressed in SF9 cells infected with a recombinant baculovirus could form 
stable dimers. This evidence supports the findings reported here, and demonstrates that 
these dimers are not attributed to the presence of the 6xHis tag utilised in the purification 
process. Monomeric VP23His which was detected by size exclusion chromatography and 
hydrodynamic studies is probably a result of the disassociation of VP23 dimers due to the 
non-physiological nature of the purification buffers used in the isolation of VP23His. The 
presence of NP-40 and/or NaCl in these buffers may be sufficient to interfere or compete
109
200 kDa -
2 3  4 5  6 7 8 9  10 11
97.4 kDa - 
69 kDa - BSA
46 kDa
30 kDa - b
(A)
VP23His
BSA
VP23
80-
ox
60-V3C
<L>-t—>c
<L»
|  40-
O>
20 -
(B) Fraction Number
Fig. 3.3.11: Sucrose gradient sedimentation and SDS-PAGE analysis of 
Ni-NTA purified VP23His in buffer O.
VP23His was purified in buffer O (as described in Methods and fig. 3.3.5). 
300pl of purified VP23His and 50jnl BSA (5mg/ml resuspended in buffer
O) were mixed and layer onto a 5ml 5-25% sucrose gradient and 
sedimented together at 4°C for 16 hours at 40,000 r.p.m. in a AH650 rotor 
and fractions collected (as described in Methods). (A) 20pl of fractions 
17-26 (lanes 2-11 respectively) and Rainbow markers (lane 1) were 
analysed by SDS-PAGE and stained with Coomassie Brilliant Blue. The 
position of BSA and VP23His are indicated by the appropriate arrows. The 
relative intensity of the Coomassie stained protein profiles was calculated 
individually for both VP23His and BSA protein profiles using Quantity 
ONE software (BIO-Rad) as described in Methods. The data was plotted 
as percentage (%) change in volume intensity for each individual protein 
profile against their eluted fraction number (B). An arrow indicates the 
gradient peak elution of VP23His.
Results: 3.3
with any hydrophobic or electrostatic interactions between VP23 molecules and therefore 
result in the monomerisation of VP23.
3.3.6 Characterisation of purified VP23His dimers
3.3.6.1 Thermolability o f VP23 dimers
Newcomb et al., (1996) were the first group to identify a procapsid transition during the 
assembly of the HSV-1 capsids. Rixon and McNab (1999) subsequently showed that 
HSV-1 procapsids could be detected in vivo using a mutant of HSV-1 (/si 201) which had a 
temperature sensitive lesion in the UL26 protease. One of the defining characteristics of 
procapsids is their thermolability and they were shown to disassemble at 0°C (Newcomb et 
al., 1996; Rixon and McNab, 1999). In order to test whether or not this thermolability, and 
consequent disassembly at 0°C, was due to the disintegration of VP23 dimers, purified 
VP23His in buffer O was analysed by size exclusion chromatography before and after 
incubation at 4°C. Size exclusion chromatography was carried out on VP23His in buffer O 
and the peak elution fraction was collected and incubated o/n at 4°C to allow any 
disassociation to occur. This sample was subsequently re-analysed by size exclusion 
chromatography in buffer O at RT. Fig. 3.3.12 shows a compilation plot of the size 
exclusion chromatography profiles of dimeric VP23His purified in buffer O and the 
reanalysis of isolated VP23His dimers after a 4°C incubation. Both samples have the same 
peak elution volume. This would therefore indicate that VP23 dimers are not thermolabile 
at 4°C, as any VP23 monomers would have eluted at the approximate position indicated by 
the arrow on fig.3.3.12. The reduction in the size of the peak can be attributed to the 
dilution of the sample during its first passage through the column.
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Fig. 3.3.12: Size exclusion chromatography o f  Ni-NTA agarose 
purified VP23His in buffer O before and after incubation at 4°C.
VP23His was purified in buffer O as described in Methods and 
fig. 3.3.5. Purified VP23His in buffer O was analysed by size 
exclusion chromatography using a lml superloop and fractions 
collected (as described in Methods). The peak fraction was 
collected and subsequently incubated o/n at 4°C before being 
reanalysed. The arrow indicates the position of the protein 
standard carbonic anhydrase (29,000 Da).
Results: 3.3
3.3.7 Disulphide linkage analysis of VP23
3.3.7.1 VP23 dimer formation in the absence o f reducing agents
Initial observations made by Dr Andrew Davison on purified B-capsids analysed by SDS- 
PAGE showed that VP23 migrated differently in the presence and absence of the reducing 
agent P-mercaptoethanol. Fig. 3.3.13 shows the protein profiles of purified B-capsids and 
of VP23His purified in sonication buffer analysed by SDS-PAGE in the presence or 
absence of 20mM p-mercaptoethanol. A distinct shift can be observed both for VP23 
present in B-capsids and for purified VP23His. Although no obvious dimeric band could 
be observed in the purified B-capsid sample when analysed in the absence of p- 
mercaptoethanol (fig. 3.3.13, lane A), a distinct dimeric band could be detected for purified 
VP23His (fig. 3.3.13, lane B and C). This dimeric band was the same MW as the dimeric 
bands observed by SDS-PAGE analysis of purified VP23His in buffer O (fig.3.3.9). 
However, it is interesting to note that not all the purified VP23His analysed by SDS-PAGE 
in the absence of P-mercaptoethanol showed a mobility shift from monomer to dimer. The 
majority of the purified VP23His remained in the monomeric form but appeared as 
multiple bands rather than the single species seen in the presence of p-mercaptoethanol. 
These observations suggest the possibility of intra-molecular disulphide bonds within 
VP23 rather than an inter-molecular disulphide bond between VP23 dimeric molecules. 
The apparent dimerisation of purified VP23His in the absence of p-mercaptoethanol may 
be due to an increased proportion of VP23 dimers being resistant to SDS denaturation as a 
direct result of the conformational stability generated by non-reduced internal disulphide 
bonds. The VP23His monomer doublet which is observed, could be due to different types 
of intra-molecular disulphide linkages, generating a population of VP23His molecules 
which have a different migratory speed through the acrylamide gel. Zweig et al., (1979) 
demonstrated using two dimensional gel electrophoresis, both in a reducing and a non­
reducing plane, that the only inter-molecular disulphide linkages within HSV-2 capsids 
were those between VP5 and VP 19c and those between molecules of the scaffold protein 
VP22a. This supports the conclusion that dimerisation of VP23 is not due to inter- 
molecular disulphide linkage.
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In order to analyse further the suspected intra-molecular disulphide linkages within VP23, 
purified VP23His in buffer O was analysed by size exclusion chromatography in the 
absence or presence of the reducing agent DTT. Size exclusion chromatography was 
carried out on VP23His in buffer O and the peak elution fraction was collected. 1M DTT 
was added to this fraction to a final concentration of lOmM and incubated at RT for 30 
minutes to allow for disulphide bond reduction. This sample was subsequently re-analysed 
by size exclusion chromatography in buffer O. Fig. 3.3.14 shows a compilation plot of the 
size exclusion chromatography profiles of dimeric VP23His purified in buffer O 
(unreduced) and the reanalysis after DTT treatment. Both samples gave the same elution 
peak volume with no shift to the position expected for monomers being seen. This further 
confirms that inter-molecular disulphide linkages between VP23 molecules are not the 
cause of dimerisation. It cannot be ruled out however that intra-molecular disulphide 
linkages influence dimer stability as it is unlikely that reduction of buried disulphide 
linkages would occur. The reduction in the size of the peak can be attributed to the 
dilution of the sample during passage down the column. SDS-PAGE analysis in the 
presence of P-mercaptoethanol of the collected dimeric VP23His fraction before DTT 
reduction is shown in fig. 3.3.14 (panel B) and clearly demonstrates the presence of SDS 
resistant VP23His dimers (indicated by an *).
3.3.7.2 VP23 sequence analysis
Comparison of the VP23 related proteins from the alphaherpesvirus subfamily 
demonstrated relatively high sequence homology. The closest homologue of VP23 from 
HSV-1 is the HSV-2 UL18 protein, demonstrating 92% amino acid sequence identity. For 
the other viruses the sequence identities were significantly lower. These include; EHV-1 
43%, BHV-1 47 %, VZV 44% and PRV 48%. The full sequence alignment is shown in 
fig. 3.3.15. Examination of the pattern of cysteine residues in these proteins reveals 
several interesting trends. HSV-2 VP23 demonstrated 100% cysteine homology when 
compared to the HSV-1 protein. This is not unexpected due to the close relationship of 
these two viruses. However, comparison with the other four alphaherpesviruses revealed 
that only two out of the four cysteine residues in HSV-1 VP23 are conserved throughout. 
These are amino acid residues Cys27 and Cys297 (highlighted in red in fig. 3.3.15). 
Cysl 10 was conserved in five out of the six alphaherpesviruses tested but was not present
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Fig. 3.3.14: Size exclusion chromatography of Ni-NTA agarose purified 
VP23His in buffer O before and after incubation in the presence o f  lOmM 
DTT.
VP23His was purified in buffer O as described in Methods and fig. 3.3.5. 
Purified VP23His in buffer O was analysed by size exclusion 
chromatography (as described in Methods and fig. 3.3.7) using a 1ml 
superloop and 1.5ml fractions were collected. The peak fraction incubated 
in the presence o f  lOmM DTT for 30 minutes before being reanalysed. 
The arrow indicates the predicted position o f  the protein standard 
carbonic anhydrase (29,000 Da) (A). (B) 20pl o f  the peak elution fraction 
collected before DTT treatment was analysed by SDS-PAGE and stained 
with Coomassie Brilliant Blue. * indicates the presence o f  dimeric 
VP23His. The positions o f  the size markers are shown.
27 (c y s i )
HSVl MLADGFETDIAIPSGISRPDAAALQRCEGRVVFLPTIRRQLTLADVAHESFVSGGVSPDT 
HSV2 MITDCFEADIAIPSGISRPDAAALQRCEGRVVFLPTIRRQLALADVAHESFVSGGVSPDT 
HSVEB MASAAFEIDILLPSDLSPADLSALQKCEGKLVFLTALRRRVMLSSVTLSSYYVNGAPPDT 
VZVD -MAMPFEIEVLLPGELSPAETSALQKCEGKIITFSTLRHRASLVDIALSSYYINGAPPDT 
BHV1 MAQPEAFEVEIVLPGDLSHGDLAALQKCEGKVVFFTTLRRRVPLADVALASFSVNGVAPDT
PRV  MEVDIALPT-LSPGDLSALQRCEGRVVFLETLRRHATLREVA LPCGG DV
Con. -------- E----- LP —  LS----- ALQ-CEG--------- R---- L------------- G ----D-
8 6 (c y s 2) 1 1 0 (c y s 3)
HSVl LGLLLAYRRRFPAVITRVLPTRIVACPLDVGLTHAGTVNLRNTSPVDLCNGDPISLVPPV 
HSV2 LGLLLAYRRRFPAVITRVLPTRIVACPVDLGLTHAGTVNLRNTSPVDLCNGDPVSLVPPV 
HSVEB LSLMAAFRRRFPAIIQRVLPNKMIAAALGVAPLPPGAF-IQNTGPFDLCNGDSVCALPPI 
VZVD LSLLEAYRMRFAAVITRVIPGKLLAHAIGVGTPTPGLF-IQNTSPVDLCNGDYICLLPPV 
BHV1 LGLMAAYRCRFPAVVLRVAPGRMMAAPLGVGPMPRGAF-LQNTGPFDLCNGDAVCLLPPL 
PRV LAAM-ADRRRFAAVITRVTPHRMLATPLGVGGRGQSLV-LQNTGPFDLTNGDHVCLVPPL 
Con. L ---- A-R-RF-AV— RV-P---- A ------------------- NT-P-DL-NGD------ PP-
HSV1 FEGQATDVRLDSLDLTLRFPVPLPSPLAREIVARLVARGI-RDLNPSPRNPGG-LP--DL 
HSV2 FEGQATDVRLESLDLTLRFPVPLPTPLAREIVARLVARGI-RDLNPDPRTPGE-LP--DL
HSVEB LDVE-DKLRLGSVGEEILFPLTVPLAQARELIARLVARAV-QALTPNAQAQRG-A-----
VZVD F-GSADSIRLDSVGLEIVFPLTIPQTLMREIIAKVVARAVERTAAGAQILPHEVLR— GA 
BHV1 L-GPARALALASAGAELLFPMTVPLPQARALVARVVARAV-EALGDRAAAARA-RA--A-
PRV LGDEC--LRLTSANLELRFPMTLPLAQARELTARVVARAAETLR------- GGAPAR--GA
Con. -----------L-S------- FP--- P-----R ----A — VAR--------------------------
HSVl NVLYYNGSRLSLLADVQQLGPVNAELRSLVLNMVYSITEGTTIILTLIPRLFALSAQDGY 
HSV2 NVLYYNGARLSLVADVQQLASVNTELRSLVLNMVYSITEGTTLILTLIPRLLALSAQDGY 
HSVEB EVMFYNGRKYNVTPDLRHRDAVNGVARSLVLNMIFAMNEGSLVLLSLIPNLLTLGTQDGF 
VZVD DVICYNGRRYELETNLQHRDGSDAAIRTLVLNLMFSINEGCLLLLALIPTLLVQGAHDGY 
BHV1 DVMYHNGRRYQVTPDVLCREGADAAARTLVLNMVFNVNEGSLLLLSLIPNLLTQGLQDGV 
PRV DVVFSNGRRYQL--PPPHRDNAEAATRSLVLNMIFLLNEGAVILLSLIPNLLTLGAQDGY 
Con. -V NG----------------------- R-LVLN------- EG------- LIP-L------- DG-
HSV1 VNALLQMQSVTREAAQLIH-PEAPALMQDGERRLPLYEALVAWLTHAGQLGDTLALAPVV 
HSV2 VNALLQMQSVTREAAQLIH-PEAPMLMQDGERRLPLYEALVAWLAHAGQLGDILALAPAV 
HSVEB VNAIIQMGSATREVGQLVH-QQPVPQPQDGARRFCVYDALMSWISVASRLGDVVGGKPLV 
VZVD VNLLIQTANCVRETGQLINIPPMPRI-QDGHRRFPIYETISSWISTSSRLGDTLGTRAIL 
BHV1 ANAIVQLGSASREAGQLLR-LEPAEPRQDGGRRFCLYGALAAWISSATRLGDAVGARPLA 
PRV ANAVIQLGSATRELGQLVR-QPPPPLPQDHARRFCVFEALEAWIASASRLGDTLGTRPVA 
Con. -N Q ------RE— QL ------------ QD--RR---------- W --------LGD---------
297 (c y s  4)
HSVl RVCTFDGAAVVRSGDMAPVIRYP 
HSV2 RVCTFDGAAVVQSGDMAPVIRYP 
HSVEB RICTFEGQATISRGEKAPVIQTLL 
VZVD RVCVFDGPSTVHPGDRTAVIQV 
BHV1 KVCTFDGPSVVRVGEKAPIVVPL 
PRV RVCIFDGPPTVPPGEKAAVVEV 
Con. — C —F~G G
Fig. 3.3.15: Amino acid sequence alignment of VP23 homologues.
Compilation of the amino acid sequence alignment of VP23 
homologues from the alphaherpesvirus subfamily. HSVl (Herpes 
Simplex virus type-1, strain 17), HSV2 (Herpes Simplex virus type- 
2, strain HG52), EHV1 (equine herpesvirus type-1, strain AB4P), 
VZV (Varicella-Zoster virus, strain Dumas), BHV1 (Bovine 
Herpesvirus type-1), PRV (Pseudorabies virus (Suid herpesvirus
1)), and Con. (consensus sequence alignment). Cysteine residue 
are highlighted in red.
Results: 3.3
in PRV, whereas Cys86 was only conserved in HSV-2. Several other cysteine residues 
were found in the other alphaherpesvirus VP23 homologues, which are not present in 
either HSV-1 or HSV-2. This high degree of conservation of Cys resides 27 and 297 
suggests that they may perform a specific functional role within the protein, which has 
been conserved despite the divergence of the alphaherpesvirus sequences. It is interesting 
to note that the Cys residue at 116 is conserved in all the alphaherpesviruses, except HSV- 
1 and HSV-2 where it is replaced by Ser .
3.3.8 VP23 cysteine mutagenesis
In order to determine whether or not the cysteine residues in VP23 were functionally 
important, site directed mutagenesis was performed on pETUL18 (as described in 
Methods). The synthetic oligonucleotides used in each case were designed to convert the 
cysteine residues to serine residues. This is a structurally conservative change since the 
only difference is that the S-H of cysteine is an O-H in serine. In order to select plasmids 
containing the mutations, unique restriction sites were incorporated into the 
oligonucleotide sequences (fig.3.3.16, panel A), which did not introduce any other changes 
into the primary amino acid sequence. Recombinant colonies were isolated and plasmid 
DNA purified as described in Methods. Clones were analysed by restriction enzyme 
mapping, utilising the appropriate unique restriction sites (data not shown). Colonies that 
proved positive by restriction digest were subsequently confirmed by sequencing using 
generic oligonucleotides for the T7 promoter (as described in Methods). The automated 
sequence analysis of their respective sequence changes is shown in fig. 3.3.16 (panels B- 
E).
3.3.8.1 Expression ofVP23His cysteine mutants.
In order to determine whether the cysteine mutants were expressed efficiently within 
induced BL21 DE3 bacteria, Western blot analysis was performed. Fig. 3.3.17 (panel A) 
shows the results of the Western blot analysis using a polyclonal VP23 antibody (187). 
Mutants pETUL18CYS-l, -3, and -4 expressed efficiently reaching levels comparable to 
that of the WT pETUL18. However, there was no detectable expression of
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( 1 )  5 '  A TA CCACCCGCCCTTCAGATCTCTGCAGCGCCGCCGCATCGGGGC 3 '
Nhel
(2 )  5 '  GCCCACGTCCAGGGGGCTAGCGACGATTCGCGTGGG 3 '
BstBl
(3 )  5 '  GATGGGGTCCCCGTTCGAAAGATCAACGGGGGAGGTGTTG 3 '
Mlul
(4 )  5 '  CGCGCCGTCAAAGGTAGAAACGCGTACCACGGGAGCCAGGG 3 '
(A)
p E T U L 1 8  ( F w d )
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5 '  CGCCCCGATGCGGCGGCGCTGCAGCGCTGCGAAGGGCGGGTGGTA 3 '  
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p E T U L l 8 (F w d )
R N T S  P V D L C N G D P I  S 
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3 '  CACAACGGCCGCGCCGTCAAAGGTGCACACCCGAACCACGGGAGC 5 
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Fig. 3.3.16: Cysteine mutagenesis of UL18
(A) Oligonucleotides used in the site directed mutagenesis o f  4 cysteine 
residues within the UL18 ORF (numbered 1-4 respectively from the VP23 
N-termini). The unique restriction sites incorporated into each 
oligonucleotide are highlighted in red. (B-E) Automated sequence 
analysis using standard T7 primers of pETULl8CYS mutants compared 
to the WT pE T U L l8 sequence. FWD (forward) and REV (reverse) 
indicate the direction of sequence analysis. Above and below each 
nucleotide sequence is the appropriately encoded amino acid sequence 
(site specific amino acid changes are highlighted in red).
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pETULl8CYS-2. It seemed possible that regeneration of the pET28MOD expression 
vector by T7 polymerase may have generated mutations outwith those desired in the UL18 
ORF, and consequently abolished expression activity. Therefore the UL18CYS2 ORF was 
subcloned out of its existing pET28MOD backbone vector, ligated into a new pET28MOD 
vector, and reanalysed for the expression of VP23HisCYS2 by SDS-PAGE and Western 
blot analysis (data not shown). However, this failed to produce detectable levels of full 
length VP23HisCYS2. Various strategies were employed in order to generate a functional 
expressing pETULl 8CYS2 vector, but all failed to produce detectable levels of full length 
protein. This would seem to suggest therefore that during mutagenesis a frame shift and/or 
the incorporation of a stop codon may have occurred within the UL18CYS2 ORF and thus 
preventing protein expression.
3.3.8.2 Ni-NTA purification ofVP23 cysteine mutants
VP23HisCYS mutants -1, -3, and -4 were readily purifiable from bacteria using Ni-NTA 
agarose affinity chromatography. Fig. 3.3.17 (panel B) shows the SDS-PAGE profile of 
elution faction 1 from each of the VP23HisCYS mutants -1,-3, and -4 compared to that of 
WT VP23His. The samples were purified in sonication buffer and analysed by SDS- 
PAGE in the presence or absence of 20mM P-mercaptoethanol. In the presence of P- 
mercaptoethanol a single prominent band was present both in VP23His and the 
VP23HisCYS mutants. A faint 70kDa band could be detected in mutants 1 and 3 
(fig.3.3.17, panel B, lane 2 and 3 (+) p-mercaptoethanol respectively). This band migrates 
with the same MW as dimeric VP23His (described in section 3.3.3.2 and figs.3.3.9 and 
3.3.10). The presence of dimeric VP23His could be seen clearly when the VP23HisCYS 
mutants were analysed in the absence of p-mercaptoethanol (fig.3.3.17, lanes 2, 3, and 4 (- 
) p-mercaptoethanol). However, rather than the single band usually associated with 
dimeric VP23, two bands could be detected that were also present in the WT VP23His (fig. 
3.3.17, lane 1). This probably represents different disulphide linkages within VP23. 
Differences in the oligomeric status of the VP23HisCYS mutants were further highlighted 
when they were purified in buffer O (fig. 3.3.18). Numerous prominent bands could be 
detected by SDS-PAGE analysis in the presence of p-mercaptoethanol which were absent 
from VP23His purified in sonication buffer (fig. 3.3.5, lane 2) and buffer O (figs. 3.3.9, 
panel A and 3.3.14, panel B), which resulted in the appearance of a single dimeric band.
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Fig. 3.3.17: Western blot and SDS-PAGE analysis of VP23His and
VP23His cysteine mutants
(A) BL21 DE3 bacteria containing either pETULl8 (lane 1) or a 
pETUL18CYSl-4 (lanes 3-6 respectively) mutant plasmid were grown and 
induced (as described in Methods). 1.5 ml of the culture supernatant was 
centrifuged at 14,000 r.p.m. for 30 seconds. The supernatant was removed 
and the bacterial pellet was resuspended in 200pl of BM and heated for 2 
minutes at 100°C in a dry block. 20pl of each sample were analysed by 
SDS-PAGE against purified B-capsids (lane 2) and transferred to a nitro­
cellulose membrane (as described in Methods). The nitro-cellulose 
membrane was probed with a 1:1000 dilution of a polyclonal VP23 
antibody (187). The position of VP23 is indicated by the arrow. (B) 
VP23His (lane 1) and VP23HisCYS mutants 1, 3, and 4 (lanes 2-4 
respectively) were purified in sonication buffer (as described in Methods 
and fig. 3.3.5). 20jil of each elution fraction 1 was analysed by SDS- 
PAGE against Rainbow markers in the presence (+) or absence (-) of 
20mM p-mercaptoethanol and stained with Coomassie Brilliant Blue.
2 0 0  k D a  -
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Fig. 3.3.18: SDS-PAGE analysis o f  purified VP23His Cysteine 
mutants -1 ,-3, and -4 in buffer O.
VP23His cysteine mutants -1 (lane 2), -3 (lane 4), and -4 (lane 6) 
were purified by Ni-NTA affinity chromatography (as described in 
Methods and fig. 3.3.5) in buffer O. 20pl of the appropriate 
VP23HisCYS elution fraction 1 was analysed by SDS-PAGE 
against Rainbow markers (lanes 1 and 5) and purified B-capsids 
(lane 3), and stained with Coomassie Brilliant Blue.
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Western blot analysis of purified VP23HisCYS mutants failed to detect the presence of 
these higher MW bands (data not shown), unlike that of the dimeric VP23His band 
purified in buffer O (3.3.9, panel B). It is possible, but unlikely, that the epitope specificity 
of the antibody used did not recognise the oligomeric forms of purified VP23HisCYS 
protein. However, a more plausible explanation for the presence of these additional higher 
MW bands is that the cysteine mutagenesis resulted in non-specific disulphide bond 
formation between unlinked cysteine residues within VP23 and those present in bacterial 
proteins. In order to further characterise VP23HisCYS mutants and to determine whether 
or not they could interact with VP 19c, the mutated UL18 ORFs were subcloned into the 
pCMVio expression vector and analysed for their intracellular localisation by 
immunofluorescence.
3.3.9 Immunofluorescence analysis of VP23 and VP23CYS mutants
3.3.9.1 Cloning ofUL18 and UL18CYS mutant ORFs into pCMVjo
The construction of the pCMV10 expression vector is described by Stow et al., (1993). It 
utilises the immediate-early promoter from HCMV to regulate recombinant gene 
expression in mammalian cells. The appropriate UL18 ORFs were subcloned individually 
from their pET vector as Xbal/Hindlll fragments. This retained the 5' sequences encoding 
the 6x His epitope tag. The DNA fragments were purified from a 1% agarose TAE gel (as 
described in Methods) and ligated into Xbal/Hindlll digested and CIP treated pCMVio to 
generate pE18H and pE18HCYS-l, -3, and -4. Single colonies were screened for the 
presence of the UL18 ORF by Xbal/Hindlll digestion. The identity of mutant UL18 ORFs 
in each construct was confirmed by restriction mapping using restriction enzymes that 
recognised the unique sites incorporated into the CYS mutant primers (described in section 
3.3.8 and fig. 3.3.16, panel A). The cloning strategy is summarised schematically in fig. 
3.3.19. The cloning of the UL38 ORF into the pCMVio expression vector to generate pE38 
was performed by Dr Frazer Rixon and is described in Rixon et al., (1996).
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Fig. 3.3.19: Schematic representation o f  the cloning strategy for UL18 ORF 
and mutant UL18CYS ORFs into pCM V I0
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3.3.9.1 Intracellular localisation ofVP23His and VP 19c.
The intracellular localisation of both VP23 and VP 19c within BHK-21 C13 cells has been 
reported previously (Nicholson et al., 1994; Rixon et al., 1996). These experiments 
demonstrated that VP23, when expressed on its own, was present throughout the cell, 
whereas VP 19c had a predominantly nuclear localisation. When VP 19c and VP23 were 
co-expressed the localisation of VP23 altered to a predominantly nuclear distribution. This 
led the authors to conclude that VP 19c could interact with VP23 and redirect it to the 
nucleus where it would be required for capsid assembly. In order to confirm this 
behaviour and to examine the ability of VP 19c to direct VP23His to the nucleus, BHK 
cells were transformed with the appropriate plasmids expressing either VP 19c or VP23His 
(as described in Methods). The polyclonal VP23 antibody (187) and the monoclonal 
VP 19c antibody (CB2040) were used in conjunction with the appropriate secondary 
antibodies. Fig. 3.3.20 shows the distribution of VP23His when expressed individually 
within BHK cells. In the majority of cells VP23His could be detected throughout the cell 
(panel A). However, a few cells demonstrated a predominantly cytoplasmic VP23His 
distribution (fig. 3.3.20, panel B). When expressed alone, VP 19c was only found in the 
nucleus (fig. 3.3.20, panel C). Fig. 3.3.21 (panels A and C) show that VP23His was 
present within the nucleus of cells co-expressing both VP23His and VP 19c. These results 
repeat the observations of Nicholson et al., (1994) and Rixon et al., (1996) and show that 
the 6xHis tag does not alter the behaviour of the protein. BHK cells transformed with 
plasmids individually expressing VP23HisCYS mutants demonstrated the same cellular 
distribution as that of the parental VP23His (fig. 3.3.22, panels A, C, E, and G). Similarly, 
when co-expressed with VP 19c, all three cysteine mutants demonstrated a WT VP23 like 
nuclear distribution (fig. 3.3.22, panels B, D, F, and H). This therefore indicates that 
mutating the cysteine residues within VP23 does not affect the proteins ability to interact 
with VP 19c within the cytoplasm of BHK cells and become translocated to the nucleus. 
Furthermore, the 6xHis epitope tag present on the N-terminus of VP23 does not appear to 
affect the interaction with VP 19c. Since, the N-terminal tag on VP23 is probably present 
on the exterior of the protein this suggests that the N-terminus of VP23 is not directly 
involved in the interaction with VP 19c.
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Fig. 3.3.20: Immunofluorescence analysis showing the intracellular
localisation of VP23 and VP 19c.
BHK21 C13 cells were transfected with plasmids either expressing VP23His 
(pE18H) or VP 19c (pE38, panel C) as described in Methods. The cellular 
distribution of VP23 (panels A and B) was detected by using a polyclonal 
VP23 antibody (187). The immunofluorescence observed was due to a 
secondary goat-anti rabbit IgG conjugated to CY3. The cellular distribution 
of VP 19c (panel C) was detected using a monoclonal VP 19c antibody 
(CB2040). The immunofluorescence observed was due to a goat anti-mouse 
IgG secondary antibody that was conjugated to FITC. Specific details on 
antibody dilutions, transfection, and immunofluorescence procedures are 
detailed in Methods.
(A) (B) (C)
Fig. 3.3.21: Immunofluorescence analysis showing intracellular localisation 
o f  VP23 and VP 19c co-expressed within BHK-21 C l 3 cells.
BHK-21 C l 3 cells were co-transfected with plasmids expressing VP23His 
(pE18H) and VP 19c (pE38), as described in Methods. The cellular 
distribution of VP23 and VP 19c was analysed by double immunolabelling. 
VP23 was detected using a polyclonal VP23 antibody (187). VP 19c was 
detected using a monoclonal VP 19c antibody (CB2040). 
Immunofluorescence observed was due to goat anti-mouse, and goat anti­
rabbit IgG conjugated to FITC and CY3 respectively. Both primary and 
secondary antibodies were mixed at the appropriately dilutions (as described 
in Methods). Panels A shows the cellular distribution o f  VP23His. Panels B 
shows the cellular distribution of VP 19c. Panel C shows a merged image of 
panels A and B.
(A) (B)
(C) (D)
(E) (F)
Fig. 3.3.22: Immunofluorescence analysis showing the intracellular 
distribution o f  VP23His and VP23HisCYS mutants 1, 3, and 4 with 
VP19c.
BHK-21 C l 3 cells were transfected singly with plasmids pE18H 
(VP23His), pE18HCYSl (VP23HisCYSl), pE18HCYS3 
(VP23HisCys3), or pE18HCYS4 (VP23HisCys4 ), or co-transfected 
with pE38 (VP 19c ) as described in Methods. The cellular 
distribution o f  VP23His and VP23HisCYS mutants was detected 
using a monoclonal VP23 antibody (CB0040) and goat anti-mouse 
IgG conjugated to FITC. Panels A, C, E, and G show the cellular 
distribution of VP23His, VP23HisCYSl, VP23HisCYS3, and 
VP23HisCYS4 respectively. Panels B, D, F, and H show the cellular 
distribution of VP23His, VP23HisCYSl, VP23HisCYS3, and 
VP23HisCYS4 respectively when co-expressed with VP 19c.
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3.3.10 Viral growth analysis of UL18CYS mutants
Desai et al., (1993) performed experiments utilising a permissive Vero cell line expressing 
VP23 (G5-11 Vero cells) to demonstrate that a lacZ insertion mutant (K23Z) within the 
UL18 ORF of HSV-1 abolished capsid formation. Saad et al., (1999) have recently shown 
VP23 may play a role in development of the capsid floor after procapsid formation. It was 
therefore decided to test whether or not VP23 cysteine mutants were able to sustain capsid 
formation. A complementation assay was performed utilising the K23Z mutant and the 
permissive G5-11 Vero cell line to test the ability of VP23HisCYS mutants to produce 
infectious progeny virus. The construction of K23Z VP23 null mutant virus and the 
permissive G5-11 Vero cell line expressing VP23 is described in Desai et al., (1993).
To test the functionality of the VP23CYS mutants, BHK-21 C13 cells were transfected 
with lpg of the appropriate pCMVio plasmid DNA expressing either VP23His or a 
VP23HisCYS mutant protein (as described in Methods). 24 hours post-transfection the 
cells were infected with the K23Z VP23 null mutant virus at a m.o.i of 3. Progeny viruses 
were harvested at 24 hours post infection and titred on both permissive and non-permissive 
Vero cells (as described in Methods). Fig. 3.3.23 shows the titres of harvested virus in both 
permissive and non-permissive cells. No significant amount of revertant K23Z virus was 
isolated from the complementation assay, as shown by the very low titres of all the 
progeny virus on non-permissive Vero cells. Both WT and UL18CYS mutants were able 
to complement growth of K23Z. However, a considerable contrast was observed in the 
ability for the UL18CYS mutant 1 to produce infectious virus progeny compared to that of 
the WT and UL18CYS mutants 3 and 4. The assay was repeated and produced a similar 
titration profile (data not shown). It is possible that the VP23HisCYSl mutant is more 
efficient in capsid assembly leading to an increase in the number of infectious progeny 
produced and consequently a higher titre. However, it is more likely the differences reflect 
differing transfection efficiencies of the individual plasmid DNAs. Further analysis has to 
be performed in order to substantiate these findings.
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3.3.11 Conclusions
3.3.11.1 VP23 dimerisation
Newcomb et al., (1993) were the first group to demonstrate that VP23 was a component of 
the triplex of HSV-1 capsids and that it was present in two copies per triplex. However, it 
was not known whether VP23 within the triplex occurred as a dimer or two separate 
monomeric subunits interacting separately with VP 19c. Examining purified VP23 by size 
exclusion chromatography and sucrose gradient sedimentation has shown that it can exist 
as a stable dimer (figs. 3.3.10 and 3.3.11). The dimer is not held together by inter- 
molecular disulphide linkages and is stable at 4°C (figs. 3.3.12 and 3.3.14). Therefore, 
findings that capsid formation is inhibited in the presence of DTT (Newcomb et al., 1994) 
and procapsid disassociation is induced upon incubation at 0°C (Newcomb et al., 1996) 
cannot be attributed to VP23 dimer disassociation. Cryo-EM has also provided additional 
evidence that VP23 forms dimers in the capsid (Zhou et al., 2000). Utilising cryo-EM and 
difference mapping of HSV-1 B-capsids and VP5-VP19c particles, Saad et al., (1999) 
determined the position of VP 19c within WT B-capsids. From these data they concluded 
that VP 19c was located on the top of the triplex, interconnecting adjacent capsomers. The 
remaining mass, forming the two legs of the triplex which connect to the capsid floor, was 
proposed to be VP23. These two legs had an extensive interface suggesting that the two 
copies of VP23 formed a dimer within the triplex (discussed further within section 4.0).
Desai and Person (1996) demonstrated that the deletion of the N-terminal 77 residues of 
VP23 prevented VP23 from interacting with VP 19c (as determined by the yeast two hybrid 
system). Similar deletion mutagenesis performed by Spencer et al., (1998) upon the N- 
terminus of VP23 also demonstrated that mutated VP23 inhibited in vivo capsid assembly 
within insect cells. These experiments clearly indicate an essential role for the N-terminal 
region of VP23. However, the removal of such a large number of residues from the N- 
terminus makes it difficult to determine whether these residues are required for a direct 
protein-protein interaction with VP 19c or simply to maintain the protein conformation 
required for interaction. Furthermore, interpretation of results from mutagenesis on VP23 
is complicated by the fact that VP23 forms dimers. Therefore, it is difficult to assess
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whether or not mutations in VP23 which prevent the interaction with VP 19c specifically 
disrupt this interaction or disrupt VP23 dimer formation leading to a shift in 
conformational stability. Functional analysis demonstrated that both dimeric and 
monomeric VP23 can form capsids which resemble those of WT B-capsids (discussed in 
section 3.6 and fig. 3.6.1). This would suggest that dimerisation of VP23 may not J>e 
essential for initial capsid protein interactions and procapsid assembly. However, the 
maturation into a polyhedral capsid would appear to require some form of VP23 
dimerisation as the mature triplex clearly show VP23 molecules in close proximity 
(discussed further in section 4.0, Saad et al., 1999). Desai and Person (1996) were unable 
to detect any such self-interaction between VP23 molecules utilising the yeast two-hybrid 
system. This could possibly be attributed to the GAL4 domains which are fused to the N- 
terminus of VP23 molecules which may interfere with dimerisation. It is interesting to 
note that the N-terminal 6xHis tag used in the purification of VP23His does not interfere 
with the dimerisation of VP23, or with its interaction with VP19c (fig. 3.3.10 and 3.6.1). 
This would suggest that the N-terminus itself might not be involved in these interactions 
but that steric inhibition may occur when larger domains are fused to the N-terminus.
Immunofluorescence analysis performed on BHK cells expressing pE18H demonstrated a 
small population of cells that had no intranuclear VP23 (fig. 3.3.20, panel B). It could be 
speculated that this distribution of VP23 to the nucleus is prevented due to the dimerisation 
of VP23 within the cytoplasm and as a consequence the increase in mass preventing 
diffusion through the nuclear pore into the nucleus. Immunofluorescent studies performed 
by Nicholson et al., (1994) and Rixon et al., (1996) on the cellular distribution of VP23 
within cells did not present any evidence to support this observation. However, it is 
unlikely that the cellular distribution of VP23 in these cells is an in vivo artefact due to the 
co-localisation of VP23 to the nucleus when expressed in BHK cells containing the pE38 
plasmid expressing VP 19c. The variation in the cellular distribution of VP23His is more 
likely to reflect differences in the level of expression of VP23His from the pCMVio vector 
within particular cells.
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3.3.11.2 VP23 cysteine analysis
Many viruses rely heavily on disulphide bonding to stabilise large capsid protein 
structures. Li et al., (1998) showed that mutating the papillomavirus capsid protein LI 
carboxy terminal Cys424 residue to a Gly prevented the formation of icosahedral capsids 
in vitro. The change from Cys to Gly did not prevent pentamer assembly but prevented 
papillomavirus capsids from forming stable structures via an inter-pentamer disulphide 
bond. Similarly, the simian virus 40 (SV40) Vpl capsid protein has a large network of 
cysteine linkages. Jao et al., (1999) demonstrated by mutating all 7 cysteine residues, that 
Cys residues at Cys9, Cys 104, and Cys207 were essential for the formation of multi- 
pentameric complexes through inter-pentamer disulphide bonds. Examination of the 
published X-ray crystal structure of Vpl (Liddington et al., 1991) revealed that residues 
Cys 104 and Cys207 reside in interconnecting pentamer loops positioning them in a ideal 
situation for capsid stabilisation through disulphide bonding. The Cys9 residue is located 
in the amino terminal arm of Vpl which is exposed on a Vpl pentamer. Although not 
visualised by X-ray crystallography it is proposed to be involved in disulphide bonding 
through interconnections at the pentamer base. Conversely, Fox et al., (1997) 
characterised the isolation of a mutant of the cowpea chlorotic mottle virus (CCMV) which 
was unable to disassemble during infection and therefore was uninfectious. Subsequent 
analysis revealed an Arg to Cys change at residue 26 within the coat protein. The N- 
terminus of the coat protein is directly involved in hexameric capsomer formation and 
demonstrated a six-fold related symmetry. The mutation of residue 26 to a Cys generates a 
disulphide bond at a three-fold axis and consequently increases virion stability to a point 
where it became non-infectious.
Comparison of VP23 homologues from the alphaherpesvirus demonstrated a strong 
conservation for three out of the four cysteine residues within the HSV-1 VP23. Size 
exclusion chromatography of purified dimeric VP23His following DTT reduction showed 
that the VP23 dimer was not held together by inter-molecular disulphide linkages (fig. 
3.3.14). Furthermore, site directed mutagenesis and functional analysis of three of these 
cysteine residues had no detectable effect on the ability of VP23 to interact with VP 19c or 
to produce infectious virus progeny (figs. 3.3.22 and 3.3.23). Analysis of purified 
VP23HisCYS mutants by non-reducing SDS-PAGE demonstrated that mutating the
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cysteine residues within VP23 did not prevent dimer formation but did result in slightly 
different banding patterns which might be attribute to different intra-molecular disulphide 
linkages formed within the VP23 dimer (figs. 3.3.17 and 3.3.18).
Although these cysteine residues do not play an essential role in the capsid assembly 
pathway of HSV-1, disulphide bond formation may help to strengthen the capsid post­
assembly and thus stabilise progeny virions. Lee et al., (1996) reported similar findings 
during the dimerisation of the rubella virus capsid protein (C protein). Site directed 
mutagenesis on either Cys 152 or Cys 196 prevented dimerisation of the C protein but did 
not prevent virion assembly. They speculated that the disulphide mediated C protein 
association might be required for fixing the intersubunit interface, therefore locking the 
dimer into a specific conformation. The conservation of the 3 cysteine residues within the 
VP23 homologues would suggest some kind of structural involvement. Locking of the 
VP23 conformation may be an appropriate role due to its molten globule nature (discussed 
in section 3.6). However, to identify any specific requirement for these conserved cysteine 
residues and their possible implication in the folding of VP23 requires further analysis.
3.3.11.3 Future Work.
Further analysis is required to specifically identify the oligomeric status of VP23HisCYS 
mutants when purified in buffer O. The likelihood is that they are different disulphide 
linked oligomeric complexes of VP23, as VP23HisCYS mutants purified in sonication 
buffer yield similar but yet reducible bands corresponding to the same MWs. It would also 
be interesting therefore to analyse these complexes by two-dimensional gel 
electrophoresis, both in reducing and non-reducing conditions, in order to determine the 
exact composition of these higher MW complexes.
Deletion of individual cysteine residues might lead to non-specific disulphide bond 
formation with bacterial proteins present within lysed extracts. It would be interesting 
therefore to perform multiple mutagenesis to replace several or all of the cysteine residues 
within VP23, particularly those conserved throughout the alphaherpesvirus family, for 
example cysteine residues 27 (CYS1) and 297 (CYS2).
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Results presented within this thesis (section 3.1) and those by Desai and Person (1996) 
demonstrated that VP23 and VP 19c interact sufficiently within the yeast two-hybrid 
system to induce the transcriptional activation of GAL4. It would be interesting, therefore, 
to analyse the strength of interaction between VP23CYS mutants and VP 19c utilising the 
yeast two-hybrid system. Using this system any interactions detected could be accessed 
for their strength of association and compared to that of the WT interactions utilising a P- 
galactosidase liquid culture assay. This would therefore provide additional evidence as to 
the specific requirement of these conserved cysteine residues for the formation of capsid 
protein interactions.
It would also be interesting to map the positions of the cysteine residues within the triplex 
structure. This could be accomplished through the use of colloidal gold mapping and cryo- 
EM analysis on in vitro assembled capsids where VP23HisCYS protein(s) have been 
substituted in place of VP23His. This could provide additional structural information on 
the folding of VP23 within the triplex.
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3.4 Characterisation of the triplex protein VP19c
3.4.1 Construction and expression of pETUL38.
3.4.1.1 Cloning o f the UL38 ORF into pET28MOD
The cloning of UL38 ORF into the modified bacterial expression vector pET28MOD was 
carried out by David McNab. Briefly, the UL38 ORF was subcloned out of the transfer 
vector pBJ382 (constructed by Peter Nicholson and described in Nicholson, 1992) as a 
BamHI/Hindlll fragment and ligated into a BamHI/Hindlll digested pET28a bacterial 
expression vector to generate pETBJ382. pETBJ382 was then digested with 
BsrDl/EcoRV and ligated with a dsDNA oligonucleotide. This introduced a unique EcoRI 
site at the 5’ end of the UL38 ORF to generate pET38oli. The UL38 ORF was subcloned 
out of pET38oli as an EcoRI/Hindlll fragment and ligated into pET28MOD to generate 
pETUL38. The construction of pET28MOD is described in Kirkitadze et al., (1998) and 
schematically illustrated in section 3.3.1 (fig. 3.3.1). The expression plasmid pETUL38 is 
illustrated in fig. 3.4.1.
3.4.1.2 Bacterial expression ofVP19cHis
BL21 DE3 bacteria were electroporated in the presence of approximately lpg of pETUL38 
or pET28MOD vector DNA and recombinant colonies were isolated (as described in 
Methods). Single recombinant colonies were grown and induced, as described in methods 
and fig. 3.4.2, and analysed for the expression of VP19cHis by SDS-PAGE analysis. Fig.
3.4.2 (panel A) shows the comparative protein profiles of induced pETUL38 and 
pET28MOD transformed BL21 DE3 bacteria. No novel 50kDa band corresponding to 
VP19cHis could be detected in the pETUL38 sample by SDS-PAGE analysis and 
Coomassie Brilliant Blue staining (fig. 3.4.2, lanes 3 and 4). The absence of a 50kDa 
VP19cHis band suggests a poor level of expression from the pETUL38 vector. In order to 
ascertain whether there was any expression of VP19cHis in the induced cultures, Ni-NTA 
agarose affinity chromatography was performed (as described in Methods) and the
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Fig. 3.4.1: Schematic representation of the bacterial expression vector pETUL38
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protein(s) bound to the Ni-NTA agarose were eluted and analysed by Western blot. The 
principles of Ni-NTA chromatography are discussed in section 3.3. Due to the lack of a 
monoclonal antibody against VP 19c, a monoclonal Penta His antibody, which specifically 
recognises the 6xHis epitope tag, was used to detect purified VP19cHis. Fig. 3.4.2 (panel 
B) shows the presence of a band with an approximate MW of 50kDa. The MW of 50kDa 
is in good agreement with the predicted 50260Da MW of VP 19c from the amino acid 
sequence (McGeoch et al., 1988). This band was strongest in the Ni-NTA agarose elution 
fraction 1 (fig. 3.4.2, lane 4). However, low levels could be detected in the crude bacterial 
extracts, bacterial pellet and bacterial supernatant samples collected before Ni-NTA 
agarose purification. This suggests that the expression of the VP19cHis is extremely 
inefficient. The low recovery of VP19cHis was not due to the formation of insoluble 
inclusion bodies as little protein could be detected by Western blot analysis in either crude 
bacterial extracts or bacterial pellet samples post lysis. In an attempt to increase the 
efficiency of transcription and/or translation of pETUL38 within BL21 DE3 bacteria 
various induction conditions were tested. However, none of the conditions tested 
increased the level of VP19cHis expression (data not shown). The low level of expression 
of VP19cHis compared to that of VP23His, which is expressed from the same plasmid 
vector, may indicate a predominance of certain codons which are not recognised by the 
BL21 DE3 bacteria. Alternatively, VP19cHis expression may be toxic. This could 
possible be attributed to the presence of hydrophobic domains on the exterior of the 
VP19cHis protein leading to its incorporation into bacterial membranes thereby generating 
a toxic phenotype (Qiagen Ni-NTA trouble shooting protocol, 1998). Alternatively, 
VP19cHis expressed within bacteria may be broken down or degraded. Smaller MW 
bands are detected in the Ni-NTA VP19cHis elution fraction 1 (see fig. 3.4.2, lane 4) 
which could represent breakdown products. However, at the time no monoclonal antibody 
to VP 19c was available to conclusively demonstrate this.
3.4.2 VP19cHis isolation from recombinantly expressed triplexes
Due to the difficulty in preparing VP 19c from bacteria it was decided to investigate 
whether or not it would be possible to isolate VP19cHis from triplexes purified from SF21 
cells infected with Ac 18386. Triplex purification from Ac 18386 infected cells is discussed
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Fig. 3.4.2: SDS-PAGE and Western blot analysis of VP19cHis expression 
in BL21 DE3 bacteria.
BL21 DE3 bacterial cultures containing either pET28MOD vector (lane 3) 
or pETUL38 (lane 4) were grown and induced (as described in Methods). 
1.5 ml of the culture supernatant was centrifuged at 14,000 r.p.m. for 30 
seconds. The supernatant was removed and the bacterial pellet was 
resuspended in 200pl of BM and heated for 2 minutes at 100°C in a dry 
block. 15 pi of each sample was analysed against purified C-capsids (lane 
2) and Rainbow markers (lane 1) by SDS-PAGE and stained with 
Coomassie Brilliant Blue. Arrow indicates the position of VP 19c as 
determined from the C-capsid profile (A). VP19cHis was purified from a 
1200ml culture of induced BL21 DE3 bacteria containing pETUL38 using 
700pl of Ni-NTA agarose equilibrated in sonication buffer (as described in 
Methods). VP19cHis was eluted from the agarose in 3x 1ml fractions of 
250mM imidazole in sonication buffer. Western blot analysis was 
performed to detect the presence of purified VP19cHis using a 
monoclonal Penta His antibody (Qiagen; 1:1000 dilution) which 
specifically recognises the 6x His epitope tag. Lane 1; induced BL21 DE3 
bacteria containing pETUL38. Lane 2; pETUL38 pellet fraction after 
lysis. Lane 3; pETUL38 supernatant fraction after lysis. Lane 4; 20pl of 
elution fraction 1 of Ni-NTA agarose purified VP19cHis. The position of 
VP 19c is indicated by an arrow. * indicates possible break down products 
of VP 19c.
Results: 3.4
in detail in section 3.5. The 6xHis epitope tag is located on the N-terminus of the VP19c 
component of the heterotrimer protein complex. This means that VP19cHis will bind to 
Ni-NTA agarose but VP23 will not if affinity chromatography is carried out on denatured 
triplexes. Fig. 3.4.3 shows the elution profile of VP19cHis following treatment of the Ni- 
NTA agarose with 3M urea. 3M urea was sufficient to disassociate the majority of VP23 
from triplexes. However, some VP23 could still be detected by Coomassie staining 
indicating substantial but not complete disassociation of triplexes in 3M urea.
Purified VP19cHis was dialysed against buffer O to remove any residual urea and to allow 
the VP19cHis the opportunity to undergo refolding. Fig. 3.4.4 (panel A) shows the SDS- 
PAGE profile of purified VP19cHis before and after dialysis (lanes 2 and 3 respectively). 
In order to analyse the conformational effects of urea denaturation on the VP19cHis 
purified by this method, fluorescence spectroscopy was performed (as described in 
Methods). Fluorescence spectroscopy can be used to measurer the extent to which 
tryptophan side chains are buried within the interior of a protein molecule. Fig. 3.4.4 
(panel B) shows the intrinsic tryptophan fluorescence spectra of the dialysed VP19cHis 
sample following excitation at 295nm. An emission maximum (Amax) at approximately 
356nm corresponds to the intrinsic >max value associated with tryptophan residues within 
small model compounds that are exposed to the solvent. A shift in Amax towards 330nm 
indicates tryptophan residues which are buried or partially buried within the interior of a 
folded protein molecule (Freifelder 1982; Grimmel et al., 1983). The Amax obtained from 
the fluorescence profile for VP19cHis purified by denaturation of triplexes was around 
360nm. This indicates that the tryptophan residues were exposed to the solvent and 
suggests that the urea treatment used in the isolation procedure for VP19cHis, denatured 
the molecule and that dialysis alone was not sufficient to induce the refolding of 
VP19cHis. Fluorescence spectroscopy analysis carried out subsequently on VP19cHis 
purified from SF21 cells infected with Ac381 gave a Amax of around 330nm showing that 
VP19cHis can be purified as a folded molecule (discussed in section 3.6, fig. 3.6.2).
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Fig. 3.4.3: SDS-PAGE analysis o f VP19cHis isolated from Ni-NTA agarose
purified triplexes denatured in 3M urea.
300ml of SF21 cells ( l x l 0 6 cells/ml) were infected with the recombinant 
baculovirus Ac 18386 co-expressing the triplex proteins VP23 and VP19cFIis 
(as described in Methods). Triplexes were purified using 700pl o f  Ni-NTA 
agarose equilibrated in buffer O. The Ni-NTA agarose was washed with 5 ml 
o f  buffer O containing 15mM imidazole to remove weakly bound cellular 
proteins from the agarose resin. The Ni-NTA agarose and associated proteins 
were then resuspended in 5ml o f  buffer OU (buffer O containing 10% glycerol 
+ 3M urea) and incubated for 30 minutes at RT. The supernatant was removed 
and the Ni-NTA agarose washed with a further 5ml o f  buffer O. Proteins were 
eluted from the Ni-NTA agarose by stripping the Ni2+ atoms in 500pl o f  buffer 
O containing 250mM EDTA (pH8.0). 20pl of elution fractions 1-5 (lanes 3-7 
respectively) and 5pl of Ac 18386 infected SF21 cell supernatant (lane 1) were 
analysed by SDS-PAGE against Rainbow markers (lane 2) and stained with 
Coomassie Brilliant Blue. The positions of VP 19c and VP23 are indicated by 
the arrows.
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Fig. 3.4.4: SDS-PAGE and fluorescence spectroscopy analysis of Ni-NTA
agarose purified VP19cHis isolated from denatured triplexes in 3M urea
VP19cHis was purified in buffer O (as described in Methods and fig. 5.4.3). 
(A) SDS-PAGE analysis of VP 19c stripped from triplexes, before and after 
dialysis (lane 2 and 3 respectively). 20pl of each sample was analysed 
against Rainbow markers and stained with Coomassie Brilliant Blue. (B) 
Intrinsic tryptophan fluorescence profile of dialysed VP19cHis (0.1 mg/ml) 
in buffer O following excitation at 295nm. Trace was corrected for the 
effect of buffer by subtraction of a blank buffer control spectrum.
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3.4.3 Purification of recombinantly expressed VP19cHis from SF21 cells 
infected with Ac381
Attempts were made throughout my PhD to purify VP19cHis by Ni-NTA agarose affinity 
chromatography using a variety of purification buffers. Generally these attempts proved 
unsuccessful until the phosphate based purification buffer (buffer O), which was found to 
stabilise the solubility of Ni-NTA agarose purified triplexes from SF21 cells infected with 
either Ac 1863 8 or Ac 183 86, was utilised in the purification of VP19cHis from SF21 cells 
infected with Ac381.
3.4.3.1 Cloning o f the UL38 ORF into pAcCL29-l
Cloning of the UL38 ORF into the baculovirus expression vector pAcCL29-l was carried 
out by A. McGregor. Briefly, the UL38 ORF was amplified by PCR using forward and 
reverse primers, which encoded the unique restriction sites BamHI and PstI respectively. 
PCR amplification removed sequences which encoded the 13 N-terminal amino acids of 
VP 19c and replaced them with sequences encoding amino acids which reconstituted the 
methionine start codon followed by Arg, Ser and 6x His residues. The PCR product was 
subcloned into the pAcCL29-l baculovirus transfer vector as a BamHI/PstI fragment. This 
transfer vector was then used to generate recombinant baculoviruses by co-transformation 
into SF21 cells with parental baculovirus (PAK6) DNA (as described in Methods). 
Recombinant viruses were isolated and used to generate virus stocks. Virus stock 1 
(Ac381) was selected for the production of high titre virus stocks which were used for the 
recombinant expression of VP19cHis. The pAcCL29381 transfer vector is schematically 
represented in fig. 3.4.5.
3.4.3.2 Expression and purification ofVP19cHis
Fig. 3.4.6 shows the SDS-PAGE protein profiles of SF21 cells infected with Acl8386 or 
Ac381 which express the same UL38His ORF. The level of VP19cHis expression within 
Ac381 infected SF cells is comparable to that of VP19cHis when co-expressed with VP23 
in Ac 18386 infected cells (fig. 3.4.6, lanes 3 and 2 respectively). Early attempts to purify
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Fig. 3.4.6: SDS-PAGE analysis o f SF21 cells infected with Ac381
60mm dishes containing approximately 70% confluent SF21 cells were infected 
at an m.o.i. o f 5 with either Ac 18386 (lane 2), Ac381 (lane 3), or mock infected 
(lane 4) (as described in Methods). 48 hours post infection SF21 cells were 
harvested (as described in Methods) and pelleted by centrifugation at 14,000 
r.p.m. for 5 minutes at RT. The supernatant was removed and the cell pellet 
resuspended in 200pl o f BM buffer and heated for 2 minutes at 100°C in a dry 
block. 5pil o f each sample and purified B-capsids (lane 5) were analysed by SDS- 
PAGE against Rainbow markers and stained with Coomassie Brilliant Blue. The 
positions o f VP 19c and VP23 are indicated by the arrows.
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VP19cHis through Ni-NTA agarose chromatography resulted in low levels of recovery. 
Fig. 3.4.7 shows a typical SDS-PAGE profile of VP19cHis purified in buffer O (150mM 
Na2HPC>4 (pH7.5), 0.1% Octyl-p-glucoside, 0.1% glycerol). The recovery of VP19cHis 
was significantly improved when the cell lysis was carried out in buffer OL (buffer O 
containing 150mM NaCl and 0.05% NP40). Fig. 3.4.8 (panel A) shows the typical SDS- 
PAGE profile of VP19cHis purified from SF21 cells infected with Ac381 when buffer OL 
was utilised in cell lysis. The presence of NaCl and NP40 in buffer OL evidently increases 
the availability of VP19cHis to the Ni-NTA agarose resin compared to that of buffer O 
(fig.3.4.7). Although the mechanism by which buffer OL accomplishes this is unclear, the 
presence of NaCl or NP40 within the buffer may increase the efficiency of cell lysis or 
prevent the aggregation of VP 19c during purification. Using buffer OL during the lysis of 
SF21 cells infected with the Ac381 results in the co-purification of a 90kDa protein that 
typically elutes from the Ni-NTA resin in the first elution fraction (see fig. 3.4.8, lane3). 
Western blot analysis using a VP 19c polyclonal antibody (TrpE/VP19c fusion) 
demonstrates that the prominent 50kDa protein band is VP 19c and but failed to detect the 
co-purified 90kDa protein. Purification of VP19cHis often resulted in the co-purification 
of breakdown products of VP 19c. The presence of such breakdown products is 
highlighted in fig. 3.8.4 (panels B and C). A prominent 40kDa MW band is readily 
detected as well as smaller breakdown products (indicated by *). Western blot analysis 
using the Penta His monoclonal antibody (Qiagen) demonstrated that the major breakdown 
product was formed by the loss of the C-terminal portion of VP 19c as the N-terminal His 
tag was readily detected (fig. 3.4.8, panel C). It is interesting to note the presence of 
similar MW VP 19c related breakdown bands within purified B-capsids (fig. 3.4.8, panel B, 
lane 1). Other groups have also described the formation of C-terminally truncated VP 19c 
products (Newcomb et al., 1996; Spencer et al., 1998). This suggests that the C-terminal 
truncation described here is not a direct result of the incorporation of the 6x His epitope tag 
making VP19cHis susceptible to proteolytic cleavage. The inclusion of a cocktail of 
protease inhibitors (see Materials and Methods for details) during the purification of 
VP19cHis did not prevent the accumulation of the C-terminally truncated VP 19c 
molecules. This does not preclude the generation of the C-terminally truncated forms of 
VP 19c by proteolytic digestion. One of the disadvantage in utilising Ni-NTA agarose 
affinity chromatography is that metal chelators, such as EDTA or EGTA that can inhibit 
metalloproteases, cannot be used as they strip Ni2+ ions from the NTA matrix.
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Fig. 3.4.7: SDS-PAGE analysis o f VP19cHis purified in buffer O.
VP19cHis was purified from 300mls o f SF21 cells ( lx l  06 cells/ml) infected with 
Ac381at an m.o.i. o f 5. Cells were resuspended in buffer O (150mM Na2H P 0 4 
(pH7.5), 0.1% glycerol, 0.1% Octyl-P-glucoside ) + protease inhibitors and lysed by 
bath sonication (as described in Methods). VP19cFlis was purified using 500pl o f 
Ni-NTA agarose equilibrated in buffer O. The Ni-NTA agarose was washed in 2x 
10 ml o f buffer O before VP19cFIis was eluted in 3x 350pl fractions o f lOOmM 
imidazole in buffer O. 20pl of each elution fraction (lanes 2-4) was analysed by 
SDS-PAGE against Rainbow markers and stained with Coomassie Brilliant Blue. 
The arrow indicates the position o f VP19cHis.
VP19cHis
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Fig. 3.4.8: SDS-PAGE and Western blot analysis of Ni-NTA agarose purified
VP19cHis.
VP19cHis was purified from 300mls of SF21 cells (lxlO6 cells/ml) infected 
with Ac381 (as described in Methods and fig. 5.4.7). Cells were resuspended 
and lysed in buffer OL (buffer O containing 150mM NaCl and 0.1% NP40) + 
protease inhibitors (as described in Methods). Subsequent steps in VP19cHi$ 
purification were carried out in buffer O (as described in fig.5.4.7). VP19cHi$ 
was eluted from the Ni-NTA agarose in 350pl fractions of lOOmM imidazole 
in buffer O. 20pl of each elution fraction (lanes 2-6) was analysed by SDS- 
PAGE against Rainbow markers (lane 1) and stained with Coomassie Brilliant 
Blue (A). (B) Western blot analysis of purified VP19cHis (lane 2) and 
purified B-capsids (lane 1). The nitro-cellulose membrane was probed with a 
1:1000 dilution of a polyclonal UL38 antibody (TrpE/VP19c fusion). The 
position of VP19cHis is indicated by an arrow. (C) Western blot analysis of 
purified VP19cHis. The nitro-cellulose membrane was probed with 1:1000 
dilution of the monoclonal Penta His antibody (Qiagen) which specifically 
recognises the 6x His epitope tag. (*) indicates the position of prominent break 
down products of VP19cHis.
Results: 3.4
Attempts to remove the 90kDa protein which co-purified with VP19cHis by washing the 
Ni-NTA agarose with low concentrations of imidazole in buffer O failed since washing 
with imidazole at concentrations as low as 5mM resulted in the elution of both the 90kDa 
protein and VP19cHis (data not shown). The relatively weak binding of VP19cHis to the 
Ni-NTA agarose could possibly be attributed to the N-terminal 6x His tag being partially 
buried within the interior of the VP19cHis molecule and therefore not totally accessible to 
the Ni-NTA agarose. Biophysical experiments described in section 3.6 were performed on 
third and subsequent VP19cHis elution fractions that were checked for the presence of the 
contaminating 90kDa higher MW protein by SDS-PAGE and Coomassie Brilliant Blue 
staining before analysis.
3.4.4 Ni-NTA pull down assays
In order to determine if purified VP19cHis could interact in vitro with VP23, a pull down 
assay was developed. Lysates from SF21 cells infected individually with Ac381 or 
AcUL18 expressing VP19cHis and VP23 respectively were mixed together with Ni-NTA 
agarose and pelleted (as described in Methods). Fig. 3.4.9 (panel A) shows the SDS- 
PAGE analysis of a Ni-NTA pull down assay using VP19cHis as bait to fish VP23 from 
the appropriately infected SF21 cell lysate. A novel band of approximately 34kDa was 
purified from mixed Ac381 and AcUL18 infected cell lysates that was not present in Ni- 
NTA agarose pull downs of individually infected AcUL18 or Ac381 infected cell lysates. 
Western blot analysis using a polyclonal anti VP23 antibody (187) confirmed that this 
34kDa band corresponded to VP23 (fig. 3.4.9, panel C). It is interesting to note that the 
40kDa C-terminal truncated version of VP19cHis (described above) was more abundant in 
Ni-NTA pull downs from infected cell lysates which contained VP19cHis alone compared 
to those from lysates containing both VP23 and VP19cHis (fig. 3.4.9, lanes 6 and 7 
respectively). This would suggest that VP23 may be able to protect full length VP19cHis 
from protease digestion. This result also confirms that the 13 amino acid residues deleted 
from the N-terminus of VP 19c during the construction of VP19cHis are not required for 
interaction with VP23 and that the 6x His epitope tag on the N-terminus of VP 19c does not 
inhibit this interaction.
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Fig. 3.4.9: SDS-PAGE and Western blot analysis of Ni-NTA agarose
VP19cHis pull down of VP23.
Pellets from 60mm plates of SF cells infected singly with either AcUL18 
(VP23) or Ac381 (VP19cHis) (as described in Methods) were resuspended 
in 150pl of buffer O containing lOOmM NaCl and 1% NP40. After 
incubating on ice for 15 minutes with intermittent vortexing they were 
clarified by ultracentrifugation at 35,000 r.p.m. for 10 minutes. 200pl of 
each extract was mixed or an additional 200pil of buffer O was added before 
being incubated for 1 hour at 28°C (as described in Methods). 30pl of Ni- 
NTA agarose equilibrated in buffer O was added to each sample and 
incubated for an additional 15 minutes at RT with intermittent vortexing. 
The Ni-NTA agarose was pelleted and washed (as described in Methods), 
resuspended in 30pl of BM loading buffer containing 250mM imidazole and 
heated for 10 minutes in a dry block at 100°C. 15pi of each sample was 
used for SDS-PAGE analysis or Western blotting. (A) SDS-PAGE analysis 
of cell lysates containing VP23 (lane 1), VP19cHis (lane 2), or mixed cell 
lysates containing VP23 and VP19cHis (lane 3). Ni-NTA pull downs were 
carried out on lysates containing either VP23 (lane 5) or VP19cHis (lane 6) 
or following mixing of VP23 and VP19cHis (lane 7). 5pl of cell lysate was 
analysed by SDS-PAGE against purified B-capsids (lane 4) and Rainbow 
markers (lane 8). Proteins were visualised by Coomassie Brilliant Blue 
staining. (B and C) Western blot analysis of purified B capsids (lane 1) and 
15pl of samples from the Ni-NTA pull down assay. Ni-NTA pull downs 
were carried out on lysates containing either VP23 (lane 2) or VP19cHis 
(lane3), or following mixing of VP23 and VP19cHis (lane 4). (B) Nitro­
cellulose membrane was probed with a 1:1000 dilution of the polyclonal 
VP 19c antibody (TrpE/VP19c fusion). (C) Nitro-cellulose membrane probed 
with a 1:1000 dilution of the polyclonal VP23 antibody (187). Arrows 
indicate the positions of VP19cHis and VP23.
Results: 3.4
3.4.4.1 Characterisation o f  in vitro triplex formation
The in vitro pull down assay (described above) was used to analyse the association of 
VP19cHis and VP23 in the presence of high concentrations of NaCl. High NaCl 
concentrations have been reported to disrupt capsid protein interactions in other viruses. 
Parker and Prevelige (1998) demonstrated that procapsid assembly of P22 could be 
inhibited by 1M NaCl. They went onto demonstrate that this inhibition was specifically 
due to the disruption of electrostatic interactions between the C-terminus of the scaffold 
molecule and the coat protein of P22. Similarly, Fox et al., (1997) characterised the 
isolation of a mutant of cowpea chlorotic mottle virus (CCMV, K42R) which produced 
virions that were more stable in high NaCl concentrations than WT CCMV virions which 
disassembled in 1M NaCl. Preliminary experiments in our laboratory demonstrated that 
HSV-1 capsid assembly could also be inhibited by 1M NaCl thereby suggesting the 
involvement of electrostatic interactions between capsid proteins during capsid assembly. 
In order to examine whether or not the interaction between VP23 and VP 19c was affected, 
an Ni-NTA pull down assay was performed in the presence and absence of 1M NaCl (fig. 
3.4.10). This showed that VP23 could be co-purified with VP19cHis when lysates from 
SF21 cells individually infected with AcUL18 and Ac381 were mixed in the presence of 
1M NaCl (fig. 3.4.10, lanes 4 and 5 respectively). This result suggests that VP19cHis and 
VP23 do not interact primarily through electrostatic interactions.
Newcomb et al., (1996) and Rixon and McNab (1999) demonstrated that HSV-1 
procapsids disassemble at temperatures of 0°C (discussed further within the introduction of 
this thesis, section 1.9). It was therefore decided to examine the association of VP19cHis
and VP23 at 0°C. Fig. 3.4.11 shows the protein profiles of Ni-NTA agarose pull downs 
carried out on extracts of VP23 and VP19cHis incubated for 1 hour at 28°C or at 0°C. Co­
purification of VP23 with VP19cHis was greatly reduced at 0°C (fig. 3.4.11, panel A, lane 
5) compared to 28°C (fig. 3.4.11, panel A, lane 4). However, Western blot analysis using
the polyclonal VP23 antibody 187 did detect VP23 in the 0°C sample (fig. 3.4.11, panel B, 
lane 5). This suggests that the association of VP19cHis with VP23 is partially inhibited at
0°C. It is interesting to note that once triplexes have formed they are not destabilised by 
incubation at 0°C (fig.3.4.11, panel C). Therefore, although the association of VP19cHis
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Fig. 3.4.10: SDS-PAGE analysis o f VP19cHis/VP23 interaction in the 
presence or absence o f 1M NaCl.
Ni-NTA agarose pull downs were performed (essentially as described in 
Methods and fig. 5.4.9) with 1M NaCl present in (lanes 2, 3, and 4) or 
absent (lane 5) all purification buffers. 15pl o f each sample was 
analysed by SDS-PAGE against purified B-capsids (lane 1) and stained 
with Coomassie Brilliant Blue. SF cells were infected singly with 
either AcUL 18 (VP23) or Ac381 (VP19cHis). Ni-NTA pull downs were 
carried out on lysates containing either VP23 (lane2) or VP19cHis (lane 
3) or following mixing o f VP23 and VP19cFlis (lanes 4 and 5). Arrows 
indicate the positions o f VP 19c and VP23
VP19c
VP23
VP23
Fig. 3.4.11: SDS-PAGE analysis of VP19cHis/VP23 interaction at 0°C.
Ni-NTA pull downs were performed essentially as described in Methods 
and fig. 5.4.9. Incubations were either carried out at 0°C on ice (lane 5) or 
28°C (lanes 2, 3, and 4) for 1 hour. For reactions carried out at 0°C all 
buffers were prechilled before use with clarification and washing stages 
performed at 4°C. 15pi of each sample was analysed by SDS-PAGE 
against purified B-capsids (lane 1) and stained with Coomassie Brilliant 
Blue (A). SF cells were infected singly with either AcUL18 (VP23) or 
Ac381 (VP19cHis). Ni-NTA pull downs were carried out on lysates 
containing either VP23 (lane2) or VP19cHis (lane 3) or following mixing 
of VP23 and VP19cHis (lanes 4 and 5) at the appropriate temperatures. 
(B) Western blot analysis of Ni-NTA pull downs carried out at 0°C or 
28°C. Samples were analysed by SDS-PAGE (as described for A) and 
transferred to a nitro-cellulose membrane. The membrane was probed 
with a 1:1000 dilution of the polyclonal VP23 antibody (187). (C) SDS- 
PAGE analysis of Ni-NTA purified triplexes carried out at 28°C (lane 2) 
or 0°C (lane 3). SF cells were infected with Ac 18386 co-expressing 
VP19cHis and VP23. Ni-NTA triplex purifications were carried out at 
28°C or 0°C and analysed by SDS-PAGE against purified B-capsids and 
stained with Coomassie Brilliant Blue. The positions of VP 19c and VP23 
are indicated by the arrows.
Results: 3.4
and VP23 may be less efficient at 0°C, the intact triplexes are not cold labile, in as much
that they do not disassemble at 0°C. It is unlikely therefore, that this accounts for the 
thermolability of the procapsid.
3.4.5 Size exclusion chromatography of VP19cHis
In order to determine an accurate native MW, size exclusion chromatography was carried 
out on purified VP19cHis utilising a 25ml (1 by 30 cm) Superose 12 gel filtration column 
(Pharmacia), as described in Methods. Fig. 3.4.12 (panel A) shows the elution profile of 
VP19cHis analysed in buffer O. No distinct elution peak could be detected. SDS-PAGE 
analysis confirmed that the material loaded onto the column contained purified VP19cHis 
(fig. 3.4.12, panel B, lane 1). The small peak (indicated by an arrow in fig. 3.4.12, panel 
A) was collected and TCA precipitated (as described in Methods). SDS-PAGE analysis of 
this peak demonstrated that it corresponded to VP19cHis (fig. 3.4.12, panel B, lane 3). 
However, the amount of VP 19c in this peak was far less than the amount injected onto the 
column for analysis. The poor recovery of VP19cHis may be due to non-specific binding 
to the Superose or formation of aggregates which could not pass through in situ filters 
before entering the column. However, purified VP19cHis was clarified by 
ultracentrifugation before size exclusion chromatography analysis to remove insoluble 
aggregated material and no detectable precipitate was recovered. Numerous attempts were 
made to determine the native MW for VP19cHis by size exclusion chromatography 
including the addition of 150mM NaCl to the purification and column buffers to minimise 
non-specific binding to the Superose (as recommended by the manufacturer’s guidelines). 
However, all attempts failed to generate a reproducible elution spectrum for VP19cHis. 
Indeed, consecutive attempts to size purified VP19cHis in buffer O resulted in an increase 
of column pressure above the limits recommended by the manufacturer. Since VP19cHis 
is reasonably stable in buffer O and shows good solubility over the time periods required 
for size exclusion chromatography analysis, these results suggest that VP19cHis is non- 
specifically binding to the Superose.
In order to determine if the cysteine residues within VP 19c were forming random 
intermolecular disulphide bonds which could be responsible for generating protein
130
m
A
U
1 0 0
3020100
(A) Elution Volume (ml.)
VP19c
(B)
Fig. 3.4.12: Size exclusion chromatography and SDS-PAGE
analysis of Ni-NTA agarose purified VP19cHis in buffer O.
VP19cHis was purified in buffer O from 300ml of SF cells (lxlO6 
cells/ml) infected with Ac381 (as described in Methods and in fig. 
5.4.7). Elution fractions 1-4 were combined (total concentration of 
0.3mg/ml), and analysed on a 25 ml (1 by 30 cm) Superose 12 gel 
filtration column (Pharmacia) using a 1 ml injection superloop (as 
described in Methods). (A) Size exclusion chromatography 
profile for VP19cHis purified and analysed in buffer O. The 
fractions containing the peak marked with the arrow were TCA 
precipitated and the protein pellet was resuspended in 20pl of BM.
(B) 20pl of purified VP19cHis combined elution fractions 1-4 
(lane 1) and 20pl of the TCA precipitated size exclusion 
chromatography peak elution fraction (lane 3) were analysed by 
SDS-PAGE against purified B-capsids (lane 2) and stained with 
Coomassie Brilliant Blue.
p-mercaptoethanol P-mercaptoethanol
Fig. 3.4.13: SDS-PAGE analysis Ni-NTA agarose purified VP19cHis in 
the presence or absence o f 20mM P-mercaptoethanol.
VP19cHis was purified from 300mls o f SF21 cells ( lx lO6 cells/ml) 
infected with Ac381 (as described in Methods and fig. 5.4.7). 20pl of 
elution fraction 1 (lane 2) was analysed by SDS-PAGE and Coomassie 
Brilliant Blue staining in the presence (+) or absence (-) o f 20mM  p- 
mercaptoethanol. Purified B capsids (lane 1) were analysed in the 
presence or absence o f 20mM p-mercaptoethanol for comparison.
Results: 3.4
aggregates and thereby preventing effective sizing, SDS-PAGE analysis was performed on 
purified VP19cHis in the presence and absence of p-mercaptoethanol (fig. 3.4.13). No 
VP19cHis oligomers were detected in the absence of P-mercaptoethanol suggesting that 
inter-molecular disulphide bonds were not formed. VP19cHis also appeared to behave in a 
similar manner to VP 19c from purified B-capsids during SDS-PAGE analysis in the 
absence of reducing agents (fig. 3.4.13, lanes 1 and 2, no P-mercaptoethanol).
3.4.6 Sucrose gradient sedimentation
Sucrose gradient sedimentation was employed to analyse the native MW of purified 
VP19cHis in buffer O. Purified VP19cHis was co-sedimented with the protein standard, 
BSA (66kDa) through a 5ml 5-25% sucrose gradient made in buffer O and 150pl fractions 
were collected (as described in Methods). The fraction distribution of VP19cHis was 
determined by Western blot analysis of every third fraction (data not shown). Fig. 3.4.14 
(panel A) shows the SDS-PAGE analysis of fractions 17 to 28, out of a total of 35 
fractions, collected from the gradient. The relative intensities were calculated for each 
fraction for both VP19cHis and BSA and plotted as a percentage (%) change in volume 
intensity against the appropriate fraction number for each individual protein profile (fig.
3.4.14, panel B). BSA was detected over a number of fractions with the peak intensity 
corresponding to fraction 20. VP19cHis sedimented through the gradient as a single 
species which had a peak intensity in fraction 24. Therefore, VP19cHis demonstrated a 
four fraction shift in peak intensity compared to BSA. As fractions were collected from 
the bottom of the gradient this indicates that VP19cHis has a lower MW than BSA 
(66kDa). This would suggest that the native MW for VP19cHis cannot be significantly 
different from the predicted 50kDa MW derived amino acid sequence (McGeoch et al., 
1988). On this basis, purified VP19cHis is likely to be in the form of a monomer of 
approximately 50kDa rather than a dimer (lOOkDa) or larger complex.
3.4.6.1 in vitro formation o f triplexes from purified proteins
In order to determine whether purified VP19cHis and purified bacterially expressed 
VP23His could form triplexes in vitro, the proteins were mixed and analysed by sucrose
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Fig. 3.4.14: Sucrose gradient sedimentation and SDS-PAGE analysis
of Ni-NTA purified VP19cHis in buffer O.
VP19cHis was purified in buffer O from 300mls of SF cells (lxlO6 
cells/ml) infected with Ac381 (as described in Methods and fig. 5.4.7). 
300pl of purified VP19cHis from elution fraction 1 and 50pl BSA 
(5mg/ml) resuspended in buffer O were mixed and sedimented together 
on a 5ml 5-25% sucrose gradient at 40,000 r.p.m. for 16 hours at 4°C in 
a AH650 rotor and fractions collected (as described in Methods). (A) 
20pl of fractions 17-28 (lanes 2-13 respectively) were analysed by 
SDS-PAGE against Rainbow markers (lane 1) and stained with 
Coomassie Brilliant Blue. The positions of BSA and VP19cHis are 
indicated by the appropriate arrows. The relative intensity of the 
Coomassie stained bands was calculated individually for both 
VP19cHis and BSA protein profiles using Quantity ONE software 
(Bio-Rad) as described in Methods. The data for VP19cHis and BSA 
was plotted as percentage (%) change in volume intensity for each 
individual protein profile against their eluted fraction number (B). The 
peak fraction for VP19cHis is indicated by an arrow.
Results: 3.4
gradient sedimentation in buffer O. Purified VP23His was added in excess to encourage 
all VP19cHis molecules to participate in triplex formation. Therefore, VP23His and 
VP19cHis were mixed in a 3:1 ratio and incubated for 1 hour at 28°C to allow the 
formation of triplexes to occur. The samples were subsequently sedimented together with 
the internal protein standard BSA (66kDa) through a 5ml 5-25% sucrose gradient made in 
buffer O and 150pl fractions were collected (as described in Methods). Fig. 3.4.15 (panel 
A) shows the SDS-PAGE profile of BSA for fractions 17-28 collected from the gradient. 
Western blot analysis was performed on the same fractions using the Penta His monoclonal 
antibody (Qiagen) which specifically recognises the 6xHis epitope tags on VP23His and 
VP19cHis. Fig. 3.4.15 (panel B) shows the Western blot analysis of fractions 17-28. Both 
VP23His and VP19cHis sedimented profiles are visible. The relative intensities of each 
fraction were calculated for both VP19cHis and BSA and plotted as a percentage (%) 
change in volume intensity against the appropriate fraction number (fig. 3.4.13, panel B). 
When mixed with VP23His, VP19cHis was found throughout a large proportion of the 
gradient. The peak intensity was in fraction 18, which in contrast to VP19cHis alone (fig.
3.4.14, panel B), is further down the gradient than the BSA peak fractions (fractions 21- 
22). The position of this peak with respect to the BSA standard is similar to that of 
purified triplexes (fig. 3.5.16) and suggests that the purified VP19cHis and VP23His are 
able to interact to form heterotrimeric complexes in the absence of other capsid proteins. It 
is interesting to note that two additional peaks could be detected (arrows b and c 
respectively in fig. 3.4.15). Peak b could correspond to VP19cHis interacting with a single 
copy of VP23His generating a protein complex which sediments further through the 
gradient then BSA. Peak c probably corresponds to uncomplexed VP19cHis as its 
positions on the gradient is similar to that of purified VP19cHis when sedimented without 
VP23. The fact that some of VP19cHis remained uncomplexed, in the presence of excess 
VP23His, suggests that either the interaction between VP23 and VP 19c is in an 
equilibrium or that the interaction in vitro is not particularly efficient. Size exclusion 
chromatography of triplexes purified from SF21 cells infected with Ac 183 86 and analysed 
in buffer O (section 3.5, fig. 3.5.15, panel A) suggests that triplexes do not exist in 
equilibrium with their constituent proteins. This would seem to suggest therefore either 
that a proportion of VP19cHis maybe mis-folded and unable to interact with VP23His, or 
that, the association of purified VP19cHis and VP23His in vitro may require additional 
factors, such as chaperones, for efficient complex formation.
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Fig. 3.4.15: Sucrose gradient sedimentation and SDS-PAGE/Westem blot analysis
of Ni-NTA purified VP19cHis and VP23His in buffer O.
VP19cHis and bacterially expressed VP23His were purified in buffer O (as 
described in Methods and figs. 5.4.7). VP23His and VP19cHis were mixed in a 
3:1 ratio to a final volume of 300pl and incubated for 1 hour at 28°C. 50pl of BSA 
(5mg/ml resuspended in buffer O) was then added to the VP23His/VP19cHis 
mixture, which was sedimented on a 5ml 5-25% sucrose gradient at 40,000 r.p.m. 
for 16 hours at 4°C in a AH650 rotor and fractions collected (as described in 
Methods). (A) SDS-PAGE profile of fractions 17-28 (lanes 1-12 respectively) 
stained for BSA with Coomassie Brilliant Blue (20pl/fraction analysed). (B) 
Western blot analysis of fractions 17-28 (lanes 1-12 respectively) probed with a 
monoclonal Penta His antibody (at a 1:1000 dilution, Qiagen) which specifically 
recognises the 6xHis epitope tag on VP23His and VP19cHis. The position of 
BSA, VP19cHis and VP23His are indicated by the appropriate arrow. The relative 
intensities of the Coomassie stained protein profile for BSA and of the VP19cHis 
detected by Western blot was calculated individually using Quantity ONE 
software (Bio-Rad) as described in Methods. The data for VP19cHis and BSA 
profiles was plotted as percentage (%) change in volume intensity for each 
individual protein profile against their eluted fraction number (B). The peak 
intensities for VP19cHis are indicated by arrows a-c.
Results: 3.4
3.4.7 Conclusions
Recombinantly expressed VP19cHis has consistently proven to be difficult to purify 
utilising Ni-NTA agarose affinity chromatography from either bacterial or baculovirus 
expression systems. Newcomb described similar difficulties when attempting to purify 
untagged VP 19c from insect cells (personal communication, Newcomb, 1998). The reason 
why VP 19c is difficult to purify is unclear but sensitivity to proteolytic digestion and poor 
solubility seem to be consistent factors. Published observations by Spencer et al., (1998) 
and Newcomb et al., (1996) demonstrated by SDS-PAGE and Western blot analysis, that 
purified VP 19c samples consistently contained a smaller product. This is probably due to 
proteolytic digestion of VP 19c as opposed to poor translation of the UL38 ORF since a 
similar sized form of VP 19c can be found within purified capsids (fig. 3.4.8, panel B). The 
same UL38 ORF when present in both Ac381 and Ac 18386 results in similar levels of 
recombinant expression of VP19cHis. Despite this it is much easier to purify triplexes 
than isolate VP 19c. This suggests that VP23 may stabilise recombinantly expressed 
VP19cHis. In part this seems to be due to the reduction of proteolytic digestion by 
endogenous protease’s since less of the 40kDa breakdown product is seen when VP23 
present. However, another major factor appears to be the increased solubility of triplexes 
compared to VP 19c.
Chowdhury and Batterson (1994) fused small segments of VP 19c to p-galactosidase and 
demonstrated that two domains (amino acid residues 1-30 and 302-327) could translocate 
P-galactosidase to the nucleus of Vero cells. Analysis of the amino acid sequence between 
residues 1-30 of VP 19c identified a sequence homology to a small canonical sequence 
responsible for transporting proteins to the endoplasmic reticulum (ER). From this and 
immunofluorescence data the authors concluded that VP 19c was transported from the 
perinuclear space into the nucleus via the inner nuclear membrane and therefore bypassed 
the nuclear pore complex. If this is correct it could provide an explanation of why 
VP19cHis is difficult to purify, since VP 19c might be aggregating at membrane sites 
within or around the nucleus and therefore become immobilised and prevented from 
entering the soluble fraction of cell lysates used during Ni-NTA agarose affinity 
purification. However, it should be noted that this would be an unprecedented route for 
transport to the nucleus and seems especially unlikely as VP 19c is also partly responsible
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for the selective nuclear localisation of VP5 and VP23 (Nicholson et al., 1994; Rixon et 
al., 1996). An alternative explanation of Chowdhury and Batterson’s results could be due 
to the instability and mis-folding of over expressed VP 19c within Vero cells. The ER 
lumen has been shown to be the site at which mis-folded or unfolded proteins are directed 
for corrective folding by the ‘unfolded protein response’ (UPR) pathway. Here, ER- 
resident proteins, such as heat shock chaperone proteins, assist the refolding of proteins, or 
induce the specific degradation of incorrectly folded proteins thereby removing them from 
the cell (reviewed by Hampton, 2000). As VP 19c appears to be less stable in the absence 
of other capsid proteins, in particular VP23, over expressed VP 19c may become mis- 
folded and as a consequence become directed to the ER for refolding. Such mis-folding 
could itself contribute to the difficulty in purifying VP19cHis in the absence of VP23.
Immunofluorescence studies performed by Ward et al., (1996) and de Bruyn Kops et al., 
(1998) have also demonstrated that VP 19c can localise to specific sites within the nucleus 
near the nuclear membrane where capsid assembly is thought to take place. The presence 
of NP40 and NaCl in buffer OL, compared to buffer O, may therefore be sufficient to 
disassociate or disrupt any VP 19c associated with membrane structures, for example mis- 
folded VP 19c within the ER or nuclear membranes. Alternatively, the presence of NaCl or 
NP40 within buffer OL may be sufficient to disassociate any aggregated complexes of 
VP19cHis and/or increase the solubility of VP19cHis during Ni-NTA agarose purification. 
The cloning strategy for VP19cHis involved the deletion of the N-terminal 13 amino acids 
of VP 19c. Removing these residues and incorporating the 6x His tag in their place did not 
affect the protein’s ability to interact with VP23 in vitro as demonstrated by Ni-NTA pull 
downs (fig. 3.4.9). Nor did it prevent the formation of triplexes that could be purified by 
Ni-NTA agarose affinity chromatography (fig. 3.4.11, panel C). This indicates that the N- 
terminus of VP 19c is not essential for the interaction with VP23 and is not deeply buried 
within the interior of the protein molecule. These findings are supported by deletion 
mutagenesis performed by Spencer et al., (1998) who demonstrated that the N-terminal 45 
amino acids were not required for VP 19c to participate effectively in the production of 
capsids in vivo.
The isolation of VP19cHis from purified triplexes by denaturation in urea yields 
interesting structural data. Newcomb et al., (1993) tested the resistance of purified B-
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capsids to denaturation by both urea and GdnHCl. Using SDS-PAGE and cryo-EM 
analysis they could not detect any significant structural changes in B-capsids when 
analysed in the presence of 3M urea. However, treating capsids with 6M urea resulted in 
the loss of the pentons and the triplexes Ta and Tc. Urea denaturation experiments 
performed during my project on recombinantly purified triplexes to isolate VP19cHis, 
demonstrated that VP23 and VP 19c disassociated when they were incubated in the 
presence of 3M urea for 30 minutes at RT (fig. 3.4.3). This suggests that the extra stability 
of the triplex to urea induced denaturation in the context of the capsid may come from 
contacts formed between the triplex and VP5 from surrounding capsomers. Such contacts 
may enforce a greater stability upon the triplex and therefore increase the resistance of the 
triplex to denaturation. Denaturation of triplexes is discussed in further detail in section 
3.6.
It is interesting to note that VP19cHis isolated by urea denaturation of triplexes remained 
unfolded even when dialysed to remove residual urea, as shown by the intrinsic tryptophan 
fluorescence spectra (fig. 3.4.4). This implies that the 50kDa VP 19c molecule is unable to 
refold by itself in vitro.
Although no reproducible data could be obtained from size exclusion chromatography 
analysis of purified VP19cHis, the native MW could be estimated from sucrose gradient 
sedimentation analysis. This suggests that VP19cHis was purified as a monomer with a 
native MW smaller than that of the 66kDa internal protein standard, BSA (fig. 3.4.14, 
panel B). This is in agreement with published GdnHCl denaturation experiments on HSV- 
1 B-capsids (Newcomb et al., 1993). From these experiments Newcomb and co-workers 
proposed that the triplexes are composed of a single copy of VP 19c and two copies of 
VP23. More recently, Spencer et al., (1998) demonstrated through sucrose gradient 
sedimentation analysis of baculovirus infected SF9 extracts that contained VP 19c and 
VP23 that in vivo formed triplexes had a native MW greater than that of BSA. The 
calculated sedimentation co-efficient was consistent with the formation of a heterotrimer 
complex composed of one copy of VP 19c and two copies of VP23. Data presented within 
this chapter utilising similar sucrose gradient sedimentation analyses upon complexes 
formed from purified VP23His and VP19cHis showed that these two proteins could indeed 
form triplexes in the absence of other capsid and cellular proteins (fig.3.4.15, panel B).
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However, the interaction did not appear particularly efficient with two secondary peaks 
being detected (fig. 3.4.15, panel B, peaks b and c). Newcomb et al., (1999) reported that 
capsids could be formed from individually purified capsid components. However, they 
used pre-assembled purified triplexes and their conclusion, that capsids could be formed in 
the absence of other cellular proteins, in particular chaperone proteins, cannot be applied to 
the formation of triplexes. The results presented within this thesis do suggest that cellular 
proteins are not required for triplex formation and the low efficiency of the process in this 
case may simply reflect the conditions under which the experiments were performed. For 
example, the use of detergents within the purification protocol may hinder possible 
hydrophobic interactions that are required for triplex formation. Alternatively, since 
sucrose has also been shown to disassemble procapsids (Newcomb et al., 1999), some of 
the triplexes which had not completely folded into a stable conformation may have 
disassembled during sucrose sedimentation analysis. Furthermore, Ni-NTA pull downs 
have shown that triplex formation is partially inhibited at 0°C (fig. 3.4.11). This raises the 
possibility that complexes, which are not conformationally stable, may disassemble during 
the 4°C sedimentation analysis. The complexities of triplex formation are discussed in 
subsequent chapters within this thesis.
3.4.7.1 Future work
Further investigation of the conditions for purifying of VP19cHis may be required in order 
to purify it at high enough concentrations to perform comprehensive biophysical 
characterisation experiments (discussed within section 3.6). It would also be interesting to 
characterise the 90kDa MW band which co-purified with VP19cHis using Ni-NTA agarose 
affinity chromatography (fig. 3.4.8, panel A). Since this band was not detected by Western 
blotting with a polyclonal VP 19c antibody it is unlikely to represent an 
oligomeric/aggregated form of purified VP19cHis which is resistant to SDS denaturation. 
It would be interesting therefore to determine whether or not this 90kDa protein interacts 
specifically with VP19cHis.
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3.5 Characterisation of the HSV-1 triplex
Triplexes can be stripped from purified capsids, in particular the triplexes Ta and Tc, in low 
concentrations of GdnHCl (Newcomb et al., 1991; Newcomb et al., 1993). It was 
considered unlikely that this technique would provide sufficient quantities of material in a 
suitable condition for subsequent analyses following purification. Therefore, attempts 
were made to co-express triplex proteins utilising both prokaryotic and eukaryotic 
expression systems.
3.5.1 Construction and expression of pETUL1838.
Recombinant expression of the single triplex protein VP19cHis within induced BL21 DE3 
bacteria was very poor (previously described in section 3.4). In an attempt to increase the 
protein production and/or stability of VP19cHis within bacteria it was decided to co­
express both VP23His and VP19cHis from the same expression vector.
3.5.1.1 Cloning o f the 6xHis tagged UL18 ORF into pETUL38.
As the cloning strategy required the use of a methylation sensitive Xbal restriction site at 
the 3’ end of the UL18 ORF, pETUL18 was electroporated into GM48 (DAM-) bacteria 
and unmethylated pETUL18 DNA was isolated (as described in Methods). The UL18 
ORF, including sequences encoding the 6xHis epitope tag, was subcloned out of pETUL18 
as an Xbal fragment and ligated into Xbal digested and CIP treated pETUL38 to generate 
pETUL1838. The strategy for cloning the UL18 ORF into pETUL38 is illustrated 
schematically in fig. 3.5.1.
3.5.1.2 Expression o f triplex proteins VP23His and VP19cHis in BL21 DE3 bacteria.
BL21 DE3 bacteria were electroporated in the presence of approximately lpg of 
pETUL1838 or pET28MOD DNA and colonies were isolated from a L-broth agar plate 
containing kanamycin (50mg/ml). Single colonies were grown and induced (as described
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Fig. 3.5.2: SDS-PAGE analysis o f pETUL1838 expression in BL21
DE3 bacteria.
BL21 DE3 bacterial cultures containing either pET28MOD (lane 2) or 
pETUL 1838 (lane 3) were grown and induced (as described in 
Methods). 1.5 ml o f the culture was centrifuged at 14,000 r.p.m. for 30 
seconds in a microfuge. The supernatant was removed and the bacterial 
pellet was resuspended in 200pl o f BM and heated for 2 minutes at 
100°C in a dry block. 15pl o f each sample was analysed against purified 
C-capsids (lane 1) by SDS-PAGE and stained with Coomassie Brilliant 
Blue. The presence o f novel bands is indicated by arrows.
VP23His
Fig. 3.5.3: Western blot analysis of pETUL 18 and pETUL 1838
expression in BL21 DE3 bacteria.
BL21 DE3 bacterial cultures containing either pETUL 18 (lane 1) or 
pETUL1838 (lane 3) were grown and induced (as described in 
Methods). 1.5 ml of the culture was centrifuged at 14,000 r.p.m. for 30 
seconds in a microfuge. The supernatant was removed and the 
bacterial pellet was resuspended in 200pl of BM and heated for 2 
minutes at 100°C in a dry block. Western blot analysis was performed 
on 40pl of each sample and purified C-capsids (lane 2). (A) 
Nitrocellulose membrane was probed with 1:1000 dilution of the Penta 
His monoclonal antibody (Qiagen). (B) Nitrocellulose membrane was 
stripped (as described in Methods) and re-probed with a 1:1000 dilution 
of the polyclonal VP23 antibody 187. The arrow indicates the position 
of VP23His.
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in Methods) and analysed for the expression of VP19cHis and VP23His by SDS-PAGE 
and Coomassie Brilliant Blue staining. Fig. 3.5.2 shows the comparative protein profile of 
induced BL21 DE3 bacteria containing either the pETUL 183 8 or pET28MOD bacterial 
expression vectors. Two bands could be detected by Coomassie Brilliant Blue staining in 
the pETUL 1838 sample that were not present in the pET28MOD sample (indicated by a 
(+) in fig. 3.5.2). These bands migrated with a MW just higher than that of VP23 and 
VP 19c from purified C-capsids (indicated by arrows in fig. 3.5.2) and reflects the addition 
of extra sequences on their respective N-termini. Western blot analysis utilising a 
commercial Penta His monoclonal antibody (Qiagen) detected the presence of two protein 
bands in bacterial extracts expressing pETUL1838 (fig.3.5.3, panel A, lane 3). In 
comparison, only a single band could be detected within bacterial extracts expressing 
pETUL18 (fig.3.5.3, panel A, lane 1). Western blot analysis utilising a polyclonal VP23 
antibody (187) confirmed this lower MW band within the pETUL 183 8 sample was 
VP23His (fig.3.5.3, panel B, lane 3). This data therefore confirms that the successful 
cloning and expression of the UL18 ORF within the pETUL 1838 expression vector. 
However, due to the lack of a specific antibody against VP 19c it was not possible at this 
time to determine whether or not the higher MW band detected by the monoclonal Penta 
HIS antibody corresponded to the bacterial expression of VP19cHis. Nevertheless, the 
estimated MW of 50kDa and the co-migration with VP 19c from purified C-capsids 
supported the case for this being VP19cHis.
3.5.1.3 Ni-NTA agarose purification o f VP23His and VP19cHis from induced BL21 DE3 
bacteria expressingpETUL1838.
Various attempts were made to purify the bacterially expressed triplex proteins utilising 
different buffers (data not shown). However, in each case only VP23His could be purified 
by Ni-NTA agarose affinity chromatography with little or no purification of VP19cHis 
detectable by Coomassie Brilliant Blue staining. Fig. 3.5.4 shows a typical SDS-PAGE 
profile of Ni-NTA purified triplex proteins in PBSa. No VP19cHis could be observed in 
either the 20mM imidazole washes (lanes 1 and 2) or 250mM imidazole elution fractions 1 
and 2 (lanes 4 and 5). In subsequent experiments attempts were made to purify triplex 
proteins without washing the Ni-NTA agarose in 20mM imidazole to ensure that 
VP19cHis was not eluted from the Ni-NTA resin in low concentrations of imidazole.
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Fig. 3.5.4: SDS-PAGE analysis o f Ni-NTA agarose purified bacterially 
expressed triplex proteins (VP23His+VP19cHis).
BL21 DE3 bacteria cultures containing the pETUL1838 were grown and 
induced (as described in Methods). Proteins purified using 700pl o f Ni- 
NTA agarose equilibrated in PBSa. The Ni-NTA agarose was washed in 
10ml (lOx 1ml) o f 20mM imidazole in PBSa to remove non-specifically 
bound proteins from the Ni-NTA matrix. Samples were eluted from the 
Ni-NTA agarose in 3ml (3x lm l fractions) o f 250mM imidazole in PBSa. 
20pl o f the 20mM imidazole wash fractions 1 and 2 (lanes 1 and 2 
respectively) and 20pl o f the 250mM elution fractions 1 and 2 (lanes 4 
and 5 respectively) were analysed by SDS-PAGE and stained with 
Coomassie Brilliant Blue. Eluted Ni-NTA agarose proteins were 
analysed against purified B-capsids (lane 3).
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However, in all cases SDS-PAGE analysis and Coomassie Brilliant Blue staining failed to 
reveal the presence of a 50kDa protein band corresponding to VP19cHis (data not shown).
Previous Western blot analysis utilising the monoclonal Penta His antibody (Qiagen) did 
not detected the presence of a 50kDa MW protein in bacterial extracts expressing 
pETUL38 (discussed in section 3.4). Therefore, the detection of a 50kDa band in bacterial 
extracts expressing the pETUL1838 seems to imply that the expression and/or stability of 
this 50kDa protein is enhanced when co-expressed in the presence of VP23His. This 
resembles the stabilisation of VP19cHis by VP23 seen in the recombinant baculovirus 
expression (discussed below). The difficulty associated with the purification of bacterially 
expressed VP19cHis suggests that it may be forming insoluble aggregates which may 
prevent its purification under the buffering conditions employed. Attempts to purify 
VP23His and VP19cHis under denaturing conditions, for example in 8M urea, which could 
solubilise any aggregated and insoluble proteins, were not pursued. Instead efforts were 
directed towards the expression and purification of triplex proteins within SF21 cells 
utilising recombinant baculoviruses.
3.5.2 Co-expression of VP23 and VP19c triplex proteins within SF21 
cells.
Due to the apparent insolubility of VP19cHis within the prokaryotic expression system it 
was decided to co-express VP 19c and VP23His within the eukaryotic baculovirus 
expression system in an attempt to produce triplexes for purification and analysis.
3.5.2.1 Cloning o f the UL18 ORF into the baculovirus transfer vector pAcAB3 containing 
the UL38 ORF (PAcAB3.10).
The UL18 ORF plus sequences containing the 6xHis tag was subcloned out of the bacterial 
expression vector pETUL18. The pETUL18 plasmid was Xbal digested at a unique Xbal 
restriction site. Following digestion, the DNA was phenol/chloroform extracted and 
ethanol precipitated (as described in Methods). The linear DNA molecule was then blunt 
ended using T4 polymerase and BamHI linkers were inserted (as described in Methods).
139
Xba I Hindl l l
N otlEcoRINcol
T7
promoter UL18 0R F
pETULl 8
Endonuclease restriction digestion 
and BamHI linker ligation 
performed individually upon Xbal 
and Hindlll cloning sites.
Baml II BamHI
N otlEcoRINcol
pETUL18BamHI
pETUL18BamHI digested with 
BamHI, the UL18 ORF BamHI 
fragment purified and ligated 
into BamHI digested and C1P 
treated pAcAB3.10 to generate 
I  pAcABUL 18638.
Baml II Smal Xbal Bglll
P10 Polyhedrin 
promoter promoter UL38 ORF
P10
promoter
pAcAB3.10 Icont.
BamHI BamHI 
Smal
Xbal
UL18 0 R F
E
UL38 ORF
pA cA BU Ll 8638
on
Amp
pAcABUL18638 
( - 1 2 5 9 6  bn')
UL18 
ORF
6x His 
tag p 10 
promoter
plO 
promoter
UL38 
polyhedrin ORF 
promoter
Fig. 3.5.5: Schematic representation o f the cloning strategy 
for the insertion o f the UL18 ORF into the baculovirus 
transfer vector pAcAB3.10 to generate pAcABUL 18638 
(Ac 18638).
1
200 kDa -
i VP 19c
VP23HIS
97.4 kDa - 
66 kDa -
46 kDa - 
30 kDa -
21.5 kDa -
Fig. 3.5.6: SDS-PAGE analysis o f [35S]methionine-labelled SF21 cell 
infected with the recombinant baculovirus Ac 18638 co-expressing 
VP23His and VP 19c.
35mm dishes containing approximately 70% confluent SF21 cells were 
infected with lOOpl o f plaque purified Ac 18386 recombinant baculovirus 
(lane 1), AcUL26.5 at an m.o.i. o f 5 (lane 2), or mock infected (lane 3). 
24 hours post infection SF21 cells were labelled with [35S]methionine (as 
described in Methods) and incubated for a further 24 hours. The cells 
were harvested and pelleted by centrifugation in a 1.5ml reaction vial at
14,000 r.p.m. for 5 minutes at RT in a microfuge. The supernatant was 
removed and the cell pellets resuspended in 200pl o f BM buffer and 
heated for 2 minutes at 100°C in a dry block. 20pl o f each sample and 3pl 
o f Rainbow markers were analysed by SDS-PAGE and stained with 
Coomassie Brilliant Blue. The gel was dried onto W hatmann 3mm paper 
and [35S]methionine labelled proteins were detected by exposing the gel 
o/n to Kodak film (as described in Methods). The arrows mark the 
position o f recombinantly expressed triplex proteins VP 19c and VP23Flis. 
The positions o f the size markers are indicated.
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The BamHI linker insertion procedure was repeated utilising a unique Hindlll restriction 
site (fig. 3.5.5) to generate pETUL18BamHI. The UL18 ORF and sequences encoding the 
6xHis epitope tag was then subcloned out of the pETUL18BamHI vector as a BamHI 
fragment and ligated into a BamHI digested and CIP treated baculovirus transfer vector 
(pPAcAB3.10), which already contained the UL38 ORF. This generated pAcABUL18638. 
The cloning strategy for the insertion of the UL18 ORF into pAcAB3.10 is schematically 
illustrated in fig. 3.5.5. The cloning of the UL38 ORF into the baculovirus transfer vector 
pAcAB3 was performed by Jacqueline Tatman (previously described in Tatman, 1996). 
Briefly, the UL38 ORF was cloned out of pBJ382 (described in section 3.4) as a 
Xbal/HincII fragment and ligated into Xbal/StuI digested and CIP treated pPAcAB3 
(Pharmingen) baculovirus transfer vector to generate pAcAB3.10.
3.5.2.2 Expression o f Acl8638 within SF21 cells.
Recombinant baculoviruses expressing VP23His and VP 19c were obtained by co­
transforming SF21 cells with the pAcABUL18638 baculovirus transfer vector and parental 
baculovirus (PAK6) DNA (as described in Methods). Fig. 3.5.6 shows the [35S] 
methionine-labelled profiles of SF21 cells infected with a third round plaque purified 
isolate of Acl8638 virus (lane 1). For comparison AcUL26.5 (lane 2) and mock (lane 3) 
infected samples are shown. In Ac 1863 8 infected SF21 cells two novel protein bands of 
34 and 50kDa (corresponding to VP23His and VP 19c respectively) could be detected 
which were not present in either the mock or AcUL26.5 infected SF21 cells.
3.5.3 Cloning and expression of Acl8386
During the course of working out a solubilisation strategy for Ni-NTA agarose purified 
triplex proteins from SF21 cells infected with Ac 18638, it was noted that the ratio of 
VP23His to VP 19c was higher than the predicted 2:1 ratio of VP23 and VP 19c in triplexes 
(Newcomb et al., 1993). Furthermore, purification of triplexes utilising the 6xHis epitope 
tag on VP23 resulted in the co-purification of truncated forms of VP 19c (indicated by * in 
fig. 3.5.7). In an attempt to produce a homogenous population of recombinant triplexes 
and avoid an excess purification of VP23, it was decided to express the 6xHis tag on
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VP 19c rather than VP23. Purification of triplexes through the use of Ni-NTA agarose 
affinity chromatography would therefore result in the co-purification of only those VP23 
molecules that were associated with VP 19c as part of a heterotrimer complex.
3.5.3.1 Cloning o f the 6x His epitoped tagged UL38 ORF and UL18 ORF into the 
baculovirus transfer vector pAcAB3.
The cloning of the UL18 ORF and the UL38 ORF, which contained sequences encoding 
the 6xHis epitope tag, was performed by D. McNab. The UL38 ORF was cloned by PCR 
amplification and ligated into the transfer vector pTZ18U as a BamHI/PstI fragment 
(described in section 3.4 and Nicholson, 1992) to generate pTZ386. The UL38 6xHis ORF 
was then subcloned out of pTZ386 as a Hindlll fragment and filled in using Klenow (as 
described in Methods). BamHI linkers were inserted and the fragment ligated into a 
BamHI digested and CIP treated pTZ18U to generate pTZ386BamHI. The UL38 6xHis 
ORF was then isolated from pTZ386BamHI as a BamHI fragment and ligated into a 
BamHI digested and CIP treated pPAcAB3 baculovirus transfer vector (Pharmingen) to 
generate pAcAB386. The UL18 ORF had been previously cloned into the pT3T7 vector 
(described in Tatman, 1996). The pT3T7 vector containing the UL18 ORF was digested 
with Sail and filled in using Klenow (as described in Methods). A BamHI linker was 
inserted and the vector ligated to generate pT3T7UL18BamHI. The UL18 ORF was then 
subcloned out of pT3T7UL18BamHI as a BamHI fragment and ligated into a Bglll 
digested and CIP treated pAcAB386 transfer vector to generate pAcABUL18386. The 
baculovirus transfer vector pAcAB3 and the pAcABUL18386 transfer vector are 
schematically illustrated in fig. 3.5.8 and 3.5.9.
3.5.3.2 Expression o f Ac18386 in SF21 cells
Recombinant baculovirus (Ac 183 86) co-expressing VP19cHis and VP23 was obtained by 
co-transforming SF21 cells with pAcABUL18386 and parental baculovirus (PAK6) DNA 
(as described in Methods). Fig.3.5.10 shows the SDS-PAGE protein profile of SF21 cells 
either mock infected (lane 2), infected with Acl8386 (lane 3), or infected with AcUL26.5 
(lane 4). Two proteins (indicated by the appropriate arrows) could be detected by 
Coomassie Brilliant Blue staining which were not present in either mock infected or
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Fig. 3.5.10: SDS-PAGE analysis o f SF21 cells infected with Ac 18386 
co-expressing the triplex proteins VP19cHis and VP23.
60mm dishes containing approximately 70% confluent SF21 cells were 
infected at an m.o.i. o f 5 with either Ac 18386 (lane 3), AcUL26.5 (lane 
4), or mock infected (lane 2). 48 hours post infection SF21 cells were 
harvested (as described in Methods) and the cells pelleted by 
centrifugation at 14,000 r.p.m. for 5 minutes at RT in a microfuge. The 
supernatant was removed and the cell pellet resuspended in 200pl o f BM 
buffer and heated for 2 minutes at 100°C in a dry block. 5pl o f each 
sample and 3pi o f purified B capsids (lane 1) were analysed by SDS- 
PAGE and stained with Coomassie Brilliant Blue. The arrows indicate 
the positions o f VP23 and VP19cFlis.
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AcUL26.5 infected, SF21 cell extracts. These protein bands migrated with the same MW 
as VP 19c and VP23 from purified B-capsids (lane 1). This would, therefore, imply that 
infection of SF21 cells with Ac 183 86 results the successful co-expression of VP23 and 
VP19cHis.
3.5.4 Ni-NTA agarose purification of triplex proteins expressed within 
SF21 cells infected either with Acl8638 or Acl8386.
3.5.4.1 Purification o f triplexes
Utilising Ni-NTA agarose affinity chromatography, triplex proteins were readily purified 
from SF21 cells infected with either Ac 18638 or Ac 18386 (fig. 3.5.11, panel A lanes 2 and 
3; panel B lanes 2-4 respectively) at protein concentrations of 0.5-2.0 mg/ml for elution 
fraction 1 (as determined by OD28o)- This would imply, therefore, that the N-terminus of 
both VP23His (Ac 18638) and VP19cHis (Ac 18386), where the 6xHis epitope tags are 
located are freely exposed to the solvent and readily available to bind to the Ni-NTA 
agarose. This suggests that the N-termini of these proteins are neither directly involved in 
the interaction with their appropriate triplex partner nor buried within the interior of their 
respective proteins. Furthermore, in each case, co-purification of the untagged triplex 
protein partner demonstrated that these proteins can interact in the absence of other capsid 
proteins and confirms previous experimental findings from Ni-NTA pull downs (described 
in section 3.4).
3.5.4.2 Solubility o f triplexes at 4°C
Although the triplex proteins could be readily purified their long-terms solubility, in 
particular that of VP 19c, at either RT or 4°C was poor. Visible precipitates were observed 
over different periods of time post column elution, ranging from a few minutes to several 
hours depending on the purification buffer employed and their initial concentration of the 
eluted samples. Fig. 3.5.11 (panels A and B) shows the solubility of Ni-NTA agarose 
purified triplex proteins from SF21 cells infected with Ac 18638 (panel A) or Ac 18386 
(panel B) respectively. Purified triplex proteins were incubation o/n at 4°C. Precipitates
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Fig. 3.5.11: SDS-PAGE analysis of Ni-NTA agarose purified triplex
proteins upon incubation at 4°C.
Triplex proteins were purified from SF21 cells infected with either 
Ac 1863 8 (panel A) or Ac 183 86 (panel B), as described in Methods and fig. 
3.5.7. Triplex proteins in (A) were purified in TB2 buffer (lOOmM 
Na2HP04, 50mM NaCl, 0.1% glycerol, 1% DMSO, 0.05% Triton X-100). 
The Ni-NTA agarose was washed with 25ml of 20mM imidazole and the 
proteins were eluted in 6ml (4x 1.5ml fractions) of 250mM imidazole in 
buffer TB2. Triplex proteins in (B) were purified in TB3 buffer (20mM 
Na2HP04, lOOmM Na2S04, 0.05% NP40). The Ni-NTA agarose was 
washed with 25ml of 20mM imidazole and the proteins eluted in 5ml (5x 
lml fractions) of 250mM imidazole in TB3 buffer. In each instance 20pl 
of the appropriate elution fraction was immediately transferred into BM 
and stored at -20°C. The elution fractions were then stored o/n at 4°C. 
Precipitated proteins were sedimented by ultracentrifugation either at
50.000 r.p.m. for 5 minutes at 4°C in a Beckman TLA 100.2 rotor (A) or at
14.000 r.p.m. for 5 minutes at RT in a bench top microfuge (B). The 
supernatant containing the soluble protein fraction was transferred to a 
fresh 1.5ml reaction vial immediately following centrifugation. 20pl of the 
appropriate soluble protein fractions were compared with 20pl of the 
original protein elution fractions by SDS-PAGE and stained with 
Coomassie Brilliant Blue. (A) Lanes 1 and 4: Rainbow markers. Lanes 2 
and 3: 250mM imidazole elution fractions 1 and 2 respectively. Lanes 5 
and 6: soluble protein fraction from elution fractions 1 and 2 respectively 
after incubation o/n at 4°C . (B) Lanes 1 and 5: Rainbow markers. Lanes 
2-4: 250mM imidazole elution fractions 1-3 respectively. Lanes 6-8: 
soluble protein fraction from elution fractions 1-3 respectively after 
incubation o/n at 4°C .
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were sedimented by centrifugation (as described in legend) and the soluble protein 
fractions were analysed by SDS-PAGE to investigate which triplex protein constituents 
had precipitated out of solution during their respective incubations. In all incidences 
precipitation primarily affected VP19cHis and VP 19c, while VP23His and VP23 generally 
remained more soluble (fig. 3.5.11, panel A, lanes 5 and 6, panel B, lanes 6-7). In an 
attempt to increase the solubility and stability of the purified triplexes a range of 
purification buffers were tested. It should be noted that in some instances purification 
buffers, although retaining triplex solubility, were unsuitable for many biophysical 
characterisation experiments (described in section 3.6), in particular Far-UV CD. These 
buffers tended to include comparatively high concentrations of NaCl (typically >150mM) 
and/or glycerol (>1%) which can lead to excessive noise within absorption spectra. In 
particular, Cf ions absorb strongly below 195nm (Kelly and Price, 1996; Price, 1995). 
Such affects could be countered in most instances by analysis and subtracting buffer 
control spectra. However, buffer constituents including certain detergents, such as Triton 
X-100, and imidazole were completely unsuitable for Far-UV CD analysis. Table 3.5.1 
shows a summary of the buffers used in the analysis of purification and solubilisation of 
Ni-NTA agarose purified triplex proteins.
Comparatively good triplex solubility was maintained utilising buffer OG (150mM 
Na2HPC>4 (pH7.5), 0.1% octyl-p-glucoside, 5% glycerol). Fig. 3.5.12 shows the solubility 
following a 48 hour incubation at 4°C of Ni-NTA agarose purified triplex proteins from 
SF21 cells infected with Ac 18386. The triplex proteins appeared to remain completely 
soluble under these conditions. Further analysis revealed that the triplex proteins purified 
in buffer OG remained soluble for up to 4-5 days at 4°C (data not shown). However, far- 
UV CD analysis of triplex proteins in buffer OG (in the absence of imidazole) still proved 
problematic, possibly due to the high absorption factor of the glycerol component of 
buffer. Reduction in the concentration of glycerol from 5% to 0.1% (buffer O) removed
1
i this problem and still permitted triplex purification while maintaining good solubility.i
j  Buffer O was, therefore, used for all biophysical characterisation experiments employed.
j
i
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Buffer
compositon
Purification 
of VP23
Purification 
of VP19c
Analysis Comments
Sonication buffer
(20 mM Tris (pH 7.0), 
10% Glycerol, 0.1% NP40)
+++ + SDS-
PAGE
PBSa
(170mM NaCl, 3.5mM 
KC1, lOmM NaH2P 0 4, 
3mM KH,P04)
+++ ++ SDS-
PAGE
ppt. at RT
G-150 buffer
(150mM NaCl, 20mM Tris 
(pH 8.0), 0.1% Tween)
+ + SDS-
PAGE
30mM Tris (pH 8.0), 2M 
urea, 200mM NaCl, 
10% glycerol
++++ + SDS-
PAGE
G-150 + 1M urea ++ + SDS-
PAGE
500mM NaCl, 20mM Tris, 
3M Urea, 0.5% NP40, 
pH 7.0
+ + SDS-
PAGE
TB4: 20mM Tris (pH 7.5), 
0.1% NP40, 1M Urea
+++ ++ SDS-
PAGE
FPLC
o/n 4°C 
VP 19c ppt.
20mM Tris (pH7.5), 0.25M 
Urea, 0.05% NP40
+++ +++ SDS-
PAGE
CD -VE
0.5M Urea, 20mM Tris 
(pH7.5), 0.05% NP40
+++ +++ SDS-
PAGE
FPLC
CD -VE
20mM Tris (pH7.5), 0.05% 
NP40, 500mM NaCl
++++ ++++ SDS-
PAGE
FPLC
DSC
CD -VE
20mM Tris (pH7.5), 0.05% 
NP40, 500mM NaCl, 8M 
Urea
++++ SDS-
PAGE
No
inter­
disulphide
bond
20 mM Tris (pH7.5), 
250mM NaCl, 0.05% NP40
++++ ++++ SDS-
PAGE
FPLC
Peak frac. 
(2 mg/ml)
20mM Na2HP04(pH 7.5), 
0.1% glycerol, 0.05% 
NP40
++++ ++++ SDS-
PAGE
FPLC
o/n 4°C 
VP 19c ppt.
Cont.
20mM Na2HP04 (pH6.0), 
lOOmM Na2S 04, 0.05% 
NP40
N/A N/A FPLC o/n RT & 
4°C 
VP 19c ppt.
TB3: 20mM Na2HP04 
(pH8.0), lOOmMNa2S 04, 
0.05% NP40
++++ ++++ SDS-
PAGE
o/n RT & 
4°C 
VP 19c ppt.
20mM Na2H P04, 0.05% 
triton, 0.1% glycerol, 10% 
DMSO
++++ +++ SDS-
PAGE
o/n RT & 
4°C 
VP 19c ppt.
TB1: PBScomplete, 
l%glycerol, lOmM 
Na2S04, 2.5% DMSO, 
0.05% Triton X-100
++++ +++ SDS-
PAGE
FPLC:
+++
Low 4°C 
VP 19c ppt. 
CD -VE
TB2: lOOmMNa2HP04, 
50mM NaCl, 0.1% 
glycerol, 1 % DMSO, 
0.05% Triton X-100
++++ ++++ SDS-
PAGE
o/n 4°C 
VP 19c ppt.
lOOmM Na2HP04, 0.1% 
glycerol, 1 % DMSO, 
0.05% Triton X-100
++++ ++++ SDS-
PAGE
FPLC
CD -VE
lOOmM Na2HP04, 0.001% 
NP40 (pH 8.65)
++++ + SDS-
PAGE
lOOmM Na2HP04, 0.001% 
Octyl-p-glucoside, 0.1% 
glycerol, 1% DMSO, 
30mM NaCL (pH 8.65)
+++ + SDS-
PAGE
20mM Tris, 0.1% Octyl-p- 
glucoside, 20mM NaCl, 
1% glycerol
++++ +++ SDS-
PAGE
VP 19c ppt. 
on dialysis
Buffer OG
150mM Na2HP04 0.1% 
Octyl-p-glucoside, 5% 
glycerol (pH7.75)
++++ ++++ SDS-
PAGE
FPLC
VP19c 
Soluable 
o/n at 4°C 
CD -VE
Buffer O
150mM Na2HP04 0.1% 
Octyl-p-glucoside, 0.1% 
glycerol (pH7.75)
++++ ++++ SDS-
PAGE
FPLC
CD +VE 
DSC +VE
Table 3.5.1: Summary table of buffers used in the solubilisation of Ni-NTA agarose purified triplex 
proteins. Triplex proteins were purified from SF cells infected with either Acl8638 or Acl8386 
(as described in Methods and fig. 3.5.7). Purified proteins were analysed (as described in table) 
and rated for the presence of both VP 19c and VP23; ++++ (very good), +++ (good), ++ (poor), + 
(detectable), - (not detectable).
200 kDa -
97.4 kDa - 
69 kDa -
46 kDa -
30 kDa -
Fig. 3.5.12: SDS-PAGE analysis o f Ni-NTA agarose purified triplex proteins in 
buffer OG before and after o/n storage at 4°C.
Triplex proteins were purified from SF21 cells infected with Ac 18386 in buffer 
OG (as described in Methods and fig. 3.5.7). 20pl o f each 250mM imidazole 
elution fraction 1-3 (lanes 2-4 respectively) and Rainbow markers (lane 1) were 
analysed by SDS-PAGE and stained with Coomassie Brilliant Blue. Elution 
fraction 2 was subsequently incubated at 4°C for 48 hours. Following 
incubation, 25pi o f elution fraction 2 was transferred into BM buffer. 
Precipitated proteins were sedimented by ultracentrifugation at 80,000 r.p.m. 
for 5 minutes at 4°C in a Beckman TLA 100.2 rotor. The supernatant fraction 
containing soluble proteins was immediately transferred to a fresh 1.5ml 
reaction vial. 25pl o f the pre-incubation elution fraction 2 and 25pl o f the 
supernatant fraction post incubation was analysed by SDS-PAGE (lanes 5 and 
6 respectively) and stained with Coomassie Brilliant Blue.
1 2  3 4 5 6
Results: 3.5
3.5.5 Disulphide bond analysis of purified triplex proteins.
Zweig et al., (1979) demonstrated through the use of non-reducing SDS-PAGE analysis 
that VP 19c and VP5 from purified HSV-2 capsids were disulphide linked. In order to 
determine whether or not HSV-1 encoded VP 19c and VP23 were also disulphide linked, 
the triplex proteins were purified from SF21 cells infected with Ac 1863 8 in the presence 
(fig. 3.5.13, lanes 4 and 6) or absence (fig. 3.5.13, lanes 3 and 5) of 8M urea. Only a single 
prominent band corresponding to VP23His was purified in the presence of 8M urea. This 
indicates that inter-molecular disulphide bonds do not link VP 19c and VP23His. This 
result is in agreement with published observations by Zweig et al., (1979) who could not 
detect any alteration in the behaviour of VP23 from purified HSV-2 capsids when analysed 
by non-reducing SDS-PAGE. This result also demonstrates that interaction between 
VP23His and VP 19c is specific and conformation dependent and not a result of VP 19c 
non-specifically binding to the Ni-NTA agarose.
SDS-PAGE analysis of purified triplex proteins in the presence and absence of p* 
mercaptoethanol demonstrated a minor shift in migratory position of these purified 
complexes. Fig. 3.5.14 shows the non-reducing SDS-PAGE analysis of Ni-NTA agarose 
purified triplex proteins from SF21 cells infected with Acl8386. In the absence of 20mM 
P-mercaptoethanol two faint bands, corresponding to approximately 150 and 175kDa, can 
be observed by Coomassie Brilliant Blue staining (fig. 3.5.14, lanes 2 and 3, (-) p- 
mercaptoethanol). The homogeneity of the reduced triplex proteins (fig. 3.5.14, lanes 2 
and 3, (+) P-mercaptoethanol) strongly suggests that these bands are related to the 
VP23/VP19cHis complexes but their nature is unclear. This data, therefore, supports the 
evidence from triplex purification in 8M urea (fig. 3.5.13) and suggests that no intra­
molecular disulphide linkages are formed between VP23 and VP 19c within the triplex. 
However, there may be cysteine residues within either VP23 or VP19cHis that are required 
for the formation of intra-molecular disulphide linkages. Such linkages may be required 
for maintaining a suitable conformation for the interaction with the complementing triplex 
protein partner and as a consequence generating SDS resistant complexes, as seen by SDS- 
PAGE in the absence of p-mercaptoethanol.
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Fig. 3.5.13: Ni-NTA agarose purification o f triplex proteins in the
presence o f 8M urea.
Triplex proteins were purified form SF21 cells infected with Ac 18638 as 
described in Methods. The cells were split into two fractions and 
sedimented by centrifugation at 3,000 r.p.m. in a Sorval RT7 centrifuge for 
5 minutes at RT. The supernatants were removed and the cell pellets 
resuspended in either TB4 buffer (20mM Tris pH7.5, 0.1% NP40, 500mM 
NaCl) (lanes 3 and 5) or TB4 buffer + 8M urea (lanes 4 and 6). Triplex 
proteins were subsequent purified (as described in Methods and fig. 3.5.7) 
in their respective buffers. The Ni-NTA agarose was sequentially washed 
in 10ml o f TB4 buffer and 5ml o f 20mM imidazole in TB4 buffer to 
remove any non-specifically bound proteins and residual urea from the Ni- 
NTA matrix. Proteins were eluted in 1.5ml (5x 300pl) o f 250mM 
imidazole in buffer TB4. 20pl o f the appropriate elution fraction and 5pl 
o f Ac 18638 infected SF21 total cell extract (lane 1) was analysed against 
Rainbow markers (lane 2) by SDS-PAGE and stained with Coomassie 
Brilliant Blue.
+
P-mercaptoethanol p-mercaptoethanol
200  k D a  -
97.4 kDa - 
69 kDa -
46 kDa -
hm
■
30 kDa -
175 kDa 
150 kDa
■
Fig. 3.5.14: SDS-PAGE analysis o f Ni-NTA agarose purified 
triplex proteins in the presence (+) or absence (-) o f 20mM P- 
mercaptoethanol.
Triplex proteins were purified from SF21 cells infected with 
Ac 18386 as described in Methods and fig. 3.5.7 in buffer OG. 
Rainbow markers (lane 1) and 20pl o f elution fractions 1 and 2 
(lanes 2 and 3 respectively) were analysed in the presence (+) 
or absence (-) o f 20mM P-mercaptoethanol. Samples were 
analysed by SDS-PAGE and stained with Coomassie Brilliant 
Blue.
Results: 3.5
3.5.6 Size exclusion chromatography analysis of purified triplex proteins
In order to determine whether or not Ni-NTA agarose purified triplex proteins formed 
heterotrimeric complexes and to determine an accurate native MW for the triplex size 
exclusion chromatography analysis was performed on Ni-NTA agarose purified triplex 
proteins in buffer O. Fig. 3.5.15 (panel A) shows a single elution peak obtained with Ni- 
NTA agarose purified triplexes purified from SF21 cells infected with Ac 18386. The 
elution profile is plotted against a standard curve generated by analysis of protein 
standards (as described in Methods). The elution volume of the single peak detected 
corresponded to a native MW of 103kDa. This is a shift from the predicted MW of 
approximately 118kDa estimated from the amino acid sequence of VP23 and VP 19c in a 
2:1 ratio (McGeoch et al., 1988). Furthermore, the native MW of 103kDa for purified 
triplexes is also considerably different from the estimated triplex mass determined by 
Newcomb and co-workers of 115kDa to 135kDa by STEM density mapping of hexon 
associated triplexes (Newcomb et al., 1993). Although several N-terminal amino acids of 
VP 19c were removed during the cloning of the UL38 ORF this would not account for a 
15kDa shift in observed and predicted triplex MW. The shift in MW may represent 
resolving limitations in separation of the Superose 12 column or alternatively reflect the 
compact native structure of in vivo preformed triplexes. A more likely explanation for the 
apparent low MW of the triplexes is the anomalous behaviour of the BSA protein standard 
(66kDa, highlighted in red in fig. 3.5.15). The elution volume from this standard reduces 
the slope of the standard curve away from that of the other protein standards and therefore 
alters the Logio MW reading derived from the triplex elution volume. Indeed, if the 
standard curve is plotted without BSA elution volume the triplex MW increases to 
approximately 115kDa. Recently, Spencer et al., (1998) published data on the 
sedimentation coefficients of triplexes and triplex proteins analysed on sucrose gradients. 
The triplexes analysed were formed in vitro by mixing SF9 cell extracts individually 
expressing VP23 and VP 19c. Sedimentation analysis determined their triplexes to have a 
MW of 129kDa, 1 lkDa larger then that of the predicted MW derived from the amino acid 
sequence. However, experiments performed by Spencer et al., (1998) relied on a single 
protein standard (BSA) to act as a MW marker during sedimentation analysis and therefore 
inaccuracies in estimating the MW of triplexes may have occurred.
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Fig. 3.5.15: Ni-NTA agarose purification of triplex proteins and 
size exclusion chromatography.
(A) Triplexes were purified in buffer O from SF21 cells infected 
with Acl8386 (as described in Methods and in fig. 3.5.7). Triplex 
proteins (0.5mg/ml) were analysed on a 25ml (1 by 30 cm) 
Superose 12 gel filtration column (Pharmacia) using a 1ml injection 
superloop. The column was equilibrated and run in buffer O at a 
constant flow rate of 0.5 ml/min. 0.5 mg/ml of commercially 
available protein standards; P-amylase (MW, 200,000), alcohol 
dehydrogenase (MW, 150,000), bovine serum albumin (MW,
66.000), ovalbumin (MW, 45,000), and carbonic anhydrase (MW,
29.000) were analysed individually in buffer O (as described in 
Methods and fig. 3.3.7). A standard curve was generated plotting 
Log10 MW against peak elution volume using Origin 3.5 software. 
The triplex MW was calculated using linear regression analysis 
software within the Origin 3.5 software package from the standard 
curve using the peak elution volume from the triplex elution 
profile. The position of the BSA standard is highlighted by a red 
square. (B) 20pl of the Ni-NTA agarose purified triplexes ( lane 2) 
and 20pl of the peak elution fraction (lane 3) following gel 
filtration was analysed against purified B-capsids by SDS-PAGE 
and Coomassie Brilliant Blue staining. The arrows indicate the 
position of the triplex proteins VP23 and VP19cHis.
Results: 3.5
By size exclusion chromatography analysis only a single peak could be detected 
corresponding to purified triplexes. This would imply therefore that preformed 
VP19cHis/VP23 complexes do not exist in equilibrium with their individual components. 
SDS-PAGE analysis of the peak elution fraction (fig. 3.5.15, panel B, lane 3) indicated the 
presence of both VP19cHis and VP23 and confirms that the triplex proteins VP19cHis and 
VP23 are interacting to form a specific complex. The calculated native MW of 103kDa 
suggests a 2:1 ratio of VP23 to VP19c within the triplex using the predicted MWs of 
34268 (VP23) and 50260 (VP19c) Da respectively (McGeoch et al., 1988). In order to 
confirm this ratio the intensity of Coomassie Brilliant Blue staining was compared for 
triplex proteins within purified B-capsids, Ni-NTA agarose purified triplex proteins, and 
triplex proteins collected from the peak fraction collected during size exclusion 
chromatography. Fig. 3.5.16 (panel A) shows the SDS-PAGE elution profiles used in the 
analysis and (panel B) shows the quantitative estimates of Coomassie Brilliant Blue bound 
to the triplex proteins. Using these analyses and determining their intensities relative to 
the total predicted triplex mass, copy numbers could be estimated for VP 19c and VP23 
within the triplex. Analysis of triplex proteins from purified B-capsids demonstrated that 
VP23 and VP 19c exist in a 1.8:1.0 ratio which is in agreement with the 2:1 ratio reported 
by Newcomb et al, (1993). Analysis of the peak fraction from size exclusion 
chromatography showed a similar ratio (1.7:1.0) of VP23 to VP 19c to that obtained from 
purified B-capsids. This therefore confirms that the single triplex peak seen by size 
exclusion chromatography represents a VP23/VP19cHis 2:1 heterotrimeric complex.
Analysis of the Ni-NTA purified triplex protein profile before size exclusion 
chromatography demonstrated a 1.4:1.0 ratio of VP23 to VP19cHis. The slight increase in 
the proportion of VP19cHis compared to that within purified B-capsids is probably due to 
the presence of a truncated VP 19c molecule which co-purifies with the full length 
VP19cHis. It is interesting to note that the truncated VP 19c protein was not present in the 
peak fraction purified by size exclusion chromatography. This suggests it is not a 
component of a triplex complex. The retention in the ability to bind to Ni-NTA agarose 
would imply that this lower MW form of VP 19c is due to the truncation of the C-terminus, 
resembling those truncation forms of VP19cHis from Ac381 infected cells (section 3.4). 
The fact that the truncated VP 19c molecule does not produce an elution peak during size 
exclusion chromatography is probably due to the non-specific binding of VP 19c to the
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VP23
BG (A) BG (B) BG (C)
(A)
Sample % Adj. Vol. Relative intensity to 
triplex mass (%)
Copy number per 
triplex
VP 19c VP23 VP 19c VP23 VP19c VP23
B-Capsid (A l) (A2) (A l) (A2) (A l) (A2)
45.14 54.86 53.63 65.17 1.0 1.8
Elution (B l) (B2) (B l) (B2) (B l) (B2)
frac. 1 50.88 49.12 60.44 58.35 1.0 1.4
FPLC (C l) (C2) (C l) (C2) (Cl )  (C2)
peak frac. 45.84 54.16 54.46 64.34 1.0 1.7
(B)
Fig. 3.5.16: SDS-PAGE and ratio analysis of triplex proteins.
Triplexes were purified in buffer O from SF21 cells infected with 
Acl8386 (as described in Methods and in fig. 3.5.7). (A) 20pl of 
purified triplex proteins (lane 2) and 20pl of the peak elution 
fraction collected post gel filtration (lane 3) were analysed against 
purified B-capsids (lane 1) by SDS-PAGE and stained with 
Coomassie Brilliant Blue. (B) Using Quantity ONE software 
(BIO-Rad) the intensity of Coomassie Brilliant Blue binding to the 
triplex proteins was analysed and adjusted against the appropriate 
background (BG) control. Using the predicted MWs for triplex 
proteins (McGeoch et al., 1988) in a 2:1 ratio of VP23 (34268 Da) 
to VP 19c (50260 Da) a total predicted MW could be calculated for 
a single triplex molecule (118796 Da). Using the predicted MW 
of the triplex a percentage (%) intensity relative to triplex mass 
could be calculated for each band analysed. Using the individual 
predicted MW for the corresponding triplex protein the copy 
number per triplex could be calculated. Copy numbers are 
highlighted in bold type.
Results: 3.5
Superose column (discussed in the size exclusion chromatography of VP19cHis in section 
3.4). Taken together, these observations suggest that the C-terminus of VP19c is required 
for interaction with VP23 and confirms published deletion mutagenesis studies performed 
by Desai and Person (1996) and Spencer et al., (1998). Spencer et al., (1998) 
demonstrated that the removal of 15 amino acids from the C-terminus of VP 19c, abolished 
the interaction with VP23 and as a consequence prevented capsid formation.
3.5.7 Sucrose gradient sedimentation analysis of Ni-NTA agarose purified 
triplexes
Sucrose gradient sedimentation of Ni-NTA agarose purified triplex proteins from SF21 
cells infected with Ac 18386 generated a profile which resembled that of individually 
purified and mixed VP23His and VP19cHis triplex proteins in buffer O (fig. 3.5.17, panel 
C compared to fig. 3.4.15, panel C). Fig. 3.5.17 (panels A and B) shows the SDS-PAGE 
and Western blot profiles of BSA and purified triplexes respectively following sucrose 
gradient centrifugation. The relative intensities were calculated for each fraction for both 
BSA and VP19cHis and plotted as a percentage (%) change in volume intensity against 
their appropriate fraction number (fig. 3.5.17, panel C). As with the in vitro mixing of 
individually purified triplex proteins the Ni-NTA co-purification of VP19cHis and VP23 
gave rise to three detectable peaks (arrows a-c) with the peak intensity occurring in 
fraction 18 (indicated by arrow a). This peak sediments substantially further through the 
gradient than BSA and represents the majority of the purified protein present on the 
gradient. This presumably represents the expected heterotrimeric triplex complex. The 
two additional peaks (arrows b and c) could represent partially assembled triplexes (a 1:1 
ratio ofVP23/VP19cHis for peak b) or uncomplexed VP19cHis (peak c). Indeed, peak c 
corresponds exactly to the position on the sucrose gradient (fraction 24) of individually 
purified VP19cHis in buffer O (fig. 3.4.14, panel B). Size exclusion chromatography 
analysis of purified triplexes demonstrated that triplexes do not exist in equilibrium with 
their basic protein constituents. Furthermore, Coomassie Brilliant Blue binding analysis 
demonstrated that the Ni-NTA purified triplex proteins existed primarily in a 2:1 ratio if 
the C-terminal break down product of VP 19c is taken into consideration. As no evidence 
of the C-terminal truncated product could be detected by Western blot analysis the two
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Fig. 3.5.17: Sucrose gradient sedimentation analysis of Ni-NTA
purified triplex proteins.
Triplexes were purified in buffer O from SF cells infected with 
Acl8386 (as described in Methods and fig. 3.5.7). 300pl of 
purified protein (~0.2mg/ml) and 50pl BSA (5mg/ml) resuspended 
in buffer O was layered onto a 5ml 5-25% sucrose gradient. The 
proteins were centrifuged at 4°C for 16 hours at 40,000 r.p.m. in a 
AH650 rotor and 150pl fractions collected (as described in 
Methods). To analyse the distribution of BSA across the gradient 
20pl of fractions 17-28 (lanes 1-12) were analysed by SDS-PAGE 
and stained with Coomassie Brilliant Blue (A). To analyse the 
distribution of triplexes across the gradient 20pl of fractions 17-28 
were resolved by SDS-PAGE and analysed by Western blotting
(B). VP19cHis distribution was detected by probing the 
Nitrocellulose membrane with a 1:1000 dilution of the Penta His 
antibody (Qiagen). The relative intensity of the protein profiles 
was calculated individually for both VP19cHis and BSA using 
Quantity ONE software (BIO-Rad) (as described in Methods). 
The data for the triplex and BSA protein profiles was individually 
plotted as % change in relative intensity against their appropriate 
elution fraction number (C). The arrows (a-c) mark the peak 
intensities in the distribution of VP19cHis across the gradient.
Results: 3.5
additional peaks observed (peaks b and c) might represent the break up of in vivo formed 
Ni-NTA purified triplexes. As previously discussed in section 3.4 sucrose has been 
implicated in the disassembly of procapsids isolated by immune precipitation and 
centrifugation through a 30% sucrose cushion (personal communication, Newcomb, 1999; 
Newcomb et al., 1999; Newcomb et al., 2000). Taking this into consideration sucrose may 
be able to disrupt triplex protein-protein interactions. Although the sedimentation analysis 
demonstrated a distinct triplex peak (fig. 3.5.17, peak a), the sucrose in the gradient may be 
able to disassemble complexes, which have not completely associated, or complexes that 
have not correctly folded into a native heterotrimeric complex. Alternatively, Ni-NTA 
agarose purification of triplexes from Ac 18386 infected SF cells may result in the 
purification of uncomplexed VP19cHis. Although, the expression of VP19cHis is 
generally lower than that of VP23 (as determined by Coomassie Brilliant Blue staining), 
some of the VP19cHis molecules may be mis-folded as individual molecules. Thus, 
although these molecules may not be able to form triplexes they could be purified using 
Ni-NTA agarose. Size exclusion chromatography would be unable to detect the presence 
of such mis-folded molecules due to the non-specific binding of VP 19c to the Superose 
column (discussed in section 3.4). However, further analysis is required in order to 
specifically identify these lower MW peaks.
3.5.8 Conclusions
Triplexes could be readily purified from SF21 cells infected with either Acl8638 or 
Ac 183 86 utilising Ni-NTA agarose affinity chromatography that maintained reasonable 
solubility in buffer O. The insolubility of the purified triplex proteins in other purification 
buffers probably reflects the aggregation of triplexes and/or VP 19c molecules due to non­
specific hydrophobic interactions. The non-ionic detergent octyl-p-glucoside is apparently 
able to bind to exposed hydrophobic domains and prevent the aggregation of triplexes 
during purification. Indeed, octyl-p-glucoside has been shown to be efficient in the 
solubilisation of a number of membrane associated glycoproteins (Rohrer et al., 1990). 
The generally poor solubility of purified triplexes is not surprising considering the number 
of functions VP 19c performs during procapsid formation, capsid maturation, and 
ultimately virion assembly. VP 19c has been shown not only to form extensive interactions
148
Results: 3.5
with VP23 within the triplex but also to interact with VP5 from adjacent capsomers (Zhou 
et al., 1994; Saad et al., 1999; Zhou et a l, 2000). Recent cryo-EM analysis has revealed 
that VP 19c may also play an integral role within the structural organisation of the 
tegument that surrounds the capsid during virus infection (Zhou et al., 1999). Although 
the relevant tegument proteins have yet to be identified, cryo-EM analysis has revealed 
extensive interactions between tegument proteins and the triplexes (Ta and Tc). 
Furthermore, cryo-EM can only detect those protein-protein interactions that display an 
icosahedrally ordered symmetry. It is possible therefore that the other triplexes (Tb, Td, Te 
and, Tf) may also play a role in the structural organisation of the tegument. Indeed, cryo- 
EM analysis of the SCMV virion has established that the triplex protein homologues 
within SCMV B-capsids binds to a tegument protein dimer postulated to be the 119kDa 
basic phosphoprotein (BPP). These protein dimers were present on all of the triplexes 
within the SCMV B-capsid (Trus et al., 1999). Furthermore, cryo-EM analysis of HCMV 
virions demonstrates that the VP 19c homologue component within the triplex of HMCV 
capsid, the minor capsid protein (mCP), also demonstrates a significant amount of 
interaction with as yet unknown HCMV tegument capsid proteins. Although the mCP 
binding protein is 17kDa smaller than its HSV counterpart VP 19c (50kDa), the function of 
the mCP binding protein within the HCMV capsid as part of a heterotrimeric complex 
appears similar (Butcher et al., 1998). The mCP binding protein interacts with and joins 
adjacent pentons and hexons through the interaction with the major capsid protein (MCP), 
the homologue to VP5 within the HSV capsid, within the HCMV capsid. The mCP 
binding protein also interacts with several tegument proteins within the HCMV virion in 
the same manner in which VP 19c appears to within the HSV-1 virion and therefore 
demonstrates the conserved nature of the triplex function throughout the herpesvirus 
family.
Ni-NTA agarose purification in the presence of 8M urea showed that the triplex proteins 
VP23 and VP 19c were not linked by inter-molecular disulphide bonds (fig. 3.5.13). 
However, non-reducing SDS-PAGE analysis demonstrated that there may be some intra­
molecular disulphide bonding in triplexes (fig. 3.5.14). Size exclusion chromatography 
analysis of Ni-NTA purified triplexes gave a native MW of 103kDa and suggested that 
triplexes do not exist in equilibrium with their constituent protein. Measuring the intensity 
of Coomassie Brilliant Blue stain binding to triplex proteins from purified B-capsids and
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from the peak elution fraction from size exclusion chromatography analysis of Ni-NTA 
purified triplex proteins confirmed that the triplex was indeed composed of one copy of 
VP 19c to two copies of VP23. This is in agreement with the 2:1 ratio of VP23 to VP 19c 
determined by comparing 2M GdnHCl treated B-capsids with WT B-capsid by STEM 
analysis (Newcomb et al., 1993). More recently, high-resolution cryo-EM analysis of 
HSV-1 B capsids and difference mapping using VP5-VP19c particles has determined the 
locations of VP 19c and VP23 proteins within the triplex (Saad et al., 1999). By 
computationally comparing the triplex and VP 19c connecting densities, Saad and co­
workers could identify masses within the triplex that corresponded to a single copy of 
VP 19c and two copies of VP23 (discussed in detail within section 4).
3.5.9.1 Future work
Much work has been done to solubilise the Ni-NTA purified triplexes from both Acl8638 
and Acl8386 infected SF cells (table 3.5.1). It would be interesting, therefore, to continue 
and improve upon this solubilisation strategy utilising octyl-p-glucoside in order to 
produce higher concentrations of purified triplexes. This would allow further structural 
analysis to be performed, such as NMR or X-ray crystallography, which could provide 
further information into the triplexes unique asymmetrical structure within the HSV-1 
capsid.
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3.6 Functional and biophysical characterisation of 
purified triplexes and triplex proteins
3.6.1 In vivo and in vitro capsid assembly analysis
To test whether or not recombinantly expressed and Ni-NTA agarose purified 6xHis 
tagged proteins were functional, purified triplexes and triplex proteins were analysed for 
their ability to participate in the formation of capsids particles in vitro. Tatman et al., 
(1994) and Thomsen et al., (1994) characterised the formation of capsid particles in vivo 
by co-infecting insect cells with panels of recombinant baculoviruses individually 
expressing the major structural capsid proteins. Newcomb et al., (1994) went onto to 
demonstrate that capsid assembly could occur in vitro when lysed, individually infected 
SF9 cell extracts expressing VP5, VP 19c, VP23, and preVP22a were mixed and incubated 
o/n at 27°C. Subsequently, Newcomb et al., (1999) has shown that in vitro assembly could 
occur using purified VP5, preVP22a and VP23/VP19c (triplexes), and concluded that 
capsid assembly did not require additional cellular proteins.
In order to test whether or not the 6xHis tag affected essential protein-protein interactions 
required for capsid assembly, in vivo capsid assembly was examined in SF21 cells, which 
were co-infected with the appropriate set of recombinant baculoviruses (as described in 
Methods and fig. 3.6.1). Thin sections were obtained from SF21 cell pellets harvested 48 
hours post infection and analysed for the presence of capsids by EM (as described in 
Methods). The presence of the 6xHis tag on either VP23 or VP 19c, when co-expressed 
together (Ac 18638 or Ac 18386) or expressed individually in the case of VP19cHis 
(Ac381), did not appear to effect the formation of capsids in vivo. Fig. 3.6.1 (panel A), 
shows a typical thin section micrograph of in vivo formed capsids from SF21 cells co­
infected with a three baculoviruses expressing the capsid proteins VP5 (AcUL19), 
preVP22a (AcUL26.5) and co-expressing VP23His and VP 19c (AcUL18638) respectively. 
In vivo formed capsids had similar morphological characteristics to those of WT HSV-1 
capsids. Most contained either a scaffold core (panel A, arrow 1), although a small number 
of coreless particles were also observed (panel A, arrow 2).
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Fig. 3.6.1: Functional analysis of recombinantly expressed 6xHis
tagged proteins.
Capsid assembly was performed either in vivo (panels A and F) or in 
vitro (panels B to E) (as described in Methods). Capsid particles were 
detected by electron microscopy either from thin sections of pelleted 
infected cells (panel A) or by negative stain of pelleted material 
(panels B to F) as described in Methods. Panel A; SF21 cells were 
co-infected with a panel of recombinant baculoviruses, AcUL19 
(VP5), AcUL26 (VP21/VP24), and Ac 18638 (co-expressing 
VP23His and VP 19c). 48 hours post infection the cells were
harvested, fixed and analysed by thin section for the presence of 
capsid particles. Small cored B-capsids (1), empty A-capsids (2) and 
baculovirus capsids (3) are indicated by the appropriate arrows. 
Panels B to E represent negative stained images of capsid particles 
assembled in vitro from lysed crude SF cell extracts individually 
infected with; AcUL19 (VP5), AcUL26.5 (preVP22a), and Acl8386 
(co-expressing VP19cHis and VP23) (panel B); AcUL19 (VP5) and 
AcUL26.5 (preVP22a), supplemented with purified (VP19cHis/VP23) 
triplexes (Panel C); AcUL19 (VP5), AcUL26.5 (preVP22a), AcUL18 
(VP23), supplemented with purified VP19cHis (Ac381) (Panel D); 
AcUL19 (VP5), AcUL26.5 (preVP22a), supplemented with 
individually purified VP19cHis (Ac381) and VP23His (bacterially 
expressed) (Panel E). (Panel F) Positive control of capsids prepared 
from SF cells that were co-infected with a panel of baculoviruses, 
AcUL19 (VP5), AcUL26.5 (preVP22a), AcUL18 (VP23), and 
AcUL38 (VP 19c), which expressed recombinant proteins without any 
epitope tags. Capsid particles assembled in vivo were released from 
cells by bath sonication and prepared for EM analysis (as described in 
Methods). Scale bars represent 500 nm.
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Utilising the in vitro assembly procedure described by Newcomb et al., (1994) Ni-NTA 
agarose purified triplexes and triplex proteins were analysed for their ability to form 
capsids. In vitro capsid assembly analysis was particularly important for purified VP23His 
since it was expressed in bacteria and its functionality in vivo could not be analysed. It 
was also important to establish that purification of the proteins did not inhibit their ability 
to participate in capsid assembly. Typically, 1/10th of an SF21 burrler extract(s) was used 
to supplement the appropriately purified capsid protein(s) under analysis (as described in 
Methods). Mixed extracts were left o/n at 28°C before the sample was prepared for 
electron microscopy (as described in Methods). Fig. 3.6.1 (panel B) shows a negative 
stained image of capsids assembled in vitro from lysed SF21 cell extracts individually 
infected with recombinant baculoviruses expressing VP5 (AcUL19), preVP22a 
(AcUL26.5), and triplexes (AcUL18386). Distinctive capsid particles are evident, which 
are identical to those of in vivo formed negatively stained capsids (fig. 3.6.1, panel F). Fig.
3.6.1 (panels C-E) show typical examples of the negative stained images obtained from in 
vitro assembled capsids when purified triplexes (VP19cHis/VP23, panel C), purified 
VP19cHis (panel D), and separately purified VP23His (bacterially expressed pETUL18) + 
purified VP19cHis (panel E), were mixed with the appropriate infected SF21 cell extracts. 
In all incidences capsid assembly only occurred when Ni-NTA agarose purified protein(s) 
were supplemented with the appropriate complementing infected SF21 cell extracts. This 
clearly demonstrates that the 6x His tag does not inhibit the formation of capsids in vitro. 
The bacterially expressed and purified VP23His participated in in vitro capsid assembly in 
both of the purification buffers used. This suggests that both monomeric (purified in 
sonication buffer, see section 3.3.3.1) and dimeric (purified in Buffer O, see section 
3.3.3.2) VP23His participate effectively in capsid assembly. Furthermore, individually 
purified VP23His (bacterially expressed) and VP19cHis (baculovirus expressed) were 
j shown to participate in in vitro capsid assembly when mixed together (fig. 3.6.1, panel E).
j  Therefore, the purified VP23His and VP19cHis must be capable of forming functional
I
| triplexes in vitro. Table 3.5.1 summarises both the in vivo and in vitro capsid assembly
!
data for the Ni-NTA agarose purified triplexes and triplex proteins, and the purification 
buffers in which the analyses were performed.
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Test Sample Buffer In vitro 
capsid assembly
In vivo 
capsid assembly
Purified VP23His Sonication buffer + N/A
Purified VP23His Buffer 0 + N/A
Ac 1863 8 infected 
SF21 cells/extracts
PBSa + +
Ac 183 86 infected 
SF21 cells/extracts
PBSa + +
Purified triplexes 
(Ac18638)
Buffer 0 + N/A
Purified triplexes 
(Ac 183 86)
Buffer 0 + N/A
Ac381 infected 
SF21 cells/extracts
Buffer 0 + +
Purified VP23His + 
purified VP19cHis
Buffer 0 + N/A
Table 3.6.1: Functional analysis of triplexes and triplex protein samples to 
support in vitro and in vivo capsid formation
Results: 3.6
It should be noted that in vitro capsid formation using Ni-NTA agarose purified triplexes 
and triplex proteins was particularly sensitive to protein concentration. The formation of 
capsids in vitro was much less efficient when purified protein samples were <0.3mg/ml. 
This probably represents a limiting factor during the formation of capsids and/or the 
polymerisation of capsid protein subunits. Thus, although capsid assembly may begin 
there may not be a sufficient local concentrations of uncomplexed purified protein 
immediately available to drive capsid assembly to completion (Zlotnick, 1994). Indeed, 
concentration dependent in vitro capsid assembly has also been reported for P22 and (|)29 
bacteriophages (Prevelige et al., 1993b; Lee and Guo, 1995).
3.6.2 Biophysical characterisation of the HSV-1 triplexes and triplex 
protein constituents
Although the individual protein components of the HSV-1 capsid have been known for 
some time (Gibson and Roizman, 1972) virtually nothing is known about their properties 
before they become associated within the mature icosahedral capsid. It is now becoming 
clear that capsid assembly in icosahedral viruses requires numerous complex folding 
stages where a capsid protein’s conformation may change throughout the course of capsid 
assembly (Johnson, 1996; Tuma et al., 1998). Techniques such as fluorescence, near/far- 
UV circular dichroism (CD), nuclear magnetic resonance (NMR), differential scanning 
calorimetry (DSC), and 8-anilino-l-naphthalenesulfonate (ANS) binding studies are 
becoming increasing popular for studying the dynamics of protein folding and 
conformational stability of proteins. These techniques were applied whenever possible to 
Ni-NTA agarose purified triplexes and triplex proteins in an attempt to understand their 
properties better.
3.6.2.1 Homogeneity o f Ni-NTA agarose purified triplexes and triplex proteins used for  
biophysical experimental analysis
Purification protocols for the isolation and solubilisation of triplexes and triplex proteins 
have been discussed in detail in previous sections. Biophysical characterisation 
experiments were carried out on Ni-NTA agarose purified triplexes from SF21 cells
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infected with Acl8386. To ensure an accurate 2:1 ratio of VP23 to VP19cHis within the 
heterotrimer complex, triplexes were further purified by size exclusion chromatography. 
The peak elution fraction was collected and used for biophysical analysis. In Ni-NTA 
agarose purified VP19cHis samples a 90kDa protein typically eluted from the Ni-NTA 
agarose in the first and second elution fractions. Therefore, for all VP 19c biophysical 
characterisation experiments only the third and subsequent elution fractions were used for 
experimental analysis. Due to the importance of maintaining protein sample homogeneity 
in order to obtain consistent and reproducible biophysical data, all Ni-NTA agarose 
purified samples were analysed by SDS-PAGE and Coomassie Brilliant Blue staining. 
Accurate protein concentrations were obtained by measuring protein absorbance at OD280 
using a Beckman DU-60 spectrophotometer (as described in Methods).
3.6.2.2 Ni-NTA purified triplexes and triplex proteins are folded protein molecules
As previously discussed in section 3.4, fluorescence spectroscopy can be used to measure 
the extent of which tryptophan (Trp) side chains are buried within the interior of a protein 
molecule. Fig. 3.6.2 (panels A-C) shows the fluorescence emission spectra for purified 
VP23His, VP19cHis, and purified triplexes following excitation at 295nm. The emission 
spectra all demonstrate a significant shift in Xmax from the value of 356nm which is 
associated with exposed Trp side chains within small model compounds. This indicates 
that the single Trp residue within VP23His and the 7 Trp residues within VP19cHis are 
buried or partially buried within the interior of a folded protein molecule. This is 
confirmed by comparing the tanax value of 335nm for purified native VP19cHis (fig. 
3.6.2, panel B) with the value of approximately 360nm for VP19cHis purified by urea 
denaturation of triplexes isolated from SF21 cells infected with Ac 18386 (fig.3.4.4, panel 
B). The Xmax for purified triplexes (331nm) also demonstrates that the 9 Trp residues (2 
Trp residues from 2x VP23 molecules and 7 from lx VP 19c molecule) are buried or 
partially buried within the interior of the complex. This implies that the protein-protein 
interaction between VP23 and VP19cHis within the triplex does not lead to conformational 
rearrangements that result in the exposure of these Trp residues to the solvent.
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Fig. 3.6.2: Intrinsic fluorescence spectra of Ni-NTA agarose purified
VP23His, VP19cHis and triplexes.
Fluorescence profiles for purified VP23His (0.2mg/ml) in buffer P (A), 
purified VP19cHis (0.1 mg/ml) in buffer O (B), purified triplexes (0.2 mg/ml) 
in buffer O (C) were monitored following excitation at 295nm (as described 
in Methods). All spectra were corrected for buffer absorbance by subtraction 
of the appropriate buffer-only spectra. The peak values are marked by the 
appropriate arrows.
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3.6.2.3 GndHCl induced unfolding o f triplexes and triplex proteins
Fluorescence spectroscopy can also be used to monitor the induced unfolding of protein 
molecules and complexes by measuring the fluorescence of a protein or protein complex in 
the presence of guanidine hydrochloride (GdnHCl). Exposure to increasing concentrations 
of GdnHCl results in the loss of protein structure and will eventually lead to a protein 
molecule adopting a random coil conformation where all the Trp residues are exposed to 
the solvent (Nishina et al., 1977). Unfolding of purified triplexes and triplex proteins 
induced by GdnHCl denaturation was therefore monitored by measuring their intrinsic Trp 
fluorescence. Fig. 3.6.3 (panels A-C) shows the spectra of purified VP23His, VP19cHis 
and triplexes in the presence of increasing concentrations of GdnHCl. VP23His, 
VP19cHis, and triplexes all demonstrated a shift in Xmax towards 356nm which clearly 
indicates the progressive unfolding of protein structure, resulting in the increased exposure 
of Trp side chains to the solvent. Fig. 3.6.3 (panel D) shows the profile of GdnHCl 
induced protein unfolding of as a plot of the percentage change in A,max against the 
molarity of GdnHCl. VP23His exhibited a rapid loss in protein structure with 70% of the 
total shift occurring in the presence of 2M GdnHCl, compared to a shift of 30% and 20% 
for VP19His and triplexes respectively. Increasing the concentration of GdnHCl to 4M 
resulted in little further shift in Xmax for VP23His but had a major effect on protein 
structure for VP19cHis and triplexes. Increasing the GdnHCl concentration above 4M 
GdnHCl resulted in a gradual loss of the remaining protein structure for VP23His with 
little further effect on VP19cHis and triplexes. These data suggest that VP23His unfolds 
in the presence of low concentrations of GdnHCl (1-2M GdnHCl), while the induced 
protein unfolding of triplexes and VP19cHis proves to be more resistant to GdnHCl 
denaturation with the loss of the majority of protein structure occurring between 2-3 M 
GdnHCl. Ni-NTA agarose purification experiments of VP19cHis performed by 
denaturation of triplexes in 3M urea (approximately 1.5M GdnHCl) resulted in the almost 
complete loss of the VP23/VP19cHis heterotrimer interaction, as determined by SDS- 
PAGE and Coomassie Brilliant Blue staining (fig. 3.4.3). This suggests that the transition 
observed for purified triplexes between 1-2M GdnHCl might be attributed to the 
denaturation of structural elements that are involved in the association of VP23 with 
VP19cHis. Furthermore, VP19cHis can be seen to begin unfolding in 1M GdnHCl 
whereas triplexes do not appear to undergo any significant transitions in unfolding until
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Fig. 3.6.3: Structural stability analysis of Ni-NTA agarose purified
VP23His, VP19cHis and triplexes by GdnHCl induced unfolding.
Trp fluorescence was monitored for purified VP23His (0.2mg/ml) in 
buffer P (A); VP19cHis (0.2mg/ml) in buffer O (B); triplexes (0.2mg/ml) 
in buffer O (C); in the presence of increasing concentrations of GdnHCl 
(0-6M). (D) The observed change in Xmax was plotted as a percentage 
change in tanax against the appropriate concentration of GdnHCl used to 
induce unfolding. All traces were corrected for buffer absorbance by 
subtraction of the appropriate buffer only spectra.
Results: 3.6
incubated in the presence of 2M GdnHCl. It is interesting to note that GdnHCl 
denaturation experiments performed by Newcomb et al., (1993) on purified B-capsids 
resulted in the loss of pentons and the triplexes Ta and Tc in the presence of 2M GdnHCl. 
Newcomb and co-workers further reported that increasing the GdnHCl concentration to 
2.5M GdnHCl did not lead to the additional loss of triplexes from the capsid but did result 
in the partial disintegration in hexon structure, although no hexons were removed from the 
capsids. Incubating purified B-capsids in the presence of 3M GdnHCl resulted in the 
complete solubilisation of capsids (Newcomb and Brown, 1991). Incubating purified 
triplexes in the presence of 2-3M GdnHCl resulted in the largest shift in Xmax. Although 
it is tempting to speculate that the loss of Ta and Tc triplexes in 2M GdnHCl was a direct 
result of triplex unfolding not all triplexes were disassociated from treated capsids 
(Newcomb et al., 1993). This implies that the stability of the triplex varies depending 
upon their position within the capsid. Observations made by cryo-EM analysis of HSV-1 
capsids demonstrates that this stability may be attributable to significant differences in the 
intercapsomeric connections formed by the triplexes Ta-Tf with their surrounding 
capsomers (Zhou et al., 1994; Zhou et al., 1998; Zhou et al., 2000). Furthermore, triplexes 
have recently been shown to form substantial interactions with the capsid floor (Saad et al., 
1999; Zhou et al., 2000). Although these interactions have yet to be fully characterised, 
the observed differences in the various triplex connections highlights the increased 
conformational stability that could to be gained by the triplex when in association with 
other capsid proteins.
3.6.2.4 Far-UV CD analysis o f the secondary structure within triplexes and triplex 
proteins
Circular dichroism (CD) can be used to determine the extent of secondary and tertiary 
structure within a protein molecule or complex by measuring the differential absorbance of 
chromophores. The chirality of these chromophores can either be intrinsic or because they 
a placed within an asymmetric environment within the protein structure. Proteins contain a 
range of chromophores, in particular the aromatic amino acid side chains of phenylalanine 
(Phe), tyrosine (Try), and tryptophan (Trp). Such aromatic side chains and the disulphide 
bonds between cysteine residues absorb strongly over the near-UV region of 250-290nm.
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Fig. 3.6.4: Far-UV CD analysis and CONTIN estimation of
secondary structure of purified VP23His, VP19cHis, and triplex.
Absorbance spectra in the Far-UV CD region (180-240nm) for 
purified VP23His (0.2mg/ml) in buffer P (A); triplexes 
(0.05mg/ml) in buffer O (B); VP19cHis (0.1 mg/ml) in buffer O
(C). All traces were corrected for buffer absorbance by 
subtraction of the appropriate buffer-only spectra. (D) 
Comparison of secondary structure content of purified triplexes 
and triplex proteins derived from amino acid sequences submitted 
to PHD predict (WWW.embl-heidelberg.de/predictprotein) and 
CONTIN estimations of secondary structure content of a-helix 
and |3-sheet from Far-UV CD analysis of A, B, and C.
Results: 3.6
However, the strongest absorption within the UV range is that of peptide bonds which 
absorb in the far-UV region (180-240nm) (Price, 1995; Kelly and Price, 1996). Far-UV 
CD analysis can be used to assess quantitatively the overall secondary structure content of 
a protein due to the characteristically different absorption’s of a-helix and p-sheet within 
the far-UV region. For example, a-helices give characteristic absorption peaks at 208 and 
222nm (Hirst and Brooks, 1994). By applying the CONTIN procedure of Provencher and 
Glockner (1981) the amount of secondary structure within a protein molecule can be 
determined. The CONTIN procedure utilises the far-UV CD absorption spectrum and 
applies a linear combination of CD spectra from 16 proteins that have had their structures 
resolved by X-ray crystallography. Within this procedure greater weight is automatically 
applied to those reference spectra that closely resemble those of the analysed sample. This 
therefore allows reliable and quantitative measurement of the amount of secondary 
structure a protein molecule or protein complex contains. Fig. 3.6.4 (panels A-C) shows 
the far-UV CD spectra for Ni-NTA purified VP23His, VP19cHis and triplexes after 
subtraction of the appropriate buffer control spectra. VP23His, VP19cHis and triplexes all 
produce absorption spectra that demonstrate significant amounts of secondary structure 
associated with folded protein molecules (Kelly and Price, 1996). Application of the 
CONTIN procedure to these spectra provides a quantitative assessment of the secondary 
structure content of a-helix and (3-sheet within these protein molecules. Fig. 3.6.4 (panel 
D) shows the comparison between the estimated secondary structures determined from the 
application of the CONTIN procedure and the predicted secondary structures from the 
secondary structure prediction program PHD (Rost and Sander, 1993). PHD predictions 
were acquired by submitting the amino acid sequences of VP23 and VP 19c, or in the case 
of the triplex a compilation made by assembling a VP 19c and two VP23 sequences. It 
should be noted that experimental values obtained by CD can be affected by small errors in 
protein concentration determination and high levels of noise, particularly in the absorption 
region below 190nm, which may be brought about by components within purification 
buffers, especially imidazole and Cl" ions. Utilising Ni-NTA agarose affinity 
chromatography to purify recombinantly expressed 6x His tagged proteins resulted in the 
presence of imidazole within the elution buffer (typically >100mM). In all incidences the 
imidazole was removed from the protein samples prior to analysis by dialysis or gel 
filtration of purified protein samples. Far-UV CD analysis was repeated multiple times on 
different samples. Both VP23His and triplexes gave reproducible spectra and consistent
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CONTIN estimations for the content of secondary structure (fig.3.6.4, panel D). However, 
attempts to obtain a reproducible far-UV CD spectra for VP19cHis proved difficult. 
Dialysis of purified VP19cHis (o/n at 4°C) to remove imidazole from the elution buffer 
resulted in the majority of VP19cHis precipitating out of solution. Shorter periods of 
dialysis were employed, both at RT and 4°C, but either resulted in the protein precipitating 
out of solution or were ineffective in lowering the concentration of imidazole sufficiently 
to reduce the high level of noise in the far-UV absorption region. Attempts to remove 
imidazole from purified VP19cHis protein samples by size exclusion chromatography also 
failed due to the non-specific binding of VP19cHis to the Superose matrix (discussed in 
section 3.4.5). Similarly, attempts to remove imidazole through the use of desalting 
columns failed due to non-specific binding of VP19cHis to the various column matrices 
(data not shown). A CONTIN prediction of secondary structure obtained from a 
successful scan of purified and dialysed VP19cHis is shown in fig. 3.6.4 (panel D 
highlighted in red). However, it should be noted that this result has yet to be confirmed.
Furthermore, it should also be noted that protein prediction programs such as PHD rely 
heavily on the degree of similarity between the submitted amino acid sequences and that of 
protein sequences compiled within the database. Therefore, errors in the estimation of 
secondary structure content for a given amino acid sequence may occur due to no suitable 
sequence counterpart within the database.
Comparison of the secondary structure of VP23His and triplexes derived experimentally 
from far-UV CD/CONTIN analysis with the predicted secondary structure reveals a 
reasonably close correlation although the figures for VP 19c are more divergent. 
Nevertheless, the spectra for both VP23His and triplexes, as well as the spectra obtained 
for purified VP19cHis, demonstrated that triplexes and individual triplex proteins contain a 
significant degree of secondary structure. Purified triplexes and triplex proteins therefore 
represent, at least, partially folded protein molecules. Although difficulties were 
experienced in obtaining far-UV CD spectra for VP19cHis, the CONTIN prediction for 
secondary structure for purified triplexes has approximately 10% more a-helix content 
compared to that of purified VP23His. This would suggest, therefore, that VP19cHis is 
contributing to the level of secondary structure within the triplex.
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3.6.2.5 Near-UV CD analysis o f  the tertiary structure within triplexes and triplex proteins
Near-UV CD (250-320nm) can be used to analyse the tertiary structure of a protein 
molecule by measuring the absorbance of the aromatic amino acid side chains, principally 
those of Phe (255nm), Tyr (275nm), and Trp (290nm). The folding of a polypeptide chain 
places the aromatic amino acids side chains of these amino acids in a variety of 
environments which affect their ability to absorb in the near-UV region. The intensity of 
absorbance by these aromatic side chains reflects the degree to which they are incorporated 
within a given protein structure. If the protein contains rigid tertiary structure and tightly 
packed aromatic amino acid side chains then their absorbance within the near-UV CD 
region is high. Conversely, if the protein lacks substantial tertiary structure and the 
aromatic side chains can move more freely, then the intensity of absorbance is lower 
(Kelly and Price, 1996). The near-UV CD spectrum therefore reflects the degree to which 
stable interactions occur between amino acids and provides a measure of the tertiary 
structure of a protein molecule.
Fig. 3.6.5 shows the near-UV CD spectra for monomeric and dimeric VP23His and 
triplexes. The near-UV CD spectra for both monomeric and dimeric VP23His (panels A 
and B) appear as flat traces. There is no evidence of the distinct peaks expected if the 
aromatic amino acid side chains occupy fixed positions within the protein structure. This 
suggests that any tertiary interactions within VP23His are weak and do not result in the 
formation of rigid tertiary structural domains. Conversely, the near-UV CD spectrum for 
purified triplexes (fig. 3.6.5, panel C) demonstrated a strong absorbance peak. Therefore, 
some or all of the aromatic amino acid side chains within the heterotrimeric protein 
complex occupy fixed positions suggesting that defined tertiary structure exists within the 
triplex. Because of the relatively high protein concentrations required for near-UV CD 
analysis, typically 0.5-2 mg/ml, no trace could be obtained for purified VP19cHis due to its 
relative poor recovery from SF21 cells infected with Ac381 (discussed previously in 
section 3.4). Therefore, it was impossible to determine whether the near-UV CD spectrum 
of the triplex solely represents the contribution of VP 19c to the heterotrimer complex, or if 
the tertiary structure observed is at least partly a result of the interaction between the
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Fig. 3.6.5: Near-UV CD analysis of monomeric, and dimeric 
VP23His and triplexes
Near-UV CD absorbance spectra for purified monomeric VP23His 
(1.5mg/ml) in buffer P (A), dimeric VP23His (1.5mg/ml) in buffer 
O (B), and triplexes (1.5mg/ml) in buffer O (C). All traces were 
corrected for buffer absorbance by subtraction of the appropriate 
buffer-only spectra.
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VP 19c and VP23 protein molecules. For example, if tertiary structure within the triplex is 
developed through mutual co-folding of VP 19c and VP23 during triplex formation.
3.6.2.6 DSC analysis o f the tertiary structure within triplexes and triplex proteins
The tertiary structure of protein molecules and protein complexes can also be analysed by 
temperature-induced denaturation through the use of differential scanning calorimetry 
(DSC). Analysing the heat capacity of a protein molecule provides a thermodynamic 
description of its conformational stability and provides valuable information on the state of 
folding adopted under specific conditions (Privalov et al., 1995). The presence of an 
endothermic transition on a plot of heat capacity versus temperature is usually considered 
to be a result of co-operative melting of a protein’s tertiary structure (Privalov and 
Potekhin, 1986). A positive enthalpy transition primarily represents the exposure of buried 
hydrophobic amino acids to the solvent due to the heat induced disruption of van der 
Waals interactions within the interior of a protein molecule (Dill, 1990; Murphy et al., 
1990; Makhatadze and Privalov, 1993; Privalov, 1997). Fig. 3.6.6 (panel A) shows the 
DSC profile obtained for monomeric VP23His (0.7 mg/ml) purified in buffer P. The 
profile shows no heat absorption peak suggesting that no endothermic transition has 
occurred due to the co-operative melting of tertiary structure. The decline in heat capacity 
above 60°C is due to the irreversible exothermic aggregation of VP23His molecules post- 
denaturation and reflects the precipitation of unfolded VP23His molecules out of solution 
(Cooper, 1999). The DSC spectrum for VP23His therefore confirms observations made by 
near-UV CD analysis and indicates the lack of a rigid tertiary structure within the VP23His 
protein molecule. Hydrodynamic studies performed by Marina Kirkitadze (Kirkitadze et 
al., 1998) demonstrated that Ni-NTA agarose purification of VP23His in sonication buffer 
and subsequent dialysis into buffer P resulted in a predominantly monomeric population of 
VP23His molecules at concentrations below 0.8mg/ml. Therefore, the DSC analysis 
described above for VP23His in buffer P represents the native level of tertiary structure 
within a single monomeric molecule of VP23His. Ni-NTA agarose purification of 
VP23His in buffer O resulted in the isolation of VP23His dimers (discussed in section 3.3). 
Fig. 3.6.6 (panel B) shows the DSC profile for dimeric VP23His (0.5mg/ml) purified in
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Fig. 3.6.6: Differential scanning calorimetry (DSC) of Ni-NTA
agarose purified VP23His.
Heat absorption profiles of VP23His (0.7mg/ml) purified in buffer P 
(A), and VP23His (0.5mg/ml) purified in buffer O + 250mM 
imidazole (B). Profiles were obtained by heating the protein solutions 
through a temperature range of 10 to 100°C at a scan rate of l°C/min. 
The spectrum was corrected by subtracting the buffer control 
spectrum for the appropriate buffer heated in the same manner.
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buffer O. A small heat absorption peak was observed at approximately 58°C suggesting 
that a small endothermic transition had occurred. However, as the near-UV CD trace for 
dimeric VP23 in buffer O was flat, suggesting an absence of tertiary structure within 
dimeric VP23, the endothermic transition observed probably represents the exposure of 
hydrophobic surfaces at the interface between the VP23 molecules and not the co­
operative melting of tertiary structure. As with the monomeric VP23His DSC spectra, 
dimeric VP23His also showed a sharp decline in heat capacity above 60°C demonstrating 
the irreversible unfolding of VP23His molecules during temperature denaturation.
One of the advantages of DSC analysis over far-UV and near-UV CD analysis, is that the 
experimental procedure can be carried out in the presence of imidazole. DSC therefore 
provides a means of analysing of the conformational stability of purified VP19cHis, which 
circumvents the difficulties associated with removing imidazole from the protein sample. 
Fig. 3.6.7 shows the DSC profile of Ni-NTA agarose purified VP19cHis (0.5mg/ml) in 
buffer O. The temperature-induced denaturation of VP19cHis produced an 
uncharacteristic, but reproducible, DSC spectrum. Typically, a buffer normalised DSC 
profile for a compact globular protein is comparatively flat with a defined peak, or peaks, 
representing the co-operative unfolding of tertiary structure upon temperature induced 
denaturation. However, no distinctive peak could be detected from DSC analysis of 
purified VP19cHis, with different samples consistently producing a similar curve. 
Throughout the purification procedure and preceding DSC analysis the solubility of the 
VP19cHis was examined to ensure that it had not precipitated out of solution. Special care 
was also taken during loading of the sample into the cell to prevent complications, for 
example the presence of air bubbles within the cell, that could have affected the DSC 
analysis. Despite this, different batches of VP19cHis produced the same profile over a 
range of protein concentrations (0.2-0.5mg/ml, data not shown). Therefore, the DSC 
profiles generated for purified VP19cHis must be assumed to provide an indication of the 
native conformational stability of VP19cHis during temperature induced denaturation. As 
no endothermic transition was observed for purified VP19cHis this would suggest that 
VP19cHis has little or no stable tertiary structure.
The uncharacteristic DSC profiles could possibly be explained by conformational 
instability of purified VP19cHis molecules. If the native state of purified VP19cHis 
molecules is never fully populated by a particular conformation, due to the protein’s
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Fig. 3.6.7: Differential scanning calorimetry (DSC) of Ni-NTA agarose 
purified VP19cHis.
Heat absorption profile of VP19cHis (0.5mg/ml) purified in buffer O + 
lOOmM imidazole. The profile was obtained by heating the protein solution 
through a temperature range of 10 to 100°C at a scan rate of l°C/min. The 
spectrum was corrected by subtracting the control spectrum for the 
purification buffer heated in the same manner.
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conformational instability, then the conventional baseline subtraction cannot be performed 
to provide accurate temperature transitions (Privalov et a l, 1995). Indeed, this can be seen 
to occur in proteins that show cold denaturation, very specific and strong temperature- 
dependent interactions of non-polar groups with water. Hydration of these residues is 
atypical, in that it is thermodynamically favourable, and as a result a cold sensitive protein 
will unfold at sufficiently low temperatures exposing its internal non-polar residues to the 
environment (Privalov, 1990). Experiments performed by Privalov et al., (1986) 
demonstrated that the tertiary structure of metmyoglobin unfolds completely upon cooling. 
This results in the polypeptide demonstrating similar characteristics to those of a random 
coil with only residual helicity remaining in the unfolded polypeptide, as determined by 
NMR and CD analysis. The transition in unfolding of metmyoglobin due to cold 
denaturation was monitored by DSC and was shown to occur when metmyoglobin was 
cooled between 10°C and -7°C. A transition could be detected between 10 and 0°C, 
similar to, but not as broad as, the DSC profile of VP19cHis. Although there is no direct 
evidence to show that purified VP19cHis undergoes cold denaturation there may be 
exposed hydrophobic residues, which might be required for future protein interactions with 
VP23, VP5, and HSV-1 tegument proteins. These may promote protein instability in the 
absence of these other proteins. In vitro purification of VP19cHis is also likely to promote 
the possible hydration of non-polar residues, due to the removal of cellular factors within 
the cytosol that could maintain protein conformation and stability, for example cellular 
chaperones. Chaperone proteins have been implicated in the stabilisation of cold labile 
proteins, in preventing irreversible aggregation by stabilising intermediate folded protein 
structures during their assembly, and in some circumstances disassembly, of oligomeric 
complexes (Guy et al., 1998). Indeed, molecular chaperones GroEL and GroES have been 
implicated in the in vivo capsid assembly pathway of ts mutants of P22 bacteriophage 
(Nakonechny and Teschke, 1998). Thus, the instability of purified VP19cHis in vitro may 
result in a population of protein molecules in different states of unfolding which do not 
conform to a particular conformation and therefore are unable to provide a uniform 
endothermic transition to which a buffer base line can be subtracted.
It is noteworthy that Ni-NTA agarose pull downs have shown that the interaction between 
VP23 and VP19c is partially inhibited at 0°C (discussed in section 3.4 and fig. 3.4.11). 
This could be explained if the conformational stability of VP19cHis is altered at low
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temperatures. However, it should be emphasised that further analysis is required in order 
to accurately determine the conformational stability of purified VP19cHis and determine 
whether it undergoes cold-denaturation similar to that of previously characterised cold 
labile proteins.
Fig. 3.5.8 (panel A) shows the DSC profile for triplexes (0.5mg/ml) purified in buffer O. 
A distinct heat absorption peak was observed at approximately 60°C. This represents a 
substantial endothermic transition indicating the co-operative melting of tertiary structure 
leading to the exposure of non-polar residues to the solvent. This confirms the 
experimental observations made by near-UV CD analysis, which suggested that the triplex 
contains rigid tertiary structure. DSC analyses of multi-domain proteins sometimes 
demonstrate the presence of several endothermic transitions during heat denaturation. 
Experiments performed by Novokhatny et al., (1984) on plasminogen, demonstrated seven 
independent co-operative transitions which were specifically associated with the co­
operative unfolding of structural domains linked together by disulphide bonds. In contrast, 
only a single endothermic transition was detected during the heat denaturation of the 
triplex. This would suggest that the purified triplexes may only contain a single rigid 
tertiary structural domain which co-operatively unfolds in a manner similar to that of small 
compact globular proteins (Privalov, 1997). If the VP23 and VP19cHis molecules within 
the triplex had independent rigid tertiary structures, then two or more endothermic 
transitions might be expected due to the co-operative unfolding of the complex followed 
by the unfolding of tertiary structure within the individual triplex protein molecules. The 
fact that only a single transition was detected would further imply that VP19cHis and 
VP2His lack any rigid tertiary structure as individual triplex proteins. It is likely therefore 
that some form of mutual co-folding between VP 19c and VP23 triplex proteins is 
occurring during triplex formation.
In order to analyse the association of purified VP23His and VP19cHis molecules, DSC 
analysis was performed on in vitro formed triplexes. VP23His and VP19cHis were 
individually purified by Ni-NTA agarose affinity chromatography in buffer O, mixed in a 
2:1 molar ratio to a final protein concentration of 0.5mg/ml and allowed to associate for 1 
hour at 28°C. Fig. 3.6.8 (panel B) shows the DSC profile of the samples, following this 
procedure. A distinctive heat absorption peak could be detected at approximately 55°C. 
Although this peak is smaller than that for an equivalent amount of purified in vivo formed
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Fig. 3.6.8: Differential scanning calorimetry (DSC) of Ni-NTA 
agarose purified triplexes
Heat absorption profile of triplexes (0.5mg/ml) purified in buffer O
(A) and in vitro assembled triplexes (0.5mg/ml) (B). In vitro 
assembled triplexes were made by mixing a 2:1 ratio of individually 
purified VP23His and VP19cHis in buffer O + 250mM imidazole for 
1 hour at 28°C before analysis. Profiles were obtained by heating the 
protein solutions through a temperature range of 10 to 100°C at a scan 
rate of l°C/min. The spectrum was corrected by subtracting the 
control spectrum for the appropriate buffer heated in the same manner.
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triplexes, it demonstrates that individually purified triplex proteins can interact to form 
complexes that have tertiary structure which undergoes co-operative unfolding upon heat 
denaturation. The endothermic transition occurs at a slightly lower temperature than that 
of purified in vivo formed triplexes (60°C). The smaller heat absorption peak seen with the 
in vitro formed complexes could mean that some, but not all, of the individually purified 
triplex proteins form complexes in vitro. This would appear to mirror the behaviour of the 
in vitro assembled triplexes analysed on sucrose gradients (fig. 3.4.15). The reason for the 
incomplete association of purified triplex proteins and the observed lower temperature of 
co-operative unfolding remains unclear.
Sucrose gradient sedimentation analysis has shown that individually purified triplex 
proteins mixed in vitro form complexes which sediment to the same position as purified in 
vivo formed triplexes (section 3.4.6, fig. 3.4.15). This, together with their ability to 
support in vitro capsid assembly, demonstrates that the individual proteins are capable of 
assembling into functional heterotrimeric complexes. Protein concentration has been 
shown to be important for the successful formation of capsid structures. Prevelige et al., 
(1993b) demonstrated that P22 capsid assembly could not occur below a critical protein 
concentration (0.3mg/ml) due to the unsuccessful polymerisation of coat and scaffold 
protein subunits. The same could be true for triplex formation. The equilibrium 
established between individual protein subunits (VP23His and VP19cHis) and polymerised 
complexes (triplexes) may be stalled when the concentration of free triplex subunits 
required to drive the formation of triplexes falls below a concentration critical for subunit 
polymerisation (Zlotnick, 1994). Alternatively, the purification procedure of VP23His and 
VP19cHis may affect their ability to form complexes. For example, the presence of 
detergents may inhibit formation by concealing external hydrophobic residues required for 
efficient complex formation. The purification of individual triplex proteins could also 
remove cellular components required for efficient interaction.
The endothermic transition of in vitro assembled triplexes occurs at a slightly lower 
temperature than for triplexes formed in vivo. This implies that the tertiary structure of in 
vitro formed triplexes is not as stable as that of purified in vivo triplexes. Alternatively, the 
lack of a sharp transition may indicate that in vitro triplexes represent a partially folded 
intermediate state in triplex assembly. Fuchs et al., (1991) demonstrated that the refolding 
of the trimeric tail spike of P22 bacteriophage produced a non-native trimer intermediate
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(Tp). Although the monomeric subunits associated into trimers comparatively quickly (1.5 
hours) without passing through a detectable dimeric intermediate state, the native SDS- 
resistant trimers took 3 days to form at 10°C. The formation of triplexes in vitro may 
therefore require longer periods of incubation. Although, incubation for 1 hour at 28°C 
may be sufficient time to allow the association of triplex protein molecules, which may 
undergo some degree of co-operative folding, but insufficient to form the specific native 
tertiary structure as seen within the in vivo formed purified triplexes. One of, or a 
combination of, these factors may be responsible for the incomplete polymerisation of all 
the individual purified triplex protein constituents and consequently a reduction in the heat 
absorption capacity of in vitro formed triplexes compared to that of purified in vivo formed 
triplexes.
3.6.2.7 Partial folding within purified triplexes and triplex proteins
The use of non-covalent probes, such as 8-anilino-l-naphthalinenesulfonate (ANS), has 
become increasingly popular in analysing protein conformation. The binding of ANS to a 
protein molecule was generally regarded as a sensitive test for partial folding which allows 
ANS access to the hydrophobic interior of a protein molecule where it can become 
fluorescent upon excitation at 370nm. Indeed, ANS has been used in the detection and 
analysis of molten globules (protein molecules in an intermediate state of protein folding) 
which have a compact conformation with pronounced secondary structure but with little or 
no rigid tertiary structure (Semisotnov et al., 1991; Ptitsyn, 1995a). The increased ability 
of ANS to bind to proteins that are in a molten globule-like state, which can become 
fluorescent upon excitation, is primarily due to an increase in the number of exposed 
binding sites within the hydrophobic core of molten globule-like proteins where ANS is 
not exposed to the quenching effect of the surrounding solvent.
Fig. 3.6.9 (panels A-C) shows the ANS binding profiles of Ni-NTA agarose purified 
VP23His, VP19cHis and triplexes receptively. Triplexes and the individual triplex 
proteins all demonstrated a large increase in ANS fluorescence at 470nm over that seen for 
ANS in buffer or for protein samples analysed in the absence ANS. This indicates that 
ANS molecules were binding to the protein molecules and that the organic moiety 
responsible for ANS fluorescence was buried within their hydrophobic interiors. As
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Fig. 3.6.9: ANS binding analysis to Ni-NTA agarose purified
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ANS fluorescence at 440-540nm was monitored following 
excitation at 370nm (as described in Methods). ANS was mixed 
(to a final concentration o f 20pM ) with purified VP23His 
(0.2mg/ml) in buffer P (A); purified VP19cHis (0.1 mg/ml) in 
buffer O (B); and purified triplexes (0.2mg/ml) in buffer O (C). 
Control fluorescence spectra were measured for ANS in the 
appropriate buffer and for protein samples in the absence o f ANS.
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purified triplexes demonstrate ANS fluorescence, there must be additional accessible 
internal areas of hydrophobicity within VP23 and VP19cHis, which are not lost due to the 
interactions between VP19cHis and VP23. This would indicate that triplexes still contain 
a degree of partial folding allowing ANS access to hydrophobic pockets away from the 
quenching environment of the solvent. It should be noted that recent studies have shown 
that ANS can bind to solvent accessible polar groups on native, non-molten globular 
proteins through electrostatic interactions. However, the fluorescence of such ANS 
molecules binding to exposed sites is typically quenched by water molecules within the 
solvent (Matulis and Lovrien, 1998; Matulis et al., 1999). Denatured VP23His and VP5, 
unfolded in the presence of 6M GdnHCl, have been shown not to produce an increase in 
ANS fluorescence following excitation (Kirkitadze et al., 1998). This would suggest that 
ANS only becomes fluorescent following excitation when in association with capsid 
proteins that have a degree of folding, where ANS molecules can gain access to a 
hydrophobic core.
3.6.3 Conclusions
3.6.3.1 Ni-NTA agarose purified triplexes and triplex proteins are functionally active.
Utilising in vitro capsid assembly analyses it has been demonstrated that Ni-NTA agarose 
purified triplexes and triplex proteins are capable of participating in the formation of 
capsid particles that morphologically resemble WT HSV-1 capsids (as determined by 
electron microscopy). Capsid formation only occurred when VP5, VP19c, VP23, and the 
scaffold component preVP22a were present as purified proteins or in SF21 whole cell 
extracts. This confirms previously published observations which reported that the in vitro 
formation of capsids does not require the presence of VP26 (UL35) (Newcomb et al., 
1994; Newcomb et al., 1999; Newcomb et al., 2000).
In vitro capsid assembly utilising purified triplexes and triplex proteins demonstrated that 
the 6x His epitope tag located on the N-terminus of VP19cHis or VP23His, either as an 
individual protein molecule or as part of the heterotrimer complex, did not affect protein
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functionality. This ability to form capsid particles indicates that the N-termini are not 
directly involved in the interactions occurring during capsid assembly. Indeed, Desai and 
Person (1996) and Spencer et al., (1998) have shown that small deletions from the N- 
termini of VP23 and VP 19c do not affect protein functionality, as determined by the yeast 
two hybrid system and in vivo capsid assembly respectively.
The purification protocols/buffers used in the isolation of the recombinantly expressed 
proteins do not appear to affect protein functionality. However, in the case of VP23His, 
the oligomeric status of VP23 appears to be buffer dependent. Both monomeric VP23His 
(purified in sonication buffer) and dimeric VP23His (purified in buffer O), appeared 
equally efficient at forming capsids. The buffer dependency on the oligomeric status of 
VP23His would imply that the VP23His molecules within the dimer are weakly associated 
and that dimer formation is not specifically required for triplex and capsid formation. This 
relatively weak intra-molecular association is highlighted by the absence of a near-UV CD 
signal and the small endothermic transition observed during DSC analysis of dimeric 
VP23His purified in buffer O (figs. 3.6.5, panel B and 3.6.6, panel B respectively).
3.6.3.2 Molten globularity o f purified VP23His and VP19cHis
Far-UV CD and fluorescence analysis of purified VP23His and VP19cHis demonstrated 
that these molecules are folded and contain pronounced secondary structure. However, 
DSC and near-UV CD revealed that both these proteins lacked rigid tertiary structure. 
Moreover, both VP23His and VP19cHis bound ANS and demonstrated an increase in 
fluorescence following excitation. These data, taken together, indicate that both VP23His 
and VP19cHis are in partially folded states and fit the defining criteria of molten globule 
like-proteins. Molten globule-like proteins are partially folded protein molecules that have 
a compact state with distinct secondary structure elements but lack rigid tertiary structure 
(Ptitsyn, 1995a; Privalov, 1996). The lack of rigid tertiary structure in the molten globule­
like state is generally considered to reflect the absence of tight packing of amino acid side 
chains within the hydrophobic core of the protein molecule (Ptitsyn, 1995a; Privalov, 
1996). This allows a greater degree of domain flexibility, in particular by allowing the 
secondary structural elements to move in relation to each other (Semisotnov et al., 1991).
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Many proteins have been shown to adopt a molten globular state during induced protein 
unfolding under non-physiological conditions, for example at low pH and/or in the 
presence of denaturants. The partially folded state is thought to represent an equilibrium 
intermediate in the protein folding pathway (Ptitsyn et al., 1990). One of the most 
extensively studied proteins to demonstrate a partially folded intermediate state, is apo-a- 
lactalbumin, which adopts a molten globule-like form when incubated in the presence of
denaturants such as GdnHCl or low pH. Yutani et al., (1992) also demonstrated that apo-
21
a-lactalbumin could form a molten globule-like state at neutral pH in the absence of Ca 
ions. Utilising DSC and CD analysis they characterised this partially folded intermediate 
state and demonstrated that it contained no detectable tertiary structure. However, it 
retained a comparable amount of secondary structure to that of the native apo-a- 
lactalbumin when analysed by Far-UV CD. Similar observations were reported when 
structural studies were performed by Uversky et al., (1995) on the glycoprotein a- 
fetoprotein (AFP). AFP demonstrates significant conformational rearrangements when 
subject to low pH (pH3.1) which lead to the development of attributes characteristic of a 
molten globule-like state. Far-UV CD analysis demonstrated that AFP contained similar 
levels of secondary structure at pH 3.1 to that of native AFP, while AFP denatured in 9M 
urea contained no detectable secondary structure. Conversely, the lack of a distinct 
endothermic transition detectable by DSC analysis showed that at pH 3.1 AFP contained 
no rigid tertiary structure. This was in contrast to native AFP molecules analysed at pH 
7.2. This led the authors to conclude that the transition from native to molten globule-like 
state for AFP might play an important role in the proteins functionality. They 
hypothesised that the increased flexibility of the molten globule state could facilitate ligand 
disassociation at membrane structures, where the intracellular pH is lower than that of the 
cytsol.
Molten globule-like states have not been widely characterised within virus structural 
proteins. This is probably due to the relatively limited investigations of the folding 
pathways of such proteins compared to those of smaller more amenable globular proteins. 
However, a partially folded intermediate state has been proposed for the coat protein 
subunit of P22 bacteriophage. Teschke and King (1993) analysed the ability of denatured 
P22 coat protein to refold in vitro. Upon refolding the coat protein molecule was fully 
functional and actively participated in capsid assembly when associated with its scaffold
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protein counterpart. During refolding an intermediate was identified which exhibited an 
increase in both intrinsic fluorescence and the number of sites that bound ANS compared 
with the fully folded form. The increased number of ANS sites led the authors to propose 
that this folding intermediate was in an molten globule-like transitional state. They further 
proposed that the native coat protein, which had not associated with a scaffold subunit, was 
in a partially folded intermediate state and only became fully folded when polymerised 
within the capsid during assembly in association with scaffold protein molecules.
3.6.3.3 Mutual protein co-folding within the triplex
DSC analysis of purified VP19cHis and VP23His demonstrated that they contain little or 
no rigid tertiary structure. Conversely, DSC analysis of purified in vivo and in vitro 
formed triplexes, and near-UV CD analysis of in vivo purified triplexes, showed that they 
contain considerable tertiary structure. As the individual triplex proteins appear to lack 
any independent tertiary structure, the tertiary structure within the triplex would appear to 
be formed by the association of VP 19c and VP23 during triplex formation. The formation 
of such rigid tertiary structure is probably a direct result of mutual co-folding of secondary 
structural elements from each protein during complex formation (discussed further in 
section 4).
3.6.3.4 Partial folding within the triplex
Although the classical definition of the molten globule-like state does not apply to the 
triplex, it still binds the hydrophobic probe ANS strongly and shows enhanced 
fluorescence following excitation (fig. 3.6.9, panel C). This indicates that ANS has access 
to the hydrophobic interior of the heterotrimer and suggests that although the triplex is 
fully folded and contains rigid tertiary structure, other regions within the complex still 
retain the characteristics of a partially folded molten globule-like intermediate.
Although there are few examples of trimeric protein complexes that exhibit partial folding, 
one example is that of the cytokine tumour necrosis factor-a (TNFa). TNFa is a 52kDa
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globular trimeric protein composed of identical subunits of approximately 17.3kDa 
(Wingfield et al., 1987). TNFa has been shown to partially unfold at low pH and 
demonstrates the usual characteristics of an acid induced molten globule-like state (Hlodan 
and Pain, 1994). Experiments performed by Hlodan and Pain (1995) demonstrated that 
TNFa could be denatured into unfolded monomers in 3M GdnHCl and upon refolding 
passed through a transient trimeric intermediate (I3) molten globule-like state. This I3 
intermediate bound ANS more effectively than the native compact conformation. During 
refolding there was desorption of ANS which was thought to reflect the conformational 
rearrangement and re-packing of side chains into the native trimeric conformation. The 
fact that HSV triplexes still retain the ability to bind strongly to ANS could therefore 
indicate that further conformational rearrangements have yet to occur within the triplex. 
The triplex itself may therefore represent a partially flexible intermediate in respect to 
capsid assembly, which only adopts its final native conformation following capsid 
maturation (discussed further in section 4.0).
Although the classical definition of the molten globule is associated with a lack of rigid 
tertiary structure, some proteins have been shown to have a bipartite structure comprised of 
both molten globule-like and fully folded protein domains. For example, the molten 
globule-like state of a-lactalbumin contains two domains, an a-helical and P-sheet 
domains, which exhibit different degrees of folding. The P-sheet domain is largely 
unstructured whilst the structure of the a-helical domain closely resembles that of the 
native protein (Peng et al., 1995). This folded structure is thought to be due to a small 
subset of hydrophobic residues within the a-helical domain which form a densely packed 
core. This step is thought to direct the overall folding of the protein molecule in the early 
stages of folding before specific packing of amino acid side chains occurs (Peng and Kim, 
1994; Wu and Kim, 1998; Song et al., 1998). Therefore, in a multi-domain polypeptide, 
molten globule properties can be limited to portions of the polypeptide with individual 
domains folding independently (Peng and Kim, 1994; Peng et al., 1995). Indeed, it is now 
becoming clear that folding of some protein molecules requires a number of folding stages 
with the protein molecule passing through several conformational intermediates before it 
takes on its final native structure. For example, interleukin-4 at low pH has been shown by 
NMR studies to take on a late folding intermediate conformation that contains extensive 
tertiary interactions within a highly ordered hydrophobic core but still displays extensive
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disorder within regions which link the structural domains. This has lead to the 
terminology of the ‘highly ordered molten globule’ (Redfield et al., 1994). Similar NMR 
analysis of cytochrome b562) with (halo-) and without (apo-) the prosthetic haem group, has 
revealed that the overall topology of the molecule is conserved between apo- and halo- 
forms (Feng et al., 1994). However, significant differences were detected in the helix- 
helix packing, in particular around the haem-binding pocket of apo-cytochrome b562 which, 
although conserved, was exposed to the solvent.
Purified in vivo formed triplexes seem to belong to this class of proteins which contains 
both highly structured and flexible domains. The flexible domains may assist further 
protein folding events during the course of capsid assembly (discussed further in section 
4.0). In the absence of a high resolution structure, it is difficult to speculate where the 
structured and flexible portions are located within the triplex. The highly structured 
component of the triplex may represent the product of mutual co-folding between VP23 
and VP 19c and/or be the direct result of tertiary structure developed within the individual 
triplex proteins during triplex formation. Cryo-EM analysis to 8A resolution has shown 
that the triplex appears as a compact globular heterotrimer (Zhou et al., 2000). However, 
this triplex structure is derived from a mature icosahedral B-capsid and is likely to differ 
from that of isolated triplexes, due to possible additional conformational rearrangements 
that occur during association of the triplex with other capsid protein subunits during capsid 
assembly. Indeed, as described in the introduction to this thesis, such conformational 
changes are evident, albeit at comparatively low resolution, when comparing the triplex 
conformation within procapsids to that of mature capsids (triplex conformational flexibility 
is discussed in further detail within section 4.0).
3.6.3.5 Future work
The stability of purified VP19cHis in vitro is poor compared to that of VP23His and 
triplexes. It has therefore been consistently difficult to perform biophysical analysis upon 
VP 19cHis due to the low concentrations of homogenous samples. Further biophysical 
analysis is therefore required on VP19cHis, such as near and far-UV CD, in order to 
accurately determine the degree of secondary and tertiary structure. Although attempts to
171
Results: 3.6
concentrate purified VP19cHis have failed, primarily due to non-specific binding to 
various agarose matrixes, it would be worth attempting to concentrate VP19cHis through 
other methods, such as micro-dialysis. Similarly, it would also be beneficial to develop 
other suitable purification buffers utilising octyl-p-glucoside in order to increase the 
solubility of VP19cHis at higher concentrations.
Teschke and King (1993) demonstrated that the coat protein of bacteriophage P22 passed 
through a kinetic molten globule-like intermediate and that the binding of ANS to either 
the coat protein or scaffold subunits prevented the formation of icosahedral capsid particles 
in vitro. Although the binding of ANS had no affect upon the overall secondary structure 
of the coat protein, it did induce conformational changes within the secondary structure of 
the scaffold protein molecule, which altered its ability to undergo maturation. It would be 
interesting, therefore, to compare the number of ANS molecules that bound to VP23 and 
VP 19c with the number bound to triplexes and to determine whether or not ANS prevented 
triplex polymerisation. This might provide a clearer insight into how these two triplex 
proteins interact and to further elucidate the role in which the triplex plays within capsid 
assembly. Similarly, it would be interesting to determine, as with P22 capsid assembly, 
whether or not ANS inhibited the polymerisation of capsid particles, as little is currently 
known about the folding processes of other HSV-1 capsid proteins molecules, in particular 
VP5.
Furthermore, it would also be interesting to analyse by DSC the endothermic transition of 
triplexes in the presence of increasing concentrations of denaturants such as urea and 
GdnHCl. 3M urea has been shown to disassociate triplex molecules into their basic 
constituent proteins (section 5.42). DSC analysis of triplexes in the presence of 
denaturants would therefore provide more information upon the co-operative unfolding of 
these two molecules and might reveal whether or not the tertiary structure within the 
triplex is derived specifically from the association of VP23 with VP 19c. Similarly, it 
would be interesting to follow the changes in the tertiary structure of purified capsid 
proteins in real time by near-UV CD analysis. This could be accomplished by separately 
purifying individual capsid proteins and mixing them just prior to analysis. This would 
provide a sequence of folding events involved during procapsid assembly and subsequent 
procapsid maturation.
172
Chapter 4 
Discussion
Discussion: 4
4.0 Discussion
4.1 Quasi-equivalence and conformational flexibility within the HSV-1 
capsid.
The HSV-1 capsid is among the largest and most complex of virus particles and as such 
there has been considerable interest in analysing its three dimensional structure. However, 
to date there has been no X-ray crystallography structure published of the complete capsid, 
nor any of its individual outer shell structural components. This, in part, reflects the 
complexity of the HSV-1 capsid, in particular its size (-1250A in diameter), and the 
difficulties associated with acquiring high concentrations of homogenous and intact 
samples from infected cell nuclei (Gibson and Roizman, 1972; Steven et al., 1997). 
Attempts to recombinantly express and purify individual full length capsid polypeptides at 
concentrations required for X-ray crystallography (typically >10mg/ml) have also proved 
to be difficult due to their relative insolubility at high concentrations (personal 
communication, Bowman, 1999). Consequently, the majority of the structural information 
derived from the HSV-1 capsid has been determined through the use of cryo-EM 
examination in conjunction with image processing and computer reconstruction analysis 
(Schrag et al., 1989; Booy et al., 1991; Newcomb et al., 1993; Zhou et al., 1994, Zhou et 
al., 1995, Zhou et al., 1998; Zhou et al., 2000). Through the use of cryo-EM the structure 
of the HSV-1 B capsid has recently been resolved to a resolution of 8.5A (fig. 4.1, Zhou et 
al., 2000). Although the strict bonding relationships between protein molecules within the 
HSV-1 capsid still remains unresolved at this resolution, it has been possible to determine 
mass boundaries of individual protein molecules and predict secondary structural elements, 
in particular a-helices, within subunit structures. EM and cryo-EM analysis has long since 
established that the outer capsid shell of the HSV-1 capsid is composed of 150 hexons and 
12 pentons that are interconnected by 320 triplexes (Wildy et al., 1960; Schrag et al., 
1989). The interactions between these individual capsomeric subunits, in particular the 
triplexes, within the T=16 icosahedral lattice and their deviations away from their 
predicted quasi-equivalent bonding arrangements are discussed below in relation to the 
molten globule-like characteristics of the triplex and triplex protein constituents.
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4.2 Non-equivalent interactions of triplexes within the HSV-1 capsid
Cryo-EM analysis of the HSV-1 capsid has established that triplexes occupy the local and, 
with respect to the triplex ‘Tf’, global 3-fold rotational symmetry axes. However, the 
asymmetry of the triplex and its heterotrimeric nature (2 copies of VP23:1 copy of VP 19c) 
make it difficult to envisage how this complex can occupy a position of 3-fold rotational 
symmetry, since rotation of a triplex around its axis would not lead to equivalent 3-fold 
symmetries and bonding arrangements with adjacent capsomers (Schrag et al., 1989; Booy 
et al., 1991; Conway et al., 1993; Zhou et al., 1994; Zhou et al., 1998). The apparent 3- 
fold symmetry observed for triplex ‘Tf’ is a direct result of 3-fold averaging during the 
computer reconstruction process. The inter-capsomeric bonding of triplex ‘Tf’ within the 
HSV-1 capsid is, therefore, currently unresolved and shall not be discussed further here 
(Schrag et al., 1989; Conway et al., 1993; Zhou et al., 1994).
Early low-resolution cryo-EM analysis of the HSV-1 capsid demonstrated different 
bonding interfaces between the triplexes ‘Ta-Te* and their surrounding capsomers. The 
most different of these inter-capsomeric connections is that of the triplex ‘Ta’ compared to 
that of triplexes ‘Tb-Te’. Triplex ‘Ta’ appears to make a single prominent head connection 
compared to that of two head connections observed for triplexes ‘Tb-Te’ to their respective 
capsomers (fig. 4.1) (Zhou et al., 1994; Zhou et al., 1998; personal communication, Zhou, 
1999). The substantial differences in the inter-capsomeric bonding arrangements of 
triplexes ‘Ta-Te’ and the general asymmetry of these complexes clearly violate the rules 
depicted by the theory of quasi-equivalence proposed by Caspar and Klug (1962). 
Furthermore, this degree of variation in triplex inter-capsomeric bonding can be detected 
biochemically. Structural and biochemical analysis performed by Newcomb et al., (1993) 
on purified HSV-1 B capsids treated with various concentrations of denaturants 
demonstrated that the peripentonal triplex ‘Ta‘ and the perihexonal triplex ‘Tc‘ were more 
readily disassociated from capsids than those perihexonal ‘Tb, Td, Te, Tf’ triplexes. 
Conway et al., (1993) reported similar observations when comparing low and high dose 
irradiated HSV-1 B-capsids. It is clear therefore from both biochemical and structural 
analysis of HSV-1 capsids that triplexes *Ta-Tf have distinctly different inter-capsomeric 
bonding arrangements to their surrounding capsomeric subunits within the HSV-1 capsid.
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Fig. 4.1: Surface reconstruction of the HSV-1 capsid at 8.5A
resolution
Radially colour-coded representation of the HSV-1 capsid at 8.5A 
(dark to light colours represent low to high positions of mass 
density respectively). A single asymmetric unit is enclosed by the 
white outline connecting the five, three, and two-fold axes 
(indicated by 5, 3, and 2 respectively). The penton (at the 5-fold 
axes), the three types of hexon (designated P, E, and C) and the six 
types of triplexes (Ta, Tb, Tc, Td, Te, and Tf) are appropriately 
labelled.
This picture was reproduced with permission from W. Chiu, Baylor 
college of medicine, USA.
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4.3 How do the triplexes occupy a 3-fold rotational axis?
Cryo-EM and computer image processing analysis of the triplex connections to the capsid 
floor at 8.5A resolution has suggested how the asymmetrical triplex occupies a 3-fold 
symmetrical position. The densities at the base of the triplex appear to exhibit a limited 3- 
fold symmetry. The lower third of the triplex molecule consists of two legs, assigned to 
VP23, and a tail formed by VP 19c. These are triangularly related with two copies of VP23 
forming an angle of approximately 120° and VP 19c occupying the third triangular position 
(fig. 4.2, panel B(l)). The triplex therefore forms a pseudo-trimer at its base with each of 
the triplex proteins interacting with the floor densities provided by surrounding hexon 
capsomer subunits (Zhou et al., 2000). However, the pseudo-trimer relationship within the 
triplex becomes significantly altered further up the triplex away from the capsid floor. 
Within the middle domain of the triplex the triangular arrangement of the triplex proteins 
is lost and the dimeric relationship between the VP23 molecules becomes more evident. 
The relative angle between VP23 molecules within the middle domain changes from 120° 
to approximately 180° with the mass density attributed to VP 19c no longer having an 
equivalent relationship to that of the dimer of VP23 molecules (fig. 4.2, panel B(2)). The 
upper domain of the triplex is entirely composed of protein mass relating to VP 19c and is 
responsible for interconnecting adjacent capsomers above the capsid floor (fig. 4.2, panel 
A and panel B(3)) (Saad et al., 1999, Zhou et al,. 2000). Computer analysis of the local 
symmetry within the hexon demonstrated a high 6-fold local symmetry running throughout 
the entire structure with the tower region being particularly conserved (personal 
communication, Jing He, 2000). Computer analysis of the local symmetry within the 
triplex has demonstrated that they have no detectable mathematical local 3-fold symmetry 
(personal communication, Jing He, 2000). However, there does appear to be some 
functional symmetry between the triplex proteins, especially at the points of contact the 
triplex makes with the capsid floor (personal communication, Jing He, 2000). The ‘Ta-Tf’ 
triplexes therefore represent highly unusual but essential building blocks within the mature 
HSV-1 capsid particle (Tatman et al., 1994, Thomsen et al., 1994, Zhou et al., 2000).
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Fig. 4.2: Heterotrimeric arrangement of VP23 and VP 19c interactions
within the triplex
(A) Side view of a triplex obtained by averaging the four triplexes (Tb, Tc, 
Td, Te) around the C-hexon. The different colours represent individual 
capsid proteins; VP 19c (green), VP23 (white), and the capsid floor 
composed of VP5 (blue). Red lines numbered 1-3 represent the position 
of cross sections taken through the averaged triplex shown in panel B.
(B) Three cross sections representing 1.4A slices through the averaged 
triplex at positions 1-3 (indicated by red lines above). Contour colouring 
represents high (red), median (purple) and low (green) density levels. 
Slice (1) illustrates the pseudo 3-fold symmetry at the base of the triplex 
(highlighted by the orange lines). The two copies of VP23 (highlighted 
by yellow dotted circles) have an approximate 120° relationship to one 
another with the single copy of VP 19c occupying the third position. Slice 
(2) indicates the conformation change in the orientation of VP23 
molecules which now have an approximate 180° relationship to one 
another (highlighted by the orange line). Slice (3) shows the asymmetric 
appearance of the density at the top of the averaged triplex mass relating 
to VP 19c. The scale bar represents 20A in length.
This picture was reproduced with permission from W. Chiu, Baylor 
College of medicine, USA.
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4.4 Conformational flexibility within the triplex
Computational averaging of triplexes resolved to 8.5A has demonstrated that triplexes 
contain a degree of domain variation between the two VP23 molecules within each 
individual triplex. Computational alignment of the individual VP23 molecules obtained 
from averaging triplexes ‘Ta-Te’ demonstrated an overall conservation of the gross 
conformation and putative a-helical content. However, significant domain movements 
were evident between individual VP23 molecules within the triplex, in particular the 
degree of orientation for the predicted upper a-helix (fig. 4.3). This implies that these 
protein molecules have non-equivalent bonding relationships within individual triplexes 
and therefore must possess a degree of conformational flexibility in order to accommodate 
the observed domain movements. Indeed, the non-equivalent relationship between VP23 
molecules within the triplex is particularly highlighted by their respective interfaces with 
VP 19c. One side of a VP23 molecule (coloured in white in fig. 4.4) forms an extensive 
protein interface with VP 19c, while the equivalent side of the other VP23 molecule 
(coloured in grey in fig. 4.4) interacts directly with the opposing VP23 molecule (also 
highlighted in fig. 4.2, panel B(l)). Thus, the dimer of VP23 within the heterotrimer is 
itself asymmetrical with the VP23 molecules taking on different conformations and 
presumably different bonding attributes within the triplex. This arrangement is structurally 
irregular as dimeric molecules, or subunits composed of dimers, generally demonstrate 
identical bonding interfaces. Furthermore, the few instances where such non-equivalent 
dimeric interfaces occur necessitate the appropriate subunit to have a degree of flexibility. 
For example, the inner subcore of BTV forms a T=2 shell from dimers of the polypeptide 
VP3. The VP3 interacts through non-equivalent interfaces and these provide the flexibility 
to form a closed spherical shell. The inherent flexibility of VP3 therefore circumvents the 
geometrical constrictions placed upon capsomer subunits within spherical particles 
predicted by Caspar and Klug (1962) (discussed in further detail within the introduction of 
this thesis and in Grimes et al., 1998). Such asymmetry within dimeric molecules can also 
be seen within the black widow neurotoxin a-latrotoxin (LTX). LTX is a hydrophilic 
pore-forming toxin where the pore subunit is a tetramer composed of two asymmetrical 
dimers of LTX. In the presence of divalent cations the dimers associate to form a pore 
complex that contains a 25A channel running through its centre. Although the relative
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Fig. 4.3: Predicted a-helices within the two VP23 molecules o f an averaged 
triplex
The putative a-helices within the two VP23 molecules o f an averaged triplex 
are indicated as red and orange cylinders respectively o f 5A in diameter. 
Protein mass densities relating to the capsid floor (composed o f VP5) and 
VP 19c have been removed. The remaining mass density attributed to the 
VP23 dimer was extracted and the two VP23 molecules aligned to a similar 
orientation. The white * highlights the difference in the angle o f the upper 
a-helix  between VP23 molecules.
This picture was reproduced with permission from W. Chiu, Baylor College 
o f medicine, USA.
(A)
(B)
(C)
Fig. 4.4: Visualisation of the heterotrimeric interactions within the
triplex
(A) Side view of an averaged triplex obtained by averaging the four 
triplexes (Tb, Tc, Td, Te) around the C-hexon (opposite view from fig. 
4.2). The different colours represent individual capsid proteins; 
VP 19c (green), VP23 (white and grey), and the capsid floor composed 
of VP5 (blue). (B) Averaged triplex rotated 120° around the 3-fold 
local axis from position (A). (C) Same view of the averaged triplex as 
in (B) but VP 19c and VP23 molecules separated to demonstrate their 
conformational organisation within the triplex.
This picture was reproduced with permission from W. Chiu, Baylor 
College of medicine, USA.
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structural domains are similar within the dimer and tetramer, consisting of body, head and 
wing domains, the relative angle of orientation of these domains between dimer and 
tetramer is considerably different, ranging between 10-20° (Saibil, 2000). Thus, 
oligomerisation from dimer to tetramer must require flexibility within the dimeric subunit 
in order to accommodate these domain movements. The need for this substantial 
conformational change remains ambiguous but may reflect a functional role in the 
penetration of the pore complex through membrane structures (Orlova et al., 2000).
4.5 Molten globule characteristics of the triplex
As previously discussed (within section 3.6) the individual triplex protein molecules 
represent partially folded protein structures that contain a high degree of secondary 
structure with little or no stable tertiary structure. These characteristics are similar to those 
of molten globules, proteins that are in an intermediate state of protein folding. The lack 
of rigid tertiary structure within proteins in this partially folded state is thought to be 
necessary to accommodate the arrangement of certain secondary structural elements, such 
as a-helices, during folding (Ptitsyn, 1995b). The protein-protein interactions that occur 
upon association of VP 19c and VP23 during triplex formation, result in the development 
of rigid tertiary structure (as determined by DSC analysis). The generation of this tertiary 
structure appears to involve the mutual co-folding of protein domains from both VP23 and 
VP 19c, as dimeric VP23 has little rigid tertiary structure of its own. However, the 
triplexes still appear to retain a degree of partial folding, with the fluorescent hydrophobic 
probe ANS having access to the interior of the triplex molecule. Thus, although at least 
some domains of the triplex have defined tertiary structure, the triplex as a whole retains 
flexible elements that can undergo further conformational rearrangement and folding. In 
relation to the macromolecular assembly of the capsid the triplex would therefore represent 
a flexible intermediate protein subunit and as such could be defined as a ‘highly ordered 
molten globule-like’ protein complex (Redfield et al., 1994). The plasticity inherent in 
such from such a molten globule-like state would provide the flexibility necessary to attain 
such non-equivalent interactions as those seen within the mature polyhedral HSV-1 capsid.
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4.6 Gross conformational rearrangements and the capsid floor
One of the largest conformational changes to regularly occur during virus assembly is the 
transition from procapsid to mature capsid (figs. 1.13 and 1.15). Procapsids have been 
documented in a number of dsDNA viruses, such as the bacteriophage P22 (discussed in 
the introduction of this thesis), and more recently within HSV-1 capsids (Newcomb et al., 
1996; Trus et al., 1996; Tuma and Thomas, 1997; Newcomb et al., 2000). However, 
procapsids are not limited to dsDNA viruses and have recently been observed as assembly 
intermediates of non-enveloped small RNA viruses such as Nudaurelia capensis at virus 
(Canady et al., 2000). In dsDNA viruses, procapsids are thought to represent an 
intermediate capsid assembly stage at which point the scaffold protein subunits are 
removed from the precursor capsid shell before the packaging of the nucleic acid genome 
(King et al., 1976; Prevelige and King, 1993; Iiag et al., 1995). DNA packaging during 
bacteriophage assembly has been demonstrated to occur specifically during the procapsid 
transition and this is also thought to be the stage at which DNA packaging occurs within 
the HSV-1 capsid. During assembly, the HSV-1 capsid has been shown to be 
progressively built up by the incremental addition of VP5 and scaffold subunits inter­
linked by triplexes. The increasing addition of subunits to the growing structure leads to 
the formation of partial capsids and eventually to closed spherical particles ‘procapsids’ 
(fig. 1.14) (Newcomb et al., 1996; Newcomb et al., 1999). Procapsids are spherical, 
lacking the flat facets, angular edges and vertices associated with the mature polyhedral 
form. They exhibit no local 6-fold symmetry, for example the P, E, and C hexon capsomer 
subunits taking on oval, highly oval, and triangular appearances respectively, and their 
respective protomers have little or no interconnecting density. In comparison, their 
structures within the mature polyhedral capsid are hexagonal and tightly packed in 
appearance, with strong interconnecting densities (Trus et al., 1996; Zhou et al., 1994; 
Zhou et al., 1998). Thus, the procapsid of HSV-1 could in itself be considered as a flexible 
protein intermediate on a macromolecular scale where considerable protein rearrangements 
occur upon procapsid maturation.
One of the most significant differences between procapsids and mature polyhedral capsid 
is within the floor domain. Capsomers in the HSV-1 procapsid have little contact with 
each other except through the triplexes located at the 3-fold axes. The capsid floor is
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largely undefined and contains large gaps between the capsomeric subunits. The triplexes 
connecting adjacent capsomers appear to make no contact with the floor domain unlike 
triplexes within the mature capsid. Furthermore, triplexes in the procapsid appear to 
interact triangularly with all three adjacent capsomers. Maturation of the procapsid 
therefore results in large-scale conformational changes. Individual capsomeric subunits 
become more compact taking on their respective hexavalent or pentavalent structures and 
develop connections leading to the formation of the capsid floor, thought in part to be 
interconnected by the N-terminal a-helices of VP5 protomers (Zhou et al., 2000). The 
triplexes become anchored to the capsid floor and develop their unique non-equivalent 
connections between capsomeric subunits (Trus et al., 1996; Zhou et al., 2000). At the 
current resolution of the HSV-1 procapsid structure the processes involved in such radical 
conformational changes remain unclear. However, it is clear that the observed changes 
would require particular flexibility within subunit structures in order to accommodate such 
gross conformational rearrangements in inter/intra-capsomer interactions. Therefore, the 
experimental findings described above, that the triplex forms a partially flexible protein 
subunit with both highly ordered and molten globule-like characteristics, are consistent 
with the known procapsid and mature HSV-1 capsid structures.
Once maturation is complete further stability may be provided through the formation of 
disulphide bonds. Zweig et al., (1979) demonstrated that VP5 and VP 19c were disulphide 
linked within mature HSV-2 icosahedral capsids. Although the VP5/VP19c disulphide 
linkage has yet to be identified within HSV-1 capsid, significant band shifts can be 
detected when analysing purified HSV-1 capsids by non-reducing SDS-PAGE analysis 
(for an example see fig. 3.3.13). This would therefore indicate a role for disulphide 
bonding within the HSV-1 capsid. However, Newcomb et al., (1994) demonstrated that 
the assembly of capsids could occur in the presence of lOmM DTT, which would imply 
that disulphide bond formation is not essential for capsid polymerisation to occur. As 
disulphide bond formation is generally considered to occur as a late event in the protein- 
folding pathway, these disulphide connections could be seen to fix the partially flexible 
structures into rigid conformations in order to provide structural reinforcement leading to a 
more robust capsid structure. Cysteine residues within the triplex, in particular those 
conserved cysteines within VP23 molecules, might also aid the inter-molecular locking of 
the triplex structure through the formation of intra-molecular disulphide bonds once
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maturation is completed and stability is required over flexibility. Such a late role could 
explain why the highly conserved cysteine residues within VP23 are not essential for 
capsid formation (discussed further in the conclusion of section 3.3).
4.7 Heterotrimer opposed to homotrimer, the requirement for VP23 
within the triplex
Ever since the composition of the triplex was postulated by Newcomb et al., (1993) to be a 
ratio of 2:1 of VP23 to VP 19c, one of the fundamental questions in respect to HSV-1 
capsid structure has been; ‘why are triplexes organised as heterotrimers rather than 
homotrimers’? Viruses have strict limitations in their coding capacity and therefore the 
evolution of the triplex as a heterotrimer of two unrelated proteins seems inefficient. 
Furthermore, small homotrimers have been identified at those local 3-fold symmetry 
positions interconnecting hexons in other icosahedral virus capsids, for example 
bacteriophages T4 (soc) and X (gpD), and animal viruses such as adenovirus (polypeptide 
IX) (Ishii and Yanagida, 1977; Colby and Shenk, 1981; van Oostrum and Burnett, 1985; 
Perucchetti et al., 1988; Dokland and Murialdo, 1993). In such cases these homotrimers 
have been shown to bind to their respective capsids post-assembly and although not 
specifically required for assembly are thought to stabilise the capsid by providing 
structural reinforcement (Furcinitti et al., 1989). DSC analysis on T4 capsids showed that 
the presence or absence of soc proteins altered their thermostability during temperature 
denaturation, reinforcing the idea that these homotrimeric proteins are specifically 
involved in capsid stabilisation (Ross et al., 1985; Steven et al., 1992).
However, all herpes viruses studied to date contain triplexes at all local 3-fold positions 
and where the capsid composition is known they are composed of heterotrimers of two 
unrelated proteins (Davison, 1993; Davison 1995). Although their relative sequence 
homology is not particularly conserved their structural position at the 3-fold symmetry axis 
and their stoichiometry within their appropriate capsid structures appears to be well 
conserved in those capsid structures analysed to date (Baker et al., 1990; Booy et al., 1996; 
Davison et al., 1995).
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4.7.1 The function o f VP23 within the triplex
It has been established through cryo-EM analysis that one of the primary functions of 
VP 19c during capsid assembly is to interconnect adjacent capsomers and that this function 
is essential for the assembly of capsids. Indeed, the expression of VP5 and VP 19c in the 
baculovirus system has been shown to lead to the production of smaller icosahedral 
particles with T=7 symmetry (Tatman et al., 1994; Saad et al., 1999). One might assume 
therefore that the addition of the scaffold protein subunits would be sufficient to direct 
capsid assembly to produce T=16 icosahedral particles. However, the baculovirus system 
has demonstrated that the co-expression of VP5, VP 19c, and scaffold (either preVP22a or 
VP21 /VP24) without VP23 results in the formation of irregular capsids. VP23 is therefore 
essential for the production of mature T=16 polyhedral capsids (Tatman et al., 1994; 
Thomsen et al., 1994).
Analysis of VP5/VP19c particles has also demonstrated that T=7 particles lack the intricate 
network of interactions found within the capsid floor of polyhedral HSV-1 capsids (Saad et 
al., 1999). Procapsids have also been shown to lack such interconnecting densities within 
the capsid floor (Trus et al., 1996; Newcomb et al., 2000). As VP23 appears to make 
contact with VP5 within the floor domain of mature capsids, VP23 may be responsible for 
initiating or directing the conformational rearrangements of protein densities within the 
capsid floor from surrounding capsomers during procapsid maturation.
It is of interest to note that homotrimers associated with capsid assembly, for example 
polypeptide IX homotrimers from adenovirus capsids, have only been shown to interact 
around the local 3-fold axes of symmetry surrounding hexon capsomeric subunits (van 
Oostrum and Burnett, 1985). The conformational differences in the bonding arrangements 
within the floor domains surrounding pentons and hexons may therefore require additional 
flexibility within subunits occupying the 3-fold symmetry axes surrounding the penton 
capsomers. The non-equivalent nature of VP23 molecules within the triplex and their 
molten globule like structure may provide the conformational flexibility needed to direct 
folding events during floor development at all 3-fold axes surrounding both pentons and 
hexons. In a similar manner to the homotrimers found in other icosahedral capsids, the 
contacts made by VP23 and VP 19c to the capsid floor act as cement by interlocking the
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floor protein interfaces and providing increased rigidity throughout the capsid. Such 
conformational variation in protein interfaces within the capsid floor between pentons and 
hexons, and between the different quasi-equivalent hexons, may also account for the 
observed differences in the bonding of VP 19c within triplexes ‘Ta-Te’ to their respective 
capsomers. For example, although the triplex appears to be partially flexible the 
constrictions placed upon VP23 during floor maturation could force VP 19c to alter its 
triangular capsomeric arrangement within the procapsid so that VP 19c becomes anchored 
to the capsid floor. The differences observed in the binding of VP 19c to its surrounding 
capsomers would therefore reflect the degree of conformational variation in VP23 
interactions made during floor development. Indeed, those triplexes that appear to have 
the most variation in their VP 19c capsomer binding interfaces, namely ‘Ta* and ‘Tc’, are 
located at peripentonal or close to peripentonal positions respectively within the 
icosahedral lattice (Zhou et al., 2000). The flexibility derived from the molten globule-like 
state of individual triplex protein molecules, in particular VP23, would provide the 
conformational flexibility to form contacts at all positions 3-fold axes of symmetry within 
the icosahedral lattice.
It seems reasonable to speculate that, as a trimeric complex appears essential at all 
positions of 3-fold symmetry within the HSV-1, the virus has evolved the triplex complex 
as a conformationally flexible heterotrimer. The development of such conformational 
flexibility through the association of VP23 and VP 19c as a heterotrimer allows the triplex 
to play an essential and dynamic role in the assembly and maturation of the HSV-1 capsid. 
The transitions in triplex conformation during capsid assembly are schematically 
illustrated in fig. 4.5.
4.8 VP5 capsomer flexibility
As previously discussed in the introduction to this thesis VP5 makes up the entire mass of 
pentons (5 copies of VP5) and the majority of the mass of hexons (6 copies of VP5). 
Computational comparison of VP5 molecules from pentons and hexons has demonstrated 
that they have similar overall conformations. However, pentons and hexons have 
distinctly different properties. For example, pentons interact with tegument proteins
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following capsids assembly while VP26 only binds to hexons (Zhou et a l, 1995; Zhou et 
al., 1999). Such differences in biological properties between pentons and hexons can be 
attributed to conformational differences between their VP5 subunits. These differences are 
evident post-assembly and consequently when VP5 is fully folded. Thus, the attachment of 
VP26 to the tips of the hexons requires VP5 molecules within the hexavalent capsomers to 
have undergone their conformational rearrangement, as VP26 molecules do not associate 
with the hexons in purified HSV-1 procapsids (Newcomb et al., 1999; Newcomb et al., 
2000; Chi and Wilson, 2000). The conformational differences between VP5 protomers in 
hexons and pentons have also been detected immunogenically. Trus et al., (1992) 
demonstrated that monoclonal antibodies raised against purified VP5 recognised specific 
capsomer epitopes on hexons or pentons but not both.
VP5 molecules within pentons have also been shown to contain an extra density of mass 
within the middle domain of the penton that is absent from hexons thought to be attributed 
to the closure of the penton channel following the packaging of viral DNA. This extra 
density has been attributed to the movement of a bundle of short a-helices, which 
constricts and thus closes the 25A channel running through the penton (Zhou et al., 1994; 
Zhou et al., 2000; personal communication, Frazer Rixon, 2000). Further differences have 
been seen within the lower domain of the VP5 molecule, in particular the orientation of the 
predicted long N-terminal a-helix. Differences in the angle of this a-helix can be seen not 
only between VP5 molecules from pentons and hexons but also seen between VP5 
molecules from P, E and C hexons (Zhou et al., 1994; Zhou et al., 2000). The 
conformational differences between VP5 molecules from hexons and pentons, and between 
the various quasi-equivalent hexons would therefore require a degree of flexibility within 
specific domains of VP5 during capsid assembly and procapsid maturation. Like the 
triplex, VP5 must be partially folded as an individual capsid protein in order to account for 
such conformational flexibility. Indeed, VP5 has been shown to bind ANS and to produce 
a characteristic increase in fluorescence following excitation (McCelland, 1999 
unpublished observations). This would therefore imply that the hydrophobic core of VP5, 
like that of the triplex, is exposed or partially exposed to the solvent and can undergo 
further folding. As purified VP5 has been shown to exist as a monomer in solution 
(Newcomb et al., 1999) this would indicate that VP5 forms hexons and pentons as a 
partially folded intermediate within the nucleus during the progressive assembly of the
183
Discussion: 4
capsid. This is consistent with the evidence generated through cryo-EM analysis of 
procapsids where individual capsomers appear rounded making little or no intra- 
capsomeric connections (Trus et al., 1996; Newcomb et al., 2000) and supports the notion 
that VP5 must be able to form a flexible intermediate that can undergo conformational 
rearrangements during capsid maturation. Like the triplex, VP5 is likely to undergo 
several changes in conformation before mature capsomers are formed and take on their 
respective appearances as hexons and pentons within the polyhedral capsid. The final step 
in the conformational maturation of VP5 protomers presumably creates the structural 
epitope specificity required for VP26 subunits to bind to the tips of hexons, thereby 
completing the procapsid maturation transition into WT polyhedral capsids.
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Fig. 4.5: Model for the folding events and cellular localisation of the 
triplex proteins during capsid assembly
Late gene expression results in the translation of triplex proteins VP23 and 
VP 19c within the cytoplasm of infected cells. Individual triplex proteins 
are partially folded and take on their respective molten globule like 
conformations with no rigid tertiary structure. VP23 dimerises, developing 
some independent tertiary structure, and associates with VP 19c resulting in 
further folding and the development of significant tertiary structure 
possible through mutual co-folding. Triplexes become localised to the 
nucleus and associate with VP5 and scaffold proteins resulting in the 
initiation of capsid assembly. Progressive assembly of triplexes, VP5 
complexes, and scaffold occurs until procapsid formation is complete. 
Scaffold particles exit the procapsid and maturation begins resulting in the 
angularisation of the capsid and the packaging of the viral dsDNA genome 
at an unknown point during maturation. Successful packaging of the 
genome results in mature polyhedral C-capsids that can then go on to 
produce infectious progeny virions. Unsuccessful attempts in the 
packaging of the viral DNA or scaffold disassembly results in the 
production of A and B-capsids respectively. The coloured bar represents 
the transitions in folding of the triplex proteins during capsid assembly 
from molten globule (yellow), to “highly ordered molten globule” (orange), 
to fully folded (red).
Chapter 5 
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5.0 Summary
5.1 Partial folding and capsid assembly
High-resolution analysis of various viral capsid structures, either by X-ray crystallography 
or cryo-EM, has demonstrated that capsids are architecturally complex macromolecular 
assemblies. It is becoming increasing evident that the assembly of such capsids does not 
represent the straightforward geometrical association of static protein subunits. In other 
words, it is becoming appreciated that capsid assembly is a dynamic folding cascade on a 
macromolecular level and not just the progressive association of fully folded rigid building 
blocks. This is particularly evident in those capsid structures that do not conform to the 
classic quasi-equivalence model, such as the SV40 capsid (Liddington et al., 1991). The 
nature of the association between subunits within such structures requires that individual 
molecules must have a degree of flexibility in order to accommodate the differing 
interactions with their surrounding subunits that are required to produce a closed spherical 
particle. Similarly, the intricate network of associations between complex subunit or 
protomer structures seen within a number of viral capsids must require the association of 
these capsomer structures to pass through a series of partially folded intermediate stages 
before forming the conformationally mature structures seen in a high-resolution image. 
For example, X-ray crystallography analysis of the adenovirus type-2 hexon has 
demonstrated that it is composed of three copies of the major coat protein. The three major 
coat protein molecules have been shown to interpenetrate each other to form a compact 
homotrimer (Athappilly et al., 1994). The association of rigid coat protein subunits could 
not account for such an intricate association, which could only be achieved by extensive 
mutual co-folding of individual coat protein molecules during hexon formation. Therefore, 
it is likely that individual hexon protein molecules are partially folded and pass through a 
number of intermediate folding stages to form a conformational mature hexon subunit 
structure. In addition, all capsids that undergo large-scale conformational changes during 
assembly, for example during procapsid maturation, must by definition, contain flexible 
elements in order to accommodate the necessary domain movements. Partial folding of 
individual capsid protein components could provide the flexibility required for such gross 
conformational rearrangements during capsid assembly.
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5.2 Partial folding and HSV-1 capsid assembly
Unlike the adenovirus hexon and SV40 capsid, the structure of the HSV-1 capsid has yet to 
be resolved by X-ray crystallography and therefore little can be specifically concluded 
about the exact protein-protein interactions within the mature polyhedral capsid. However, 
high-resolution cryo-EM analysis has provided clear indications of specific protein mass 
densities within the HSV-1 capsid and has highlighted significant differences in capsomer 
interactions throughout the icosahedral lattice. Although it is difficult to speculate whether 
or not the differences in bonding arrangements of quasi-equivalent VP5 protomers between 
hexons and pentons exceeds those predicted by quasi-equivalence, it is clear that domain 
flexibility throughout individual VP5 molecules is required. Such flexibility could be 
achieved by individual VP5 molecules existing in a ‘highly ordered molten globule-like’ 
state post-translation (currently under analysis within our laboratory).
However, it is clear from cryo-EM analysis of HSV-1 capsids that the asymmetry of the 
‘Ta-Te* triplexes and the transitions observed from procapsid to polyhedral capsid do 
violate the rules of deformable bonds predicted by the theory of quasi-equivalence (Caspar 
and Klug, 1962). The assembly of the HSV-1 capsid has been shown to occur through the 
progressive addition of subunits to a growing shell (Newcomb et al., 1996). As discussed 
above, proteins within this growing macromolecular structure must posses a degree of 
domain flexibility in order to assemble efficiently and mature into polyhedral capsids that 
are capable of packaging the viral nucleic acid. Triplexes play a fundamental role in the 
assembly of the HSV-1 capsid from the initiation of precursor shells, to procapsid 
formation, and eventually to the maturation into polyhedral capsids. Although the 
energetics of the folding transitions of proteins involved in the assembly of the HSV-1 
capsid have yet to be analysed, folding though flexible intermediates would provide a basis 
for efficient polymerisation of viral capsids without resulting in cumulative dead end 
abortive structures incapable of producing infectious progeny virions. The molten globule­
like characteristics of the individual triplex proteins and the highly ordered molten 
globule-like characteristics of the triplex provide some explanation to how these observed 
structural transitions can occur and provide a deeper insight into the complexities of 
folding pathways for large macromolecular structures.
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